The University of Alabama at Birmingham

Report on Federal Awards in Accordance with the OMB Uniform Guidance For the Year Ended September 30, 2021

EIN: 63-6005396

The University of Alabama at Birmingham

Index

For the Year Ended September 30, 2021

| | Page(s) |
|---|---------|
| Part I Federal Award Programs | |
| Report of Independent Auditors on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i> | 1–2 |
| Report of Independent Auditors on Compliance with Requirements that Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with the Uniform Guidance | 3–5 |
| Schedule of Expenditures of Federal Awards | 6–40 |
| Notes to Schedule of Expenditures of Federal Awards | 41–42 |
| Part II Schedule of Findings and Questioned Costs | |
| Schedule of Findings and Questioned Costs | 43 |
| Management's Views and Corrective Action Plan | 45 |
| Part III Summary Schedule of Prior Audit Findings and Status | |
| Summary Schedule of Prior Audit Findings and Status | 46 |
| Part IV 2021 Financial Report | |

Part I Federal Award Programs



Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards

To the Board of Trustees of The University of Alabama:

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States, the financial statements of the business-type activities and the discretely presented component unit of The University of Alabama at Birmingham ("UAB"), a campus of the University of Alabama System, which is a component unit of the State of Alabama, which comprise the statements of net position as of September 30, 2021, and the related statements of revenues, expenses, and changes in net position and of cash flows (where applicable) for the year then ended, and the related notes to the financial statements, which collectively comprise UAB's basic financial statements, and have issued our report thereon dated January 24, 2022. Our report includes a reference to other auditors who audited the financial statements of Southern Research Institute, as described in our report on UAB's financial statements. This report does not include the results of the other auditors' testing of internal control over financial reporting or compliance and other matters that are reported on separately by those auditors. The financial statements of Triton Health Systems, L.L.C., UAB Athletics Foundation and UAB Research Foundation were not audited in accordance with Government Auditing Standards and accordingly, this report does not include reporting on internal control over financial reporting or instances of reportable noncompliance associated with the aforementioned component units.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered UAB's internal control over financial reporting ("internal control") as a basis for designing the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the UAB's internal control. Accordingly, we do not express an opinion on the effectiveness of the UAB's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



Compliance and Other Matters

As part of obtaining reasonable assurance about whether UAB's basic financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Birmingham, Alabama

Tricewaterhouse Coopers LLP

January 24, 2022



Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with the Uniform Guidance

To the Board of Trustees of The University of Alabama:

Report on Compliance for Each Major Federal Program

We have audited The University of Alabama at Birmingham's ("UAB"), a campus of The University of Alabama System, which is a component unit of the State of Alabama, compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of UAB's major federal programs for the year ended September 30, 2021. UAB's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of UAB's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about UAB's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of UAB's compliance.

Opinion on Each Major Federal Program

In our opinion, The University of Alabama at Birmingham complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended September 30, 2021.

Other Matters

As indicated in Part I to the accompanying Schedule of Findings and Questioned Costs, we have audited the Student Financial Assistance cluster as a major program. Also, as indicated in the first paragraph of this report, we performed our audit of compliance using the compliance requirements



contained in the OMB Compliance Supplement, including those contained in Part V 5.3, Compliance Requirement N, Special Tests and Provisions, Section 10 "Gramm-Leach-Bliley Act-Student Information Security." This section includes three suggested audit procedures with respect to verification that the institution (1) designated an individual to coordinate the information security program, (2) performed a risk assessment that addresses the three required areas in 16 CFR 314.4(b), and (3) documented a safeguard for each risk identified. Our procedures in relation to these three items were limited to inquiry of and obtaining written representation from management and obtaining and reading management's documentation related to these three items. Our procedures did not include an analysis of the adequacy or completeness of the risk assessment performed or the safeguards for each risk identified by management.

The results of our auditing procedures disclosed instances of noncompliance, which are required to be reported in accordance with the Uniform Guidance and which are described in the accompanying schedule of findings and questioned costs as item 2021-001. Our opinion on each major federal program is not modified with respect to these matters.

The University's response to the noncompliance finding identified in our audit is described in the accompanying corrective action plan. The University's response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Management of UAB is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered UAB's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of UAB 's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the financial statements of the business-type activities and the discretely presented component unit of UAB as of and for the year ended September 30, 2021, and the related notes to the financial statements, which collectively comprise UAB's basic financial statements. We issued our report thereon dated January 24, 2022, which contained unmodified opinions on those financial statements. Our audit was conducted for the purpose of forming opinions on the financial statements that collectively comprise the basic financial statements. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the basic financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the basic financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the basic financial statements or to the basic financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the basic financial statements as a whole.

Pricewaterhouse Coopers LLP

June 22, 2022, except for our report on the Schedule of Expenditures of Federal Awards required by the Uniform Guidance, as to which the date is January 24, 2022

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|---|--|--|--|--|--|---|----------------------------|
| RESEARCH AND DEVELOPMENT CLUSTER Department of Agriculture Agriculture and Food Research Initiative (AFRI) 10.310 Total | 10.310 | \$ 112,971 112,971 | \$ - | | 0.15 | 112,971 | \$ 5,573 5,573 |
| Solid Waste Management Grants 10.762 Total Total Department of Agriculture | 10.762 | 112,971 | 146,667 146,667 | ROWAN UNIVERSITY | CPAP000000598654 | 146,667 146,667 259,638 | 5,573 |
| | | | | | | | |
| <u>Department of Commerce</u> Cluster Grants 11.020 Total | 11.020 | 144,151 144,151 | | | | 144,151 144,151 | |
| Unallied Science Program 11.472 Total | 11.472 | | 38,304 38,304 | AUBURN UNIVERSITY | ACQ-210-039-2019-AU | 38,304 38,304 | <u> </u> |
| Coral Reef Conservation Program 11.482 Total | 11.482 | | 29 29 | COLLEGE OF CHARLESTON | NA18NOS4820181 | 29 29 | |
| Measurement and Engineering Research and Standards 11.609 Total | 11.609 | | 162,725 162,725 | TROY STATE UNIVERSITY | 70NANB18H289 | 162,725 162,725 | |
| Total Department of Commerce | | 144,151 | 201,058 | | | 345,209 | |
| <u>Department of Defense</u> Basic and Applied Scientific Research 12.300 Total | 12.300 | | 518,386 518,386 | WRIGHT STATE UNIVERSITY | N00014-16-1-3159 | 518,386 518,386 | <u>-</u> |
| Military Medical Research and Development | 12.420 12.420 12.420 12.420 12.420 12.420 12.420 12.420 12.420 12.420 12.420 | 8,394,179 - - - - - - - - - | 1,834,147 494,528 434,141 96,624 43,507 43,223 35,832 23,878 14,111 7,083 | MISSISSIPPI STATE UNIVERSITY JOHNS HOPKINS UNIVERSITY OCEAN STATE RESEARCH INSTITUTE NOVAN INC THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS REGENTS OF THE UNIVERSITY OF COLORADO SUNFIRE BIOTECHNOLOGIES, LLC CHILDREN'S HOSPITAL BOSTON ADVANCED TECHNOLOGY INTERNATIONAL COALITION FOR NATIONAL TRAUMA RESEARCH | W56HZV-17-C-0095 MCS BAA 17-01 W81XWH-17-0619 W81XWH-1910850 W81XWH201340 W81XWH-17-0597 W81XWH-17-0597 W81XWH-17-0532 W81XWH-18-9-0001-11 W81XWH-20-2-0032 | 8,394,179 1,834,147 494,528 434,141 96,624 43,507 43,223 35,832 23,878 14,111 7,083 | 892,197 104,893 |
| Military Medical Research and Development Military Medical Research and Development 12.420 Total Basic Scientific Research | 12.420 12.420 | 8,394,179 | 5,343 (15,979) 3,016,438 | UNIVERSITY OF MINNESOTA JOHNS HOPKINS UNIVERSITY | W81XWH1810577 W8IXWH-10-2-0090 | 5,343 (15,979) 11,410,617 | 997,090 |
| 12.431 Total | 12.431 | | 634 634 | THE UNIVERSITY OF MONTANA | W911NF-15-2-0020 | 634 634 | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|---|--|--|---|---|---|----------------------------|
| Uniformed Services University Medical Research Projects | 12.750 | - | 96,091 | TRISERVICE NURSING RESEARCH PROGRAM | 11052-N21-05 | 96,091 | |
| Uniformed Services University Medical Research Projects | 12.750 | - | 74,703 | THE GENEVA FOUNDATION | 11052-N21-17 | 74,703 | |
| Uniformed Services University Medical Research Projects | 12.750 | - | 54,922 | THE GENEVA FOUNDATION | HU00011920043 N19-A09 | 54,922 | |
| Uniformed Services University Medical Research Projects | 12.750 | 7,151 | - | | | 7,151 | |
| Uniformed Services University Medical Research Projects | 12.750 | - | 1,051 | HENRY M JACKSON FOUNDATION | HU0001-17-2-0023 | 1,051 | |
| Uniformed Services University Medical Research Projects 12.750 Total | 12.750 | 7,151 | 119 226,886 | THE GENEVA FOUNDATION | 11052-N2101GR | 119 234,037 | |
| Air Force Defense Research Sciences Program Air Force Defense Research Sciences Program 12.800 Total | 12.800 12.800 | 143,753 - 143,753 | 15,643 15,643 | UNIVERSITY OF CALIFORNIA - BERKELEY | FA9550-21-1-0230 | 143,753 15,643 159,396 | <u> </u> |
| Research and Technology Development Research and Technology Development Research and Technology Development Research and Technology Development 12.910 Total | 12.910 12.910 12.910 12.910 | | 551,164 389,871 258,551 54,730 1,254,316 | UNIVERSITY OF MICHIGAN UNIVERSITY OF MICHIGAN UNIVERSITY OF MICHIGAN MOUNT SINAI SCHOOL OF MEDICINE | W56HZV-19-2-0001 W56HZN-19-2-0001 W56HZV-1920001 HR001118S0023 | 551,164 389,871 258,551 54,730 1,254,316 | <u> </u> |
| Contract #FA910118D0004/FA910121F0009 Contract Contract Contract #FA9101-18-D-0004 Contract #FA441716PR26P0008 | 12.RD 12.RD 12.RD 12.RD 12.RD | 574,468 - - 202,739 59,663 | 507,951 214,752 - | STEEL FOUNDER'S SOCIETY OF AMERICA FLORIDA INSTITUTE FOR HUMAN & MACHINE COGNITION, I | SP4701-17-D-1161 HR001119S0021 | 574,468 507,951 214,752 202,739 59,663 | |
| Contract Contract #FA441721P0040 Contract Contract Contract Contract Contract Contract Contract | 12.RD 12.RD 12.RD 12.RD 12.RD 12.RD 12.RD | 44,463 - - - - | 49,781 - 23,857 22,976 8,713 3,981 229 | ADVANCED TECHNOLOGY INTERNATIONAL JOHNS HOPKINS UNIVERSITY ADVANCED TECHNOLOGY INTERNATIONAL THE GENEVA FOUNDATION ADVANCED TECHNOLOGY INTERNATIONAL TDA | 2016-517 W81XWH1810810 SP4701-17-D-1134 HU0001172T504 (N17-A06) SP4701-15-C7003 W81XWH-17-C-0141 | 49,781 44,463 23,887 22,976 8,713 3,981 229 | |
| Contract #W911QY-15-C-0134 12.RD Total | 12.RD | (896) 880,437 | 832,240 | | | (896) 1,712,677 | - |
| Total Department of Defense | | 9,425,520 | 5,864,543 | | | 15,290,063 | 997,090 |
| Department of Interior Marine Turtle Conservation Fund 15.645 Total Total Department of Interior | 15.645 | 7,460 7,460 7,460 | - | | | 7,460 7,460 7,460 | - |
| Department of Justice National Institute of Justice Research, Evaluation, and Development Project Grants National Institute of Justice Research, Evaluation, and Development Project Grants 16.560 Total | 16.560 16.560 | 146,689 | 139,901 139,901 | NATIONAL ORGANIZATION OF BLACK LAW ENFORCEMENT EXE | 2019-BJ-BX-0011 | 146,689 139,901 286,590 | |
| Total Department of Justice | | 146,689 | 139,901 | | | 286,590 | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|---|--|---|--|---|--|--|----------------------------|
| <u>Department of Transportation</u> Highway Training and Education 20.215 Total | 20.215 | 51,483 51,483 | | | | 51,483 51,483 | <u>-</u> |
| University Transportation Centers Program 20.701 Total | 20.701 | | 170,581 170,581 | UNIVERSITY OF FLORIDA | 69A3551747104 | 170,581 170,581 | |
| Contract #DTNH2217D00066 OPT 3 Contract #DTNH2217D00066 Opt 2 Contract 20.RD Total | 20.RD 20.RD 20.RD | 313,454 40,341 - 353,795 | 65 65 | UNIVERSITY OF FLORIDA | 69A3551747104 | 313,454 40,341 65 353,860 | <u> </u> |
| Total Department of Transportation | | 405,278 | 170,646 | | | 575,924 | = |
| National Aeronautics and Space Administration Space Operations 43.007 Total | 43.007 | 47,631 47,631 | | | | 47,631 47,631 | <u> </u> |
| Education Education Education Education 43.008 Total | 43.008 43.008 43.008 43.008 | - - - - | 73,789 49,926 14,074 13,070 150,859 | UNIVERSITY OF ALABAMA IN HUNTSVILLE | 80NSSC20M0134 80NSSC20M0044 80NSSC19M0051 NNX15AJ18H | 73,789 49,926 14,074 13,070 150,859 | |
| Contract #80JSC021D0001 Contract #NNJ15HA80B Contract Contract Contract Contract 43.RD Total | 43.RD 43.RD 43.RD 43.RD 43.RD 43.RD | 4,369,085 1,604,643 - - - - - - 5,973,728 | 37,500 30,726 12,703 9,956 90,885 | GEOCENT, LLC GEOCENT, LLC GEOCENT, LLC GEOCENT, LLC | 80NSSC20P0385 80NSSC19-C-0134 80NSSC18C0169 80NSSC20M0188 | 4,369,085 1,604,643 37,500 30,726 12,703 9,956 6,064,613 | |
| Total National Aeronautics and Space Administration | | 6,021,359 | 241,744 | | | 6,263,103 | - |
| National Foundation on the Arts and the Humanities Promotion of the Arts_Grants to Organizations and Individuals 45.024 Total | 45.024 | 266 266 | <u>-</u> | | | 266 266 | |
| Total National Foundation on the Arts and the Humanities | | 266 | | | | 266 | <u>-</u> |
| National Science Foundation Engineering Grants Engineering Grants Engineering Grants Engineering Grants Engineering Grants 47.041 Total | 47.041 47.041 47.041 47.041 47.041 | 181,481 - - - - - 181,481 | 100,935 71,255 42,384 20,985 235,559 | GEORGIA INSTITUTE OF TECHNOLOGY AL METRICS, LLC ROWAN UNIVERSITY BOSTON UNIVERSITY MEDICAL CAMPUS | 1643289 IIP-20232534 ECCS-1903466 4500003100 | 181,481 100,935 71,255 42,384 20,985 417,040 | 25,000 |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|--|---|---|---|---|---|----------------------------|
| Mathematical and Physical Sciences 47.049 Total | 47.049 | 871,092 871,092 | | | | 871,092 871,092 | <u> </u> |
| Geosciences 47.050 Total | 47.050 | 387,040 387,040 | | | | 387,040 387,040 | 248 248 |
| Computer and Information Science and Engineering 47.070 Total | 47.070 | 678,789 678,789 | | | | 678,789 678,789 | 40,142 40,142 |
| Biological Sciences Biological Sciences 47.074 Total | 47.074 47.074 | 1,822,147 - 1,822,147 | 116,704 116,704 | BROWN UNIVERSITY | IOS-1923445 | 1,822,147 116,704 1,938,851 | 63,179 23,841 87,020 |
| Social, Behavioral, and Economic Sciences 47.075 Total | 47.075 | 33,947 33,947 | | | | 33,947 33,947 | |
| Education and Human Resources Education and Human Resources Education and Human Resources 47.076 Total | 47.076 47.076 47.076 | 1,476,621 - - 1,476,621 | 103,513 11 103,524 | UNIVERSITY OF ALABAMA IN TUSCALOOSA SKAGIT VALLEY COLLEGE | HRD1619659 1617-184 | 1,476,621 103,513 11 1,580,145 | 161,120 |
| International Science and Engineering (OISE) International Science and Engineering (OISE) 47.079 Total | 47.079 47.079 | 17,975 - 17,975 | (32,557) (32,557) | MEDICAL UNIVERSITY OF SOUTH CAROLINA | NSF 15-517 | 17,975 (32,557) (14,582) | |
| Office of Integrative Activities 47.083 Total | 47.083 47.083 47.083 47.083 47.083 47.083 | 86,393 - 86,393 | 556,158 131,809 104,577 - 42,020 25,809 860,373 | UNIVERSITY OF ALABAMA IN HUNTSVILLE LOUISIANA STATE UNIVERSITY CLEMSON UNIVERSITY UNIVERSITY OF SOUTHERN MISSISSIPPI UNIVERSITY OF THE VIRGIN ISLANDS | OIA-1655280 OIA-1632891 OIA-1632881 OIA-1632825 OIA-1946412 | 556,158 131,809 104,577 86,393 42,020 25,809 | |
| Total National Science Foundation | | 5,555,485 | 1,283,603 | | | 6,839,088 | 313,530 |
| Department of Veterans Affairs Contract - Intergovernmental Personnel Agreements Contract #VA247-17-C-0209 Contract #36C24720P1328 BASE Contract #36C24221D0018 Contract #A GILMORE Contract #36C24720P1379 Contract #36C24720P1297 Contract #36C24718P2511 64.RD Total | 64.RD 64.RD 64.RD 64.RD 64.RD 64.RD 64.RD 64.RD | 3,145,343 319,202 20,284 12,768 6,308 2,467 128 (570) 3,505,930 | - - - - - - - - | | | 3,145,343 319,202 20,284 12,768 6,308 2,467 128 (570) 3,505,930 | <u>_</u> |
| Total Department of Veterans Affairs | | 3,505,930 | | | | 3,505,930 | = |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|--|--|--|---|---|--|----------------------------|
| Department of Energy Office of Science Financial Assistance Program Office of Science Financial Assistance Program Office of Science Financial Assistance Program 81.049 Total Fossil Energy Research and Development 81.089 Total Stewardship Science Grant Program | 81.049 81.049 81.049 81.089 | 1,066,243 - - 1,066,243 - - - 149,357 | 50,513 28,406 78,919 34,613 34,613 | ARIZONA STATE UNIVERSITY APPLIED DIAMOND INC. SOUTHERN STATES ENERGY BOARD | DE-SC0021230 DE-SC0020499 DE-FE0031888 | 1,066,243 50,513 28,406 1,145,162 34,613 34,613 | 122,364 |
| 81.112 Total Predictive Science Academic Alliance Program 81.124 Total Contract 81.RD Total | 81.124 81.RD | 149,357 | 104,960 104,960 25,228 25,228 | UNIVERSITY OF NEW MEXICO UNIVERSITY OF CALIFORNIA LAWREN LIVERMORE NATL LAB | PSAAP-III (FIC) DE-AC52-07NA27644 | 149,357 104,960 104,960 25,228 25,228 | |
| Total Department of Education Education Research, Development and Dissemination 84.305 Total Total Department of Education | 84.305 | 1,215,600 159,218 159,218 159,218 | 243,720 | | | 1,459,320 159,218 159,218 159,218 | 122,364 |
| Department of Health and Human Services Global AIDS Global AIDS Global AIDS Global AIDS 93.067 Total Chronic Diseases: Research, Control, and Prevention 93.068 Total | 93.067 93.067 93.067 93.067 93.068 | 696,378 696,378 | 71,985 38,138 9,686 3,129 122,938 | CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA | 5HU2GGH001920-05-00 6NU2GGH002251-01-00 5NU2GGH001920-05-00 1NU2GGH001920-01-S01 | 71,985 38,138 9,686 3,129 122,938 696,378 | 50,103 50,103 |
| Family Smoking Prevention and Tobacco Control Act Regulatory Research 93.077 Total Blood Disorder Program: Prevention, Surveillance, and | 93.077 | 16,067 16,067 | <u>-</u> | | | 16,067 16,067 | <u> </u> |
| Research Blood Disorder Program: Prevention, Surveillance, and Research Blood Disorder Program: Prevention, Surveillance, and Research 93.080 Total | 93.080 93.080 93.080 | 115,771 | 39,095 2,100 41,195 | HEMOPHILIA OF GEORGIA INC HEMOPHILIA OF GEORGIA INC | NU27DD000020-01-00 5NU27DD001155-05-00 | 115,771 39,095 2,100 156,966 | <u>-</u> |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|---|--|-------------------------------|--|---|---|--|----------------------------|
| Food and Drug Administration_Research Food and Drug Administration_Research Food and Drug Administration Research | 93.103 93.103 93.103 | - 87,343 | 268,407 - (1,790) | YALE UNIVERSITY NEW YORK PRESBYTERIAN HOSPITAL-WEILL CORNELL MEDIC | 5U01FD005938-05 5U01FD005478-04 | 268,407 87,343 (1,790) | 11,391 |
| 93.103 Total | 93.103 | 87,343 | 266,617 | NEW YORK PRESENTERIAN HOSPITAL-WEILE CORNELL MEDIC | 5001FD005476-04 | 353,960 | 11,391 |
| Environmental Health Environmental Health | 93.113 93.113 | 7,003,890 | 25,658 | WAYNE STATE UNIVERSITY | 2R01ES022606-06 | 7,003,890 25,658 | 1,040,797 |
| 93.113 Total | | 7,003,890 | 25,658 | | | 7,029,548 | 1,040,797 |
| Oral Diseases and Disorders Research | 93.121 93.121 93.121 93.121 93.121 | 7,592,540 - - - - | 63,057 30,167 28,211 16,818 | UNIVERSITY OF PUERTO RICO OREGON HEALTH & SCIENCES UNIVERSITY KAISER FOUNDATION RESEARCH INSTITUTE KAISER FOUNDATION RESEARCH INSTITUTE | R01DE028195 5R01DE028329-04 1U01DE028727-01 5U01DE028727-03 | 7,592,540 63,057 30,167 28,211 16,818 | 3,572,619 |
| Oral Diseases and Disorders Research 93.121 Total | 93.121 93.121 93.121 93.121 93.121 | 7,592,540 | 14,528 11,145 5,996 5,861 (2,924) 172,859 | HENNEPIN HEALTH & SCIENCES UNIVERSITY OREGON HEALTH & SCIENCES UNIVERSITY OREATV MICROTECH, INC. UNIVERSITY OF UTAH UNIVERSITY OF ROCHESTER | UG3DE029973 7R01DE022350-08 1R41DE022475-01A1 5R01DE027493-04 1R01DE027245-01 | 14,528 11,145 5,996 5,861 (2,924) 7,765,399 | 3,585,350 |
| Injury Prevention and Control Research and State and Community Based Programs 93.136 Total | 93.136 | 410,235 410,235 | | | | 410,235 410,235 | |
| Community Programs to Improve Minority Health Grant Program 93.137 Total | 93.137 | 229,456 229,456 | | | | 229,456 229,456 | <u>-</u> |
| NIEHS Hazardous Waste Worker Health and Safety Training NIEHS Hazardous Waste Worker Health and Safety | 93.142 | (183) | - | | | (183) | |
| Training 93.142 Total | 93.142 | (183) | (1,279) | ALABAMA FIRE COLLEGE | 3U45ES006155-29S1 | (1,279) (1,462) | |
| NIEHS Superfund Hazardous Substances_Basic Research and Education 93.143 Total | 93.143 | 1,634,485 1,634,485 | | | | 1,634,485 1,634,485 | 133,991 133,991 |
| AIDS Education and Training Centers 93.145 Total | 93.145 | | 82,392 82,392 | VANDERBILT UNIVERSITY MEDICAL CENTER | 5 U1OHA30535-05-00 | 82,392 82,392 | |
| COVID-19 Coordinated Services and Access to Research for Women, Infants, Children, and Youth 93.153 Total | 93.153 | (218) | | | | (218) | |
| Human Genome Research Human Genome Research Human Genome Research Human Genome Research Human Genome Research 93.172 Total | 93.172 93.172 93.172 93.172 93.172 | 1,373,314 | 418,998 170,488 146,285 (3,403) 732,368 | HUDSON ALPHA INSTITUTE FOR BIOTECHNOLOGY HARVARD MEDICAL - SCHEPHENS EYE RESEARCH HUDSON ALPHA INSTITUTE FOR BIOTECHNOLOGY HUDSON ALPHA INSTITUTE FOR BIOTECHNOLOGY | 5UO1HG007301-07 2U01HG007530-05 5UO1HG007301-08 5U01HG007301-06 | 1,373,314 418,998 170,488 146,285 (3,403) 2,105,682 | 33,692 |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|------------------|------------|--------------------|--|---------------------------------------|-----------------------|----------------------------|
| Research Related to Deafness and Communication | | | | | | | |
| Disorders Research Related to Deafness and Communication | 93.173 | 848,179 | - | | | 848,179 | 273,416 |
| Disorders Research Related to Deafness and Communication | 93.173 | - | 70,914 | UNIVERSITY OF ALABAMA IN TUSCALOOSA | R01DC016303 | 70,914 | |
| Disorders | 93.173 | | 38,282 | UNIVERSITY OF MINNESOTA | 1R01DC017613-01A1 | 38,282 | |
| 93.173 Total | | 848,179 | 109,196 | | | 957,375 | 273,416 |
| Research and Training in Complementary and Alternative Medicine Research and Training in Complementary and Alternative | 93.213 | 1,005,298 | - | | | 1,005,298 | 24,534 |
| Medicine Research and Training in Complementary and Alternative | 93.213 | - | 84,494 | UNIVERSITY OF MINNESOTA | 5R01HL150053-02 | 84,494 | |
| Medicine | 93.213 | - | 41,557 | NORTHWESTERN UNIVERSITY | 5R01HL149866-02 | 41,557 | |
| Research and Training in Complementary and Alternative Medicine 93.213 Total | 93.213 | 1,005,298 | 20,757 146,808 | HARVARD COLLEGE | 5R01ES022981-06 | 20,757 1,152,106 | 24,534 |
| Family Planning_Services 93.217 Total | 93.217 | | 154,033 154,033 | ALABAMA DEPT OF PUBLIC HEALTH | C00119095B-FPHPA006461 | 154,033 154,033 | |
| Research on Healthcare Costs, Quality and Outcomes | 93.226 | 683,356 | - | | | 683,356 | 22,186 |
| Research on Healthcare Costs, Quality and Outcomes Research on Healthcare Costs, Quality and Outcomes | 93.226 93.226 | - | 49,391 3,801 | UNIVERSITY OF ARKANSAS FOR MEDICAL STUDIES UNIVERSITY OF ALABAMA IN TUSCALOOSA | 1R01HS025703-01A1 1R21HS026571-01 | 49,391 3,801 | |
| Research on Healthcare Costs, Quality and Outcomes | 93.226 | - | (142) | INDIANA UNIVERSITY | 5R01HS025411-03 | (142) | |
| 93.226 Total | | 683,356 | 53,050 | | | 736,406 | 22,186 |
| National Center on Sleep Disorders Research | 93.233 | 972,975 | - | | | 972,975 | 428,553 |
| National Center on Sleep Disorders Research 93.233 Total | 93.233 | 972,975 | 23,950 23,950 | NORTHWESTERN UNIVERSITY | 1R01HL152442-01 | 23,950 996,925 | 428,553 |
| Mental Health Research Grants | 93.242 | 10,927,834 | - | | | 10,927,834 | 1,663,476 |
| Mental Health Research Grants | 93.242 | - | 132,456 | UNIVERSITY OF PITTSBURGH | 1R01MH115754-01A1 | 132,456 | |
| Mental Health Research Grants | 93.242 | - | 99,676 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 5R34MH119962-03 | 99,676 | |
| Mental Health Research Grants | 93.242 | - | 64,340 | BROWN UNIVERSITY | 1R01MH112386-01A1 | 64,340 | |
| Mental Health Research Grants Mental Health Research Grants | 93.242 93.242 | - | 40,051 14,864 | VANDERBILT UNIVERSITY MEDICAL CENTER MASSACHUSETTS GENERAL HOSPITAL | 5R01MH113438-03 | 40,051 14,864 | |
| Mental Health Research Grants | 93.242 | - | 14,860 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 5R01MH112385-01 5R34MH118058-03 | 14,860 | |
| Mental Health Research Grants | 93.242 | | 13,611 | CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA | 5U01MH115495-04 | 13,611 | |
| Mental Health Research Grants | 93.242 | _ | 13,576 | JOHNS HOPKINS UNIVERSITY | 5R25MH080661-13 | 13,576 | |
| Mental Health Research Grants | 93.242 | _ | 12,271 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 5U01MH110925-05 | 12,271 | |
| Mental Health Research Grants | 93.242 | _ | 10,185 | CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA | 5U01MH115495-03 | 10,185 | |
| Mental Health Research Grants | 93.242 | - | 9,375 | YALE UNIVERSITY | 2U19MH108206-05 | 9,375 | |
| Mental Health Research Grants | 93.242 | - | 9,101 | BROWN UNIVERSITY | 2R01MH112386-04 | 9,101 | |
| Mental Health Research Grants | 93.242 | - | 6,830 | UNIVERSITY OF CHICAGO | 1R01MH125744-01 | 6,830 | |
| Mental Health Research Grants | 93.242 | - | 4,039 | MERIDIAN BIOTECH, LLC | 1R41MH119793-01A1 | 4,039 | |
| Mental Health Research Grants | 93.242 | - | 2,628 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 5U01MH110925-04 | 2,628 | |
| Mental Health Research Grants | 93.242 | - | 1,177 | SOUTHERN RESEARCH INSTITUTE | 7R01MH110681-04 | 1,177 | |
| Mental Health Research Grants | 93.242 | | 334 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 5U01MH110925-03S1 | 334 | |
| 93.242 Total | | 10,927,834 | 449,374 | | | 11,377,208 | 1,663,476 |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|---|------------------|-----------|-----------------|--|---------------------------------------|-----------------------|----------------------------|
| Occupational Safety and Health Program | 93.262 | 1,586,722 | - | | | 1,586,722 | 423,193 |
| Occupational Safety and Health Program Occupational Safety and Health Program | 93.262 93.262 | - | 12,531 4,331 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 5T42OH010278-09-00 | 12,531 4,331 | |
| 93.262 Total | 93.202 | 1,586,722 | 16,862 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2T42OH010278-08-00 | 1,603,584 | 423,193 |
| | | | | | | | :==;:== |
| Alcohol Research Programs | 93.273 | 942,903 | - | | | 942,903 | 280,122 |
| Alcohol Research Programs | 93.273 | - | 47,590 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 7R34AA027200-03 | 47,590 | |
| Alcohol Research Programs | 93.273 | - | 757 | UNIVERSITY OF WASHINGTON | 5U01AA020793-08 | 757 | |
| Alcohol Research Programs | 93.273 | | 15 | UNIVERSITY OF BRISTOL | 1U01AA026209-01 | 15 | |
| 93.273 Total | | 942,903 | 48,362 | | | 991,265 | 280,122 |
| Drug Abuse and Addiction Research Programs | 93.279 | 3,715,365 | _ | | | 3,715,365 | 515,825 |
| Drug Abuse and Addiction Research Programs | 93.279 | - | 139,491 | YALE UNIVERSITY | 1UG3DA047003 | 139,491 | 010,020 |
| Drug Abuse and Addiction Research Programs | 93.279 | _ | 48,325 | UNIVERSITY OF WASHINGTON | 5R01DA047045-02 | 48,325 | |
| Drug Abuse and Addiction Research Programs | 93.279 | _ | 27,321 | NORTHWESTERN UNIVERSITY | 1R01HL152442-01 | 27,321 | |
| Drug Abuse and Addiction Research Programs | 93.279 | _ | 12,686 | THE ROYAL INSTITUTION OF THE ADVANCEMENT OF LEARNI | 2R01DA037911-06A1 | 12,686 | |
| Drug Abuse and Addiction Research Programs | 93.279 | _ | 12,602 | MASSACHUSETTS GENERAL HOSPITAL | 1R01DA050482-01A1 | 12,602 | |
| Drug Abuse and Addiction Research Programs | 93.279 | _ | 6.048 | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 5UG1DA013727-22 | 6,048 | |
| Drug Abuse and Addiction Research Programs | 93.279 | _ | 4.067 | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2UG1DA013727-21 | 4,067 | |
| Drug Abuse and Addiction Research Programs | 93.279 | _ | 76 | ALABAMA STATE UNIVERSITY | 1R15DA045564-01 | 76 | |
| 93.279 Total | | 3,715,365 | 250,616 | | | 3,965,981 | 515,825 |
| The Affordable Care Act: Centers for Disease Control and | | | | | | | |
| Prevention Investigations and Technical Assistance | 93.283 | 580,713 | | | | 580,713 | |
| 93.283 Total | 93.203 | 580,713 | | | | 580,713 | |
| 93.203 Total | | 360,713 | | | | 360,713 | <u>-</u> |
| Discovery and Applied Research for Technological | | | | | | | |
| Innovations to Improve Human Health | 93.286 | 461,612 | - | | | 461,612 | 69,254 |
| Discovery and Applied Research for Technological | | | | | | | |
| Innovations to Improve Human Health | 93.286 | | 13,593 | UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER | 7R01EB020125-06 | 13,593 | |
| 93.286 Total | | 461,612 | 13,593 | | | 475,205 | 69,254 |
| Minority Health and Health Disparities Research | 93.307 | 4,097,625 | _ | | | 4,097,625 | 514,660 |
| Minority Health and Health Disparities Research | 93.307 | -,001,020 | 20,299 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 5U01MD011279-05 | 20,299 | 0.1.,000 |
| Minority Health and Health Disparities Research | 93.307 | _ | 15,596 | UNIVERSITY OF PENNSYLVANIA | 5R01MD013558-04 | 15,596 | |
| Minority Health and Health Disparities Research | 93.307 | _ | 14,055 | UNIVERSITY OF PENNSYLVANIA | 5R01MD013558 | 14,055 | |
| Minority Health and Health Disparities Research | 93.307 | _ | 8,283 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 1R01MD016834-01 | 8,283 | |
| Minority Health and Health Disparities Research | 93.307 | - | 6,350 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 5R01MD011609-04 | 6,350 | |
| Minority Health and Health Disparities Research | 93.307 | - | 3,488 | UNIVERSITY OF PITTSBURGH | 5R01MD009118-02 | 3,488 | |
| Minority Health and Health Disparities Research | 93.307 | - | (3,415) | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 5R01MD011609-03 | (3,415) | |
| 93.307 Total | | 4,097,625 | 64,656 | | | 4,162,281 | 514,660 |
| | | | | | | | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|---|--------------------------------------|---------------------------|---------------------------------|--|--|----------------------------------|----------------------------|
| Trans-NIH Research Support Trans-NIH Research Support COVID-19 Trans-NIH Research Support | 93.310 93.310 93.310 | 1,780,928 - 283,482 | - 475,168 - | BALL STATE UNIVERSITY | 7U01AR071133-05 | 1,780,928 475,168 283,482 | 1,380,682 |
| Trans-NIH Research Support Trans-NIH Research Support Trans-NIH Research Support Trans-NIH Research Support | 93.310 93.310 93.310 93.310 | - - - | 48,394 15,881 16 (782) | YALE UNIVERSITY BRIGHAM & WOMENS HOSPITAL UNIVERSITY OF IBADAN YALE UNIVERSITY | 5UG3NS115597-02 7U01CA242109-03 1U54HG007479-01 1UG3NS115597-01 | 48,394 15,881 16 (782) | |
| Trans-NIH Research Support Trans-NIH Research Support 93.310 Total | 93.310 93.310 | 2,064,410 | (2,324) (15,235) 521,118 | REGENTS OF THE UNIVERSITY OF COLORADO MEDICAL UNIVERSITY OF SOUTH CAROLINA | 3R01DK111622-02\$1 1UG30D023316-01 | (2,324) (15,235) 2,585,528 | 1,380,682 |
| Rare Disorders: Research, Surveillance, Health Promotion, and Education 93.315 Total | 93.315 | 81,060 81,060 | | | | 81,060 81,060 | |
| COVID-19 Protecting and Improving Health Globally 93.318 Total | 93.318 | 948,439 948,439 | | | | 948,439 948,439 | |
| National Center for Advancing Translational Sciences COVID-19 National Center for Advancing Translational Sciences | 93.350 93.350 | 20,247,477 774,117 | - | | | 20,247,477 774,117 | 5,372,226 |
| National Center for Advancing Translational Sciences National Center for Advancing Translational Sciences National Center for Advancing Translational Sciences | 93.350 93.350 93.350 | - | 132,001 45,699 26,654 | UNIVERSITY OF MASSACHUSETTS WORCESTER NORTHWESTERN UNIVERSITY UNIVERSITY OF IOWA | 5U01TR001812-05 5U01TR001806-04 5UL1TR002537-03 | 132,001 45,699 26,654 | |
| National Center for Advancing Translational Sciences | 93.350 93.350 93.350 | - | 26,258 (1,325) (2,942) | UNIVERSITY OF PITTSBURGH BLONDIN BIO SCIENCE LLC | 5UL1TR001857-05 1R43TR001283-01 | 26,258 (1,325) (2,942) | |
| National Center for Advancing Translational Sciences 93.350 Total | 93.350 | 21,021,594 | (4,091) 222,254 | UNIVERSITY OF MASSACHUSETTS WORCESTER OREGON HEALTH & SCIENCES UNIVERSITY | 5U01TR001812-04 5U24TR002306-03 | (4,091) 21,243,848 | 5,372,226 |
| Research Infrastructure Programs Research Infrastructure Programs 93.351 Total | 93.351 93.351 | 2,211,102 | 42,513 42,513 | TECHNOLOGY COMMERCIALIZATION PARTNERS, LLC | 1R41OD027206-01 | 2,211,102 42,513 2,253,615 | |
| 21st Century Cures Act - Beau Biden Cancer Moonshot 21st Century Cures Act - Beau Biden Cancer Moonshot 93.353 Total | 93.353 93.353 | 986,533 - 986,533 | 39,351 39,351 | CASE WESTERN UNIVERSITY | 3P30CA043703-30S4 | 986,533 39,351 1,025,884 | 309,563 309,563 |
| Nursing Research Nursing Research Nursing Research | 93.361 93.361 93.361 | 1,824,611 | 92,642 53,016 | CASE WESTERN UNIVERSITY CASE WESTERN UNIVERSITY | 7R01NR018391-04 R01NR018391 | 1,824,611 92,642 53,016 | 369,154 |
| Nursing Research Nursing Research Nursing Research | 93.361 93.361 93.361 | : | 39,224 18,619 6,799 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK UNIVERSITY OF MINNESOTA DANA-FARBER CANCER INSTITUTE | 1R01NR019758-01 5R21NR019676-02 5R01NR016720-04 | 39,224 18,619 6,799 | |
| Nursing Research 93.361 Total | 93.361 | 1,824,611 | 3,519 213,819 | RHODE ISLAND MEMORIAL HOSPITAL | 5R01NR014782-03 | 3,519 2,038,430 | 369,154 |
| National and State Tobacco Control Program 93.387 Total | 93.387 | 398,693 398,693 | | | | <u>398,693</u> <u>398,693</u> | 21,585 21,585 |

| | | | | | Contract/Award or | Total | Passed to |
|---|------------------|-----------|--------------------|--|--------------------------------------|----------------------|---------------|
| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Pass-Through Num | Expenditures | Subrecipients |
| | | | | | | | |
| Conservation Description | 02.202 | 0.074.040 | | | | 0.274.040 | 004 007 |
| Cancer Cause and Prevention Research Cancer Cause and Prevention Research | 93.393 93.393 | 8,371,040 | 070 440 | BARTHOUTH COLUED | | 8,371,040 278,418 | 921,287 |
| Cancer Cause and Prevention Research | 93.393 | - | 278,418 184.693 | DARTMOUTH COLLEGE UNIVERSITY OF MASSACHUSETTS WORCESTER | 1R01CA225792-01A1 5R01CA218008-02 | 184,693 | |
| Cancer Cause and Prevention Research | 93.393 | - | 124,000 | UNIVERSITY OF MASSACHUSETTS WORCESTER UNIVERSITY OF TENNESSEE IN MEMPHIS | 1R01CA242737-01A1 | 124,000 | |
| Cancer Cause and Prevention Research | 93.393 | - | 105,685 | UNIVERSITY OF TENNESSEE IN MEMPHIS UNIVERSITY OF TENNESSEE IN MEMPHIS | 2R01CA242737-01A1 | 105,685 | |
| Cancer Cause and Prevention Research | 93.393 | | 95,643 | FRED HUTCHINSON CANCER RESEARCH CENTER | 5R01CA242737-02 5R01CA213130-04 | 95,643 | |
| Cancer Cause and Prevention Research | 93.393 | | 82.447 | UNIVERSITY OF KANSAS MEDICAL CENTER | 1R01CA226838-03 | 82.447 | |
| Cancer Cause and Prevention Research | 93.393 | _ | 36,536 | VANDERBILT UNIVERSITY MEDICAL CENTER | 5R01CA190612-06 | 36.536 | |
| Cancer Cause and Prevention Research | 93.393 | _ | 36,258 | DARTMOUTH COLLEGE | 6R01CA229197-02 | 36,258 | |
| Cancer Cause and Prevention Research | 93.393 | _ | 23,100 | UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE | 5U01CA235507-02 | 23,100 | |
| Cancer Cause and Prevention Research | 93.393 | _ | 15,687 | DUKE UNIVERSITY | 7R37CA233777-02 | 15,687 | |
| Cancer Cause and Prevention Research | 93.393 | _ | 8,251 | FRED HUTCHINSON CANCER RESEARCH CENTER | 5R01CA211996-04 | 8,251 | |
| Cancer Cause and Prevention Research | 93.393 | _ | 3,549 | WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE | 5R01CA199167-03 | 3,549 | |
| Cancer Cause and Prevention Research | 93.393 | _ | 800 | CHILDREN'S HOSPITAL OF PHILADELPHIA | 5R01CA211996-02 | 800 | |
| Cancer Cause and Prevention Research | 93.393 | - | (1,268) | VANDERBILT UNIVERSITY MEDICAL CENTER | 5P01CA02882-33 | (1,268) | |
| 93.393 Total | | 8,371,040 | 993,799 | | | 9,364,839 | 921,287 |
| Cancer Detection and Diagnosis Research | 93.394 | 4,845,796 | _ | | | 4,845,796 | 441,461 |
| Cancer Detection and Diagnosis Research | 93.394 | · · · · | 469,818 | PROTEOGENOMICS RESEARCH INSTITUTE FOR SYSTEMS MEDI | 5P01CA221775-05 | 469,818 | |
| COVID-19 Cancer Detection and Diagnosis Research | 93.394 | 355,895 | | | | 355,895 | |
| Cancer Detection and Diagnosis Research | 93.394 | · - | 34,323 | UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO | 5R01CA237533-02 | 34,323 | |
| Cancer Detection and Diagnosis Research | 93.394 | - | 22,326 | UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO | 1R01CA237533-01A1 | 22,326 | |
| Cancer Detection and Diagnosis Research | 93.394 | - | 21,252 | UNIVERSITY OF MARYLAND | 1R01CA228399-01A1 | 21,252 | |
| Cancer Detection and Diagnosis Research | 93.394 | - | 16,866 | UNIVERSITY OF BRITISH COLUMBIA | 1R01CA221918-01A1 | 16,866 | |
| Cancer Detection and Diagnosis Research | 93.394 | - | 7,594 | UNIVERSITY OF CALIFORNIA - BERKELEY | 5R01CA246695-02 | 7,594 | |
| Cancer Detection and Diagnosis Research | 93.394 | - | 4,550 | CHILDREN'S HOSPITAL OF PHILADELPHIA | R01CA193478-01A1 | 4,550 | |
| Cancer Detection and Diagnosis Research | 93.394 | - | 3,699 | MEMORIAL SLOAN KETTERING CANCER CENTER | 5R01CA235711-03 | 3,699 | |
| Cancer Detection and Diagnosis Research | 93.394 | - | 3,654 | MEMORIAL SLOAN KETTERING CANCER CENTER | 5R01CA235711-02 | 3,654 | |
| Cancer Detection and Diagnosis Research | 93.394 | - | 1,149 | UNIVERSITY OF MICHIGAN | 5U24CA086368-18 | 1,149 | |
| Cancer Detection and Diagnosis Research | 93.394 | - | 403 | UNIVERSITY OF MASSACHUSETTS WORCESTER | 1R01CA194787-01A1 | 403 | |
| Cancer Detection and Diagnosis Research | 93.394 | - | 218 | EMORY UNIVERSITY | 5R01CA203388-03 | 218 | |
| Cancer Detection and Diagnosis Research | 93.394 | | 66_ | NRG ONCOLOGY INC | 1U10CA180860-1 | 66 | |
| 93.394 Total | | 5,201,691 | 585,918 | | | 5,787,609 | 441,461 |
| Cancer Treatment Research | 93.395 | 3,602,620 | - | | | 3,602,620 | 258,769 |
| Cancer Treatment Research | 93.395 | - | 125,842 | CHILDREN'S HOSPITAL OF PHILADELPHIA | 5U10CA180886-07 | 125,842 | |
| Cancer Treatment Research | 93.395 | - | 99,849 | CHILDREN'S HOSPITAL OF PHILADELPHIA | 1UM1CA228823-01 | 99,849 | |
| Cancer Treatment Research | 93.395 | - | 84,531 | CHILDREN'S HOSPITAL OF PHILADELPHIA | 2U10CA180886 | 84,531 | |
| Cancer Treatment Research | 93.395 | - | 83,601 | SEATTLE CHILDREN'S HOSPITAL | 5R01CA225629-03 | 83,601 | |
| Cancer Treatment Research | 93.395 | - | 79,443 | TECHNOLOGY COMMERCIALIZATION PARTNERS, LLC | 1R43CA246883-01 | 79,443 | |
| Cancer Treatment Research | 93.395 | - | 75,956 | CHILDREN'S HOSPITAL OF PHILADELPHIA | 2U10CA180886-06 | 75,956 | |
| Cancer Treatment Research | 93.395 | - | 72,931 | JOHNS HOPKINS UNIVERSITY | UM1 CA137443 | 72,931 | |
| Cancer Treatment Research | 93.395 | - | 57,138 | CEDARS-SINAI MEDICAL CENTER | R01CA208851-05 | 57,138 | |
| Cancer Treatment Research | 93.395 | - | 21,735 | JOHNS HOPKINS UNIVERSITY | U01CA137443 | 21,735 | |
| Cancer Treatment Research | 93.395 | - | 18,675 | EASTERN COOPERATIVE ONCOLOGY GROUP | U10CA180820-06 | 18,675 | |
| Cancer Treatment Research | 93.395 | - | 13,316 | PUBLIC HEALTH INSTITUTE | 7U10CA180886-08 | 13,316 | |
| Cancer Treatment Research | 93.395 | - | 9,749 | TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER | 7R01CA219187-02 | 9,749 | |
| Cancer Treatment Research | 93.395 | - | 7,000 | NRG ONCOLOGY INC | 5U10CA180868-07 | 7,000 | |
| Cancer Treatment Research | 93.395 | - | 6,667 | UNIVERSITY OF SOUTH FLORIDA | 1R01CA244947-01 | 6,667 | |
| Cancer Treatment Research | 93.395 | - | 6,516 | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | U24CA055727 | 6,516 | |
| Cancer Treatment Research | 93.395 | - | 6,051 | SEATTLE CHILDREN'S HOSPITAL | 5R01CA175216-04 | 6,051 | |
| | | | | | | | |

| Cancer Treatment Research | Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|---------------------------|--------|-----------|--------------|--|---------------------------------------|-----------------------|----------------------------|
| Cancer Treatment Research | Cancer Treatment Research | 93 395 | _ | 5 864 | PUBLIC HEALTH INSTITUTE | U10CA180886 | 5 864 | |
| Cancer Treatment Research 93.385 - 5.105 NIG ONCO.COV INC 2010CA18088-08 5.105 Cancer Treatment Research 93.385 - 371 CHILDREN'S INSBERTAL BJICACASST72-08 584 Cancer Treatment Research 93.385 - 121 JUNE CHILDREN'S INSBERTAL BJICACASST72-08 124 CHILDREN'S INSBERTAL BJICACASST72-08 CHILDREN'S INSBERTAL BJICACASST74-08 CHILDREN'S INSBERTAL BJICACASST74-08 CHILDREN'S INSBERTAL BJICACASST74-08 CHILDREN'S INSBERTAL BJICACASST74-08 CHILDREN'S INSBERTAL | | | - | | | | | |
| Cancer Treatment Research | Cancer Treatment Research | 93.395 | _ | | | | · | |
| Cancer Treatment Research 93.395 - 371 CHILDRENT SOSPITAL OF PRILADELPHIA RESEARCH 124 Cancer Treatment Research 93.395 - (317) NRG ONCOLOGY NC UTICA18088 (317) NRG ONCOLOGY NC UTICA1808 NRG ONCOLOGY NC UTICA18088 (318) NRG ONCOLOGY NC UTICA1808 NRG ONCOLOGY NC UT | Cancer Treatment Research | | - | | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 5U24CA055727-26 | | |
| Cancer Treatment Research | Cancer Treatment Research | 93.395 | - | 371 | | R01CA212190-01A1 | 371 | |
| Cancer Treatment Research | Cancer Treatment Research | 93.395 | - | 124 | JOHNS HOPKINS UNIVERSITY | 5UM1CA137443-08 | 124 | |
| Cancer Treatment Research | Cancer Treatment Research | 93.395 | - | (317) | NRG ONCOLOGY INC | U10CA180868 | (317) | |
| Cancer Centers Support Grants 93.397 93.207 63.208 79.30 | Cancer Treatment Research | 93.395 | - | (877) | JOHNS HOPKINS UNIVERSITY | 5UM1CA137443 | (877) | |
| 93.996 Total Cancer Biology Research 93.96 | Cancer Treatment Research | 93.395 | - | (13,349) | CHILDREN'S HOSPITAL OF PHILADELPHIA | 1U10CA180886 | (13,349) | |
| Cancer Biology Research | Cancer Treatment Research | 93.395 | | (18,243) | CHILDREN'S HOSPITAL OF PHILADELPHIA | UM1CA097452 | (18,243) | |
| Cancer Biology Research | 93.395 Total | | 3,602,620 | 753,641 | | | 4,356,261 | 258,769 |
| Cancer Blokoy Research | | 93.396 | 4,606,844 | - | | | 4,606,844 | 266,266 |
| Cancer Biology Research | Cancer Biology Research | 93.396 | - | 277,027 | PENNSYLVANIA STATE UNIVERSITY (THE) | 1R01CA230628-01A1 | 277,027 | |
| Cancer Centers Support Grants 93.396 4.606,844 5383.689 4.909,713 266,266 26.000 26.00 | | 93.396 | - | 81,937 | UNIVERSITY OF MICHIGAN | 2P01CA093000-16 | 81,937 | |
| 3.396 Total 4,606,844 383,869 3,387 2,20,466 383,869 3,397 3,266,266 362,266 | | | - | 13,888 | PENNSYLVANIA STATE UNIVERSITY (THE) | 1R01CA242021-01A1 | 13,888 | |
| Cancer Centers Support Grants 93.397 9.20,466 474,772 Cancer Centers Support Grants 93.397 - 470,840 Cancer Centers Support Grants 93.397 - 400,840 Cancer Centers Support Grants 93.397 - 79,936 Cancer Centers Support Grants 93.397 - 61,331 Cancer Center Support Grants 93.398 1,780,333 - 70,701 Cancer Research Manpower 93.398 1,780,333 - 70,701 Cancer Control 93.399 - 27,831 Cancer Control 93.399 - 27,831 Cancer Control 93.399 - 12,716 Cancer Control 93.399 - 12,725 Cancer Control 93.399 Cancer Control 93.399 Cancer Control 93.399 Cancer Control 93.399 Cancer | | 93.396 | | | UNIVERSITY OF CALIFORNIA IN DAVIS | 1R01CA250338-01 | | |
| Cancer Centers Support Grants 93.397 - 40.840 BECMANN RESEARCH INSTITUTE OF THE CITY OF HOPE \$950CA107399-113 400,840 63.286 63.286 63.286 63.397 - 40.840 82.600 82.6 | 93.396 Total | | 4,606,844 | 383,869 | | | 4,990,713 | 266,266 |
| Cancer Centlers Support Grants 93,397 - 400,840 826/MAN RESEARCH INSTITUTE OF THE CITY OF HOPE SPB0CA107398-13 400,840 63,286 62,28 | | | 9,220,466 | - | | | | 357,265 |
| Cancer Centers Support Grants 93.397 - 79.936 61.331 1.000 | | | - | , | JOHNS HOPKINS UNIVERSITY | | , | |
| Cancer Centlers Support Grants 93.397 - 61.331 17.097 17.097 17.097 19.3397 17.097 19.3397 17.097 19.3398 1.780.333 - 1.780.333 11.211 1.780.333 11.211 1.780.333 11.211 1.780.333 | | | - | | | | | |
| Cancer Centers Support Grants 93.397 9,220.466 10.33.976 17,097 9,220.466 1.033.976 1.033.976 1.0254.442 498.679 1.0254.442 498.679 1.0254.442 498.679 1.0254.442 498.679 1.0254.442 498.679 1.0254.442 498.679 1.0254.442 498.679 1.0254.442 498.679 1.0254.442 498.679 1.0254.442 498.679 1.0254.442 498.679 1.0254.442 498.679 1.0254.442 498.679 1.0254.442 498.679 1.0254.442 | ••• | | - | ., | | | | 78,128 |
| 93.397 Total 9.220,466 1,033,976 Cancer Research Manpower 93.398 1,780,333 - 1,780,333 - 1,780,333 11,211 93.398 Total 93.399 - 27,891 1,780,333 11,211 Cancer Control 93.399 - 27,891 CHILDREN'S HOSPITAL OF PHILADELPHIA 5UG1CA189955-07 27,891 CAncer Control 93.399 - 27,325 OREGON HEALTH & SCIENCES UNIVERSITY 5UG1CA189974-07 27,325 CHILDREN'S HOSPITAL OF PHILADELPHIA 2UG1CA189987-07 12,716 CAncer Control 93.399 - 8,335 CHILDREN'S HOSPITAL OF PHILADELPHIA 2UG1CA189985-08 8,335 CANCER CONTROL 93.399 - 8,335 CHILDREN'S HOSPITAL OF PHILADELPHIA 2UG1CA189985-08 8,335 CANCER CONTROL 93.399 - 6,152 CANCER CONTROL 93.399 - 6,152 CANCER CONTROL 93.399 - 7, (2,337) 93 | | | - | | | | | |
| Cancer Control 93.398 1,780,333 11,211 | | 93.397 | | | INDIANA UNIVERSITY | 5U54CA196519-05 | | |
| 1,780,333 1,78 | 93.397 Total | | 9,220,466 | 1,033,976 | | | 10,254,442 | 498,679 |
| Cancer Control | • | 93.398 | | | | | | |
| Cancer Control 93.399 - 27,325 OREGON HEALTH & SCIENCES UNIVERSITY 5UG1CA189974-07 27,325 OREGON HEALTH & SCIENCES UNIVERSITY 5UG1CA189974-07 12,716 OREGON HEALTH & SCIENCES UNIVERSITY 5UG1CA189987-07 12,716 OREGON HEALTH & SCIENCES UNIVERSITY 5UG1CA189987-08 6,152 OREGON HEALTH & SCIENCES UNIVERSITY 2UG1CA189987-08 0,152 OREGON HEALTH & SCIENCES UNIVERSITY 2UG1CA189974-06 (2,337) OREGON HEALTH & SCIENCES UNIVERSITY | 93.398 Total | | 1,780,333 | | | | 1,780,333 | 11,211 |
| Cancer Control 93.399 - 12,716 Cancer Control 93.491 - 12,716 Cancer Co | | | - | | | 5UG1CA189955-07 | | |
| Cancer Control 93.399 - 8,935 CHILDREN'S HOSPITAL OF PHILADELPHIA 2UG1CA189955-06 8,935 CANCER CONTROL 93.399 - 6,152 CANCER CONTROL 93.399 - (2,337) 93.399 Total 93.399 - (2,337) - (2,337) 93.399 Total 93.421 - 59,084 93.421 Total 93.421 Total 93.421 - 59,084 - (2,337) - | | | - | , | | | , | |
| Cancer Control 93.399 - 0,152 (2,337) ORGONICOGY INC SUGICA189867-08 0,152 (2,337) ORGONIESTITY 2UGICA189974-06 (2,337) ORGONIESTITY ORGONIES | | | - | | | | | |
| Cancer Control 93.399 - (2.337) | | | - | | | | · | |
| 93.399 Total | | | - | | | | | |
| Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health 93.421 | | 93.399 | | | OREGON HEALTH & SCIENCES UNIVERSITY | 2UG1CA189974-06 | | |
| National Partnerships to Improve and Protect the Nation's Health 93.421 - 59,084 UNIVERSITY OF VERMONT COLLEGE OF MEDICINE 6NU380T000280-03-02 59,084 - 93.421 Total - 59,084 - 59,084 - Networking2Save: CDCs National Network Approach to Preventing and Controlling Tobacco-related Cancers in Special Populations 93.431 - 21,649 NATIONAL AFRICAN AMERICAN TOBACCO PREVENTION NETW: NU58DP006488 21,649 - | 93.399 Total | | | 80,682 | | | 80,682 | - |
| Health 93.421 - 59,084 UNIVERSITY OF VERMONT COLLEGE OF MEDICINE 6NU380T000280-03-02 59,084 - | | | | | | | | |
| 93.421 Total - 59,084 - 59,084 Networking2Save: CDCs National Network Approach to Preventing and Controlling Tobacco-related Cancers in Special Populations 93.431 - 21,649 NATIONAL AFRICAN AMERICAN TOBACCO PREVENTION NETW: NU58DP006488 21,649 | | 00.404 | | 50.05 | | | 50. | |
| Networking2Save: CDCs National Network Approach to Preventing and Controlling Tobacco-related Cancers in Special Populations 93.431 - 21,649 NATIONAL AFRICAN AMERICAN TOBACCO PREVENTION NETWO NU58DP006488 21,649 | | 93.421 | | | UNIVERSITY OF VERMONT COLLEGE OF MEDICINE | 6NU38OT000280-03-02 | | |
| Preventing and Controlling Tobacco-related Cancers in Special Populations 93.431 21,649 NATIONAL AFRICAN AMERICAN TOBACCO PREVENTION NETWO NU58DP006488 21,649 | 93.421 Total | | | 59,084 | | | 59,084 | <u> </u> |
| Special Populations 93.431 21,649 NATIONAL AFRICAN AMERICAN TOBACCO PREVENTION NETWO NU58DP006488 21,649 | | | | | | | | |
| | | | | | | | | |
| 93.431 lotal | | 93.431 | | | NATIONAL AFRICAN AMERICAN TOBACCO PREVENTION NETWO | NU58DP006488 | | |
| | 93.431 Total | | | 21,649 | | | 21,649 | <u> </u> |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|--|------------|--|--|---|--|----------------------------|
| ACL National Institute on Disability, Independent Living, and Rehabilitation Research ACL National Institute on Disability, Independent Living, | 93.433 | 3,481,885 | - | | | 3,481,885 | 693,443 |
| and Rehabilitation Research | 93.433 | - | 67,277 | UNIVERSITY OF CHICAGO | 90REGE0005-01-00 | 67,277 | 37,812 |
| ACL National Institute on Disability, Independent Living, and Rehabilitation Research 93.433 Total | 93.433 | 3,481,885 | 21,763 89,040 | CRAIG HOSPITAL | 90DPTB0017 | 21,763 3,570,925 | 731,255 |
| Every Student Succeeds Act/Preschool Development Grants 93.434 Total | 93.434 | | 222,606 222,606 | ALABAMA DEPT OF EDUCATION | 90TP0065-01-00 | 222,606 222,606 | 6,829 6,829 |
| Ending the HIV Epidemic: A Plan for America - Ryan White HIV/AIDS Parts A and B 93.686 Total | 93.686 | <u> </u> | 211,666 211,666 | ALABAMA DEPT OF PUBLIC HEALTH | C00119147-UT8HA33956 | 211,666 211,666 | <u> </u> |
| Preventing Heart Attacks and Strokes in High Need Areas 93.816 Total | 93.816 | <u>-</u> | 562 562 | MISSISSIPPI DEPT OF HEALTH | 5NU58DP006265 | 562 562 | <u> </u> |
| Cardiovascular Diseases Research | 93.837 93.837 93.837 93.837 93.837 93.837 93.837 93.837 93.837 93.837 93.837 93.837 | 25,724,681 | 768,356 676,727 425,976 305,590 273,912 200,681 197,238 162,830 117,407 110,181 92,110 68,492 61,129 59,441 | BOSTON UNIVERSITY MEDICAL CAMPUS BOSTON UNIVERSITY MEDICAL CAMPUS CORNELL UNIVERSITY SEATTLE BIOMEDICAL RESEARCH INSTITUTE INDIANA UNIVERSITY VANDERBILT UNIVERSITY MEDICAL CENTER CORNELL UNIVERSITY MEDICAL CENTER CORNELL UNIVERSITY MASSACHUSETTS GENERAL HOSPITAL COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK MEDICAL COLLEGE OF WISCONSIN NAVIDEA BIOPHARMACEUTICALS, INC. VANDERBILT UNIVERSITY MEDICAL CENTER CHILDREN'S HOSPITAL BOSTON MAYO CLINIC ROCHESTER | 1U01HL146382-02 3U01HL146382-03 5R01HL080477-14 5R01HL146130-03 5R01HL145528-03 5P01HL138203-05 5R01HL138199-04 1R01HL146751-01A1 1R01HL140493-03 1R41HL147640-01A1 1R01HL148661-01 1RO1HL158097-01 5R01HL158097-01 | 25,724,681 768,356 676,727 425,976 305,590 273,912 200,681 197,238 162,830 117,407 110,181 92,110 68,492 61,129 59,441 | 5,287,820 |
| Cardiovascular Diseases Research | 93.837 93.837 93.837 93.837 93.837 93.837 93.837 93.837 93.837 93.837 93.837 93.837 93.837 93.837 93.837 | | 56,167 55,164 47,366 44,200 43,403 41,322 36,807 36,534 20,869 17,973 17,510 17,030 12,593 11,131 10,612 | UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO ARCUS-MED, LLC EMORY UNIVERSITY NORTHWESTERN UNIVERSITY UNIVERSITY OF MARYLAND DUKE UNIVERSITY UNIVERSITY OF MORTH CAROLINA AT CHAPEL HILL UNIVERSITY OF KORTH CAROLINA AT CHAPEL HILL UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK OREGON HEALTH & SCIENCES UNIVERSITY UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC MASSACHUSETTS GENERAL HOSPITAL THE SOCIETY OF THORACIC SURGEONS THE SOCIETY OF THORACIC SURGEONS UNIVERSITY OF MINNESOTA UNIVERSITY OF MINNESOTA UNIVERSITY OF MINNESOTA | 1R01HL155226-01 1R41HL145838-01A1 R01HL150887-01 1R01HL149866-01A1 5U24HL134763 7R01HL133618-03 1R01HL142825-01A1 7R01HL091357-06 1R01HL146636-01A1 5R01HL126373-03 1R01HL125877-01A1 5U01HL123336-06 5R01AG047416-05S1 5R01HL130502-05 5R01HL150053-02 1R01HL142603-02 1R01HL142603-02 | 56,167 55,164 47,366 45,616 44,200 43,403 41,322 36,807 36,534 20,869 17,973 17,510 17,030 12,593 11,131 | |
| Cardiovascular Diseases Research | 93.837 | - | 9,868 | OHIO STATE UNIVERSITY RESEARCH FOUNDATION | 5R01HL128857-02 | 9,868 | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|---|------------------|------------|-----------------------------|---|--|------------------------------|----------------------------|
| | | | | | | | |
| Cardiovascular Diseases Research | 93.837 | - | 9,543 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 5R01HL143885-02 | 9,543 | |
| Cardiovascular Diseases Research | 93.837 | - | 8,111 | BRIGHAM & WOMENS HOSPITAL | 5U01HL123336-04 | 8,111 | |
| Cardiovascular Diseases Research | 93.837 | - | 7,100 | CORNELL UNIVERSITY | 5R01HL135199-05 | 7,100 | |
| Cardiovascular Diseases Research | 93.837 | - | 6,807 | UNIVERSITY OF PENNSYLVANIA | 5R01HL151292-02 | 6,807 | |
| Cardiovascular Diseases Research | 93.837 | - | 6,550 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 1R01HL143885-01A1 | 6,550 | |
| Cardiovascular Diseases Research | 93.837 | - | 6,486 | OREGON HEALTH & SCIENCES UNIVERSITY | 5R01HL136373-04 | 6,486 | |
| Cardiovascular Diseases Research | 93.837 | - | 6,060 | DUKE UNIVERSITY | 5U01HL134679-02 | 6,060 | |
| Cardiovascular Diseases Research | 93.837 | - | 4,924 | OREGON HEALTH & SCIENCES UNIVERSITY | 1UG3HL145269-01A1 | 4,924 | |
| Cardiovascular Diseases Research | 93.837 | = | 3,306 | DUKE UNIVERSITY | 5R01HL126524-04 | 3,306 | |
| Cardiovascular Diseases Research | 93.837 | - | 3,302 | INDIANA UNIVERSITY | 1R01HL158647-01 | 3,302 | |
| Cardiovascular Diseases Research | 93.837 | - | 1,712 | NORTHWESTERN UNIVERSITY | 2R01HL107577-05A1 | 1,712 | |
| Cardiovascular Diseases Research | 93.837 | - | 1,194 | NEW ENGLAND RESEARCH INSTITUTES INC | U01HL107407 | 1,194 | |
| Cardiovascular Diseases Research | 93.837 | - | 852 | MAYO CLINIC ARIZONA | 1R01HL142627-01A1 | 852 837 | |
| Cardiovascular Diseases Research | 93.837 | - | 837 | THE GEORGE WASHINGTON UNIVERSITY | U24HL140168 | | |
| Cardiovascular Diseases Research | 93.837 | - | 308 | KENT COUNTY MEMORIAL HOSPITAL | R01HL150170-01A1 | 308 | |
| Cardiovascular Diseases Research Cardiovascular Diseases Research | 93.837 | - | (680) | UNIVERSITY OF MARYLAND | 5U01HL099997-07 | (680) | |
| 93.837 Total | 93.837 | 25,724,681 | <u>(7,519)</u> 4,120,158 | DUKE UNIVERSITY | 1R01HL144773-01 | <u>(7,519)</u> 29,844,839 | 5,287,820 |
| 93.037 Total | | 25,724,001 | 4,120,156 | | | 29,044,039 | 5,267,620 |
| Lung Diseases Research | 93.838 | 12,164,746 | - | | | 12,164,746 | 751,724 |
| COVID-19 Lung Diseases Research | 93.838 | 768,931 | - | | | 768,931 | |
| Lung Diseases Research | 93.838 | - | 269,717 | EMORY UNIVERSITY | 5R01HL136414-04 | 269,717 | |
| Lung Diseases Research | 93.838 | - | 165,639 | TECHNOLOGY COMMERCIALIZATION PARTNERS, LLC | 1R41HL152921-01 | 165,639 | |
| Lung Diseases Research | 93.838 | - | 97,239 | UNIVERSITY OF SOUTH ALABAMA | 1R01HL140182-01A1 | 97,239 | |
| Lung Diseases Research | 93.838 | - | 94,674 | EMORY UNIVERSITY | 5R01HL139876-04 | 94,674 | |
| Lung Diseases Research | 93.838 | - | 76,194 | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2R01HL089897 | 76,194 | |
| Lung Diseases Research | 93.838 | - | 70,093 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 1UG3HL152323-01 | 70,093 | |
| Lung Diseases Research | 93.838 | - | 57,802 | NORTHWESTERN UNIVERSITY | 5R01HL122477-06A1 | 57,802 | |
| Lung Diseases Research | 93.838 | - | 45,229 | UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO | 5U01HL137880-04 | 45,229 | |
| Lung Diseases Research | 93.838 | = | 39,018 | UNIVERSITY OF SOUTH ALABAMA | 1R01HL148069-01A1 | 39,018 | |
| Lung Diseases Research | 93.838 | = | 23,445 | YALE UNIVERSITY | 5U01HL145567-03 | 23,445 | |
| Lung Diseases Research | 93.838 | - | 22,970 | NORTHWESTERN UNIVERSITY | 3R01HL122477-07S1 | 22,970 | |
| Lung Diseases Research | 93.838 | - | 21,479 | YALE UNIVERSITY | 1U01HL145567-01 | 21,479 | |
| Lung Diseases Research | 93.838 | - | 20,116 | NORTHWESTERN UNIVERSITY | 3U01HL146408-02S1 | 20,116 | |
| Lung Diseases Research | 93.838 | - | 18,462 | UNIVERSITY OF PENNSYLVANIA | 5U01HL145435-02 | 18,462 | |
| Lung Diseases Research | 93.838 | - | 18,268 | THE GEORGE WASHINGTON UNIVERSITY | 5R01HL098354-07 | 18,268 | |
| Lung Diseases Research Lung Diseases Research | 93.838 93.838 | - | 18,033 17,793 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL NEW YORK UNIVERSITY MEDICAL SCHOOL | 5U24HL141762-03 OT2HL161847-01 | 18,033 17,793 | |
| Lung Diseases Research | 93.838 | - | 17,793 | | | 17,793 | |
| Lung Diseases Research | 93.838 | - | 14.097 | BRIGHAM & WOMENS HOSPITAL | 1R01HL149861-01A1 | 14,097 | |
| Lung Diseases Research | 93.838 | - | 12,929 | JOAN & SANFORD I. WEILL MEDICAL COLLEGE OF CORNELL THE GEORGE WASHINGTON UNIVERSITY | 1R01HL144718-01A1 REVISED R01HL098354 | 12,929 | |
| Lung Diseases Research | 93.838 | - | 11,077 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2R01HL103676-05 | 11,077 | |
| Lung Diseases Research | 93.838 | - | 8,602 | UNIVERSITY OF PENNSYLVANIA | 5U01HL145435-03 | 8,602 | |
| Lung Diseases Research | 93.838 | | 8.034 | JOAN & SANFORD I. WEILL MEDICAL COLLEGE OF CORNELL | 5R01HL144718-02 | 8.034 | |
| Lung Diseases Research | 93.838 | - | 5,794 | UNIVERSITY OF MICHIGAN | 1R01HL147261-01A1 | 5,794 | |
| Lung Diseases Research | 93.838 | - | 1,834 | COPD FOUNDATION | 5U01HL128954-04 | 1,834 | |
| Lung Diseases Research | 93.838 | - | 1,673 | UNIVERSITY OF MICHIGAN | 1R01HL153519-01 | 1,673 | |
| Lung Diseases Research | 93.838 | _ | 1,165 | THE GEORGE WASHINGTON UNIVERSITY | 2R01HL098354-04 | 1,165 | |
| Lung Diseases Research | 93.838 | _ | 419 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2R01HL093081-09 | 419 | |
| Lung Diseases Research | 93.838 | _ | 292 | COPD FOUNDATION | 5U01HL128954-05 | 292 | |
| Lung Diseases Research | 93.838 | - | (10,393) | UNIVERSITY OF PITTSBURGH | 5U01HL1289454-04 | (10,393) | |
| 93.838 Total | 00.000 | 12,933,677 | 1,147,497 | 525.11 or 11110001011 | | 14,081,174 | 751,724 |
| | | .2,000,011 | .,, | | | | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|--|---|--|--|---|---|----------------------------|
| Blood Diseases and Resources Research 93.839 Total | 93.839 93.839 93.839 93.839 93.839 93.839 93.839 93.839 | 2,375,325 - - - - - - - - - 2,375,325 | 54,513 51,601 41,659 28,974 3,660 2,708 457 (457) | UNIVERSITY OF PITTSBURGH BETH ISRAEL DEACONESS MEDICAL CENTER MEDICAL UNIVERSITY SOUTH CAROLINA FOUNDATION UNIVERSITY OF PITTSBURGH ALL CHILDREN'S RESEARCH INSTITUTE, INC. AUGUSTA UNIVERSITY MEDICAL UNIVERSITY SOUTH CAROLINA FOUNDATION MEDICAL UNIVERSITY SOUTH CAROLINA FOUNDATION | 1UGHL143192-01A1 1P01HL131477-01A1 5U01HL133990-05 1UG3HL143192-01A1 1U01HL130048-01A1 5R25HL106365-12 5U01HL133990-03 5U01HL133990-04 | 2,375,325 54,513 51,601 41,659 28,974 3,660 2,708 457 (457) 2,558,440 | 1,006,007 |
| Translation and Implementation Science Rsrch for Heart, Lung, Blood Diseases, Sleep Disorders Translation and Implementation Science Rsrch for Heart, Lung, Blood Diseases, Sleep Disorders | 93.840 93.840 | | 30,174 22,814 | YALE UNIVERSITY CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA | 1R01HL151603-01 1UG3HL156389-01 | 30,174 22,814 | |
| 93.840 Total Arthritis, Musculoskeletal and Skin Diseases Research 93.846 Total | 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 | 7,301,855 | 52,988 77,860 66,617 23,310 9,084 6,236 6,025 4,738 2,157 (18,709) 177,318 | MEDICAL UNIVERSITY OF SOUTH CAROLINA HEBREW REHABILITATION CENTER THE HOSPITAL FOR SICK CHILDREN BRIGHAM & WOMENS HOSPITAL WASHINGTON STATE UNIVERSITY NORTHWESTERN UNIVERSITY PENNSYLVANIA STATE UNIVERSITY (THE) CHILDREN'S HOSPITAL OF PHILADELPHIA CHILDREN'S HOSPITAL OF PHILADELPHIA | 3P30AR072582-03S1 REVISED R01AR075356 5R21AR074006-02 1U01AR068043-01A1 1R01AR072615-01A1 UH2AR067681 7R01AR048266-17 1R01AR074098-02 1U19AR069525-01-REVISED | 52,988 7,301,855 77,860 66,617 23,310 9,084 6,236 6,025 4,738 2,157 (18,709) 7,479,173 | 1,473,077 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | 26,814,456 | - | | | 26,814,456 | 3,046,163 |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 402,151 | THE GEORGE WASHINGTON UNIVERSITY | 5U01DK098246-08 | 402,151 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 169,635 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 5U01DK115575-03 | 169,635 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 117,564 | UNIVERSITY OF CHICAGO | 1U01DK127786-01 | 117,564 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 105,630 | UNIVERSITY OF SOUTH FLORIDA | 1R01DK126444-01A1 | 105,630 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 94,632 | MOUNT SINAI SCHOOL OF MEDICINE | 5U54DK083909-12 | 94,632 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 94,192 | UNIVERSITY OF MIAMI | 1R01DK116875-01A1 | 94,192 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 82,782 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | RO1DK082753-10A1 | 82,782 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 66,064 | UNIVERSITY OF PENNSYLVANIA | 5U24DK060990-20 | 66,064 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 59,378 | OREGON HEALTH & SCIENCES UNIVERSITY | 7R01DK104347-03 | 59,378 | |
| Research | 93.847 | - | 54,049 | UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER | 1R56DK125960-01 | 54,049 | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|---|--------|--------|--------------|--|---------------------------------------|-----------------------|----------------------------|
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | - | 30,211 | OREGON HEALTH & SCIENCES UNIVERSITY | 7R01DK112358-02 | 30,211 | |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | _ | 30,009 | TUFTS MEDICAL CENTER INC. | 5U01DK102730-05 | 30,009 | |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | _ | 29,188 | THE CHILDREN'S MERCY HOSPITAL | 5U01DK066143-17 | 29,188 | |
| Diabetes, Digestive, and Kidney Diseases Extramural | | | | | | | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 27,999 | PENNSYLVANIA STATE UNIVERSITY (THE) | 1R01DK114888-01 | 27,999 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 27,630 | THE GEORGE WASHINGTON UNIVERSITY | 1R01DK104845-01 | 27,630 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 27,018 | SEATTLE CHILDREN'S HOSPITAL | 5R01DK103608-03 | 27,018 | |
| Research | 93.847 | - | 24,230 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 5U01DK100867-08 | 24,230 | |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | - | 23,004 | JOAN & SANFORD I. WEILL MEDICAL COLLEGE OF CORNELL | 1R01DK123205-01A1 | 23,004 | |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | - | 21,498 | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS | 2U01DK100866-08 | 21,498 | |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | - | 20,111 | INDIANA UNIVERSITY | 1R01DK128252-01 | 20,111 | |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | _ | 18.434 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 1R01DK105124-01 | 18,434 | |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | | 14,956 | MOUNT SINAI SCHOOL OF MEDICINE | 1R01DK127139-01 | 14,956 | |
| Diabetes, Digestive, and Kidney Diseases Extramural | | - | • | | | | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 13,570 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 7R01DK116603-02 | 13,570 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 11,371 | INDIANA UNIVERSITY | 1R01DK121378-01 AND 02 | 11,371 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 9,025 | TEXAS A&M UNIVERSITY | 1R01DK119497-01A1 | 9,025 | |
| Research | 93.847 | - | 8,270 | UNIVERSITY OF PITTSBURGH | 1RO1DK125001-01A1 | 8,270 | |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | - | 6,329 | UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER | 5U01DK058369-20 | 6,329 | |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | - | 4,688 | UNIVERSITY OF PITTSBURGH | 1R01DK124426-01A1 | 4,688 | |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | - | 3,428 | UNIVERSITY OF SOUTH FLORIDA | U01 DK061055 | 3,428 | |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | _ | 3,127 | DUKE UNIVERSITY | 1R01DK121007-02 | 3,127 | |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 93.847 | | 3,053 | UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO | 5R01DK120886-02 | 3,053 | |
| Diabetes, Digestive, and Kidney Diseases Extramural | | - | | | | | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 2,200 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 5U01DK115575-03 | 2,200 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 1,787 | UNIVERSITY OF MASSACHUSETTS DARTMOUTH | 1R56DK114514-01A1 | 1,787 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 1,600 | DUKE UNIVERSITY | 1K01DK121866-01A1 | 1,600 | |
| Research | 93.847 | - | 1,014 | REGENTS OF THE UNIVERSITY OF COLORADO | 5UM1DK072493-16 | 1,014 | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|--------|------------|-----------------------|--|---------------------------------------|------------------------|----------------------------|
| Diabetes, Digestive, and Kidney Diseases Extramural | | | | | | | |
| Research | 93.847 | - | 726 | EMORY UNIVERSITY | 5R01DK087694-09 | 726 | |
| Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 260 | UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER | 5U01DK058369-18 | 260 | |
| Diabetes, Digestive, and Kidney Diseases Extramural Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 161 | CHILDRENS HOSPITAL MEDICAL CENTER CINCINNATI OH | 5P50DK096418-08 | 161 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 115 | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS | 2U01DK100866-09 | 115 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | 15 | THE GEORGE WASHINGTON UNIVERSITY | R01DK104845 | 15 | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | (20) | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 1U01DK116743-01 | (20) | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | (422) | REGENTS OF THE UNIVERSITY OF COLORADO | 7UM1DK072493-12 | (422) | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | (496) | THE GEORGE WASHINGTON UNIVERSITY | 5-U01DK098246-07 | (496) | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | (868) | REGENTS OF THE UNIVERSITY OF COLORADO | 5UM1DK072493-14 | (868) | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | (1,054) | ENDOMIMETICS, LLC | 5R44DK109789-03 | (1,054) | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | (5,045) | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2U01DK100867-07 | (5,045) | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | (11,976) | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS | 5UM1DK100866 | (11,976) | |
| Research Diabetes, Digestive, and Kidney Diseases Extramural | 93.847 | - | (14,804) | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS | 2U01DK100866-07 | (14,804) | |
| Research 93.847 Total | 93.847 | 26,814,456 | (37,504) 1,659,573 | THE CHILDREN'S MERCY HOSPITAL | 2U01DK066143-16 | (37,504) 28,474,029 | 3,046,163 |
| Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | 21,247,460 | - | | | 21,247,460 | 3,040,398 |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | - | 263,466 | BROWN UNIVERSITY | 5R01NS100016-03 | 263,466 | |
| Neurological Disorders | 93.853 | - | 193,542 | STANFORD UNIVERSITY | 5U01NS110728-03 | 193,542 | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|--------|--------|--------------|--|---------------------------------------|-----------------------|----------------------------|
| Extramural Research Programs in the Neurosciences and | | | | | | | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | | - 100,342 | UNIVERSITY OF TEXAS MD ANDERSON CENTER | 1R01NS116704-01 | 100,342 | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and Extramural Research Programs in the Neurosciences and | 93.853 | | - 80,051 | UNIVERSITY OF FLORIDA | 1R01NS102624-01 | 80,051 | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | | 77,374 | MASSACHUSETTS GENERAL HOSPITAL | 1R01NS099209-01 | 77,374 | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | | 56,865 | CASE WESTERN UNIVERSITY | 1R01NS119520-01 | 56,865 | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | | - 53,581 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 5R01NS097876-05 | 53,581 | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | | 52,234 | MAYO CLINIC JACKSONVILLE | 5U01NS080168-07 | 52,234 | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | | 51,930 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 5R01NS097876-04 | 51,930 | |
| Neurological Disorders | 93.853 | | 46,062 | STANFORD UNIVERSITY | 5U01NS038455-18 | 46,062 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | | 35,696 | SOUTHERN RESEARCH INSTITUTE | 5R01NS101958-04 | 35,696 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | | - 33,809 | UNIVERSITY OF CINCINNATI | 7U01NS102353-02 | 33,809 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | | 32,688 | MASSACHUSETTS GENERAL HOSPITAL | 1U24NS107155 | 32,688 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | | 32,661 | UNIVERSITY OF UTAH | 1U01NS107486-01A1 | 32,661 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | | - 26,630 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 5R01NS097876-03 | 26,630 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | | - 17,719 | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA U | 1R01NS109023-01A1 | 17,719 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | | - 17,546 | SOUTHERN RESEARCH INSTITUTE | 5R01NS101958-06 | 17,546 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | | - 17,511 | CHILDREN'S HOSPITAL BOSTON | 5U42NS092090-07 | 17,511 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | | - 15,780 | STANFORD UNIVERSITY | 1R01NS103037-01A1 | 15,780 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | | - 14.743 | UNIVERSITY OF MIAMI | 3R01NS040807-15S1 | 14.743 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | | - 14.641 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 1R01NS122449-01 | 14.641 | |
| Extramural Research Programs in the Neurosciences and | | | ** | | | ,- | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | | - 14,003 | CORNELL UNIVERSITY | 5R01NS097443-04 | 14,003 | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | • | - 13,257 | DUKE UNIVERSITY | 1R61NS120246-01 | 13,257 | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | | - 13,173 | MAYO CLINIC ROCHESTER | 5U54NS115198-02 | 13,173 | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | - | 12,060 | MAYO CLINIC JACKSONVILLE | 2U01NS080168-08 | 12,060 | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | | - 11,566 | VIRGINIA TECH | 1R01NS120746-01 | 11,566 | |
| Neurological Disorders | 93.853 | | - 11,151 | CHILDREN'S HOSPITAL BOSTON | 2U42NS092090-06 | 11,151 | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|--------|--------|--------------|---|---------------------------------------|-----------------------|----------------------------|
| Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | - | 10,765 | UNIVERSITY OF CINCINNATI | 1U01NS095869-01A1 | 10,765 | |
| Neurological Disorders | 93.853 | - | 8,891 | NORTHWESTERN UNIVERSITY | 1R61NS120245-01 | 8,891 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | - | 8,364 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 5R01NS099368-03 | 8,364 | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | - | 8,121 | THE METHODIST HOSPITAL RESEARCH INST | 1U01NS104326-03 | 8,121 | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | - | 8,054 | UNIVERSITY OF CINCINNATI | 1U01NS106513-01A1 | 8,054 | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | - | 7,155 | UNIVERSITY OF MICHIGAN | 1R01NS092706-01A1 | 7,155 | |
| Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | - | 6,442 | MASSACHUSETTS GENERAL HOSPITAL | 1U10NS077420 | 6,442 | |
| Neurological Disorders | 93.853 | - | 6,441 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 1R01NS119897-01 | 6,441 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | - | 5,784 | UNIVERSITY OF CINCINNATI | 1U01NS106655-02 | 5,784 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | - | 5,610 | UNIVERSITY OF CINCINNATI | 1U01NS099043-01A1 | 5,610 | |
| Neurological Disorders | 93.853 | - | 5,364 | UNIVERSITY OF CINCINNATI | 1UF1NS102289-01 | 5,364 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | - | 4,585 | UNIVERSITY OF CINCINNATI | 1U01NS100699-01A1 | 4,585 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | - | 3,604 | MAYO CLINIC JACKSONVILLE | 5R01NS097876-02 | 3,604 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | - | 3,048 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 5R01NS095435-04 | 3,048 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | - | 2,677 | UNIVERSITY OF FLORIDA | SUB00002641 | 2,677 | |
| Neurological Disorders | 93.853 | - | 2,012 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 5RO1NS097507 | 2,012 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | - | 593 | STANFORD UNIVERSITY | 1U01NS110728-01 | 593 | |
| Neurological Disorders | 93.853 | - | 102 | MASSACHUSETTS GENERAL HOSPITAL | 5P01NS087997-05 | 102 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | - | 45 | MASSACHUSETTS GENERAL HOSPITAL | 1U01NS093663-01A1 | 45 | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | - | (171) | MASSACHUSETTS GENERAL HOSPITAL | 1U01NS090259-01A1 | (171) | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | - | (458) | UNIVERSITY OF MIAMI | 1R01NS084288-01A1 | (458) | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | - | (8,480) | NORTHWESTERN UNIVERSITY | 1R01NS093843-01A1 | (8,480) | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders Extramural Research Programs in the Neurosciences and | 93.853 | - | (9,293) | MAYO CLINIC ROCHESTER | 1U54NS115198-01 | (9,293) | |
| Neurological Disorders | 93.853 | - | (40,313) | NORTHWESTERN UNIVERSITY | U01NS080818 | (40,313) | |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 93.853 | - | (45,764) | OREGON HEALTH & SCIENCES UNIVERSITY | 1U01NS095926-01 | (45,764) | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|------------------|------------|--------------------|---|---------------------------------------|-----------------------|----------------------------|
| 93.853 Total | | 21,247,460 | 1,303,259 | | | 22,550,719 | 3,040,398 |
| Allergy, Immunology and Transplantation Research | 93.855 | 45.049.948 | | | | 45,049,948 | 16.163.811 |
| COVID-19 Allergy, Immunology and Transplantation | 30.033 | 40,040,040 | | | | 40,040,040 | 10,100,011 |
| Research | 93.855 | 3,099,540 | - | | | 3,099,540 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 600,367 | UNIVERSITY OF CALIFORNIA LOS ANGELES | 2UM1AI068636-15 | 600,367 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 379,207 | EMORY UNIVERSITY | 1P01AI125180-01 | 379,207 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 278,583 | FRED HUTCHINSON CANCER RESEARCH CENTER | 3UM1AI068614-14S1 | 278,583 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 277,867 | UNIVERSITY OF WISCONSIN IN MADISON | 1R01Al148379-01 | 277,867 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 253,560 | FAMILY HEALTH INTERNATIONAL | UM1AI068619 | 253,560 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 252,385 | UNIVERSITY OF CALIFORNIA LOS ANGELES | 7UM1AI068636-13 | 252,385 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 201,887 | UNIVERSITY OF CALIFORNIA LOS ANGELES | 2UM1AI106701-08 | 201,887 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 171,787 | OREGON HEALTH & SCIENCES UNIVERSITY | R01AI133712-02 | 171,787 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 152,330 | UNIVERSITY OF MARYLAND | 1R01Al125561-01 | 152,330 | |
| Allergy, Immunology and Transplantation Research Allergy, Immunology and Transplantation Research | 93.855 93.855 | - | 151,166 137,365 | SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY (SMU) UNIVERSITY OF CALIFORNIA LOS ANGELES | 1R01AI152110-01 | 151,166 137,365 | |
| Allergy, Immunology and Transplantation Research | 93.855 | | 125.117 | HARVARD COLLEGE | 2UM1AI106716-09 5R01AI145547-03 | 125,117 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 91,321 | UNIVERSITY OF VIRGINIA | 1R01Al129678-01 | 91,321 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 90.275 | UNIVERSITY OF VIRGINIA UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO | 5U01AI118594-05 | 90,275 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 88,619 | UNIVERSITY OF CALIFORNIA IN SAIN FRANCISCO | 1R01AI138970-01 | 88,619 | |
| Allergy, Immunology and Transplantation Research | 93.855 | | 81,315 | UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO | 5U01AI113362-07 | 81,315 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 69,063 | UNIVERSITY OF CALIFORNIA IN SANT NANCISCO | 5R01AI115302-07 5R01AI145905-03 | 69,063 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 63,580 | HARVARD COLLEGE | 1R01AI145547-02 | 63,580 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 62,629 | UNIVERSITY OF TEXAS HEALTH CENTER AT SAN ANTONIO | 5R01AI141877-03 | 62,629 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 60,259 | UNIVERSITY OF KANSAS | 1R01AI125093-01 | 60,259 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 58.993 | UNIVERSITY OF ROCHESTER | 5R01AI129518-05 | 58.993 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 56,751 | EMORY UNIVERSITY | 1R01AI148471-01 | 56,751 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 54.149 | MAGEE-WOMEN'S RESEARCH INSTIUTUE & FOUNDATION | 4UM1AI068633-15 | 54,149 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 53,994 | JOHNS HOPKINS UNIVERSITY | 5U01AI069918 | 53,994 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 52,846 | DUKE UNIVERSITY | 5UM1AI104681-09 | 52,846 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 52,216 | UNIVERSITY OF CALIFORNIA LOS ANGELES | 7UM1AI106701-06 | 52,216 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 50,835 | UNIVERSITY OF MARYLAND | 2U19AI110820-06 | 50,835 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 49,582 | UNIVERSITY OF ROCHESTER | 1U01AI131344 | 49,582 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 49,345 | FHI 360 | UM1AI068619 | 49,345 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 48,500 | JOHNS HOPKINS UNIVERSITY | 5UM1AI068632-14 | 48,500 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 45,672 | EMORY UNIVERSITY | 5UM1AI148684-02 | 45,672 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 43,522 | MOUNT SINAI SCHOOL OF MEDICINE | 5U01AI063594-17 | 43,522 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 42,466 | UNIVERSITY OF CALIFORNIA LOS ANGELES | 5UM1AI106716-08 | 42,466 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 39,950 | JOHNS HOPKINS UNIVERSITY | UM1AI068632 | 39,950 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 39,426 | NOVAN INC | 4R44AI143022-02 | 39,426 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 37,125 | DUKE UNIVERSITY | 2UM1AI104681-08 | 37,125 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 36,633 | UNIVERSITY OF CALIFORNIA IN DAVIS | 1R01Al143554-01 | 36,633 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 36,549 | UNIVERSITY OF TEXAS MEDICAL BRANCH | 1R01AI127744 | 36,549 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 31,533 | BENAROYA RESEARCH INSITUTE AT VIRGINIA MASON | 2UM1AI109565-08 | 31,533 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 30,780 | FRED HUTCHINSON CANCER RESEARCH CENTER | 2UM1AI068614-15 | 30,780 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 25,980 | VANDERBILT UNIVERSITY MEDICAL CENTER | 5R01AI120790-01 | 25,980 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 24,761 | UNIVERSITY OF MARYLAND | 2U19AI110820-07 | 24,761 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 21,091 | MFLUIDX | 2R44AI141044-02 | 21,091 | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|--------|--------------|--------------|--|---------------------------------------|-----------------------|----------------------------|
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 19,469 | TEXAS A&M UNIVERSITY | 1R21Al151914-01 | 19,469 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 18,447 | BENAROYA RESEARCH INSITUTE AT VIRGINIA MASON | 5UM1AI109565-07 | 18,447 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 16,172 | EMORY UNIVERSITY | 5R01AI064060-12 | 16,172 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 15,868 | UNIVERSITY OF KANSAS | 5R21AI140701-02 | 15,868 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 15,051 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1U01AI152967-01 | 15,051 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 14,819 | OHIO STATE UNIVERSITY RESEARCH FOUNDATION | 7R01Al134972-03 | 14,819 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 13,999 | INDIANA UNIVERSITY | 5R01Al137116-02 | 13,999 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 13.594 | FOODSOURCE LURE CORPORATION | 1R43AI140807-01A1 | 13,594 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 12.433 | CHILDREN'S HOSPITAL BOSTON | 1R01AI154470-01 | 12,433 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 12,064 | MAGEE-WOMEN'S RESEARCH INSTIUTUE & FOUNDATION | 5UM1AI068633-14 | 12,064 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 11,890 | UNIVERSITY OF CALIFORNIA LOS ANGELES | 5UM1AI068636-14 | 11,890 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 11,688 | MASSACHUSETTS GENERAL HOSPITAL | 5R01Al138790-03 | 11,688 | |
| Allergy, Immunology and Transplantation Research | 93.855 | _ | 11.363 | HARVARD COLLEGE | 5P30AI060354-18 | 11,363 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 10,079 | JOHNS HOPKINS UNIVERSITY | 1U01AI134591-04 | 10,079 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 9,776 | EMORY UNIVERSITY | 5R01AI064060-15 | 9,776 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 9,427 | MASSACHUSETTS GENERAL HOSPITAL | 5K08AI118538-05 | 9,427 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 8,238 | UNIVERSITY OF CALIFORNIA LOS ANGELES | 1R01AI137680-03 | 8,238 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 7,936 | FRED HUTCHINSON CANCER RESEARCH CENTER | 3UM1AI068614-15S1 | 7,936 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 6,889 | UNIVERSITY OF CALIFORNIA LOS ANGELES | 1R01AI149339-01 | 6,889 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 6,232 | EMORY UNIVERSITY | 1UM1AI148684-01 | 6,232 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 5,933 | FRED HUTCHINSON CANCER RESEARCH CENTER | 5UM1AI068614-14 | 5,933 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 4,847 | UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO | 5U54AI082973-12 REVISED | 4,847 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 3,390 | UNIVERSITY OF CALIFORNIA LOS ANGELES | 5UM1AI068636-14R | 3,390 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 2,800 | INDIANA UNIVERSITY | 1R01Al37116-01A1 | 2,800 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 2,363 | HARVARD COLLEGE | 2P30AI060354-16 | 2,363 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 1,827 | JOHNS HOPKINS UNIVERSITY | 1U01AI138897-04 | 1,827 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 1,232 | UNIVERSITY OF SOUTHERN CALIFORNIA | 1R01AI135122-03 | 1,232 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 1,160 | BRIGHAM & WOMENS HOSPITAL | 5R01AI12001-03 | 1,160 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 1,035 | UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO | 1UM1AI110498-02 | 1,035 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 794 | BENAROYA RESEARCH INSITUTE AT VIRGINIA MASON | 5UM1AI109565-025 | 794 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | 228 | UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO | 5U54AI082973-11 | 228 | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | (197) | JOHNS HOPKINS UNIVERSITY | 5U01AI069918-14 | (197) | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | (293) | EMORY UNIVERSITY | 3UM1AI148684-0AS1 | (293) | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | (360) | UNIVERSITY OF SOUTHERN CALIFORNIA | 1R21AI130927-01A1 | (360) | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | (562) | EMORY UNIVERSITY | U19AI110483-08 | (562) | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | (4,294) | UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO | 5U54AI082973-10 | (4,294) | |
| Allergy, Immunology and Transplantation Research | 93.855 | - | (6,354) | DUKE UNIVERSITY | 5UM1AI104681-08 | (6,354) | |
| Allergy, Immunology and Transplantation Research | 93.855 | - 10.110.100 | (8,019) | UNIVERSITY OF ROCHESTER | 1U01AI131344-01 | (8,019) | 10.100.011 |
| 93.855 Total | | 48,149,488 | 4,822,345 | | | 52,971,833 | 16,163,811 |
| Biomedical Research and Research Training | 93.859 | 6,624,104 | - | | | 6,624,104 | 84,823 |
| Biomedical Research and Research Training | 93.859 | - | 185,824 | JOHNS HOPKINS UNIVERSITY | 1R01GM121404-01A1 | 185,824 | • |
| Biomedical Research and Research Training | 93.859 | - | 14,054 | EMORY UNIVERSITY | 1R01GM131099-01 | 14,054 | |
| Biomedical Research and Research Training | 93.859 | - | 2,388 | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 5R01GM118578-04 | 2,388 | |
| 93.859 Total | | 6,624,104 | 202,266 | | | 6,826,370 | 84,823 |
| Emerging Infections Sentinel Networks | 93.860 | | 38,621 | OLIVE VIEW-UCLA EDUCATION & RESEARCH INSTITUTE, IN | 1U01CK000480-01/5U01CK0000480-05-1 | 38,621 | |
| Emerging Infections Sentinel Networks | 93.860 | _ | 36,872 | OLIVE VIEW-UCLA EDUCATION & RESEARCH INSTITUTE, IN | 6U01CK00480-05-03 | 36,872 | |
| 93.860 Total | 55.550 | | 75,493 | | 22.2.30.00 00 00 | 75,493 | |
| | | | | | | | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|---|------------------|------------|------------------|---|---------------------------------------|-----------------------|----------------------------|
| | | | | | | | |
| Child Health and Human Development Extramural | 93.865 | 8,682,583 | - | | | 8,682,583 | 2,023,350 |
| Child Health and Human Development Extramural | 93.865 | - | 578,029 | THE GEORGE WASHINGTON UNIVERSITY | U10HD036801 | 578,029 | 29,008 |
| Child Health and Human Development Extramural | 93.865 | - | 563,307 | RTI INTERNATIONAL | U10HD34216 | 563,307 | |
| Child Health and Human Development Extramural | 93.865 | - | 520,022 | THE GEORGE WASHINGTON UNIVERSITY | U24HD036801 | 520,022 | |
| Child Health and Human Development Extramural | 93.865 | - | 340,405 | UNIVERSITY OF MIAMI | 5R01HD101352-03 | 340,405 | 127,325 |
| Child Health and Human Development Extramural | 93.865 | - | 305,602 | RTI INTERNATIONAL | 1PL1HD101059-01 | 305,602 | |
| Child Health and Human Development Extramural | 93.865 | - | 283,619 | HARVARD COLLEGE | 1P01HD103133-01 | 283,619 | |
| Child Health and Human Development Extramural | 93.865 | - | 210,186 | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDRENS HOS | 1R01HD098175-01A1 | 210,186 | |
| Child Health and Human Development Extramural | 93.865 | - | 99,131 | NEW YORK PRESBYTERIAN HOSPITAL-WEILL CORNELL MEDIC | 3P01HD067244-08S1 | 99,131 | |
| Child Health and Human Development Extramural | 93.865 | - | 57,438 | SHARP HEALTHCARE FOUNDATION | 5R01HD088646-03 | 57,438 | |
| Child Health and Human Development Extramural | 93.865 | - | 56,398 | SHARP HEALTHCARE FOUNDATION | 5R01HD088646-05 | 56,398 | |
| Child Health and Human Development Extramural | 93.865 | - | 56,244 | HARVARD COLLEGE | 5U01HD052102-15 | 56,244 | |
| Child Health and Human Development Extramural | 93.865 | - | 44,292 | UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO | 5R01HD089918-04 | 44,292 | |
| Child Health and Human Development Extramural | 93.865 | - | 42,558 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 5U19HD089881-05 | 42,558 | |
| Child Health and Human Development Extramural | 93.865 | - | 39,789 | BAEBIES INC | 1R44HD095225-03 | 39,789 | |
| Child Health and Human Development Extramural | 93.865 | - | 39,648 | UNIVERSITY OF VIRGINIA | 5R01HD087413-04 | 39,648 | |
| Child Health and Human Development Extramural | 93.865 | - | 39,245 | THE GEORGE WASHINGTON UNIVERSITY | 5U54NS115054-02 | 39,245 | |
| Child Health and Human Development Extramural | 93.865 | - | 28,651 | UNIVERSITY OF WISCONSIN MILWAUKEE | 1R01HD096085-01A1 | 28,651 | |
| Child Health and Human Development Extramural | 93.865 | - | 26,368 | FLORIDA STATE UNIVERSITY | 5U19HD089875-06 | 26,368 | |
| Child Health and Human Development Extramural | 93.865 | - | 25,703 | RTI INTERNATIONAL | 2U24HD069031 | 25,703 | |
| Child Health and Human Development Extramural Child Health and Human Development Extramural | 93.865 | - | 24,130 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL UNIVERSITY OF TEXAS AT AUSTIN | 5R03HD096188-02 7U01HD077384-06 | 24,130 | |
| Child Health and Human Development Extramural | 93.865 93.865 | - | 23,417 18.653 | CASE WESTERN UNIVERSITY | | 23,417 18.653 | |
| Child Health and Human Development Extramural | 93.865 | - | 16,743 | VANDERBILT UNIVERSITY MEDICAL CENTER | R01HD098127-01A1 1R21HD103348-01 | 16,743 | |
| Child Health and Human Development Extramural | 93.865 | - | 15,866 | THE GEORGE WASHINGTON UNIVERSITY | 5U54NS115054-03 | 15,866 | |
| Child Health and Human Development Extramural | 93.865 | _ | 15,526 | SHARP HEALTHCARE FOUNDATION | 5R01HD088646-04 | 15,526 | |
| Child Health and Human Development Extramural | 93.865 | | 9.372 | UNIVERSITY OF TEXAS MEDICAL BRANCH | 5P2CHD065702-10 | 9.372 | |
| Child Health and Human Development Extramural | 93.865 | | 8.840 | RTI INTERNATIONAL | RFA-HD-19-025 | 8.840 | |
| Child Health and Human Development Extramural | 93.865 | _ | 6.037 | INDIANA UNIVERSITY | 1R01HD101476-01A1 | 6.037 | |
| Child Health and Human Development Extramural | 93.865 | _ | 3.803 | MISSISSIPPI STATE UNIVERSITY | 1R15HD098660-01 | 3,803 | |
| Child Health and Human Development Extramural | 93.865 | _ | 3.532 | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 1R01HD086139-01A1 | 3.532 | |
| Child Health and Human Development Extramural | 93.865 | _ | 3,492 | KESSLER FOUNDATION, INC. | 7R01HD091155-03 | 3,492 | |
| Child Health and Human Development Extramural | 93.865 | _ | 1.378 | WASHINGTON UNIVERSITY IN ST LOUIS | 1R01HD086323-02 | 1.378 | |
| Child Health and Human Development Extramural | 93.865 | - | 1,254 | UNIVERSITY OF CALIFORNIA LOS ANGELES | 1R01HD092471-01 | 1,254 | |
| Child Health and Human Development Extramural | 93.865 | - | (13) | WASHINGTON UNIVERSITY IN ST LOUIS | 1U01HD077384-02 | (13) | |
| Child Health and Human Development Extramural | 93.865 | - | (6,425) | INDIANA UNIVERSITY | 5R01HD86007-02 | (6,425) | |
| 93.865 Total | | 8,682,583 | 3,502,240 | | | 12,184,823 | 2,179,683 |
| Aging Research | 93.866 | 14,190,282 | - | | | 14,190,282 | 2,421,339 |
| Aging Research | 93.866 | - | 463,268 | UNIVERSITY OF FLORIDA | 5R37AG033906-18 | 463,268 | |
| Aging Research | 93.866 | - | 133,421 | INDIANA UNIVERSITY | 1R01AG057703-01 | 133,421 | |
| Aging Research | 93.866 | - | 121,547 | SALK INSTITUTE FOR BIOLOGICAL SCIENCE | 1RF1AG068550-01 | 121,547 | |
| Aging Research | 93.866 | - | 120,747 | JOHNS HOPKINS UNIVERSITY | 1RF1AG050609-01A1 | 120,747 | |
| Aging Research | 93.866 | - | 109,152 | UNIVERSITY OF WASHINGTON | 1R01AG056486-01 | 109,152 | |
| Aging Research | 93.866 | _ | 101,782 | WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE | 5R01AG058571-04 | 101,782 | |
| Aging Research | 93.866 | - | 97,647 | DUKE UNIVERSITY | 1R01AG062502-01A1 | 97,647 | |
| Aging Research | 93.866 | - | 90.465 | UNIVERSITY OF PENNSYLVANIA | 5R01AG062819-03 | 90,465 | |
| riging research | 33.000 | - | 90,400 | ONIVERSELL OF LEMMOTEVANIA | 51.01AG002013-03 | 90,400 | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|----------------------------------|------------------|------------|------------------|--|---------------------------------------|-----------------------|----------------------------|
| Aging Research | 93.866 | _ | 88.628 | UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER | 7R03AG056330-02 | 88,628 | |
| Aging Research | 93.866 | _ | 85,772 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 3RF1AG058067-01A1S2 | 85,772 | |
| Aging Research | 93.866 | - | 75,774 | UNIVERSITY OF SOUTHERN CALIFORNIA | R01AG053798 | 75,774 | |
| Aging Research | 93.866 | - | 75,584 | NORTHERN CALIFORNIA INST FOR RESEARCH AND EDU | 1R01AG063887-01 | 75,584 | |
| Aging Research | 93.866 | - | 73,998 | THE REGENTS OF THE UNIVERSITY OF CALFORNIA | 7R01AG056360-02 | 73,998 | |
| Aging Research | 93.866 | - | 72,328 | UNIVERSITY OF MICHIGAN | 1RF1AG068410-01 | 72,328 | |
| Aging Research | 93.866 | - | 69,256 | THE JACKSON LAORATORY | 1RF1AG063755-01 | 69,256 | |
| Aging Research | 93.866 | - | 69,245 | UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO | 1R01AG059009 | 69,245 | |
| Aging Research | 93.866 | - | 66,092 | UNIVERSITY OF WASHINGTON | 5R33AG067069-02 | 66,092 | |
| Aging Research | 93.866 | - | 63,856 | DUKE UNIVERSITY | 7RFIAG057264-02 | 63,856 | |
| Aging Research | 93.866 | - | 56,863 | UNIVERSITY OF SOUTHERN CALIFORNIA | 5U19AG02-4904-15 | 56,863 | |
| Aging Research | 93.866 | - | 47,252 | MOUNT SINAI SCHOOL OF MEDICINE | 5R01AG061186-02 | 47,252 | |
| Aging Research | 93.866 | - | 46,949 | UNIVERSITY OF SOUTHERN CALIFORNIA | 1U24AG057437-01 | 46,949 | |
| Aging Research | 93.866 | - | 46,004 | MAYO CLINIC ROCHESTER | 5U19AG063911-02 | 46,004 | |
| Aging Research | 93.866 | - | 45,888 | UNIVERSITY OF SOUTHERN CALIFORNIA | 1R01AG063689-01 | 45,888 | |
| Aging Research | 93.866 | - | 43,896 | UNIVERSITY OF MICHIGAN | 1RF1AG057540-01 | 43,896 | |
| Aging Research | 93.866 | - | 42,967 | WASHINGTON UNIVERSITY IN ST LOUIS | 5R01AG053267-02 | 42,967 | |
| Aging Research | 93.866 | - | 39,656 | CALIFORNIA PACIFIC MED. CTR. RES. INST. | 1R01AG066671-01 | 39,656 | |
| Aging Research | 93.866 | - | 38,550 | THE GEORGE WASHINGTON UNIVERSITY | 1RF1AG069121-01 | 38,550 | |
| Aging Research | 93.866 | - | 31,001 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 5U19AG062682-02 | 31,001 | |
| Aging Research | 93.866 | - | 28,195 | BETH ISRAEL DEACONESS MEDICAL CENTER | 1R01AG065554-01 | 28,195 | |
| Aging Research | 93.866 | - | 26,014 | UNIVERSITY OF SOUTHERN CALIFORNIA | 5R01AG053798-02 | 26,014 | |
| Aging Research | 93.866 | - | 25,851 | EMORY UNIVERSITY | 5R34AG058835-02 | 25,851 | |
| Aging Research | 93.866 | - | 25,505 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 7RF1AG056111-02 | 25,505 | |
| Aging Research | 93.866 | - | 20,071 | UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER | 5R01AG047290-03 | 20,071 | |
| Aging Research | 93.866 | - | 15,184 | UNIVERSITY OF PENNSYLVANIA | 1R01AG062819-01A1 | 15,184 | |
| Aging Research Aging Research | 93.866 93.866 | - | 14,195 13,030 | UNIVERSITY OF KANSAS MEDICAL CENTER | 1R01AG072895-01 | 14,195 13,030 | |
| Aging Research | 93.866 | - | 12,547 | HENNEPIN HEALTHCARE RESEARCH INSTITUTE | 5U19AG062682 | 12,547 | |
| Aging Research | 93.866 | - | 11,538 | UNIVERSITY OF WISCONSIN IN MADISON UNIVERSITY OF CALIFORNIA IN DAVIS | 5R01AG040178-07 1U14AG063720-01A1 | 11,538 | |
| Aging Research | 93.866 | - | 10.540 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 1R01AG057709 | 10,540 | |
| Aging Research | 93.866 | | 8.555 | CALIFORNIA PACIFIC MED. CTR. RES. INST. | 5R01AG066671-02 | 8,555 | |
| Aging Research | 93.866 | | 4.694 | NORTHWESTERN UNIVERSITY | 1R01AG000071-02 | 4.694 | |
| Aging Research | 93.866 | _ | 4.135 | REGENTS OF THE UNIVERSITY OF COLORADO | 1R01AG054366-01A1 | 4,135 | |
| Aging Research | 93.866 | _ | 2,327 | UNIVERSITY OF SOUTHERN CALIFORNIA | 5U01AG024904-10 | 2,327 | |
| Aging Research | 93.866 | _ | 1.676 | CLEMSON UNIVERSITY | 7U01AG062370-03 | 1.676 | |
| Aging Research | 93.866 | _ | 1.020 | CALIFORNIA PACIFIC MED. CTR. RES. INST. | 1R56AG061085-01 | 1.020 | |
| Aging Research | 93.866 | _ | 398 | UNIVERSITY OF MICHIGAN | 1R01AG062582-01A1 | 398 | |
| Aging Research | 93.866 | _ | (25) | THE JACKSON LAORATORY | 5R01AG052608-04 | (25) | |
| Aging Research | 93.866 | _ | (4,730) | UNIVERSITY OF CALIFORNIA LOS ANGELES | 5R01AG054366-03 | (4,730) | |
| Aging Research | 93.866 | _ | (59,466) | ALZHEIMER'S DISEASE COOPERATIVE STUDY | 2U01AG24904-06 | (59,466) | |
| 93.866 Total | - | 14,190,282 | 2,578,842 | | | 16,769,124 | 2,421,339 |
| Vision Research | 93.867 | 10,986,887 | | | | 10,986,887 | 2,281,866 |
| Vision Research | 93.867 | .0,000,007 | 491,110 | VANDERBILT UNIVERSITY MEDICAL CENTER | 5U24EY029893-03 | 491,110 | _,201,000 |
| Vision Research | 93.867 | - | 375,945 | UNIVERSITY OF PENNSYLVANIA | 1R01EY030192-02S1 | 375,945 | |
| | 00.007 | | 3. 3,540 | | | 3. 5,540 | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|---|------------------|------------|--------------|--|---------------------------------------|-----------------------|----------------------------|
| Vision Research | 93.867 | _ | 262,632 | UNIVERSITY OF CALIFORNIA - BERKELEY | 2R01EY023591-06 | 262,632 | |
| Vision Research | 93.867 | - | 198,736 | UNIVERSITY OF FLORIDA | 5RO1EY024280-07 | 198,736 | |
| Vision Research | 93.867 | - | 151,763 | UNIVERSITY OF PENNSYLVANIA | 1R01EY031209-01A1 | 151,763 | |
| Vision Research | 93.867 | - | 122,123 | UNIVERSITY OF FLORIDA | 1R01EY028968-01A1 | 122,123 | |
| Vision Research | 93.867 | - | 103,865 | DOHENY EYE INSTITUTE INC | 1R01EY030501-01A1 | 103,865 | |
| Vision Research | 93.867 | - | 57,855 | VANDERBILT UNIVERSITY MEDICAL CENTER | 1U54EY032442-01 | 57,855 | |
| Vision Research | 93.867 | - | 51,448 | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 5R01EY024944-03 | 51,448 | |
| Vision Research | 93.867 | - | 45,991 | UNIVERSITY OF WASHINGTON | 1R01EY028282-01A1 | 45,991 | |
| Vision Research | 93.867 | - | 41,967 | JAEB CENTER FOR HEALTH RESEARCH INC | MTS1 | 41,967 | |
| Vision Research | 93.867 | - | 37,762 | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 5R01EY024944-04 | 37,762 | |
| Vision Research | 93.867 | - | 21,483 | VANDERBILT UNIVERSITY MEDICAL CENTER | 5U24EY029893-02 | 21,483 | |
| Vision Research | 93.867 | - | 19,392 | JAEB CENTER FOR HEALTH RESEARCH INC | 5U10EY011751-20 | 19,392 | |
| Vision Research Vision Research | 93.867 | - | 17,136 | UNIVERSITY OF PENNSYLVANIA | 5R01EY015537-14 | 17,136 | |
| Vision Research | 93.867 | - | 3,724 986 | NEW YORK UNIVERSITY MEDICAL SCHOOL | 1U10EY026869-01 | 3,724 986 | |
| Vision Research | 93.867 93.867 | - | 982 | MICHIGAN STATE UNIVERSITY JAEB CENTER FOR HEALTH RESEARCH INC | 5R01EY016077-10 UG1EY011751 | 982 | |
| Vision Research | 93.867 | - | 14 | SALUS UNIVERSITY | 1U10EY022599-03 | 14 | |
| Vision Research | 93.867 | | (19,926) | UNIVERSITY OF CALIFORNIA - BERKELEY | R01EY023591 | (19,926) | |
| 93.867 Total | 33.007 | 10,986,887 | 1,984,988 | UNIVERSITY OF CALIFORNIA - BERRELET | NOTE 1023391 | 12,971,875 | 2,281,866 |
| | | 10,000,001 | 1,001,000 | | | 12,011,010 | 2,201,000 |
| Medical Library Assistance | 93.879 | 20,771 | - | | | 20,771 | |
| 93.879 Total | | 20,771 | | | | 20,771 | - |
| CDC Collaboration with Academia to Strenthen Public | | | | | | | |
| Health | 93.967 | | 2,166 | ASSOCIATION OF AMERICAN MEDICAL COLLEGES | 5NU36OE00007-03-00 | 2,166 | |
| 93.967 Total | 93.901 | | 2,166 | ASSOCIATION OF AMERICAN MEDICAL COLLEGES | 5NO36OE00007-03-00 | 2,166 | |
| 30.507 15141 | | | 2,100 | | | 2,100 | |
| International Research and Research Training | 93.989 | 184,979 | - | | | 184,979 | 62,947 |
| International Research and Research Training | 93.989 | - | 15,339 | UNIVERSIDAD PERUANA CAYETANO HEREDIA | 2D43TW009763-07 | 15,339 | , |
| International Research and Research Training | 93.989 | - | 8,857 | UNIVERSITY OF PITTSBURGH | 7U2RTW010104-06 | 8,857 | |
| International Research and Research Training | 93.989 | | 4,937 | UNIVERSIDAD PERUANA CAYETANO HEREDIA | 2D43TW009763-06 | 4,937 | |
| 93.989 Total | | 184,979 | 29,133 | | | 214,112 | 62,947 |
| Contract #HHSN272201600018C | 02 DD | 4 040 047 | | | | 4 040 047 | F00.000 |
| | 93.RD | 1,212,317 | - | | | 1,212,317 | 508,660 |
| Contract #HHSN268201800005I Opt 2 Contract | 93.RD 93.RD | 966,624 | 870,998 | ABT ASSOCIATES INC | 75D301-20-R-67897 | 966,624 870,998 | 364,702 |
| Contract #HHSN268201800007I TO 01 | 93.RD 93.RD | 659,808 | 070,990 | ABT ASSOCIATES INC | 75D301-20-R-07697 | 659,808 | |
| Contract #HHSN2682018000071 TO 01 | 93.RD | 649,663 | - | | | 649,663 | 93.915 |
| Contract #HHSN272201300012I/TO F00131 | 93.RD | 590,807 | | | | 590,807 | 284,069 |
| Contract #HHSN272201300012I/HHSN27200014 | 93.RD | 556,665 | | | | 556.665 | 419,549 |
| Contract | 93.RD | - | 490,950 | EMORY UNIVERSITY | 3UM1AI148684-01S2 | 490,950 | 410,040 |
| Contract #75N93019D00016 - B05 | 93.RD | 448.909 | - | | | 448,909 | |
| Contract #HHSN272201300012I/HHSN27200016 | 93.RD | 427,195 | - | | | 427,195 | 255,743 |
| Contract #75D30118C02929 | 93.RD | 401,196 | - | | | 401,196 | 48,993 |
| Contract #HHSN272201600017C | 93.RD | 383,908 | - | | | 383,908 | 78,096 |
| Contract #75N91019D00019/75N91019F00132 | 93.RD | 372,400 | - | | | 372,400 | 372,400 |
| Contract #75N91019D00019/75N91019F00131 | 93.RD | 347,916 | - | | | 347,916 | 347,916 |
| Contract #HHSN272201300012I/HHSN27200015 | 93.RD | 314,706 | - | | | 314,706 | 242,795 |
| Contract #HHSN261201500036I TO 10 | 93.RD | 274,664 | _ | | | 274,664 | 194,470 |
| Contract #HHSN272201300012I/TO F00132 | 93.RD | 207,292 | - | | | 207,292 | 94,111 |
| | | | | | | | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|---|----------------|---------|------------------|--|---------------------------------------|-----------------------|----------------------------|
| | | | | | | | |
| Contract #HHSN268201800005I/HHSN26 Opt 3 | 93.RD | 195,022 | _ | | | 195,022 | 29,594 |
| Contract #75D30120C09617 | 93.RD | 179,538 | - | | | 179,538 | 19,375 |
| Contract | 93.RD | - | 170,052 | WESTAT CORPORATION | HHSN275201800001I | 170,052 | 76,856 |
| Contract #HHSN261201500036I TO 11 | 93.RD | 168,506 | - | | | 168,506 | 168,506 |
| Contract | 93.RD | | 151,135 | ABT ASSOCIATES INC | 75D30120C08150 | 151,135 | |
| Contract #HHSN261201500036I TO9 | 93.RD | 147,670 | - | | | 147,670 | 147,670 |
| Contract #HHSN268201800007I/HHSN26800001 | 93.RD | 109,779 | - | | | 109,779 | 0.070 |
| Contract #HHSN268201800005I TO 01 Opt 1 Contract #75D30119C06541 | 93.RD 93.RD | 106,437 | - | | | 106,437 | 9,273 |
| Contract Contract | 93.RD 93.RD | 98,697 | 00.007 | VANDEDDILT LINIVEDCITY MEDICAL CENTED | LILIONI0700040000001 | 98,697 | |
| Contract | 93.RD 93.RD | - | 96,897 87,115 | VANDERBILT UNIVERSITY MEDICAL CENTER MRIMATH LLC | HHSN272201300023I 75N91020C00049 | 96,897 87,115 | |
| Contract | 93.RD | | 70,341 | UNIVERSITY OF WISCONSIN IN MADISON | HHSN261201200033I | 70,341 | |
| Contract | 93.RD | _ | 66,314 | UNIVERSITY OF UTAH | HHSN275201800009I | 66,314 | |
| Contract #HHSN272201100035C | 93.RD | 50,014 | - 00,514 | ONIVERSITY OF STAFF | 11110142732010000031 | 50,014 | |
| Contract | 93.RD | - | 48.987 | EASTERN COOPERATIVE ONCOLOGY GROUP | EA1151 | 48,987 | |
| Contract | 93.RD | _ | 48,426 | UNIVERSITY OF PENNSYLVANIA | 75A50120C00134 | 48,426 | |
| Contract #IPA J HYDE - DETECT STUDY | 93.RD | 43,027 | - | | | 43,027 | |
| Contract #HHSN272201300012I/HHSN27200013 | 93.RD | 41,308 | - | | | 41,308 | 41,308 |
| Contract | 93.RD | - | 36,486 | J. CRAIG VENTER INSTITUTE | 75N93019C000076 | 36,486 | |
| Contract #HHSN268201800005I TO 01 BASE | 93.RD | 32,388 | - | | | 32,388 | |
| Contract #75N91019D00019/75N91019F00130 | 93.RD | 29,103 | - | | | 29,103 | |
| Contract | 93.RD | - | 27,226 | JOHNS HOPKINS UNIVERSITY | 205742 | 27,226 | |
| Contract | 93.RD | - | 17,827 | CHILDREN'S HOSPITAL BOSTON | 75D30119C05584 | 17,827 | |
| Contract | 93.RD | - | 16,384 | RAND CORPORATION | HHSM-500-2017-00083G | 16,384 | |
| Contract | 93.RD | - | 13,597 | JANSSEN RESEARCH AND DEVELOPMENT, LLC | HHSO100201500014C | 13,597 | |
| Contract | 93.RD | | 13,240 | MAYO CLINIC ROCHESTER | HHSN261201200042I | 13,240 | |
| Contract #IPA M FOXALL | 93.RD | 13,140 | 40.747 | LINIU/EDOLEV OF MICOLOGIPPI MEDICAL OFNITED | 11110110000011000110 | 13,140 | |
| Contract Contract #HHSN261201500036I | 93.RD 93.RD | 11,653 | 12,747 | UNIVERSITY OF MISSISSIPPI MEDICAL CENTER | HHSN268201800010 | 12,747 11,653 | |
| Contract #75N93019D00016 | 93.RD 93.RD | 10,995 | - | | | 10,995 | |
| Contract | 93.RD 93.RD | 10,995 | 10,399 | JAEB CENTER FOR HEALTH RESEARCH INC | U10EY011751 | 10,399 | |
| Contract #HHSN0302201800248P | 93.RD | 10,000 | 10,555 | JAEB GENTERT OR HEAETTINESEARCH INC | 01021011731 | 10,000 | |
| Contract #HHSN272201100038C | 93.RD | 9,985 | - | | | 9,985 | 3,550 |
| Contract | 93.RD | - | 9.689 | SUMMIT OXFORD LIMITED | HHSO100201700014C | 9.689 | 0,000 |
| Contract | 93.RD | _ | 6,963 | JOHNS HOPKINS UNIVERSITY | U01CA137443 | 6,963 | |
| Contract | 93.RD | - | 6,453 | UNIVERSITY OF ROCHESTER | HHSN27220140000SC | 6,453 | |
| Contract #HHSN272201100034C | 93.RD | 4,980 | · - | | | 4,980 | |
| Contract | 93.RD | - | 4,444 | ABT ASSOCIATES INC | HHSND20002013M53890B/75D30119F069241 | 4,444 | |
| Contract | 93.RD | - | 3,606 | AI BIOSCIENCES INC. | 75N930019C00018 | 3,606 | |
| Contract | 93.RD | - | 3,328 | LEIDOS BIOMEDICAL RESEARCH, INC | 75N91019D00024 | 3,328 | |
| Contract | 93.RD | - | 3,076 | WESTAT CORPORATION | HHSN261201600007I | 3,076 | |
| Contract | 93.RD | - | 3,035 | JOHNS HOPKINS UNIVERSITY | 5UM1CA137443-10 | 3,035 | |
| Contract | 93.RD | | 2,646 | EASTERN COOPERATIVE ONCOLOGY GROUP | EA1183 | 2,646 | |
| Contract #HHSN272201300012I/Task F00132 | 93.RD | 2,967 | - | | | 2,967 | 1,998 |
| Contract | 93.RD | - | 1,893 | CONRAD, EASTERN VIRGINIA MEDICAL SCHOOL | 200-2016-91449 | 1,893 | |
| Contract | 93.RD | - | 1,501 | BAVARIAN NORDIC A/S | HHSO100201700019C | 1,501 | |
| Contract | 93.RD | - | 1,231 | NORTHWESTERN UNIVERSITY | HHSN261201200035I | 1,231 | |
| Contract | 93.RD | - | 882 | CHILDREN'S HOSPITAL LOS ANGELES | 1U01AI126612-01A1 | 882 | |

Department of Education

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|---|-------------------------|--------------------|-----------------------------|--|---|-----------------------------|----------------------------|
| Contract #HHSN272201100037C Contract | 93.RD 93.RD | 844 | - 92 | ABT ASSOCIATES INC | HHSND20002013M53890B | 844 92 | |
| Contract #HHSN272201100036C Contract Contract #HHSN272201300012I-TO12 Opt 2 | 93.RD 93.RD 93.RD | (98) - (555) | (143) | ABT ASSOCIATES INC | HHSD20002013M53890B/75D30118F03024 | (98) (143) (555) | |
| Contract Contract #HHSN272201300012I | 93.RD 93.RD | (2,248) | (1,137) | LOVELACE BIOMEDICAL RESERACH INSTITUE | HHSNO100201700023I-75A5012OF33002 | (1,137) (2,248) | |
| Contract Contract | 93.RD 93.RD | - | (2,946) (15,981) | ABT ASSOCIATES INC ATOX BIO, LTD | HHSD20002013M53890B/75D30119F06241 HHSO1002014000013C | (2,946) (15,981) | |
| Contract #HHSN261201500036I TO 07 Unknown | 93.RD 93.RD | (103,107) - | 1,018,438 | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 1OT2HL156812-01 | (103,107) 1,018,438 | 102 077 |
| Unknown Unknown Unknown | 93.RD 93.RD 93.RD | - | 929,441 82,966 37,896 | RTI INTERNATIONAL EASTERN COOPERATIVE ONCOLOGY GROUP UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 10T2HL156812-01 ECOG-ACRIN 10T3HL147154-01 | 929,441 82,966 37,896 | 123,077 |
| Unknown Unknown | 93.RD 93.RD | - | 36,352 30,360 | OREGON HEALTH & SCIENCES UNIVERSITY UNIVERSITY OF BERN INSTITUTE FOR SOCIALUND PREVENT | SWOG 5U01Al069924-15 | 36,352 30,360 | |
| Unknown Unknown Unknown | 93.RD 93.RD 93.RD | - | 30,017 28,424 19,365 | BIRMINGHAM AIDS OUTREACH UNIVERSITY OF PENNSYLVANIA NEW YORK UNIVERSITY | CNVA00055333 (129659-3) 5UH3HL141736-04 0T2HL156812 | 30,017 28,424 19,365 | |
| Unknown Unknown | 93.RD 93.RD 93.RD | - | 14,874 7,384 | NRG ONCOLOGY INC JAEB CENTER FOR HEALTH RESEARCH INC | NRG NCORP UG1EY011751 | 14,874 7,384 | |
| Unknown Unknown | 93.RD 93.RD | | 6,249 4,809 | UNIVERSITY OF PENNSYLVANIA JOHNS HOPKINS UNIVERSITY | R01-HD-098269-01A1 5UM1CA137443-10 | 6,249 4,809 | |
| Unknown Unknown 93.RD Total | 93.RD 93.RD | 8,974,115 | 2,030 260 4,526,618 | CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA MAYO CLINIC ROCHESTER | 5001GH000526-03 1UG1CA189823-01 | 2,030 260 13,500,733 | 3,926,626 |
| Total Department of Health and Human Services | | 304,993,644 | 34,394,188 | | | 339,387,832 | 61,378,965 |
| <u>Department of Homeland Security</u> Contract | 97.RD | _ | 8,505 | AUBURN UNIVERSITY | CPS AUCVM | 8,505 | |
| Contract #70RSAT18CB0000042 97.RD Total | 97.RD | (157) (157) | 8,505 | 7.055.11.51.11.11.1 | 6. 67.661 | (157) 8,348 | |
| Total Department of Homeland Security | | (157) | 8,505 | | | 8,348 | |
| U. S. Agency for International Development USAID Foreign Assistance for Programs Overseas | 98.001 | _ | 9,452 | INTL AIDS VACCINE INITIATIVE | AID-OAA-A-16-00032 | 9,452 | |
| USAID Foreign Assistance for Programs Overseas 98.001 Total | 98.001 | | 5,702 15,154 | NATL ACADEMY OF SCIENCES | AID-263-A-15-00002 | 5,702 15,154 | |
| Foreign Assistance to American Schools and Hospitals Abroad (ASHA) 98.006 Total | 98.006 | | 63,559 63,559 | UNIVERSITY OF PITTSBURGH | AID-OAA-A-17-00002/FY19-A01-6024 | 63,559 63,559 | |
| Total U. S. Agency for International Development | | | 78,713 | | | 78,713 | |
| TOTAL RESEARCH AND DEVELOPMENT CLUSTER | | 331,693,414 | 42,773,288 | | | 374,466,702 | 62,817,522 |
| STUDENT FINANCIAL ASSISTANCE CLUSTER | | | | | | | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|------------------|-----------------------------------|--|---|---------------------------------------|--|----------------------------|
| Federal Supplemental Education Opportunity Grant 84.007 Total | 84.007 | 1,455,183 1,455,183 | | | | 1,455,183 1,455,183 | <u> </u> |
| Federal Work-Study Program 84.033 Total | 84.033 | 875,302 875,302 | | | | 875,302 875,302 | |
| Federal Perkins Loan - Outstanding loans at fiscal year beginning 84.038 Total | 84.038 | 7,834,550 7,834,550 | | | | 7,834,550 7,834,550 | <u> </u> |
| Federal Pell Grant 84.063 Total | 84.063 | 23,435,204 23,435,204 | | | | 23,435,204 23,435,204 | <u> </u> |
| Direct Student Loans 84.268 Total | 84.268 | 163,230,477 163,230,477 | | | | 163,230,477 163,230,477 | |
| Teacher Education Assistance for College and Higher Education Grants (TEACH) 84.379 Total | 84.379 | 21,197 21,197 | | | | 21,197 21,197 | |
| Total Department of Education | | 196,851,913 | | | | 196,851,913 | |
| Department of Health and Human Services Nurse Faculty Loan Program - Outstanding loans at fiscal year beginning Nurse Faculty Loan Program - New loans issued during fiscal year 93.264 Total | 93.264 93.264 | 3,224,756 674,521 3,899,277 | - | | | 3,224,756 674,521 3,899,277 | |
| Health Professions Student Loans - Outstanding loans at fiscal year beginning Health Professions Student Loans - New loans issued during fiscal year 93.342 Total | 93.342 93.342 | 1,185,576 160,089 1,345,665 | - | | | 1,185,576 160,089 1,345,665 | <u>-</u> |
| Nurse Faculty Loan Program ARRA - Outstanding loans at fiscal year beginning 93.408 Total | 93.408 | 62,639 62,639 | <u>-</u> | | | 62,639 62,639 | <u>-</u> |
| Total Department of Health and Human Services TOTAL STUDENT FINANCIAL ASSISTANCE CLUSTER | | 5,307,581 202,159,494 | | | | 5,307,581 202,159,494 | <u> </u> |
| DEPARTMENT OF TRANSPORTATION - HIGHWAY PLANNING AND CONSTRUCTION CLUSTER Department of Transportation Highway Planning and Construction Highway Planning and Construction 20.205 Total Total Department of Transportation | 20.205 20.205 | - - - - | (8,144) (8,661) (16,805) (16,805) | ALABAMA DEPT OF TRANSPORTATION ALABAMA DEPT OF TRANSPORTATION | 07-04278 14-0255 | (8,144) (8,661) (16,805) (16,805) | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|---|------------------|----------------------------------|-----------------------------------|---------------------------|---------------------------------------|----------------------------------|----------------------------|
| TOTAL DEPARTMENT OF TRANSPORTATION - HIGHWAY PLANNING AND CONSTRUCTION CLUSTER DEPARTMENT OF EDUCATION - SPECIAL EDUCATION | | | (16,805) | | | (16,805) | <u>-</u> _ |
| CLUSTER (IDEA) <u>Department of Education</u> Special Education_Grants to States 84.027 Total | 84.027 | <u> </u> | 69,273 69,273 69,273 | ALABAMA DEPT OF EDUCATION | P.L. 108-446 | 69,273 69,273 | <u> </u> |
| Total Department of Education TOTAL DEPARTMENT OF EDUCATION - SPECIAL EDUCATION CLUSTER (IDEA) | | | 69,273 | | | 69,273 | |
| DEPARTMENT OF EDUCATION - TRIO CLUSTER Department of Education TRIO_Student Support Services 84.042 Total | 84.042 | 899,100 899,100 | | | | 899,100 899,100 | |
| TRIO_Upward Bound 84.047 Total | 84.047 | 557,426 557,426 | | | | 557,426 557,426 | |
| TRIO_McNair Post-Baccalaureate Achievement 84.217 Total | 84.217 | 289,403 289,403 | | | | 289,403 289,403 | |
| Total Department of Education | | 1,745,929 | | | | 1,745,929 | |
| TOTAL DEPARTMENT OF EDUCATION - TRIO CLUSTER | | 1,745,929 | | | | 1,745,929 | |
| DEPARTMENT OF HEALTH AND HUMAN SERVICES - HEAD START CLUSTER Department of Health and Human Services Head Start COVID-19 Head Start 93.600 Total | 93.600 93.600 | 1,081,311 77,474 1,158,785 | - - | | | 1,081,311 77,474 1,158,785 | 143,845 143,845 |
| Total Department of Health and Human Services TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES - HEAD START CLUSTER | | 1,158,785 1,158,785 | | | | 1,158,785 1,158,785 | 143,845 143,845 |
| OTHER PROGRAMS Department of Agriculture Distance Learning and Telemedicine Loans and Grants 10.855 Total Total Department of Agriculture | 10.855 | 22,749 22,749 22,749 | | | | 22,749 22,749 22,749 | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|--|---|--|---|---|---|--------------------------------------|
| Department of Defense Contract - Navy Medicine/Dentristry/Optometry Contract - Air Force Medical, Dentistry, Optometry Contract - Army Health Profession Students Contract - Go Army Contract - Air Force Unknown Contract - Coast Guard Unknown Contract - Army Corp of Engineers Contract - Navy Unknown 12 Total Total Department of Defense | 12.U01 12.U02 12.U03 12.U04 12.U05 12.U06 12.U07 12.U08 | 760,494 528,038 281,824 29,000 26,153 23,262 10,209 4,172 1,663,152 | - - - - - - - - - - - - | | | 760,494 528,038 281,824 29,000 26,153 23,262 10,209 4,172 1,663,152 | |
| Department of Justice Drug Court Discretionary Grant Program Drug Court Discretionary Grant Program 16.585 Total Comprehensive Opioid Abuse Site-Based Program Comprehensive Opioid Abuse Site-Based Program 16.838 Total | 16.585 16.585 16.838 16.838 | : : : | 221,444 137,555 358,999 311,234 191,120 502,354 | JEFFERSON COUNTY COMMISSION JEFFERSON COUNTY COMMISSION JEFFERSON COUNTY COMMISSION JEFFERSON COUNTY COMMISSION | 201-DC-BX-0025 2020-VC-BX-0053 2018-AR-BX-K013 2020-AR-BX-0138 | 221,444 137,555 358,999 311,234 191,120 502,354 | |
| Total Department of Justice Department of Labor H-1B Job Training Grants 17.268 Total Total Department of Labor | 17.268 | 859,837 859,837 | 861,353 | | | 859,837 859,837 859,837 | 605,920 605,920 605,920 |
| Department of Transportation Contract 20. Total | 20.U09 | | 41,681 41,681 | ALABAMA DEPT OF TRANSPORTATION | K-15-1884 | 41,681 41,681 | <u> </u> |
| Total Department of Transportation Department of the Treasury COVID-19 Coronavirus Relief Fund COVID-19 Coronavirus Relief Fund COVID-19 Coronavirus Relief Fund 21.019 Total Total Department of the Treasury | 21.019 21.019 21.019 | - - - - - - - | 41,681 26,932,983 6,436,061 5,650,736 39,019,780 39,019,780 | STATE OF ALABAMA DEPARTMENT OF FINANCE JEFFERSON COUNTY COMMISSION STATE OF ALABAMA DEPARTMENT OF FINANCE | SLT0002/SLT0223/2 JCC CARES SLT0002/SLT0223 | 26,932,983 6,436,061 5,650,736 39,019,780 | - |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|---|---------|-------------------------|--------------------|---------------------------|---------------------------------------|-------------------------|----------------------------|
| Appalachian Regional Commission Appalachian Research, Technical Assistance, and Demonstration Projects 23.011 Total | 23.011 | 12,943 12,943 | | | | 12,943 12,943 | |
| Total Appalachian Regional Commission | | 12,943 | | | | 12,943 | |
| Federal Communications Commission COVID-19 Telehealth Program 32.006 Total | 32.006 | 240,349 240,349 | <u>-</u> | | | 240,349 240,349 | <u>-</u> |
| Total Federal Communications Commission | | 240,349 | | | | 240,349 | <u> </u> |
| Small Business Administration Shuttered Venue Operators Grant Program 59.075 Total | 59.075 | 37,400 37,400 | <u>-</u> | | | 37,400 37,400 | <u>-</u> |
| Total Small Business Administration | | 37,400 | | | | 37,400 | - |
| <u>Department of Education</u> Graduate Assistance in Areas of National Need 84.200 Total | 84.200 | 145,012 145,012 | | | | 145,012 145,012 | |
| Special Education - Personnel Development to Improve Services and Results for Children with Disabilities 84.325 Total | 84.325 | 382,915 382,915 | | | | 382,915 382,915 | <u>-</u> |
| Gaining Early Awareness and Readiness for Undergraduate Programs 84.334 Total | 84.334 | 3,259,155 3,259,155 | | | | 3,259,155 3,259,155 | 1,066,479 1,066,479 |
| Child Care Access Means Parents in School 84.335 Total | 84.335 | 179,088 179,088 | | | | 179,088 179,088 | |
| English Language Acquisition State Grants 84.365 Total | 84.365 | 891,562 891,562 | | | | 891,562 891,562 | |
| Improving Teacher Quality State Grants 84.367 Total | 84.367 | | 218,891 218,891 | ALABAMA DEPT OF EDUCATION | PL 107-110 | 218,891 218,891 | |
| Investing in Innovation (i3) Fund 84.411 Total | 84.411 | | 81,833 81,833 | NATIONAL WRITING PROJECT | U411A160004 | 81,833 81,833 | |
| COVID-19 Higher Education Emergency Relief Fund (HEERF) - Student Aid Portion | 84.425E | 23,928,405 | - | | | 23,928,405 | |
| COVID-19 Higher Education Emergency Relief Fund (HEERF) - Institutional Portion | 84.425F | 12,393,806 | - | | | 12,393,806 | |
| COVID-19 Higher Education Emergency Relief Fund (HEERF) - Strengthening Institutions Program 84.425 Total | 84.425M | 1,463,595 37,785,806 | | | | 1,463,595 37,785,806 | |
| Total Department of Education | | 42,643,538 | 300,724 | | | 42,944,262 | 1,066,479 |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|------------------|--------------------------------------|------------------------------|--|---|------------------------------|----------------------------|
| Consumer Product Safety Commission Contract #61320619N0138 Option 1 Contract #61320619N0138 Base 87. Total Total Consumer Product Safety Commission | 87.U10 87.U11 | 112,413 101 112,514 112,514 | - - - - | | | 112,413 101 112,514 | |
| Department of Health and Human Services | | | | | | | |
| Training in General, Pediatric, and Public Health Dentistry 93.059 Total | 93.059 | 252,519 252,519 | | | | 252,519 252,519 | 105,044 105,044 |
| Prevention of Disease, Disability, and Death by Infectious Diseases 93.084 Total | 93.084 | 254,745 254,745 | | | | 254,745 254,745 | 47,508 47,508 |
| Enhance Safety of Children Affected by Substance Abuse 93.087 Total | 93.087 | 560,694 560,694 | | | | 560,694 560,694 | 1,200 1,200 |
| Area Health Education Centers Point of Service Maintenance and Enhancement Awards COVID-19 Area Health Education Centers Point of Service | 93.107 | 694,183 | - | | | 694,183 | 563,770 |
| Maintenance and Enhancement Awards 93.107 Total | 93.107 | 79,865 774,048 | | | | 79,865 774,048 | 62,762 626,532 |
| Maternal and Child Health Federal Consolidated Programs | 93.110 | 1,569,712 | - | | | 1,569,712 | 20,000 |
| Maternal and Child Health Federal Consolidated Programs 93.110 Total | 93.110 | 1,569,712 | 5,569 5,569 | AMERICAN COLLEGE OF OBSTETRICS & GYNECOLOGY | 2UC4MC280420500 | 5,569 1,575,281 | 20,000 |
| Project Grants and Cooperative Agreements for Tuberculosis Control Programs Project Grants and Cooperative Agreements for | 93.116 | - | 103,802 | ALABAMA DEPT OF PUBLIC HEALTH | C10114110-6NU52PS910194 | 103,802 | |
| Tuberculosis Control Programs 93.116 Total | 93.116 | | 33,746 137,548 | ALABAMA DEPT OF PUBLIC HEALTH | C00119124-NU52PS910194-01-00 | 33,746 137,548 | |
| Nurse Anesthetist Traineeships 93.124 Total | 93.124 | 72,523 72,523 | | | | 72,523 72,523 | <u> </u> |
| Emergency Medical Services for Children Emergency Medical Services for Children 93.127 Total | 93.127 93.127 | | 308,610 16,150 324,760 | ALABAMA DEPT OF PUBLIC HEALTH ALABAMA DEPT OF PUBLIC HEALTH | C10114143 -H33MC06713 C00119038-H33MC06713/0AA 184 40S | 308,610 16,150 324,760 | |
| Centers for Research and Demonstration for Health Promotion and Disease Prevention COVID-19 Centers for Research and Demonstration for | 93.135 | 578,995 | - | | | 578,995 | 11,044 |
| Health Promotion and Disease Prevention 93.135 Total | 93.135 | 169,430 748,425 | | | | 169,430 748,425 | 11,044 |
| Coordinated Services and Access to Research for Women, Infants, Children, and Youth 93.153 Total | 93.153 | 787,530 787,530 | | | | 787,530 787,530 | 100,000 100,000 |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|--------|------------------------|----------------------|---|---------------------------------------|------------------------|----------------------------|
| Disabilities Prevention 93.184 Total | 93.184 | 3,945,343 3,945,343 | | | | 3,945,343 3,945,343 | 1,977,939 1,977,939 |
| Substance Abuse and Mental Health Services_Projects of Regional and National Significance Substance Abuse and Mental Health Services Projects of | 93.243 | 721,247 | - | | | 721,247 | |
| Regional and National Significance Substance Abuse and Mental Health Services Projects of | 93.243 | - | 408,580 | JEFFERSON COUNTY COMMISSION | 1H79TI081163-01 | 408,580 | |
| Regional and National Significance Substance Abuse and Mental Health Services_Projects of | 93.243 | - | 359,572 | JEFFERSON COUNTY COMMISSION | 1H79TI082946-02 | 359,572 | |
| Regional and National Significance Substance Abuse and Mental Health Services Projects of | 93.243 | - | 54,367 | ALABAMA DEPT OF MENTAL HEALTH | HRSA-18-122 | 54,367 | |
| Regional and National Significance | 93.243 | - | 13,307 | ALABAMA DEPT OF EDUCATION | 1H79SM080971-01 | 13,307 | |
| Substance Abuse and Mental Health Services_Projects of Regional and National Significance | 93.243 | - | 3,813 | ALABAMA DEPT OF PUBLIC HEALTH | C10114080-5H79SM062921-05 | 3,813 | |
| Substance Abuse and Mental Health Services_Projects of Regional and National Significance 93.243 Total | 93.243 | 721,247 | (308) 839,331 | ALABAMA DEPT OF PUBLIC HEALTH | C00119028-5H79SM062921-03 | (308) 1,560,578 | |
| Advanced Nursing Education Grant Program 93.247 Total | 93.247 | 464,980 464,980 | | | | 464,980 464,980 | - |
| Universal Newborn Hearing Screening 93.251 Total | 93.251 | | 35,204 35,204 | ALABAMA DEPT OF PUBLIC HEALTH | C00119191-H61MC00054 | 35,204 35,204 | - |
| CSELS Partnership: Strengthening Public Health Laboratories 93.322 Total | 93.322 | <u> </u> | 4,961 4,961 | ASSOCIATION OF PUBLIC HEALTH LABORATORIES | 1U60OE000103 | 4,961 4,961 | - |
| Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Epidemiology and Laboratory Capacity for Infectious | 93.323 | - | 1,167,732 | ALABAMA DEPT OF PUBLIC HEALTH | C10114058B-NU50CK000545 | 1,167,732 | |
| Diseases (ELC) | 93.323 | - | 330,598 | ALABAMA DEPT OF PUBLIC HEALTH | C10114200-6NU50CK000545-02-06 | 330,598 | |
| Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) 93.323 Total | 93.323 | | 260,462 1,758,792 | ALABAMA DEPT OF PUBLIC HEALTH | C10114183-1NU50CK000545-01-00 | 260,462 1,758,792 | |
| Paralysis Resource Center 93.325 Total | 93.325 | | 24,301 24,301 | CHRISTOPHER & DANA REEVE FOUNDATION | 90PRRC0002-02-00 | 24,301 24,301 | |
| Behavioral Risk Factor Surveillance System 93.336 Total | 93.336 | | 287,826 287,826 | ALABAMA DEPT OF PUBLIC HEALTH | C90116144-NU58DP006015 | 287,826 287,826 | - |
| Nurse Education, Practice Quality and Retention Grants COVID-19 Nurse Education, Practice Quality and Retention | 93.359 | 1,241,008 | - | | | 1,241,008 | |
| Grants 93.359 Total | 93.359 | 70,895 1,311,903 | | | | 70,895 1,311,903 | <u> </u> |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|----------------------------|--------------------------|-------------------------------------|---|--|-------------------------------------|----------------------------|
| Sickle Cell Treatment Demonstration Program Sickle Cell Treatment Demonstration Program Sickle Cell Treatment Demonstration Program 93.365 Total | 93.365 93.365 93.365 | | 88,756 49,532 (46) 138,242 | CAROLINAS HEALTHCARE SYSTEM CAROLINAS HEALTHCARE SYSTEM CAROLINAS HEALTHCARE SYSTEM | 6U1EMC31108-02-01 6 U1EMC3110804-02 6 U1EMC31108-02-01 | 88,756 49,532 (46) 138,242 | <u>-</u> |
| Prevention and Control of Chronic Disease and Associated Risk Factors in the U.S. Affiliated Pacific Islands, U.S. Virgin Islands, and Puerto Rico 93.377 Total | 93.377 | (917) (917) | | | | (917) (917) | <u> </u> |
| Cancer Research Manpower 93.398 Total | 93.398 | 545,809 545,809 | | | | 545,809 545,809 | |
| Improving Health of Americans through Prevention/Management of Diabetes/Heart Disease/Stroke | 93.426 | - | 99,690 | ALABAMA DEPT OF PUBLIC HEALTH | C10114129-NU58DP006527 | 99,690 | |
| Improving Health of Americans through Prevention/Management of Diabetes/Heart Disease/Stroke 93.426 Total | 93.426 | | 18,123 117,813 | ALABAMA DEPT OF PUBLIC HEALTH | C10114203-NU58DP006527 | 18,123 117,813 | <u> </u> |
| Every Student Succeeds Act/Preschool Development Grants 93.434 Total | 93.434 | | 222,606 222,606 | ALABAMA DEPT OF EDUCATION | 90TP0065-01-00 | 222,606 222,606 | 6,829 6,829 |
| COVID-19 Testing for the Uninsured 93.461 Total | 93.461 | 1,311,109 1,311,109 | | | | 1,311,109 1,311,109 | <u> </u> |
| COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution 93.498 Total | 93.498 | 58,030,844 58,030,844 | | | | 58,030,844 58,030,844 | - |
| Affordable Care Act (ACA) Public Health Training Centers Program, Resources Development and Academic Support to the Public Health Training Centers Program and Public Health Infrastructure and Systems Support | 93.516 | - | 76,085 | EMORY UNIVERSITY | 5UB6H31680-03-00 | 76,085 | |
| Affordable Care Act (ACA) Public Health Training Centers Program, Resources Development and Academic Support to the Public Health Training Centers Program and Public Health Infrastructure and Systems Support 93.516 Total | 93.516 | | 23,904 99,989 | EMORY UNIVERSITY | 5U86HP31680-04-00 | 23,904 99,989 | <u>-</u> |
| University Centers for Excellence in Developmental Disabilities Education, Research, and Service COVID-19 University Centers for Excellence in | 93.632 | 564,790 | - | | | 564,790 | |
| Developmental Disabilities Education, Research, and Service 93.632 Total | 93.632 | 8,383 573,173 | | | | 8,383 573,173 | <u>-</u> |
| Foster Care_Title IV-E Foster Care_Title IV-E | 93.658 93.658 | - | 65,775 (491) | UNIVERSITY OF ALABAMA IN TUSCALOOSA UNIVERSITY OF ALABAMA IN TUSCALOOSA | A21-0027-S009 C200161203 | 65,775 (491) | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor Pass-Through Nur | | Total Expenditures | Passed to Subrecipients |
|---|----------------------------|------------------------|---|---|--|---|----------------------------|
| 93.658 Total | | | 65,284 | | | 65,284 | - |
| Medical Student Education 93.680 Total | 93.680 | 1,712,169 1,712,169 | | | | 1,712,169 1,712,169 | |
| PPHF-2012 Mental and Behavioral Health Education and Training Grants 93.732 Total | 93.732 | 312,051 312,051 | | | | 312,051 312,051 | <u> </u> |
| Children's Health Insurance Program Children's Health Insurance Program Children's Health Insurance Program 93.767 Total | 93.767 93.767 93.767 | - - - - | 431,542 68,634 (5,720) 494,456 | ALABAMA DEPT OF PUBLIC HEALTH ALABAMA DEPT OF PUBLIC HEALTH ALABAMA DEPT OF PUBLIC HEALTH | C00119199-PL 111-148 C80113063-7500515 C90116151-7590515 | 431,542 68,634 (5,720) 494,456 | 15,378 |
| Opioid STR 93.788 Total | 93.788 | | 45,779 45,779 | ALABAMA DEPT OF MENTAL HEALTH | H79TI083325 | 45,779 45,779 | |
| Cardiovascular Diseases Research Cardiovascular Diseases Research 93.837 Total | 93.837 93.837 | 37,345 37,345 | 45,016 - 45,016 | INDIANA UNIVERSITY | 2R25HL124208-06 | 45,016 37,345 82,361 | - |
| Diabetes, Digestive, and Kidney Diseases Extramural Research 93.847 Total | 93.847 | 143,778 143,778 | | | | 143,778 143,778 | <u>-</u> |
| Extramural Research Programs in the Neurosciences and Neurological Disorders 93.853 Total | 93.853 | 335,758 335,758 | | | | 335,758 335,758 | <u>-</u> |
| Biomedical Research and Research Training Biomedical Research and Research Training Biomedical Research and Research Training 93.859 Total | 93.859 93.859 93.859 | 542,264 | 14,220 1,343 15,563 | NORTHERN ILLINOIS UNIVERSITY INDIANA UNIVERSITY | 7R25GM129216-02 1R25GM141507-01 | 542,264 14,220 1,343 557,827 | |
| Child Health and Human Development Extramural Research 93.865 Total | 93.865 | 4,073 4,073 | <u>-</u> | | | 4,073 4,073 | 2,054 2,054 |
| Aging Research 93.866 Total | 93.866 | 145,059 145,059 | | | | 145,059 145,059 | |
| Maternal, Infant and Early Childhood Home visiting Grant Program Maternal, Infant and Early Childhood Home visiting Grant Program | 93.870 93.870 | - | 524,813 131,533 | ALABAMA DEPT. OF EARLY CHILDHOOD EDUCATION ALABAMA DEPT. OF EARLY CHILDHOOD EDUCATION | X10MC33563 X10MC32174AND X10MC39669 | 524,813 131,533 | |
| 93.870 Total Strengthening the Public Health System in US-affiliated Pacific Islands (Non-PPHF) 93.874 Total | 93.874 | | 32,036 32,036 | UNIVERSITY OF HAWAII | 6NU38OT000253-04-01 | 32,036 32,036 | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|--|---|---|---|---|--|----------------------------|
| Autism Collaboration, Accountability, Research, Education, and Support 93.877 Total Grants for Primary Care Training and Enhancement 93.884 Total | 93.877 93.884 | 141,256 141,256 8,949 8,949 | | | | 141,256 141,256 8,949 8,949 | <u>-</u> |
| COVID-19 National Bioterrorism Hospital Preparedness Program 93.889 Total | 93.889 | | 209,098 209,098 | ALABAMA HOSPITAL ASSOCIATION | MOU/ASPR GRANT | 209,098 209,098 | <u>-</u> |
| HIV Care Formula Grants 93.917 Total | 93.917 | | 165,894 165,894 | UNITED WAY OF CENTRAL ALABAMA INC | X07HA00049 | 165,894 165,894 | <u> </u> |
| COVID-19 Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease 93.918 Total | 93.918 93.918 | 95,906 92,422 188,328 | - | | | 95,906 92,422 188,328 | <u>-</u> _ |
| HIV Prevention Activities_Health Department Based 93.940 Total | 93.940 93.940 93.940 93.940 93.940 93.940 93.940 | - - - - - - - - - | 803,394 512,710 341,965 330,375 110,030 100,000 29,147 2,337,626 | ALABAMA DEPT OF PUBLIC HEALTH | C00119070-5 NU62PS924533-03-00 C00119100-5NU62PS924533-03-00 C10114046-NU62PS924533 C10114047-NU62PS924533 C10114048-NU62PS924533 C10114013-NU62PS924533 C00119075-NU62PS924533 C00119127-5NU62PS924533-03-00 | 803,394 512,710 341,965 330,375 110,035 110,000 100,000 29,147 2,337,626 | <u>-</u> |
| Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs 93.946 Total | 93.946 93.946 93.946 | | 23,195 17,141 1,931 42,267 | MONTANA DEPARTMENT OF PUBLIC HEALTH AND HUMAN SERV ALABAMA DEPT OF PUBLIC HEALTH ALABAMA DEPT OF PUBLIC HEALTH | 20-25-5-01-301-0 PRAMS C10119151-5U01DP006235-05-00 C90116185-5U01DP006235 | 23,195 17,141 1,931 42,267 | |
| Sexually Transmitted Diseases (STD) Provider Education Grants 93.978 Total Preventive Health and Health Services Block Grant 93.991 Total | 93.978 93.991 | 525,979 525,979 - | 5,096 5,096 | ALABAMA DEPT OF PUBLIC HEALTH | C10114035-1NB01OT009320-01-00 | 525,979 525,979 5,096 5,096 | 106,996 106,996 |
| Maternal and Child Health Services Block Grant to the States Maternal and Child Health Services Block Grant to the | 93.994 | - | 9,023 | ALABAMA DEPT OF PUBLIC HEALTH | C10114051-B04MC33819 | 9,023 | |
| States Maternal and Child Health Services Block Grant to the States | 93.994 93.994 | - | 2,552 (1,148) | ALABAMA DEPT OF PUBLIC HEALTH ALABAMA DEPT OF PUBLIC HEALTH | C90116197-B04MC32523 C90116088-B04MC32523 | 2,552 (1,148) | |

| Federal Program | ALN | Direct | Pass-through | Pass-Through Grantor | Contract/Award or Pass-Through Num | Total Expenditures | Passed to Subrecipients |
|--|--|-------------------------------|---|--|---|---|----------------------------|
| 93.994 Total | | | 10,427 | | | 10,427 | |
| Contract Contract Contract Unknown Unknown 93. Total | 93.U12 93.U13 93.U14 93.U15 93.U16 | - - - - - | 98,459 44,615 8,848 330,190 27,331 509,443 | UNIVERSITY OF NEW MEXICO CHILDREN'S HOSPITAL BOSTON BAVARIAN NORDIC A'S ALABAMA MEDICAID AGENCY FLORIDA DEPARTMENT OF HEALTH | 75Q80120C00003 75D30121C10297 HHSO100201700019C C200628856 PRAMS FL | 98,459 44,615 8,848 330,190 27,331 509,443 | |
| Corporation for National and Community Services Volunteers in Service to America 94.013 Total | 94.013 | 458,367 458,367 | <u>-</u> | | | 458,367 458,367 | <u> </u> |
| Total Corporation for National and Community Services | | 458,367 | | | | 458,367 | |
| Total Department of Health and Human Services | | 76,837,416 | 8,631,273 | | | 85,468,689 | 3,219,221 |
| TOTAL OTHER PROGRAMS | | 122,429,898 | 48,854,811 | | | 171,284,709 | 4,891,620 |
| SPECIAL FEDERAL APPROPRIATIONS Miscellaneous Lister Hill Center for Health Policy John J. Sparkman Center 93 Total | 93.U17 93.U18 | 378,891 258,971 637,862 | : | | | 378,891 258,971 637,862 | |
| Total Miscellaneous | | 637,862 | | | | 637,862 | |
| TOTAL SPECIAL FEDERAL APPROPRIATIONS | | 637,862 | | | | 637,862 | |
| TOTAL FEDERAL | | \$ 659,825,382 | \$ 91,680,567 | | | \$751,505,949 | \$ 67,852,987 |

1. Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the "Schedule") summarizes the federal expenditures of The University of Alabama at Birmingham ("UAB"), a campus of The University of Alabama System, under programs of the federal government for the year ended September 30, 2021. Other campuses of The University of Alabama System are presented in separate reports. The amounts reported as federal expenditures were obtained from UAB's general ledger. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this Schedule may differ from amounts presented in, or used in the preparation of, the statements of net position, the related statements of revenues, expenses, and changes in net position and cash flows of UAB. The federal expenditures of Southern Research Institute ("SRI"), a discretely presented component unit of UAB, have not been included within the Schedule as they have been included in a separate schedule of expenditures of federal awards that has been audited by other auditors.

The blended component units of UAB include UAB Research Foundation, UAB Athletics Foundation, UAB Hospital Management, L.L.C, and Triton Health Systems, L.L.C. These component units do not expend federal awards and therefore are not subject to requirements of the Uniform Guidance.

For purposes of the Schedule, federal awards include all grants, contracts, and similar agreements entered into directly between UAB and agencies and departments of the federal government and all subawards to UAB by nonfederal organizations pursuant to federal grants, contracts, and similar agreements. Negative amounts represent adjustments or credits to amounts reported as expenditures in prior years. Complete assistance listing numbers and pass-through numbers are provided when available.

2. Summary of Significant Accounting Policies

For purposes of the Schedule, expenditures for federal award programs are recognized on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance where certain types of expenditures are not allowable or are limited to reimbursement.

3. Facilities and Administrative Costs ("F&A Costs")

UAB applies its predetermined approved facilities and administrative rate when charging indirect cost to federal awards rather than the 10% de minimis cost rate described in Section 200.414 of the Uniform Guidance. UAB operates under predetermined fixed F&A cost rates which are effective from October 1, 2019 through September 30, 2023. The predetermined fixed rates were based on 2014 financial information. The base rate for on-campus research is 48.5% for the year ended September 30, 2021. Base rates for other F&A cost recoveries range from 5.4% to 45% for the year ended September 30, 2021.

4. Provider Relief Funds (PRF)

The Schedule includes grant activity related to the Department of Health and Human Services ("HHS") Provider Relief Fund and American Rescue Plan (ARP) Distribution Assistance Listing #93.498. As required based on guidance in the 2021 OMB Compliance Supplement, the Schedule includes all Period 1 funds received between April 10, 2020 and June 30, 2020 and expended by June 30, 2021 as reported to HRSA via the PRF Reporting Portal. The Schedule thus includes \$58,030,844 of direct expenditures and \$0 in lost revenue. Given the timing covered by Period 1 funds, certain of these expenses were reflected in UAB's fiscal year 2020 financial statements.

5. Higher Education Emergency Relief Funds

The Schedule includes grant activity related to the Department of Education Higher Education Emergency Relief Funds under Assistance Listing #84.425E, 84.425F and 84.425M. \$2,206,651 of the amounts on the Schedule are supported by lost revenue, as allowed under the terms and conditions of the program. As such, this amount represents a reconciling item between the federal expenses in the University's financial statements and the amount included on the Schedule.

6. HRSA COVID-19 Testing and Treatment for the Uninsured

The University Hospital, which is a department of UAB, conducted COVID-19 testing and/or provided treatment for uninsured individuals with a COVID-19 primary diagnosis on or after February 4, 2020 and as such has requested claims reimbursement under Assistance Listing #93.461 Health Resources and Services Administration's ("HRSA") COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment and Vaccine Administration for the Uninsured program. University Hospital has recorded \$3,329,649 on the Schedule of Expenditures of Federal Awards consisting of \$2,018,540 reimbursed to date from HRSA on claims with service dates during fiscal year 2020 and \$1,311,109 in claims with service dates in fiscal year 2021 that have either not yet been submitted to HRSA or have been submitted, but not yet been reimbursed. Claims not yet submitted or reimbursed have been estimated based on services provided and expected reimbursement rates and any adjustments based on actual cash receipts, will be reflected in UAB's fiscal year 2022 Schedule of Expenditures of Federal Awards.

7. Federal Student Loan Programs

Direct Loan Programs

The Perkins, Health Professions Student Loan ("HPSL"), Nurse Faculty Loan Program ("NFLP"), and Loans to Disadvantaged Students ("LDS") programs are administered directly by UAB, and balances and transactions relating to these programs are included in UAB's basic financial statements.

The balances of loans outstanding at September 30, 2021 under the federal student loan programs are summarized as follows:

| | (А | | | HPSL LN 93.342) | NFLP (ALN 93.264) | | LDS (ALN 93.342) | | NFLP-ARRA (ALN 93.408) | | Total | |
|--|----|-----------|----|--------------------|----------------------|-----------|---------------------|--------|---------------------------|--------|-------|------------|
| Total loan balance outstanding, September 30, 2021 | \$ | 6,350,811 | \$ | 1,023,342 | \$ | 3,675,814 | \$ | 68,978 | \$ | 53,625 | \$ | 11,172,570 |

Federal Direct Loans

The Federal Direct Student Loan (FDSL) program (Assistance Listing Number 84.268) was established under the Higher Education Act of 1965, as amended in the Student Loan Reform Act of 1993. The FDSL enables an eligible student or parent to obtain a loan to pay for the student's cost of attendance directly through UAB rather than through private lenders. UAB began participation in the FDSL on July 1, 1994. As a university qualified to originate loans, UAB is responsible for handling the complete loan origination process, including funds management and promissory note functions. UAB is not responsible for collection of these loans.

Part II
Schedule of Findings and Questioned Costs

The University of Alabama at Birmingham Schedule of Findings and Questioned Costs Year Ended September 30, 2021

Section I – Summary of Auditor's Results

| Financial Statements | | | | | | |
|---|---|---------------------------------|-------------------------|--|--|--|
| Type of auditor's report issued | | Unmodified opinion | | | | |
| Internal control over financial repo Material weakness(es) identified Significant deficiency(ies) identified Noncompliance material to finan | yes yes yes | x no x none reported x no | | | | |
| Federal Awards Internal control over major prograr Material weakness(es) identified Significant deficiency(ies) identif | | _yes _yes | x no x none reported | | | |
| Type of auditor's report issued on | Uni | modified | | | | |
| Any audit findings disclosed that a with 2 CFR 200.516(a)? | re required to be reported in accordance the | <u>x</u> yes | _no | | | |
| Identification of major prograr | ns: | | | | | |
| Assistance Listing Number(s) | Name of Federal Program or Cluster | | | | | |
| Various | Student Financial Assistance Cluster | | | | | |
| 21.019 | COVID-19 Coronavirus Relief Fund | | | | | |
| 84.425E, 84.425F and 84.425M | COVID-19 Higher Education Emergency Relief Fund (HE Education Emergency Relief Fund (HEERF) Institutional Emergency Relief Fund (HEERF) Strengthening Instution | Portion and C | | | | |
| 93.498 | COVID-19 Provider Relief Fund and American Rescue F | | ral Distribution | | | |
| 93.461 | COVID-19 Testing for the Uninsured Program | | | | | |
| 93.600 | Head Start Cluster | | | | | |
| Dollar threshold used to distinguis | sh between Type A and Type B Programs | \$ | 3,000,000 | | | |
| Auditee qualified as low-risk audit | ee? | <u>x</u> yes no | | | | |

Section II - Financial Statement Findings

None

The University of Alabama at Birmingham Schedule of Findings and Questioned Costs Year Ended September 30, 2021

Section III - Federal Award Findings and Questioned Costs

Finding 2021-001: Student Financial Assistance – Return of Title IV Funds

Federal Agency: U.S. Department of Education **Program:** Student Financial Assistance Cluster

Award(s) and Assistance Listing Numbers: Direct Loans (84.268) & Federal Pell Grant (84.063)

Award Year: Academic year 2020-2021

Criteria

34 CFR part 668 establishes rules governing the student withdrawal process including the return of unearned Title IV aid within 45 days of a student's withdrawal.

Condition

Through our Return of Title IV Funds testing, we noted 3 out of 25 selections for which the students began attendance but subsequently withdrew and their unearned title IV funds were not returned within 45 days of the withdrawal date. We noted 2 selections related to direct loans in the amount of \$1,731 & \$1,864 which were returned 48 days and 57 days after the withdrawal date. The last selection related to the Federal Pell Grant in the amount of \$149 which was returned 82 days after the withdrawal date.

Questioned Costs

None

Cause

Student Accounts Services experienced staff turnover and delayed rehiring due to COVID-19 which created staffing shortages for the department.

Effect

The University was not in compliance with the Return of Title IV Funds 45 day compliance requirement.

Recommendation We recommend the University enhance its controls and incorporate multiple individuals in the process to ensure that Title IV refunds are made timely.

Management's Views and Corrective Action Plan Management's views and corrective action plan is found on page 45 and is considered a part of this report.

.



THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESPONSE TO THE UNIFORM GUIDANCE AUDIT

The following is the University of Alabama at Birmingham's Response to the audit of Federal programs in accordance with the Uniform Guidance for the year ending September 30, 2021.

Finding 2021-001- Special Tests and Provisions: Return of Title IV

Program: Student Financial Assistance Cluster

Awards: Federal Pell Grant Program - 84.063; Federal Direct Loan Program - 84.268

Management understands the requirement to return unearned Title IV aid within 45 days of the student's withdrawal. Management acknowledges and agrees with the findings as presented. The Student Account Services experienced staff turnover shortly before the COVID-19 pandemic began creating a hardship in replacing them during limited business operations. With the staffing shortage, Student Account Services experienced inefficiencies related to the review of student withdrawals and the timely return of Title IV aid.

Management recognizes that there are peak times when withdrawals increase each semester and will have more than one person dedicated to processing these during these periods. Management will explore the option of having IT run an all-inclusive withdrawal report instead of having to identify students from a number of different reports to ensure all students who have full term withdrawals are found in a timely manner. The reports will be made available to the Student Account Services as well as the Controller's Office to further ensure all students who have full term withdrawals are identified in a timely manner.

The University of Alabama at Birmingham expects to have this item completed by August 2022. For follow-up questions and information, contact Bernard Mays, University Controller at bmaysjr@uab.edu.

Sincerely,

Stephanis Mullins

Stephanie Mullins
UAB Chief Financial Officer

FINANCE & ADMINISTRATION

Office of Financial Affairs

Part III
Summary Schedule of Prior Audit Findings and Status


The University of Alabama at Birmingham Summary Schedule of Prior Audit Findings and Status Year Ended September 30, 2021

There are no findings from prior years that require an update in this report.

Part IV 2021 Financial Report



2021 Financial Report University of Alabama at Birmingham



UAB is an equal education opportunity institution, and an equal employment opportunity employer.

This report is published by the UAB Senior Vice President for Finance and Administration. Obtain additional copies by writing:

Senior Vice President for Finance and Administration The University of Alabama at Birmingham Birmingham, Alabama 35294

University of Alabama at Birmingham

2020-2021 Annual Financial Report Table of Contents

| | Section |
|--|---------|
| | |
| | |

| Management's Responsibility for Financial Reporting | 2 |
|--|----|
| Report of Independent Auditors | 3 |
| Management's Discussion and Analysis (Unaudited) | 5 |
| Financial Statements | |
| Statements of Net Position | 23 |
| Statements of Revenues, Expenses, and Changes in Net Position | 25 |
| Statements of Cash Flows | 26 |
| Discretely Presented Component Unit | |
| Statements of Net Position | 28 |
| Statements of Revenues, Expenses, and Changes in Net Position | 29 |
| Notes to Financial Statements | |
| Note 1 Organization and Summary of Significant Accounting Policies | 30 |
| Note 2 Component Units | 34 |
| Note 3 Cash and Cash Equivalents | 37 |
| Note 4 Investments | 37 |
| Note 5 Receivables | 47 |
| Note 6 Capital Assets | 49 |
| Note 7 Long-term Debt | 51 |
| Note 8 Self-insurance | 54 |
| Note 9 Employee Benefits | 55 |
| Note 10 Post-Employment Benefits | 59 |
| Note 11 Federal Direct Student Loan Program | 66 |
| Note 12 Grants and Contracts | 66 |
| Note 13 Operating Expenses by Function | 67 |
| Note 14 Contingencies and Commitments | 68 |
| Note 15 Segment Reporting | 68 |
| Note 16 Health Care Services | 71 |
| Note 17 Recently Issued Pronouncements | 73 |
| Required Supplementary Information (Unaudited) | 75 |
| UAB Administration | 78 |
| The Board of Trustees of The University of Alabama | 79 |



Office of the Senior Vice President for Finance and Administration

Management's Responsibility for Financial Reporting

The accompanying financial statements of the University of Alabama at Birmingham (UAB) for the years ended September 30, 2021 and 2020 were prepared by UAB's management in conformity with accounting principles generally accepted in the United States of America.

The management of UAB is responsible for the integrity and objectivity of these financial statements, which are presented on the accrual basis of accounting and, accordingly, include some amounts based upon judgement. Other financial information in the annual report is consistent with that in the financial statements. The system of internal accounting controls is designed to help ensure that the financial reports and the books properly reflect the transactions of the institution, in accordance with established policies and procedures as implemented by qualified personnel.

The Board of Trustees of The University of Alabama, through its Audit, Risk and Compliance Committee, monitors the financial and accounting operations of the institution, including the review and discussion of periodic financial statements and the evaluation and adoption of budgets. The Board of Trustees of The University of Alabama, through its Audit, Risk and Compliance Committee, monitors the basis of engagement and reporting of independent auditors.

Brain D. Burnett, PhD

Senior Vice President for Finance and Administration

Stephanie Mullins

UAB Chief Financial Officer

Stephanie Mullins

Associate Vice President for Financial Affairs

The University of Alabama at Birmingham 1030 Administration Building 701 South 20th Street Birmingham, Alabama 35294-0110



Report of Independent Auditors

To the Board of Trustees of The University of Alabama:

Report on the Financial Statements

We have audited the accompanying financial statements of the business-type activities and the discretely presented component unit of The University of Alabama at Birmingham ("UAB"), a campus of The University of Alabama System, which is a component unit of the State of Alabama, which comprise the statements of net position as of September 30, 2021 and 2020, and the related statements of revenues, expenses, and changes in net position and of cash flows (where applicable) for the years then ended, and the related notes to the financial statements, which collectively comprise UAB's basic financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express opinions on the financial statements based on our audits. We did not audit the financial statements of Southern Research Institute ("SRI"), UAB's discretely presented component unit, as of January 1, 2021 and December 28, 2019 and for the years then ended. Those statements were audited by other auditors whose report thereon has been furnished to us, and our opinion, insofar as it relates to the amounts included for SRI, is based solely on the report of the other auditors. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement. The financial statements of Triton Health Systems, L.L.C., UAB Athletics Foundation, and UAB Research Foundation were not audited in accordance with *Government Auditing Standards*.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to UAB's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of UAB's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall



presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.

Opinions

In our opinion, based on our audits and the report of other auditors, the financial statements referred to above present fairly, in all material respects, the respective financial position of the business-type activities and the discretely presented component unit of The University of Alabama at Birmingham as of September 30, 2021 and 2020 and the respective changes in financial position and, where applicable, cash flows thereof for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Emphasis of Matter

As discussed in Note 1, the financial statements of UAB are intended to present the financial position, the changes in financial position and, where applicable, the cash flows of only that portion of the business-type activities of the financial reporting entity of The University of Alabama System that is attributable to the transactions of UAB. They do not purport to, and do not, present fairly the financial position of The University of Alabama System as of September 30, 2021 and 2020, the changes in its financial position, or, where applicable, its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America. Our opinion is not modified with respect to this matter.

Other Matters

Required Supplementary Information

The accompanying management's discussion and analysis on pages 5 through 22 and the accompanying supplementary information for the pension plan and postemployment benefits on pages 75 through 77 are required by accounting principles generally accepted in the United States of America to supplement the basic financial statements. Such information, although not a part of the basic financial statements, is required by the Governmental Accounting Standards Board who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audits of the basic financial statements. We do not express an opinion or provide any assurance on the information because the limited procedures do not provide us with sufficient evidence to express an opinion or provide any assurance.

Other Reporting Required by Government Auditing Standards

In accordance with Government Auditing Standards, we have also issued our report dated January 24, 2022, on our consideration of UAB's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, grant agreements, and other matters for the year ended September 30, 2021. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that



testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the UAB's internal control over financial reporting and compliance.

Birmingham, Alabama

Pricewaterhouse Coopers LLP

January 24, 2022

The University of Alabama at Birmingham

Management's Discussion and Analysis (Unaudited)

The objective of management's discussion and analysis is to help readers of The University of Alabama at Birmingham ("UAB")'s financial statements better understand the financial position and operating activities for the fiscal years ended September 30, 2021 and 2020. This discussion has been prepared by management along with the financial statements and related note disclosures and should be read in conjunction with the financial statements and notes. The financial statements, notes, required supplementary information, and this discussion are the responsibility of management. In January 2020, the World Health Organization declared the novel Coronavirus ("COVID-19") a Public Health Emergency of International Concern. The outbreak of COVID-19 has caused domestic and global disruption in operations for institutions of higher education and healthcare organizations and has impacted several areas of UAB and University Hospital's financial statements as further discussed within the MD&A and Note 1.

History, Mission and Governance

The University of Alabama at Birmingham ("UAB") became an autonomous campus within The University of Alabama System in 1969 and, in the five decades since, has grown into a world-renowned research university and medical center, occupying more than 100 city blocks in Alabama's largest metropolitan area. UAB is the state's largest single-site employer with more than 23,000 employees. *Forbes* recently ranked UAB the number one Best Large Employer in America (above the likes of Mayo Clinic, NASA and Google) and the number one best employer for diversity among colleges and universities.

UAB's mission is to serve students, patients, the community and the global need for discovery, knowledge dissemination, education, creativity and the application of groundbreaking solutions. We are a leader among comprehensive public urban research universities with academic medical centers.

UAB has an economic impact on Alabama that exceeds \$7.15 billion annually and is key in growing a robust tech and knowledge-based economy for the Birmingham region and Alabama. The UAB Harbert Institute for Innovation and Entrepreneurship generated 127 intellectual property disclosures (up 50 percent in FY2021), 19 U.S. patents and three start-up companies in FY2021 alone—the Institute's seventh straight year to achieve a positive bottom line, among only 20 percent of university tech transfer offices nationally to do so. Innovation Depot, a high-tech business incubator in which UAB is a founding partner, is home to 110 start-up companies and more than 1,500 employees, and has a five-year economic impact exceeding \$3 billion

At UAB, we have never settled on merely finding what's next—we have helped build the future through new ideas and initiatives in the classroom, the laboratory, the studio and the clinic. UAB's vision, mission and shared values provide a foundation for the strategic plan, Forging the Future.

UAB is accredited by the Southern Association of Colleges and Schools Commission on Colleges to award baccalaureate, masters, doctorate, and professional degrees. UAB's accreditation was reaffirmed during the 2015 cycle. UAB's next reaffirmation will occur in the 2025 cycle. UAB offers Baccalaureate, Master's. Specialist, Doctoral, D.M.D, M.D, and O.D degrees. At the same time, UAB continues to offer students unrivaled research opportunities and novel academic programs, such as a new BS in Entreprenuerialism that enrolled more than 90 students in its first year and PhD in neuro-engineering that is the first program of its kind in the nation. UAB graduate programs continue to rank highly in US News & World Report, with 16 programs in the top 25, including a Master's in Health Administration that is number one nationally.

UAB is governed by The Board of Trustees of The University of Alabama (the "Board"), a body corporate under Alabama Law. The Board also governs The University of Alabama and The University of Alabama in Huntsville, which, along with UAB, make up The University of Alabama System (the "System"). The Board determines policy and approves operating budgets, educational programs, facilities and capital financings for each university, and sets the separate tuition and fee schedules applicable at each university. Oversight responsibilities of the Alabama Commission on Higher Education ("ACHE") and annual requests for appropriations from the Alabama legislature are coordinated for each campus by the Chancellor of the System with the approval of the Board.

UAB Awards, Accomplishments and Accolades

University:

UAB received the Higher Education Excellence in Diversity Award from INSIGHT into Diversity Magazine for a fifth straight year and remains one of only 14 universities nationally named a Diversity Champion. In addition, in February 2021 Forbes recently ranked UAB the number one Best Large Employer in America. UAB has been a leader in combating the COVID-19 pandemic through frontline patient care, research and shared expertise. Through November 2021, UAB administered 267,000 vaccines in Birmingham and in all 67 counties of Alabama, and treated over 5,650 COVID-positive patients, offering many of them the opportunity to take part in studies of new treatments available at only a handful of medical centers worldwide, including the first clinical trials of the antiviral drug Remdesivir. UAB Infectious disease experts conducted more than 125 interviews on major media outlets such as CNN, FOX News, and NBC with an estimated audience of 3.8 billion around the U.S. and the globe.

UAB's research enterprise is more competitive than ever. In FY2021, research awards reached a record \$648 million marking a 43 percent increase since FY2016 and continuing the most successful era of research funding in the university's history. Among public universities, UAB ranks 15th (top 3 percent) in federal research funding and 8th (top 2 percent) in NIH funding, with all six of its health-related schools (Health Professions, Optometry, Nursing, Dentistry, Public Health, and Medicine) ranked in the top ten. *U.S. News & World Report* recently ranked UAB among the top 10 percent of higher education institutions globally for academic research and reputation.

As a globally respected academic medical center, UAB excels at translating research into leading-edge patient care. UAB is home to the 8th largest hospital in the U.S. (1,207 beds), the state's only Level 1 Adult Trauma Center, the only National Cancer Institute-designated comprehensive cancer center in Alabama and a four-state region, and a Level 4 Regional Neonatal Intensive Care Unit that in 2020 delivered the youngest premature infant ever to survive worldwide (per the *Guinness Book of World Records* 2021). UAB Hospital recently earned the coveted Magnet Designation for Nursing Excellence for the fifth straight time (among only 21 hospitals worldwide to do so) and UAB Highlands was designated a Level 1 Geriatric ED, the only one in Alabama, the first in the Southeast, and only the 17th globally.

University Hospital:

This year's *U.S. News and World Report*'s "Best Hospitals" special edition issue ranked eight UAB Medicine specialties among the nation's top 50 and ranked UAB Hospital as the top hospital in Alabama. *U.S. News and World Report* also ranked hospitals in adult procedures and conditions. University Hospital is ranked high performing, which is the highest ranking conferred, in 14 out of 17 adult procedures and conditions. Becker's Hospital Review named University Hospital on its most recent list of the "100 Great Hospitals in America," a compilation of hospitals that are considered industry innovators and known nationally for excellence in clinical care. University Hospital has been named a Magnet-designated organization for the fifth consecutive time by the American Nurses Credentialing Center Magnet Recognition Program®. UAB Hospital is only the 21st hospital worldwide to receive this designation five consecutive times. Magnet hospitals are recognized for excellence in nursing care and patient outcomes. UAB Medicine also ranked in the top ten in the nation on the Consumer Loyalty list, based on results from NRC Health's Market Insights survey, the largest database of health care consumer responses in the country. UAB Medicine's eMedicine program was recognized with Hicuity Health's 2021 WE SEE YOU CARE Award for its innovation, leadership, and partnership in implementing a shared services model of tele-ICU care. For the fourth time since 2016, UAB Medicine has received the LGBTQ Healthcare Equality Leader designation from the Human Rights Campaign Foundation, scoring a perfect 100 in the organization's five criteria.

Overview of Financial Statements

UAB's financial report includes three financial statements: the Statement of Net Position; the Statement of Revenues, Expenses and Changes in Net Position; and the Statement of Cash Flows. These financial statements are prepared in accordance with Governmental Accounting Standards Board ("GASB") principles, which establish standards for external financial reporting for public colleges and universities. The financial statements present comparative financial information of the University, the University of Alabama Hospital ("University Hospital"), and UAB's blended component units. The University Hospital's condensed financial information is presented at Note 15. The blended component units included within the financial information of UAB are UAB Research Foundation ("UABRF"), UAB Athletics Foundation ("UABAF"), Hospital Management L.L.C. ("LLC"), and Triton Health Systems, L.L.C. ("Triton"). In addition to the blended component unit, UAB has one discretely presented component unit in Southern Research Institute ("SRI"). The financial information of SRI does not form part of UAB's MD&A, UAB's financial statements, or UAB's footnotes. However, SRI's Statement of Net Position and Statements of Revenues, Expenses, and Changes in Net Position are disclosed separately on pages 27-28.

UAB's overall financial position remained strong, as assets totaled \$6.76, \$5.93, and \$5.53 billion at September 30, 2021, 2020, and 2019, respectively. Increases of \$831.8 million or 14.0% from September 30, 2020 to September 30, 2021 were primarily due to increases in the fair market value of the investments held. Increases of \$399.6 million or 7.2% from September 30, 2019 to September 30, 2020 were primarily due to increases in cash and cash equivalents, investments, and capital assets.

Total liabilities increased \$540.0 million or 15.7% from September 30, 2020 to September 30, 2021. The increase results primarily from pension and OPEB liability growth due to changes in actuarial evaluations. Total liabilities decreased \$101.4 million or 2.9% from September 30, 2019 to September 30, 2020. The decrease results primarily from a decrease in the OPEB liability.

The change in net position reflects the operating, nonoperating and other activity of UAB, which results from revenues, expenses, and gains and losses, and is summarized for the years ended September 30, 2021, 2020, and 2019, as follows:

| | 2021 | | | 2020 | 2019 |
|--|------|---------------|----|---------------|---------------------|
| TOTAL OPERATING REVENUES | \$ | 4,133,307,349 | \$ | 3,712,470,836 | \$ 3,602,383,812 |
| TOTAL OPERATING EXPENSES | | 4,349,258,810 | | 3,953,876,475 | 3,772,700,839 |
| NET OPERATING LOSS | | (215,951,461) | | (241,405,639) | (170,317,027) |
| TOTAL NONOPERATING INCOME, CAPITAL, ENDOWMENT AND OTHER ACTIVITIES | | 1,048,006,244 | | 450,349,699 | 403,275,983 |
| INCREASE IN NET POSITION | \$ | 832,054,783 | \$ | 208,944,060 | \$ 232,958,956 |

Statements of Net Position

The statement of net position presents the financial position of UAB at the end of the fiscal year, and includes all assets, deferred outflows, liabilities, and deferred inflows recorded on the accrual basis of accounting. The changes in net position are indicators of whether the overall financial condition of UAB has improved or worsened during the year. A summarized comparison of UAB's assets, deferred outflows, liabilities, deferred inflows, and net position at September 30, 2021, 2020, and 2019, is as follows:

| | 2021 | 2020 | 2019 |
|---|------------------|------------------|------------------|
| ASSETS AND DEFERRED OUTFLOWS OF RESOURCES | | | |
| Current assets | \$ 2,854,225,459 | \$ 2,502,144,919 | \$ 2,071,860,183 |
| Capital assets, net | 1,788,161,516 | 1,784,230,411 | 1,723,027,158 |
| Other assets | 2,120,979,244 | 1,645,174,783 | 1,737,076,833 |
| TOTAL ASSETS | 6,763,366,219 | 5,931,550,113 | 5,531,964,174 |
| Deferred outflows from debt refundings | 12,081,090 | 13,336,713 | 12,305,553 |
| Deferred outflows pension and OPEB related | 850,533,926 | 305,494,017 | 301,435,989 |
| TOTAL DEFERRED OUTFLOWS OF RESOURCES | 862,615,016 | 318,830,730 | 313,741,542 |
| TOTAL ASSETS AND DEFERRED OUTFLOWS OF RESOURCES | \$ 7,625,981,235 | \$ 6,250,380,843 | \$ 5,845,705,716 |
| LIABILITIES, DEFERRED INFLOWS OF RESOURCES AND NET POSITION | | | |
| Current liabilities | 785,042,866 | 800,205,475 | 544,331,398 |
| Noncurrent liabilities | 3,196,098,532 | 2,640,898,752 | 2,998,164,006 |
| TOTAL LIABILITIES | 3,981,141,397 | 3,441,104,227 | 3,542,495,404 |
| Deferred inflows from debt refundings | _ | _ | 40,878 |
| Deferred inflows pension and OPEB related | 525,445,555 | 521,937,116 | 224,773,994 |
| TOTAL DEFERRED INFLOWS OF RESOURCES | 525,445,555 | 521,937,116 | 224,814,872 |
| Net position | 3,119,394,283 | 2,287,339,500 | 2,078,395,440 |
| TOTAL LIABILITIES, DEFERRED INFLOWS OF RESOURCES AND NET POSITION | \$ 7,625,981,235 | \$ 6,250,380,843 | \$ 5,845,705,716 |

The major categories of current assets consist of cash and cash equivalents, short-term investments, and accounts receivable and are used to support UAB's normal operations. At September 30, 2021, the major categories totaled \$2.71 billion of the \$2.85 billion. Total current assets increased \$352.1 million or 14.1% from 2020. This increase resulted from the contributions made to the Liquidity and Capital Reserve Pool ("LCRP") throughout the year, reinvesting gains

during a period of poor market performance at the start of the year, followed by growth in unrealized gains due to improved investment performance during the middle and later part of 2021. The increase was offset by a decrease in both cash and cash equivalents and net receivables. At September 30, 2020, the major categories totaled \$2.37 billion of the \$2.50 billion and increased \$430.3 million or 20.8% from 2019. The increase is a result of more cash held on hand, some growth in short term investments due to an increase in earnings reinvested, temporary cost cutting measures out of precaution of the pandemic impact, and deferred payments of the employer share of Social Security taxes allowable under the CARES Act.

Deferred outflows represent the consumption of net assets attributable to a future period and consists of bond deferred refunding amounts (Note 7), pension obligations (Note 9), and other post-employment benefits ("OPEB") obligations (Note 10). At September 30, 2021, deferred outflows from debt refundings decreased \$1.3 million to \$12.1 million due to the annual amortization of the refundings. Deferred outflows related to the pension obligations increased \$101.7 million to \$300.3 million. The increase in deferred outflows related to the pension obligations is a result of the net difference between projected and actual earnings on pension plan investments and difference between expected and actual experience offset by a decrease in changes in actuarial assumptions. Deferred outflows related to the OPEB obligations increased \$443.3 million to \$550.2 million. The increase in the deferred outflows related to the OPEB obligations is a result of changes in actuarial assumptions and changes in proportion and differences between employer contributions and proportionate share of contributions. At September 30, 2020, deferred outflows related to the pension obligations increased \$1.0 million to 13.3 million due to a new debt issuances during the year. Deferred outflows related to the pension obligations increased \$13.6 million to \$198.6 million a result of an increase in differences between expected and actual experience. Deferred outflows related to the OPEB obligations decreased \$9.5 million to \$106.9 million as a result of a changes in proportion and differences between employer contributions and proportionate share of contributions.

Current liabilities consist primarily of accounts payable, accrued payroll and related benefits, unearned revenue, and current portion of long-term debt. At September 30, 2021, current liabilities decreased \$15.2 million to \$785.0 million. The decrease is due to University Hospital's Due to third-party payors and advances payable related to repayment of advance payments received in fiscal year 2020 from the Centers for Medicare and Medicaid Services ("CMS") Accelerated and Advance Payments Program. At September 30, 2020, current liabilities increased \$255.9 million to \$800.2 million. The increase is primarily due to the University Hospital's receipt of \$180.2 million from the Centers for Medicare and Medicaid Services ("CMS") Accelerated and Advanced Payments Program in 2020.

Deferred inflows represent the acquisition of net assets attributable to a future period and are associated with pension obligations (Note 9) and other post-employment benefits ("OPEB") obligations (Note 10). At September 30, 2021, deferred inflows related to the pension obligations decreased \$30.9 million to \$59.3 million. The decrease in deferred inflows related to the pension obligations is the result of a decrease in differences between expected and actual experiences and changes in proportion and differences between employer contributions and proportionate share of contributions. Deferred inflows related to the OPEB obligations increased \$34.4 million to \$466.1 million. The increase in deferred inflows related to the OPEB obligations is a result of differences between expected and actual experiences, a change in proportion, and differences between employer contributions and proportionate share of total contributions. At September 30, 2020 deferred inflows related to the pension obligations decreased \$52.5 million to \$90.2 million. The decrease in deferred inflows related to the pension obligations is the result of a decrease in differences between expected and actual experience, changes in proportion, and differences between employer contributions and proportionate share of total contributions. Deferred inflows related to the OPEB obligations increased \$349.7 million to \$431.8 million. The increase in deferred inflows related to the OPEB obligation is a result of a difference between expected and actual experience.

Endowment, Life Income and Other Investments

The composition of the UAB's endowment, life income and other investments at September 30, 2021, 2020, and 2019, is summarized as follows:

| | 2021 | 2020 | 2019 |
|--|-------------------|-------------------|-------------------|
| Endowment and Life income investments | \$ 711,622,472 | \$ 539,974,716 | \$ 537,457,828 |
| Investment in Professional Liability Trust Fund | 69,880,913 | 59,920,845 | 60,291,989 |
| Other long-term investments | 117,568,898 | 107,735,412 | 115,426,770 |
| TOTAL ENDOWMENT, LIFE INCOME AND OTHER INVESTMENTS | \$ 899,072,283 | \$ 707,630,973 | \$ 713,176,587 |

UAB's endowment funds are invested in an investment pool established by the Board. UAB's endowment funds held within the investment pool consists of both permanent and quasi-endowments. Permanent endowment funds are those funds received from donors with the requirement that the principal remain unspent and invested in perpetuity to produce income to be expended for the purposes specified by the donor. Quasi-endowments consist of restricted or unrestricted funds that have been set aside by actions of the Board to produce income for an established purpose until the time the Board reverses its action. Endowment income supports scholarships, fellowships, professorships, research efforts, and other programs and activities of UAB.

UAB uses its endowment funds to support operations in a way that strikes a balance between generating a predictable stream of annual support for current needs and preserving the purchasing power of the endowment funds for future periods. UAB held 1,884, 1,790, and 1,705 individual endowment funds within the pool at September 30, 2021, 2020, and 2019, respectively, the majority of which are restricted for specific purposes. UAB's contributions to the endowment funds through donor gifts were \$22.7, \$20.0, and \$32.5 million for the years ended September 30, 2021, 2020, and 2019, respectively.

The Board-approved spending rule provides for distributions from the pool to UAB. The annual distribution rate is 4.5 percent and is based on a moving five-year average of the market (unit) value. This spending rule is one element of an ongoing financial management strategy that has allowed UAB to effectively weather the uncertainties of challenging economic environments. Endowment spending rate distributions totaled \$26.0, \$24.9, and \$23.5 million for the years ended September 30, 2021, 2020, and 2019, respectively.



UAB's endowment and life income investments increased \$171.6 million to \$711.6 million from September 30, 2020 to September 30, 2021. This increase resulted from the establishment of new endowment funds through gifts and the creation of Board-designated quasi-endowments throughout the year, reinvesting of underwater endowment gains during a period of poor market performance at the start of the year, followed by growth in unrealized gains due to improved investment performance during the middle and later part of 2021. UAB's endowment and life income investments increased \$2.5 million to \$540.0 million from September 30, 2019 to September 30, 2020. This increase resulted from the establishment of new endowment funds through gifts and the creation of Board-designated quasi-endowments throughout the year, offset by weak investment performance.

University Hospital participates in The University of Alabama Professional Liability Trust Fund (the "PLTF"). The PLTF uses contributions from University Hospital and other contributing entities, together with the earnings thereon, to pay liabilities arising from performance of certain professional services by employees of these entities. University Hospital reports its share of the net position of the PLTF as a joint venture investment using the equity method in the accompanying statements of net position. At September 30, 2021, 2020, and 2019, University Hospital's investment in the PLTF totaled approximately \$69.9, \$59.9, and \$60.3 million, respectively.

At September 30, 2021, 2020, and 2019, UAB's other investments totaled \$117.6, \$107.7, and \$115.4 million, respectively. Other investment primarily consisted of investments held by UAB's blended component unit Triton Health Systems, L.L.C. ("Triton"), which totaled \$117.0, \$107.2, and \$114.9 million, respectively.

Capital and Debt Activities

An aspect of UAB's continued growth is an emphasis on the expansion and maintenance of capital assets. UAB continues to implement its long-range capital plan to modernize its existing infrastructure and strategically invest in new construction. Capital assets primarily include land, buildings, fixed equipment systems, and inventoried equipment.

Construction in progress additions totaled \$32.9 million and \$33.5 million at September 30, 2021 and 2020, respectively. Capital projects in process at September 30, 2021 include Altec/Styslinger Genomic Medicine & Data Sciences, Central Utilities, McCallum Building renovations, and Science and Engineering Building. Capital projects in process at September 30, 2020 include Central Utilities, McCallum Building renovations, Science and Engineering Building, Honors College, and Information and Technology Center.

Capital asset additions totaled \$165.9 million in 2021 as compared to \$242.0 million in 2020. Capital asset additions primarily represent renovation and new construction of academic, research, clinical and athletic facilities, as well as significant investments in equipment, including information technology. Current year capital asset additions were funded with debt proceeds designated for capital purchases of \$35.2 million and \$63.1 million, and capital funds, grants, gifts totaling \$5.3 million and \$1.9 million, in 2021 and 2020, respectively.

During fiscal year 2021, Standard & Poor's Ratings Services reaffirmed its AA rating on UAB's general revenue bonds and revised from stable to positive outlook. Long-term debt activity for the years ended September 30, 2021 and September 30, 2020 is summarized as follows:

| | 2021 | | | | | | | | |
|---------------------------------------|-------------------|---------------|----------------|------------------|--|--|--|--|--|
| | Beginning Balance | Additions | Ending Balance | | | | | | |
| Direct borrowing and direct placement | 79,022,387 | 17,754,257 | 3,045,677 | 93,730,967 | | | | | |
| General receipt bonds | 998,471,000 | | 35,990,000 | 962,481,000 | | | | | |
| | \$ 1,077,493,387 | \$ 17,754,257 | \$ 39,035,677 | \$ 1,056,211,967 | | | | | |
| | | 20 | | | | | | | |
| | Beginning Balance | Additions | Repayments | Ending Balance | | | | | |
| Direct borrowing and direct placement | 81,770,699 | 109,947 | 2,858,259 | 79,022,387 | | | | | |
| General receipt bonds | 1,033,639,000 | 75,545,000 | 110,713,000 | 998,471,000 | | | | | |
| | \$ 1,115,409,699 | \$ 75,654,947 | \$ 113,571,259 | \$ 1,077,493,387 | | | | | |

UAB's long-term debt consists of capital leases, a note payable, and general revenue bonds. Long-term debt decreased \$21.3 million to \$1.06 billion from September 30, 2020 to September 30, 2021. Long-term debt decreased \$37.9 million to \$1.08 billion from September 30, 2019 to September 30, 2020. The decrease in debt is the result of principal payments made in accordance with the debt instruments.

During 2020, the University issued \$75.5 million of general revenue bonds with a net original issue premium of \$5.8 million. Total bond proceeds of \$81.4 million were utilized to refund existing bonds of \$26 million and \$2 million for debt issuance costs. The University deposited the funds received in an escrow trust for the purpose of making subsequent payment of principal and interest on the defeased indebtedness. Under the trust agreements, funds deposited in the trust accounts were invested in obligations of the U.S. Government. The University estimates that the amounts on deposit will be sufficient to satisfy the debt service requirements on the defeased indebtedness and that the defeasance will result in lower overall debt service payments. The University remains legally obligated for the repayment of the defeased indebtedness. Neither the assets of the trust accounts nor the defeased indebtedness are included in the accompanying statements of net position. The principal outstanding on defeased indebtedness at September 30, 2021 and 2020 is approximately \$0 and \$75.5 million, respectively.

Effective interest rates on the University general revenue bonds averaged 3.02% percent and 3.09% percent in 2021 and 2020, respectively. Interest expense on general revenue bonds totaled \$18.8 million and \$21.4 million in 2021 and 2020, respectively.

Obligations For Pension and Post-employment Benefits

GASB Statements No. 68 and 75 require governmental employers participating in multi-employer cost-sharing pension and healthcare benefit plans to recognize liabilities for their proportionate share of the unfunded liability for plans whose actuarial liabilities exceed the plan's net assets. As required by Alabama statute, all eligible employees of a qualifying public educational employer must be a member of the Teacher's Retirement System of Alabama ("TRS"). As a qualifying employer, UAB is required to make certain employer contributions on behalf of its employees participating in TRS's defined benefit pension plan (the "Plan"). Additionally, Alabama statutes permitted UAB to opt-in to provide its eligible retirees with healthcare benefits through the Public Education Employees' Health Insurance Plan ("PEEHIP").

The employer contribution rates for both plans are established annually by TRS and PEEHIP, and adopted by the Alabama Legislature. Both the TRS employer contribution rate and the employer's PEEHIP cost for retiree coverage are based upon the actuarial valuations performed by TRS and PEEHIP, respectively. Although the liabilities recognized under GASB 68 and 75 meet GASB's definition of a liability within GASB's framework for accounting standards, UAB does not believe that the associated recorded liabilities associated with the TRS and PEEHIP constitute legal liability for UAB, nor do they open UAB to other claims on its resources.

Using current actuarial assumptions, and presuming a continuation of the current level of benefits, UAB's obligations for pension benefits as prescribed by GASB 68 totaled \$1.41 billion at September 30, 2021, as compared to \$1.25 billion and \$1.17 billion at September 30, 2020 and 2019, respectively. The increase in the reported liability at September 30, 2021 was driven by an increase in UAB's proportionate share of a larger collective net pension liability compared to September 30, 2020. The increase in the reported liability at September 30, 2020 was driven primarily by a decrease in the discount rate and changes to mortality tables used to derive UAB's proportionate share of the plan's net pension liability.

Using current actuarial assumptions, and presuming a continuation of the current level of benefits, UAB's obligations for postemployment benefits as prescribed by GASB 75 totaled \$680.4 million at September 30, 2021, as compared to \$265.2 million and \$659.9 million at September 30, 2020 and 2019, respectively. The increase in the reported liability at September 30, 2021 was driven primarily by a decrease in the discount rate and an increase in UAB's proportionate share of the collective net OPEB liability. The decrease in the reported liability at September 30, 2020 was driven primarily by an increase in the discount rate, as well as adjustments made to the anticipated rates of participation, spouse coverage, and tobacco use to more closely reflect actual experience.

UAB also administers a single-employer plan which offers its members hospital benefits, major medical benefits, a prescription drug program and a basic term life insurance up to an established maximum policy limit. The health care benefits cover medical and hospitalization costs for retirees and their dependents. UAB retired employees make contributions to the plan by making premium payments associated with their selected health plan option. Eligible disabled retirees are responsible for only the employee portion of those premiums and UAB is responsible for the employer portion. All other UAB retirees are responsible for the full premium cost of the plan and in no case does the employer contribute to the plan.

Using current actuarial assumptions, and presuming a continuation of the current level of benefits, UAB's obligations for postemployment benefits totaled \$5.3 million at September 30, 2021, as compared to \$6.3 million and \$17.7 million at September 30, 2020 and 2019, respectively. The decrease in the reported liability at September 30, 2021 was driven primarily by differences between expected and actual experience and benefit payments. The decrease in the reported liability at September 30, 2020 was driven primarily by differences between expected and actual experience, changes in actuarial assumptions and benefit payments.

Net Position

Net position represents the residual interest in UAB's assets and deferred outflows after liabilities and deferred inflows are deducted. The UAB's net position increased \$832.1 million during fiscal year 2021, reaching \$3.12 billion. This increase reflects the UAB's current year operations including an increase in net patient revenue, nonoperating grants and contracts revenue and investment income. During fiscal year 2020 net position increased \$208.9 million, totaling \$2.29 billion, which reflects growth in net tuition and fees, net patient revenues, and an increase in State educational appropriations in that year. UAB's net position at September 30, 2021, 2020, and 2019, is summarized as follows:

| | 2021 2020 | | 2019 | | |
|----------------------------------|---------------------|----|---------------|----|---------------|
| NET INVESTMENT IN CAPITAL ASSETS | \$ 786,585,310 | \$ | 769,281,767 | \$ | 759,496,749 |
| RESTRICTED | | | | | |
| Nonexpendable | 390,793,182 | | 405,615,948 | | 401,733,396 |
| Expendable | 600,618,098 | | 353,055,159 | | 377,422,933 |
| UNRESTRICTED | 1,341,397,693 | | 759,386,626 | | 539,742,362 |
| TOTAL NET POSITION | \$ 3,119,394,283 | \$ | 2,287,339,500 | \$ | 2,078,395,440 |

Net position invested in capital assets represent UAB's capital assets, net of accumulated depreciation and outstanding principal of debt in excess of related bond proceeds attributable to the acquisition, construction, or improvement of those assets. The \$17.3 million and \$9.8 million increase in 2021 and 2020 respectively, reflects the growth in capital assets net of annual depreciation expense, along with the decrease in total debt related to the annual principal payments.

Restricted nonexpendable net position includes UAB's permanent endowment funds, annuity and life income assets that will ultimately become pure endowment funds. The changes relates primarily to contributions made during the fiscal year.

Restricted expendable net position is subject to externally imposed restrictions governing its use. Restricted expendable net position includes UAB's assets whose use is restricted by an external restriction. The \$247.6 million increase in 2021 is the result of the investment growth in market value and an increase in new gifts during the year. The \$24.4 million decrease in 2020 is the result of fewer new gifts received during the year and market performance of investments.

Unrestricted net position includes UAB's assets whose use is not restricted by an external entity. Although unrestricted net position is not subject to externally imposed restrictions, UAB has designated available unrestricted net position to be used for academic and research programs as well as capital projects. Unrestricted net position increased by \$582.0 million in 2021, primarily due to an increase in net patient revenues. Unrestricted net position increased by \$219.6 million in 2020, primarily due to an increase in Federal and State appropriations as well as a decrease in operating expenses resulting from the suspension of non-essential spending to help alleviate the financial impact of the COVID-19 pandemic.

Statements of Revenues, Expenses, and Changes in Net Position

The statement of revenues, expenses, and changes in net position ("SRECNP") presents UAB's results of operations, as well as the nonoperating revenues and expenses. Primary components of UAB's operating revenue sources are tuition and fees, grants and contracts, and sales and services. Sales and services revenues is comprised of revenues from University Hospital operations (Hospital sales and services), revenues generated from both self-supporting departments (including intercollegiate Athletics, residence halls, food service operations) and Triton Health Systems, L.L.C., revenues a blended component unit (Auxiliary sales and services). Other significant revenue sources, which are considered nonoperating as defined by the GASB, include State educational appropriations, private gifts, and investment income.


Operating expenses are those incurred in conjunction with the fulfillment of the UAB's mission and include salaries, wages and benefits; supplies and services; depreciation; and scholarships and fellowships. The SRECNP also includes other changes affecting its net position including capital gifts and grants, additions to permanent endowments, and intragovernmental transfers between the University, University Hospital, and UAB Athletics Foundation.

Annual state appropriations are classified as nonoperating revenues according to governmental accounting standards, even though the state-appropriated funds are used to support the operations of UAB. Without the nonoperating revenues, in particular the state appropriations and private gifts, UAB would not be able to cover its costs of operations. A summarized comparison of UAB's revenues, expenses and changes in net position for the years ended September 30, 2021, 2020, and 2019 is presented below:

| | 2021 | | 2020 | | 2019 | |
|----------------------------------|------|---------------|------|---------------|------|---------------|
| OPERATING REVENUES | | | | | | |
| Student tuition and fees, net | \$ | 243,476,387 | \$ | 244,929,737 | \$ | 239,912,344 |
| Grants and contracts | | 526,727,011 | | 483,921,582 | | 494,047,342 |
| Sales and services | | 3,322,823,875 | | 2,931,632,967 | | 2,791,635,652 |
| Other revenues | | 40,280,076 | | 51,986,550 | | 76,788,474 |
| TOTAL OPERATING REVENUES | | 4,133,307,349 | | 3,712,470,836 | | 3,602,383,812 |
| OPERATING EXPENSES | | | | | | |
| Operating expenses | | 4,349,258,810 | | 3,953,876,475 | _ | 3,772,700,839 |
| OPERATING LOSS | | (215,951,461) | | (241,405,639) | | (170,317,027) |
| NONOPERATING REVENUES (EXPENSES) | | | | | | |
| Economic relief funds | | 412,719 | | 71,281,070 | | _ |
| State educational appropriations | | 314,953,056 | | 306,964,712 | | 287,691,735 |
| Grants and contracts | | 105,093,454 | | 57,856,589 | | 35,451,482 |
| Private gifts | | 61,112,310 | | 18,705,016 | | 48,327,432 |
| Investment income | | 555,919,121 | | 15,735,962 | | 32,247,107 |
| Interest expense | | (35,280,621) | | (40,126,392) | | (29,755,042) |
| Net other nonoperating revenue | | 7,377,048 | | 322,621 | | 419,384 |
| NET NONOPERATING REVENUES | | 1,009,587,087 | | 430,739,578 | | 374,382,098 |
| OTHER CHANGES IN NET POSITION | | 38,419,157 | | 19,610,121 | | 28,893,885 |
| INCREASE IN NET POSITION | | 832,054,783 | | 208,944,060 | | 232,958,956 |
| Net Position, beginning of year | | 2,287,339,500 | | 2,078,395,440 | | 1,845,436,484 |
| NET POSITION, END OF YEAR | \$ | 3,119,394,283 | \$ | 2,287,339,500 | \$ | 2,078,395,440 |

The following are graphic illustrations of revenues by source, both operating and nonoperating, which are used to fund UAB's operating activities for the years ended September 30, 2021 and September 30, 2020, respectively. Certain recurring sources of the University's revenues are considered nonoperating, as defined by Governmental Accounting Standards Board ("GASB"), such as state appropriations, distributions from investments, private gifts and federal Pell grants.


Revenue Streams 2021



Sales and Services of Hospital Activities 47.7%

Federal, State, Local, and Private Grants 10.2%

Revenue Streams 2020



Student Tuition and Fees, Net

Tuition and fees funding make up a large portion of the University's academic programs. Factors that impact gross tuition revenue include enrollment growth and changes in rates. Enrollment for the fall semester of the 2020-2021 school year is outlined in the following table.

Fall 2020

| | UNDERGRADUATE | GRADUATE | FIRST PROFESSIONAL/ ADVANCED PROFESSIONAL * | TOTAL |
|----------------------------------|---------------|----------|---|--------|
| SCHOOL OF ARTS AND SCIENCES | 6,672 | 661 | 260 | 7,593 |
| SCHOOL OF BUSINESS | 2,621 | 795 | _ | 3,416 |
| SCHOOL OF EDUCATION | 1,129 | 623 | 106 | 1,858 |
| SCHOOL OF ENGINEERING | 890 | 458 | 105 | 1,453 |
| UNCLASSIFIED | | 148 | 3 | 151 |
| SUBTOTAL | 11,312 | 2,685 | 474 | 14,471 |
| ACADEMIC HEALTH CENTER: | | | | |
| SCHOOL OF MEDICINE | _ | _ | 1,915 | 1,915 |
| SCHOOL OF DENTISTRY | 23 | _ | 380 | 403 |
| SCHOOL OF OPTOMETRY | _ | _ | 232 | 232 |
| SCHOOL OF NURSING | 1,036 | 1,396 | 538 | 2,970 |
| SCHOOL OF HEALTH PROFESSIONS | 1,156 | 1,064 | 373 | 2,593 |
| SCHOOL OF PUBLIC HEALTH | 351 | 491 | 99 | 941 |
| JOINT HEALTH SCIENCES | | 87 | 417 | 504 |
| SUBTOTAL, ACADEMIC HEALTH CENTER | 2,566 | 3,038 | 3,954 | 9,558 |
| TOTAL ENROLLMENT | 13,878 | 5,723 | 4,428 | 24,029 |

^{*} Includes 1,146 first professionals and 1,466 advanced professionals.

In fall 2020 UAB continued it's record enrollment trend with 22,563 students, of which 2,154 students were first-time freshman. Underrepresented students make up 43 percent of the enrollment and 47 percent of first-time freshman. Full-time students make up 66 percent of the enrolled students. For the years ended September 30, 2021, 2020, and 2019, net student tuition and fees revenue consisted of the following components:

| | 2021 | | 2020 | | 2019 |
|---------------------------------|------|--------------|------|--------------|-------------------|
| Student tuition and fees, gross | \$ | 335,202,452 | \$ | 330,385,766 | \$ 320,141,055 |
| Less: scholarship allowances | | (91,726,065) | | (85,456,029) | (80,228,711) |
| STUDENT TUITION AND FEES, NET | \$ | 243,476,387 | \$ | 244,929,737 | \$ 239,912,344 |

Tuition rates are reviewed annually by the University and presented to the Board for approval. Based upon the University's annual review of tuition the Board approved the management recommendation to hold all undergraduate/ graduate rates for both resident and non-resident students consistent with the prior year for the 2020-2021 academic year. However, rate increases for First Professional programs were proposed and received Board approval in April 2020 as follows: School of Medicine, 2.5% residents only (no increase for non-residents); School of Dentistry, 3.2% for residents and 3.8% for non-residents; and School of Optometry, 2% for residents only (no increase for non-residents). Fall 2020 in-state enrollment increased by 1.4% to 17,034 students and out-of-state enrollment increased by 4.7% to 5,529 students. The rate increases and enrollment growth contributed to the increase in gross tuition revenue of \$4.8 million. The increase in gross tuition and fees was offset by an increase of 7.3% or \$6.3 million in scholarship allowances. Net tuition and fees revenue decreased \$1.5 million, to \$243.5 million in 2021.

The 2019-2020 academic year rates were approved at the June 2019 board meeting, undergraduate and graduate out-of-state rates saw an increase of 3.5%. First professional schools received rate approvals as follows: School of Medicine, 2% residents only (no increase for non-residents), School of Dentistry, 3% for residents and non-residents and School of Optometry, 1.5% for residents only (no increase for non-residents). Fall 2019 in-state enrollment decreased by 0.5% to 16,797 students and out-of-state enrollment increased by 4.7% to 5,283 students. The rate increases and enrollment growth contributed to the increase in gross tuition revenue of \$10.2 million. The increase in gross tuition and


fees was offset by an increase of 6.5% or \$5.2 million in scholarship allowances. Net tuition and fees revenue increase \$5.0 million, to \$244.9 million in 2020.

Grants and contracts revenue

The University receives revenues for sponsored programs from various government agencies and private sources, which normally provide for both direct and indirect costs to perform these sponsored projects, with a significant portion related to federal research.

During fiscal year 2021, UAB recognized \$631.8 million in sponsored grants and contracts revenues. Various federal agencies provided support for these projects, with the National Institutes of Health ("NIH") being the primary sponsor. Non-federal funding sources include state agencies, local governmental agencies, and a wide variety of private sponsors. Operating revenues from grants and contracts increased \$42.8 million in 2021, as compared to an decrease of 2.0%, or \$10.1 million, to \$483.9 million in 2020. The increase in 2021 was driven primarily by an increase in federally sponsored activity. The decrease in 2020 was primarily impacted by the temporary suspension of nonessential laboratory research in response to the COVID-19 pandemic.

Operating Grants and Contract Revenue (in millions)



Figures B and B1 below are illustrations of the breakout of the funding sources for grant and contract revenue for the years ended September 30, 2021 and 2020, respectively. These funds are used to further the mission of UAB: research, education, and public service.

Figure B: Grants and Contract Revenues 2021




Figure B1: Grants and Contract Revenues 2020



Sales and services revenue of hospital activities

University Hospital is a fund of UAB and a member of the UAB Health System. For the fiscal year 2021, inpatient discharges increased 8.8% and adjusted patient discharges increased 9.9%. Operating room cases increased 9.1% over fiscal year 2020. Also emergency room visits increased 8.3% during fiscal year 2021. University Hospital had an increase in net position of \$365.3 million in fiscal year 2021. For the fiscal year 2020, inpatient discharges decreased 3.8% and adjusted patient discharges decreased 6.6%. Operating room cases decreased 7.2% over fiscal year 2019. Also emergency room visits decreased 5.0% during fiscal year 2020. The Hospital had an increase in net position of \$137.6 million in fiscal year 2020. Selected University Hospital operating statistics are outlined below:

| | 2021 | 2020 | 2019 |
|-----------------------------|---------|---------|---------|
| Beds in service | 1,172 | 1,126 | 1,128 |
| Patient discharges | 55,005 | 50,579 | 52,602 |
| Adjusted patient discharges | 90,594 | 82,418 | 88,273 |
| Patient days | 409,203 | 363,854 | 378,744 |
| Adjusted patient days | 673,966 | 592,899 | 635,578 |
| Operating room cases | 37,973 | 34,811 | 37,529 |
| Emergency department visits | 128,718 | 118,839 | 125,065 |
| Patient origin: | | | |
| Jefferson County | 48.2% | 47.2% | 46.6% |
| Other Alabama counties | 46.5% | 47.2% | 47.3% |
| Out of state | 5.3% | 5.6% | 6.1% |

For the years ended September 30, 2021, 2020, and 2019, University Hospital revenues by source is summarized as follows:

| | 2021 | | 2020 | | 2019 |
|---|---------------|-----|------------------|----|---------------|
| Net patient service revenue | \$ 2,198,201, | 564 | 1,866,934,345 | \$ | 1,785,283,429 |
| Other operating revenue | 274,428, | 638 | 242,909,060 | | 223,049,942 |
| TOTAL UNIVERSITY HOSPITAL OPERATING REVENUE | \$ 2,472,630, | 202 | \$ 2,109,843,405 | \$ | 2,008,333,371 |

Patient service revenue, net of allowances for contractual discounts, charity care and bad debt expense, was \$2.2 billion, an increase of \$331.3 million, or 18%, over fiscal year 2020. The increase was related to increased volume and contract improvements. The increase from 2019 to 2020 was \$81.7 million, or 4.6%. Contributing factors to this included increased reimbursement related to higher patient acuity and contract improvements.

Other operating revenues primarily consists of pharmacy related sales. The increase in other operating revenues from September 30, 2021 to 2020 was \$31.5 million or 13% compared to \$19.9 million in 2019 or an 8.9% increase. Both 2021 and 2020 had increases related to increases in volumes associated with retail pharmacy.

Sales and services revenue of auxiliary enterprises

Auxiliary enterprise revenue primarily includes revenue from UAB's blended component unit, Triton Health Systems, L.L.C. Refer to Note 2 for additional information on blended component units. Net auxiliary sales and service revenue totaled \$782.4, \$762.4, and \$715.7 million, an increase of 2.6% and 6.5% from 2020 to 2021 and 2019 to 2020, respectively. These increases resulted from Triton's premium revenue growth.

Other sources

Other sources consist of sales and service educational activities and other operating revenues. Net educational sales and service revenue totaled \$67.7, \$59.4, and \$67.6 million, an increase of 14.0% from 2020 to 2021 and a decrease of 12.2% from 2019 to 2020, respectively. The current year increase is due to miscellaneous external service revenue activity. Other operating revenue totaled \$40.3, \$52.0, and \$76.8 million, a decrease of 22.5% from 2020 to 2021 and a decrease of 32.3% from 2019 to 2020, respectively. The current year decrease is due to a decline in UAB Heersink School of Medicine Academic Enrichment Fund activity revenues.

Nonoperating revenues

Due to the required classification of key revenue sources such as State educational appropriations, financial aid grants, and private gifts as nonoperating revenues, UAB's operating expenses will typically exceed operating revenues, resulting in an operating loss. These nonoperating revenues are essential in offsetting the operating loss. For the years ended September 30, 2021, 2020, and 2019, UAB's nonoperating revenue is summarized as follows:

| | 2021 | | 2020 | 2019 |
|---------------------------------|----------------|----|----------------|-------------------|
| Economic relief funds | \$ 412, | 19 | \$ 71,281,070 | \$ _ |
| State educational appropriation | 314,953,0 | 56 | 306,964,712 | 287,691,735 |
| Grants and contracts | 105,093,4 | 54 | 57,856,589 | 35,451,482 |
| Gifts | 61,112,3 | 10 | 18,705,016 | 48,327,432 |
| Investment income | 555,919, | 21 | 15,735,962 | 32,247,107 |
| Capital gifts and grants | 1,645,2 | 60 | 1,854,223 | 789,319 |
| Endowment gifts | 33,163,1 | 30 | 17,755,898 | 28,104,566 |
| TOTAL UAB NONOPERATING REVENUES | \$ 1,072,299,0 | 50 | \$ 490,153,470 | \$ 432,611,641 |

In response to the impact of COVID-19, the federal government implemented the Coronavirus Aid, Relief and Economic Security ("CARES") Act. The CARES Act was signed into law in March 2020 in order to provide economic assistance for organizations and individuals that have been negatively impacted by the COVID-19 pandemic. During 2020, University Hospital received CARES Act payments primarily from the Provider Relief Fund. The Provider Relief Fund is administered through the U.S. Department of Health and Human Services and offers funding to hospitals and health care providers to offset expenses incurred or revenues lost associated due to the COVID-19 pandemic. Economic Relief Funds received and recognized by University Hospital totaled \$240 thousand and \$67.3 million in federal CARES Act provider relief funding and \$172 thousand and \$3.2 million State CARES Act funding through September 30, 2021 and 2020, respectively.

State Appropriations for UAB are made by the Alabama State Legislature based upon a process which involves requests from the Board of Trustees of The University of Alabama, and budget recommendations by the Alabama Commission on Higher Education and the Governor. State funds are appropriated annually from the Educational Trust Fund ("ETF") to UAB. In 2021, State educational appropriations from the ETF increased \$8.2 million from the prior year, reaching a total of \$305.9 million. In 2020, State educational appropriations from the ETF increased \$24.2 million over 2019 for a total received of \$297.7 million. State educational appropriations also include supplemental appropriations received from the Mental Health Trust Fund and Advancement and Technology Fund which totaled \$9.1 million and \$9.3 million in fiscal years 2021 and 2020, respectively. UAB also received Public School and College Authority funds and other state capital funds in 2021 totaling \$3.6 million.

Nonoperating grants historically consist primarily of Federal Pell grant awards. This program provides financial assistance grants to qualifying undergraduate students to promote access to postsecondary education. During fiscal years 2021 and 2020, the University received COVID-19 emergency grant funding, primarily through Higher Education Emergency Relief Funds ("HEERF") I, II, and II, and the Coronavirus Relief Fund ("CRF"). Total HEERF funds of \$57.5 million and \$12.7 million were received in fiscal years 2021 and 2020, respectively, to be distributed as emergency financial aid grants directly to students, as well as to provide funding for areas of the University negatively impacted by the COVID-19 pandemic. CRF funds of \$0 million and \$49.6 million were received during fiscal years 2021 and 2020, respectively, to offset necessary expenses incurred due to the public health emergency with respect to COVID-19. These amounts were recorded in nonoperating grants revenue. As a result, nonoperating grant revenue increased to \$105.1 million from \$57.9 million in 2021, and to \$57.9 million from \$35.5 million in 2020. Further information on COVID-19 emergency grant funding can be found in note 1.

The University Hospital recognized \$3.2 million as nonoperating revenue from CARES funds allocated from the State of Alabama in 2020 and recognized an additional \$172 thousand as nonoperating revenue in 2021. Alabama State Cares funds were required to be expended by December 30, 2020 and used to cover expenses necessary to prevent, prepare for, and respond to COVID-19.

In addition, University Hospital received \$180.2 million during 2020 in advance payments from the Centers for Medicare and Medicaid Services (CMS) Accelerated and Advance Payments Program reported as due to third party payors and advances payable, net on the Statements of Net Position. The Medicare advance payment amount was classified as a current liability in 2020 based on guidance that existed as of September 30, 2020; however, guidance issued subsequent to September 30, 2020 provided for the advance payments to be repaid over a period extending beyond twelve months after the September 30, 2020 balance sheet date. Based on current guidance, however, the

remaining Medicare advance payments are required to be paid by September 30, 2022 and are recorded as a current liability as of September 30, 2021. As of September 30, 2021, \$131.4 million remains outstanding to CMS and is recorded in due to third party payors and advances payable related to the Medicare advance payments on the Statements of Net Position.

Gift revenue consists of gifts, pledges, endowment gifts and capital gifts. UAB's gift revenue totaled \$95.9 million at September 30, 2021, which was a increase of \$57.6 million from the prior year. The change in gift revenue is primarily due to the generous Heersink pledge made to the UAB School of Medicine in 2021. In 2020 UAB gift revenues decreased \$38.9 million to \$38.3 million, primarily due to a decline in new pledges and endowment gifts during 2020.

Both investment and endowment income are combined as investment income on the SRECNP. Net investment income increased \$540.2 million from 2020 to 2021 and decreased \$16.5 million from 2019 to 2020. The increase in 2021 was the result of a much improved performance of the investments held in the UA Investment Pools, which strengthened the fair value of the investments at September 30, 2021. The decrease in 2020 was largely the result of poor performance of the investments held in the UA Investment Pools, which eroded the fair value of investments at September 30, 2020.


Operating Expenses

A comparative summary of UAB's operating expenses by natural classification for the years ended September 30, 2021, 2020, and 2019, is as follows:

| 2021 | | 2020 | | 2019 |
|---------------------|------------------------------|-----------------------------------|--|--|
| \$ 1,963,628,897 | \$ | 1,766,044,825 | \$ | 1,749,060,938 |
| 2,174,043,204 | | 2,001,552,207 | | 1,846,254,490 |
| 156,533,614 | | 150,994,130 | | 148,344,143 |
| 55,053,095 | | 35,285,313 | | 29,041,268 |
| \$ 4,349,258,810 | \$ | 3,953,876,475 | \$ | 3,772,700,839 |
| \$ | 2,174,043,204 156,533,614 | \$ 1,963,628,897 \$ 2,174,043,204 | \$ 1,963,628,897 \$ 1,766,044,825 2,174,043,204 2,001,552,207 156,533,614 150,994,130 55,053,095 35,285,313 | \$ 1,963,628,897 \$ 1,766,044,825 \$ 2,174,043,204 2,001,552,207 156,533,614 150,994,130 55,053,095 35,285,313 |

Graphic illustrations of UAB's operating expenses by natural classification for the year ended September 30, 2021 is presented as below:

2021 Operating Expenses by Natural Classification



UAB is one of the largest employers in the state with a total workforce of 23,609, 23,791, and 22,704 in 2021, 2020, and 2019, respectively. The workforce consisted of 17,674 full-time and 5,935 part-time employees, of which underrepresented employees making up approximately 40% in 2021. UAB employed 2,572 faculty of which 905 or 35% were tenured in 2021. UAB's salaries, wages, and benefits totaled \$1.96, 1.77 billion, \$1.75 billion and makes up 45.1%, 44.7%, and 46.4% of total operating expenses in 2021, 2020, and 2019, respectively. Salaries, wages, and benefits increased \$197.6 million or 11.2% to \$1.96 billion during 2021. Salaries, wages, and benefits increased \$17.0 million or 1.0% to \$1.77 billion and \$74.1 million or 4.4% to \$1.75 billion during 2020 and 2019, respectively. The increases in both years are primarily due to the growth of UAB's salary base and rising benefit costs related to growth in salary base.

Supplies and services totaled \$2.17, \$2.00, and \$1.85 billion and makes up the largest portion of total operating expenses at 50.0%, 50.6%, and 48.9% in 2021, 2020, and 2019, respectively. During 2021, Supplies and services increased \$172.5 million to \$2.17 billion due to increases in patient volume and inflationary increases in supplies and service costs and an 6% increase in Triton's medical and hospital expenses per member. Supplies and services increased \$155.3 million or 8.4% to \$2.00 billion during 2020. This increase is due to costs incurred to prevent, prepare for, and respond to the COVID-19 pandemic and inflationary increases in supplies and service costs. Supplies and services increased \$111.8 million or 6.4% to \$1.85 billion during 2019. This increase was primarily driven by increases in patient volume and inflationary increases in supplies and service costs.

Depreciation expense increased 3.7%, or \$5.5 million to \$156.5 million in 2021, as compared to an increase of 1.8%, or \$2.6 million, to \$151.0 million in 2020. This increase is due to the 3% or \$135.1 million growth in total assets in 2021. Capital assets placed in service during 2021 include the addition of an Magnetic Resonance Imaging ("MRI") on the 5th floor of the UAB Women and Infant Center and the Information and Technology Center. Depreciation expense increased, 1.8% or \$2.6 million, to \$151.0 million in 2020, as compared to an increase, of 1.1% or \$1.7 million, to \$148.3 million in 2019. This increase is due to the 5% or \$184.3 million growth in total assets in 2020. Capital assets placed in service during 2020 include the Green Hall (a new residence hall).


Scholarships and fellowships expense is reported net of scholarship allowances. The net expenses of \$55.1, \$35.3, and \$29.0 million for fiscal years 2021, 2020, and 2019, respectively, represent payments made directly to students after awards have been applied against tuition and fees and auxiliary housing charged to student accounts. Gross scholarship expenses, including allowances, totaled \$146.8, \$120.7, and \$109.3 million for the years ended September 30, 2021, 2020, and 2019, respectively. As mentioned previously, during fiscal year 2020 the University received CARES Act - HEERF funding to assist students negatively impacted by the COVID-19 pandemic. Student aid of \$6.1 million and \$6.1 million is included in scholarships and fellowships expense at September 30, 2021 and 2020, respectively.

In addition to natural classifications, operating expenses are reported by functional classifications as defined by the National Association of College and University Business Officers ("NACUBO"). It is informative to review operating expenses by functional classification. The functional classification of an operating expense (Instruction, Research, etc.) is assigned to a department based on the nature of the activity, which represents the material portion of the activity attributable to the department. This method reflects amounts expended in areas such as instruction, research, and operations and maintenance and is used most commonly for comparative reporting purposes among colleges and universities. The University's expenses by functional classification for the years ended September 30, 2021, 2020, and 2019, are summarized as follows:

| | 2021 | 2020 | 2019 |
|-------------------------------------|------------------|------------------|------------------|
| Instruction | \$ 293,021,318 | \$ 283,997,293 | \$ 287,227,119 |
| Research | 338,353,105 | 294,178,648 | 303,143,578 |
| Public service | 182,472,393 | 167,182,949 | 164,457,460 |
| Academic support | 169,903,914 | 172,297,940 | 180,576,986 |
| Student services | 39,587,573 | 38,807,497 | 42,454,858 |
| Institutional support | 240,585,350 | 218,209,882 | 156,689,652 |
| Operations and maintenance of plant | 73,252,765 | 68,708,171 | 70,747,504 |
| Scholarships and fellowships | 55,053,095 | 35,285,313 | 29,041,268 |
| University Hospital | 2,060,650,890 | 1,800,120,115 | 1,713,060,350 |
| Auxiliary | 739,844,793 | 724,094,537 | 676,957,921 |
| Depreciation | 156,533,614 | 150,994,130 | 148,344,143 |
| TOTAL OPERATING EXPENSES | \$ 4,349,258,810 | \$ 3,953,876,475 | \$ 3,772,700,839 |

Graphic illustrations of UAB's operating expenses by functional classification for the year ending September 30, 2021 is presented as follows:

2021 Operating Expenses by Functional Classification



The instruction category includes expenses for all activities that are part of an UAB's instruction programs. Instruction expenses increased \$9.0 million in 2021, and decreased \$3.2 million in 2020. The research category includes all expenses for activities specifically organized to produce research, whether commissioned by an agency external to UAB or separately budgeted by an organizational unit within UAB. Research expenses increased \$44.2 million in 2021, and decreased \$9.0 million in 2020. The institutional support category includes expenses for central, executive-level activities concerned with management of UAB. Institutional expenses increased \$22.4 million in 2021, and increased \$61.5 million in 2020. University Hospital expenses increased 14.5%, or \$260.5 million, in 2021, and increased 5.1%, or \$87.1 million, in 2020, and reflect the impact of additional patient activity and capacity expansion. Increased compensation expense related to patient care includes both growth in staff levels and wage increases. Increased medical supplies expense results from higher patient activity levels and the rising cost of pharmaceuticals. During 2020, the increase in medical supplies expense also included the additional cost of personal protective equipment acquired in response to the COVID-19 pandemic. An auxiliary enterprise exists to furnish goods or services to students, faculty, staff, other institutional departments, or incidentally to the general public, and charges a fee directly related to, although not necessarily equal to, the cost of the goods or services. The auxiliary enterprise category includes all expenses relating to the operation of auxiliary enterprises, and increased 2.2% or \$15.8 million in 2021, and increased 7.0% or \$47.1 million in 2020.

Economic Factors That Will Affect The Future

As a labor-intensive organization, UAB faces competitive pressures related to attracting and retaining faculty and staff.

The State of Alabama appropriates money each year to UAB for operating costs and nonoperating cash requirements, including capital expenditures. Because the State is mandated by its Constitution to operate with a balanced budget, the State occasionally has reduced its appropriations, through a process known as "proration," when its annual revenues are not expected to meet budgeted appropriations. As the State could potentially implement proration in future years, UAB continues to implement cost-saving measures in order to minimize the impact of any future proration.

Private gifts are an important part of the fundamental support of UAB. Economic pressures affecting donors may also affect the future level of support UAB receives from corporate and individual giving. In 2021 the University received the single largest philanthropic commitment in university history from longtime UAB supporter Marnix E. Heersink, M.D. As a result, the school of medicine will now be known as the UAB Marnix E. Heersink School of Medicine. In addition, UAB will establish the Marnix E. Heersink Institute of Biomedical Innovation and the Mary Heersink Institute for Global Health. The gift and related matching gifts will provide support with both endowed and outright funds for key initiatives of the UAB Marnix E. Heersink School of Medicine.

During fiscal year 2021, 66.0% of UAB students received financial aid, including \$193.5 million of Federal Financial Aid. In recent years, financial aid reform and reauthorization of existing aid programs have been topics in legislative sessions. Management is monitoring proposed future legislation in order to respond in a manner to assist current and future students.

The University Hospital faces significant challenges in a dynamic healthcare sector and volatile economic environment. The demand for health care services and the cost of providing them are increasing significantly while the revenues to support these services are diminishing. In addition to cost increases such as rising salary and benefit costs, the University Hospital also faces additional costs associated with new technologies, the education and training of health care professionals and provision of care for a disproportionate share of the medically underserved in Alabama. In recent years, federal legislation has been enacted to slow future rate increases in Medicare and Medicaid and reduce medical education and disproportionate share funding. Management is committed to staying abreast of pertinent issues; implementing appropriate management actions and continuing to provide quality care for all patients.

In January 2020, the World Health Organization declared the novel Coronavirus ("COVID-19") a Public Health Emergency of International Concern. The outbreak of COVID-19 has caused domestic and global disruption in operations for institutions of higher education and healthcare organizations and has impacted several areas of UAB and the University Hospital's financial statements as further discussed within Note 1.

These financial statements are prepared to provide a general overview of the University of Alabama at Birmingham and to demonstrate UAB's accountability. Questions concerning any information provided in this report or requests for additional information should be addressed to Office of the Senior Vice President for Finance and Administration, The University of Alabama at Birmingham, AB 1030, 1720 2ND AVE S, BIRMINGHAM AL 35294-0106.

Statements of Net Position September 30, 2021 and 2020

| | 2021 | | | 2020 |
|---|------|---------------|----|---------------|
| ASSETS | | | | |
| Current Assets: | | | | |
| Cash and cash equivalents | \$ | 473,086,415 | \$ | 641,920,794 |
| Short term investments | | 1,626,016,694 | | 1,196,891,055 |
| Accounts receivable, net | | 608,413,710 | | 530,828,890 |
| Loans receivable, current portion | | 1,824,938 | | 1,994,471 |
| Pledges receivable, current portion | | 8,610,396 | | 10,732,083 |
| Inventories | | 41,477,751 | | 35,827,726 |
| Prepaid expenses and unearned scholarships | | 81,226,121 | | 71,948,834 |
| Other current assets | | 13,569,435 | | 12,001,066 |
| Total current assets | | 2,854,225,459 | | 2,502,144,919 |
| Noncurrent Assets: | | | | |
| Cash designated for capital activities | | 35,225,414 | | 63,098,686 |
| Restricted cash and cash equivalents | | 12,304,675 | | 269,648 |
| Investments for capital activities | | 1,079,385,621 | | 797,791,901 |
| Endowment and life income investments | | 711,622,472 | | 539,974,716 |
| Investment in Professional Liability Trust Fund | | 69,880,913 | | 59,920,845 |
| Other long-term investments | | 117,568,898 | | 107,735,412 |
| Loans receivable, net | | 8,555,102 | | 8,347,250 |
| Pledges receivable | | 34,104,960 | | 29,408,901 |
| Due from affiliates | | 52,206,128 | | 34,552,128 |
| Capital assets, net | | 1,788,161,516 | | 1,784,230,411 |
| Other noncurrent assets | | 125,061 | | 4,075,296 |
| Total noncurrent assets | | 3,909,140,760 | | 3,429,405,194 |
| Total Assets | | 6,763,366,219 | | 5,931,550,113 |
| DEFERRED OUTFLOWS OF RESOURCES | | | | |
| Bond deferred refundings | | 12,081,090 | | 13,336,713 |
| Pension and OPEB related obligations | | 850,533,926 | | 305,494,017 |
| Total Deferred Outflows of Resources | | 862,615,016 | | 318,830,730 |
| Total Assets and Deferred Outflows of Resources | \$ | 7,625,981,235 | \$ | 6,250,380,843 |

Statements of Net Position (continued) September 30, 2021 and 2020

| | 2021 | | | 2020 | | |
|--|------|---------------|----|---------------|--|--|
| LIABILITIES | | | | | | |
| Current Liabilities: | | | | | | |
| Accounts payable and accrued liabilities | \$ | 565,985,667 | \$ | 596,371,343 | | |
| Deposits | | 17,439,588 | | 15,078,378 | | |
| Unearned revenue-grants | | 57,039,007 | | 50,928,154 | | |
| Unearned revenue-other | | 107,134,621 | | 99,077,929 | | |
| Long-term debt, current portion | | 37,443,982 | | 38,749,671 | | |
| Total current liabilities | | 785,042,866 | | 800,205,475 | | |
| Noncurrent Liabilities: | | | | | | |
| Federal advances-loan funds | | 6,780,063 | | 8,483,518 | | |
| Long-term debt, noncurrent portion | | 1,063,644,857 | | 1,087,186,699 | | |
| Pension liability | | 1,413,306,000 | | 1,245,083,000 | | |
| OPEB liability | | 685,712,303 | | 271,431,941 | | |
| Other noncurrent liabilities | | 26,655,309 | | 28,713,594 | | |
| Total noncurrent liabilities | | 3,196,098,532 | | 2,640,898,752 | | |
| Total Liabilities | | 3,981,141,397 | | 3,441,104,227 | | |
| DEFERRED INFLOWS OF RESOURCES | | | | | | |
| Pension and OPEB related obligations | | 525,445,555 | | 521,937,116 | | |
| Total Deferred Inflows Of Resources | | 525,445,555 | | 521,937,116 | | |
| NET POSITION | | | | | | |
| Net investment in capital assets | | 786,585,310 | | 769,281,767 | | |
| Restricted | | | | | | |
| Nonexpendable | | 390,793,182 | | 405,615,948 | | |
| Expendable | | 600,618,098 | | 353,055,159 | | |
| Unrestricted | | 1,341,397,693 | | 759,386,626 | | |
| Total Net Position | | 3,119,394,283 | | 2,287,339,500 | | |
| Total Liabilities, Deferred Inflows and Net Position | \$ | 7,625,981,235 | \$ | 6,250,380,843 | | |

Statements of Revenues, Expenses, and Changes in Net Position Years Ended September 30, 2021 and 2020

| | 2021 | 2020 | | |
|--|------------------|------------------|--|--|
| Operating Revenues | | | | |
| Tuition and fees | \$ 335,202,452 | \$ 330,385,766 | | |
| Less: scholarship allowance | (91,726,065) | (85,456,029) | | |
| Tuition and fees, net | 243,476,387 | 244,929,737 | | |
| Grants and contracts: | | | | |
| Federal | 431,152,917 | 392,328,131 | | |
| State | 10,601,841 | 9,637,192 | | |
| Local | 2,733,401 | 2,743,274 | | |
| Private | 82,238,852 | 79,212,985 | | |
| Sales and services: | | | | |
| Educational activities | 67,666,602 | 59,351,275 | | |
| University Hospital, net of bad debt expense of \$248.6 million in 2021 and \$187.9 million in 2020 | 2,472,801,416 | 2,109,833,577 | | |
| Other auxiliary enterprises, net of scholarship allowance of \$1.8 million in 2021 and \$2.4 million in 2020 | 782,355,857 | 762,448,115 | | |
| Other operating revenues | 40,280,076 | 51,986,550 | | |
| Total operating revenues | 4,133,307,349 | 3,712,470,836 | | |
| Operating Expenses | | | | |
| Salaries, wages and benefits | 1,963,628,897 | 1,766,044,825 | | |
| Supplies and services | 2,174,043,204 | 2,001,552,207 | | |
| Depreciation | 156,533,614 | 150,994,130 | | |
| Scholarships and fellowships | 55,053,095 | 35,285,313 | | |
| Total operating expenses | 4,349,258,810 | 3,953,876,475 | | |
| Operating loss | (215,951,461) | (241,405,639) | | |
| Nonoperating Revenues (Expenses) | | | | |
| Economic Relief Funds | 412,719 | 71,281,070 | | |
| State educational appropriations | 314,953,056 | 306,964,712 | | |
| Grants and contracts | 105,093,454 | 57,856,589 | | |
| Gifts | 61,112,310 | 18,705,016 | | |
| Investment income | 555,919,121 | 15,735,962 | | |
| Interest expense | (35,280,621) | (40,126,392) | | |
| Loss on asset dispositions, net | (1,907,293) | (567,152) | | |
| Other nonoperating income, net | 9,284,341 | 889,773 | | |
| Net nonoperating revenues | 1,009,587,087 | 430,739,578 | | |
| Income before other changes in net position | 793,635,626 | 189,333,939 | | |
| Other Changes in Net Position | | | | |
| State capital gifts | 3,610,767 | _ | | |
| Capital gifts and grants | 1,645,260 | 1,854,223 | | |
| Endowment gifts | 33,163,130 | 17,755,898 | | |
| Total other changes in net position | 38,419,157 | 19,610,121 | | |
| Increase in net position | 832,054,783 | 208,944,060 | | |
| Net Position, beginning of year | 2,287,339,500 | 2,078,395,440 | | |
| Net Position, end of year | \$ 3,119,394,283 | \$ 2,287,339,500 | | |

Statements of Cash Flows Years Ended September 30, 2021 and 2020

| | 2021 | 2020 | | |
|---|-----------------|-----------------|--|--|
| Cash flows from operating activities | | | | |
| Student tuition and fees | \$ 249,506,292 | \$ 246,333,703 | | |
| Grants and contracts: | | | | |
| Federal | 422,804,721 | 398,734,987 | | |
| State | 10,194,733 | 12,733,355 | | |
| Local | 4,307,528 | 1,981,861 | | |
| Private | 81,575,192 | 82,655,623 | | |
| Receipts from sales and services of: | | | | |
| Educational activities | 66,724,028 | 59,175,998 | | |
| Patient services | 2,361,333,048 | 2,058,613,804 | | |
| Auxiliary enterprises, net | 46,375,753 | 35,084,704 | | |
| Premium and administrative fees collected | 750,236,493 | 716,906,063 | | |
| Payment to employees and related benefits | (1,364,877,617) | (1,311,156,619) | | |
| Payment for contract labor | (536,408,405) | (448,114,236) | | |
| Payment to suppliers | (2,215,523,953) | (1,835,715,862) | | |
| Payment for scholarships and fellowships | (55,053,096) | (35,285,313) | | |
| Other receipts | 33,671,715 | 50,574,552 | | |
| Net cash (used in) provided by operating activities | (145,133,568) | 32,522,620 | | |
| Cash flows from noncapital financing activities | | | | |
| Economic relief funds | 3,368,856 | 67,325,616 | | |
| State educational appropriations | 314,953,056 | 306,964,712 | | |
| Private gifts | 89,185,963 | 59,428,944 | | |
| Student direct lending receipts | 163,479,335 | 167,856,685 | | |
| Student direct lending disbursements | (163,230,477) | (166,625,040) | | |
| Other deposits | 141,166,406 | 60,226,262 | | |
| Deposits from affiliates | (2,736,808) | (5,468,313) | | |
| Net cash provided by noncapital financing activities | 546,186,331 | 489,708,866 | | |
| Cash flows from investing activities | | | | |
| Interest and dividends from investments, net | 62,043,622 | 96,970,912 | | |
| Proceeds from notes receivable | 137,233 | 85,697 | | |
| Proceeds from sales and maturities of investments | 10,279,096 | 8,342,944 | | |
| Purchases of investments | (418,466,261) | (167,556,803) | | |
| Net cash used in investing activities | (346,006,310) | (62,157,250) | | |
| Cash flows from capital and related financing activities | | <u> </u> | | |
| Proceeds from issuance of capital debt | 758,968 | 11,037,858 | | |
| State capital appropriations | 3,610,767 | ,007,000 | | |
| Capital gifts, grants and contracts | 4,433,541 | | | |
| Proceeds from sale of capital assets | 4,985,095 | 380,128 | | |
| Purchases of capital assets | (176,474,734) | (220,801,455) | | |
| Principal payments on capital debt | (38,935,420) | (35,296,312) | | |
| Interest payments on capital debt | (38,097,294) | (35,155,526) | | |
| Net cash used in capital and related financing activities | (239,719,077) | (277,243,383) | | |
| Net (decrease) increase in cash and cash equivalents | (184,672,624) | 182,830,853 | | |
| Cash and cash equivalents, beginning of year | 705,289,128 | 522,458,275 | | |
| Cash and cash equivalents, end of year | \$ 520,616,504 | \$ 705,289,128 | | |
| - | | | | |

Statements of Cash Flows (continued) Years Ended September 30, 2021 and 2020

| | 2021 | 2020 | |
|--|------|---------------|---------------------|
| Reconciliation of cash and cash equivalents to the statements of net position | | | |
| Cash and cash equivalents | \$ | 473,086,415 | \$ 641,920,794 |
| Cash designated for capital activities | | 35,225,414 | 63,098,686 |
| Restricted cash and cash equivalents | | 12,304,675 | 269,648 |
| Total cash and cash equivalents | | 520,616,504 | \$ 705,289,128 |
| Reconciliation of operating loss to net cash (used in) provided by operating activities | | | |
| Operating loss | \$ | (215,984,292) | \$ (241,405,639) |
| Adjustments to reconcile operating loss to net cash (used in) provided by operating activities | | | |
| Depreciation expense | | 156,533,614 | 150,994,130 |
| Pension expense | | 132,530,000 | 112,188,000 |
| OPEB expense (benefit) | | 24,990,489 | (25,185,389) |
| Changes in assets and liabilities: | | | |
| Accounts receivable, net | | (121,792,057) | 165,975,517 |
| Prepaid expenses and other assets | | (16,738,475) | (17,806,662) |
| Accounts payable and accrued liabilities | | (2,296,355) | 9,577,611 |
| Pension obligations | | (96,839,000) | (98,485,000) |
| OPEB obligations | | (20,135,246) | (22,187,000) |
| Unearned Revenue | | 14,597,754 | (1,142,948) |
| Net cash (used in) provided by operating activities | \$ | (145,133,568) | \$ 32,522,620 |
| Supplemental noncash activities information | | | |
| Capital assets acquired included in accounts payable | \$ | 14,017,484 | \$ 22,430,684 |
| Capital assets acquired through capital lease | | 100,257 | 109,947 |
| Non-cash transfer of funds from the STLP to the LCRP | | _ | 547,946,709 |
| Debt proceeds immediately transferred into escrow | | _ | 81,890,469 |
| Payment of outstanding bonds principal and interest via escrow | | _ | 80,027,733 |
| | | | |

Southern Research Institute (A Discretely Presented Component Unit) Statements of Net Position January 1, 2021 and December 28, 2019

| | | • | | | | |
|--|-----------|---------------|----------|--------------|--|--|
| | | 2021 | | 2020 | | |
| Current Assets: | | | | | | |
| Cash and cash equivalents | \$ | 15,846,028 | \$ | 470,327 | | |
| Investments | | 26,287,986 | | 15,321,444 | | |
| Restricted cash and investments | | 12,226,041 | | 11,933,466 | | |
| Accounts receivable, net | | 17,227,864 | | 17,182,332 | | |
| Other receivables | | 577,048 | | 1,411,383 | | |
| Materials and supplies, net | | 974,676 | | 986,730 | | |
| Prepayments and other current assets | | 2,749,927 | | 756,048 | | |
| Total current assets | | 75,889,570 | | 48,061,730 | | |
| Noncurrent Assets: | | | | | | |
| Net OPEB asset | | 1,565,283 | | 1,187,434 | | |
| Capital assets: | | | | | | |
| Land and improvements | | 5,122,675 | | 6,274,425 | | |
| Buildings and major plant equipment | | 66,665,302 | | 67,746,523 | | |
| Laboratory equipment and fixtures | | 57,654,248 | | 64,804,143 | | |
| Office furniture and equipment | | 3,522,256 | | 3,622,526 | | |
| Intangible assets, net | | 1,906,909 | | 1,707,790 | | |
| | | 134,871,390 | | 144,155,407 | | |
| Less accumulated depreciation | | (88,209,821) | | (91,792,022) | | |
| | | 46,661,569 | | 52,363,385 | | |
| Construction-in-progress | | 1,341,134 | | 667,583 | | |
| Total capital assets, net | | 48,002,703 | | 53,030,968 | | |
| Total noncurrent assets | | 49,567,986 | | 54,218,402 | | |
| Total Assets | | 125,457,556 | | 102,280,132 | | |
| Deferred Outflows of Resources | | | | | | |
| OPEB | | 280,742 | | 319,792 | | |
| Total Assets and Deferred Outflows of Resources | \$ | 125,738,298 | \$ | 102,599,924 | | |
| | <u>*</u> | | <u> </u> | 102,000,021 | | |
| Current Liabilities: | ^ | 2 2 4 4 2 4 4 | * | 4 400 550 | | |
| Accounts payable | \$ | 3,841,344 | \$ | 4,400,559 | | |
| Accrued liabilities | | 5,769,660 | | 6,038,919 | | |
| Unearned contract revenue | | 9,491,157 | | 5,192,267 | | |
| Current maturities of long-term debt and capital lease obligations | | 8,985,991 | | 987,380 | | |
| Note payable | | | | 172,370 | | |
| Total current liabilities | | 28,088,152 | | 16,791,495 | | |
| Noncurrent Liabilities: | | | | | | |
| Long-term debt and capital lease obligations | | 13,634,937 | | 14,063,162 | | |
| Total noncurrent liabilities | | 13,634,937 | | 14,063,162 | | |
| Total Liabilities | | 41,723,089 | | 30,854,657 | | |
| Deferred Inflows of Resources | | | | | | |
| OPEB | | 1,670,887 | | 1,472,708 | | |
| Net Position | | , , | | , , | | |
| | | 22 100 475 | | 27,000,426 | | |
| Net investment in capital assets | | 33,108,475 | | 37,980,426 | | |
| Restricted | | 42 404 470 | | 42.462.004 | | |
| Expendable | | 12,401,179 | | 12,462,984 | | |
| Unrestricted | | 36,834,668 | | 19,829,149 | | |
| Total Net Position | <u></u> | 82,344,322 | • | 70,272,559 | | |
| Total Liabilities, Deferred Inflows Of Resources, and Net Position | <u>\$</u> | 125,738,298 | \$ | 102,599,924 | | |

Southern Research Institute (A Discretely Presented Component Unit) Statements of Revenues, Expenses, and Changes in Net Position Years Ended January 1, 2021 and December 28, 2019

| Operating Revenues Contract revenues Intellectual property revenues, net of direct expenses | \$ 80,481,381 | |
|---|------------------|------------------|
| Intellectual property revenues, net of direct expenses | \$ 00 401 201 | |
| | 00,401,301 | \$ 76,296,491 |
| Total apprehing various | 1,669,020 | 1,748,981 |
| Total operating revenues | 82,150,401 | 78,045,472 |
| Operating Expenses | | |
| Salaries, wages and benefits | 42,197,364 | 46,123,903 |
| Supplies and services | 31,769,278 | 30,641,540 |
| Depreciation and amortization | 6,170,775 | 6,563,411 |
| Total operating expenses | 80,137,417 | 83,328,854 |
| Operating income (loss) | 2,012,984 | (5,283,382) |
| Nonoperating Revenues (Expenses) | | |
| Contributions | 270,253 | 312,507 |
| Investment income | 916,130 | 3,258,840 |
| Interest expense | (457,436) | (384,463) |
| Gain (loss) on disposal of assets | 9,329,832 | (1,711,609) |
| Net nonoperating revenues | 10,058,779 | 1,475,275 |
| Change in net position | 12,071,763 | (3,808,107) |
| Net Position, beginning of year | 70,272,559 | 74,080,666 |
| Net Position, end of year | \$ 82,344,322 | \$ 70,272,559 |

The University of Alabama at Birmingham Notes to Financial Statements Years Ended September 30, 2021 and 2020



Organization and Summary of Significant Accounting Policies

The University of Alabama at Birmingham ("UAB") is one of three universities of The University of Alabama System ("the System"), which is a component unit of the State of Alabama ("the State"). The financial statements of UAB are intended to present the financial position, changes in financial position, and the cash flows of only that portion of the business-type activities of the financial reporting entity of the System that is attributable to the transactions of UAB. They do not purport to, and do not, present fairly the financial position of the System, its changes in financial position or cash flows in accordance with accounting principles generally accepted in the United States of America. The System is recognized as an organization exempt from Federal income tax under Section 501(a) of the Internal Revenue Code as an organization described in Section 501(c)(3) of the Internal Revenue Code.

UAB, as a public institution, prepares its financial statements in accordance with accounting principles generally accepted in the United States of America, as prescribed by the Governmental Accounting Standards Board (GASB).

GASB Statement No. 35, Basic Financial Statements and Management's Discussion and Analysis for Public Colleges and Universities, establishes standards for external financial reporting for public colleges and universities and requires that resources be classified for accounting and reporting purposes into the following three net position categories:

Net Investment in Capital Assets:

Capital assets, net of accumulated depreciation and outstanding principal balances of debt attributable to the acquisition, construction, or improvement of those assets.

Restricted:

Nonexpendable: Net position subject to externally imposed stipulations that they be maintained permanently by UAB. Such assets include UAB's permanent endowment funds.

Expendable: Net position whose use by UAB is subject to externally imposed stipulations that can be fulfilled by actions of UAB pursuant to those stipulations or that expire by the passage of time.

Unrestricted:

The net position that is not subject to externally imposed stipulations. Unrestricted net position may be designated for specific purposes by action of management. Substantially all of the unrestricted net position is designated for academic and research programs and initiatives and capital programs.

For financial reporting purposes, UAB is considered a special-purpose government engaged only in business-type activities as defined by GASB Statement No. 35. Business-type activities are those that are financed in whole or in part by fees charged to external parties for goods or services. Under the accrual basis, revenues are recognized when earned, and expenses are recorded when an obligation has been incurred.

UAB policy states that operating activities as reported by the statement of revenues, expenses, and changes in net position are those that generally result from exchange transactions such as payments received for providing services and payments made for services or goods received. Certain significant revenue streams relied upon for operations are recorded as nonoperating revenues, as defined by GASB Statement No. 35.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. The estimates susceptible to significant changes include those used in determining the allowance for contractual adjustments and uncollectible accounts, valuation of investments, accruals related to compensated absences, allowance for self-insurance, estimated amounts due to or from third-party payors, and reserves for general and professional liability claims. Although some variability is inherent in these estimates, management believes that the amounts provided are adequate.

Scope of Statements

UAB is principally comprised of a university ("the University") and the University of Alabama Hospital ("University Hospital") which are UAB's reportable segments as defined by GASB Statement No. 37, *Basic Financial Statements and Management's Discussion and Analysis-For State and Local Governments: Omnibus an Amendment of GASB Statements No. 21 and No. 34.* UAB's financial statements present the financial position, changes in financial position, and the cash flows of the University, the University Hospital, and UAB's blended component units. Condensed financial information of UAB's reportable segments is presented at Note 15. Refer to Note 2 for information regarding UAB's component units.

UAB is affiliated with the UAB Educational Foundation ("UABEF"), the University of Alabama Health Services Foundation, P.C. ("HSF"), UAB Health System ("UABHS"), Medical West, Cooper Green Mercy Health Services Authority, and the Valley Foundation ("VF"). UAB is not financially accountable for UABEF, HSF, UABHS or VF; therefore, they do not constitute component units under the provisions of GASB Statement No. 14, *The Financial Reporting Entity*, as amended. These entities are not required to be presented as component units under GASB Statement No. 39, *Determining Whether Certain Organizations are Component Units – an Amendment of GASB Statement No. 14* and No. 61, *The Financial Reporting Entity –* an *Amendment of GASB Statement No. 14* and 34. More information regarding HSF, UABHS and VF can be found at Note 16.

UABEF provides funds and certain facilities to UAB for its educational and scientific functions. UABEF has 13 board members, including seven outside members not affiliated with UAB. The UABEF Board approved to modify the fiscal year from June 30 to September 30 effective as of September 30, 2021. The current balance reflected below is for the fifteen months ended September 30, 2021. UABEF leases certain facilities to UAB, with rental expense of approximately \$3.3 million for the year ended September 30, 2021 and \$2.2 million for the year ended September 30, 2020. UABEF made contributions to UAB which totaled approximately \$3.0 million for the year ended September 30, 2021 and approximately \$4.2 million for the year ended June 30, 2020.

Implementation of new standards: During 2021, UAB adopted GASB Statement No. 84, *Fiduciary Activities*, which aims to improve guidance regarding the identification of fiduciary activities for accounting and financial reporting purposes and how those activities should be reported. The impact from its adoption of GASB 84 was not material to the financial statements.

Other significant accounting policies are as follows:

Cash and Cash Equivalents: For purposes of the statement of cash flows, UAB considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents representing assets of UAB's endowment, life income, and other long-term investments are included in noncurrent assets.

Investments: UAB's investments are reported at fair value. The majority of UAB's investment portfolio is invested in separate investment pools sponsored by the System. Fair value for the investment pools is provided by the System, based on the fair value of the underlying investment securities held by each investment pool. Fair value of the underlying securities held in each investment pool is based on quoted market prices or dealer quotes, where available, or determined using net asset values provided by underlying investment partnerships or companies. Fair value for equity securities, debt securities, mutual funds and U.S. government and agency obligations held by UAB is determined from quoted market prices or market prices of similar instruments. Real estate held as investments is reported at fair value based upon appraisals, acquisition value at the date of donation, and other valuations typically based on management assumptions or expectations. Investments received by gift are reported at fair value at date of receipt. Net investment income, including realized and unrealized gains and losses, is reported as nonoperating revenues (expenses) in the statements of revenues, expenses, and changes in net position.

Investments are reported in four categories in the statement of net position. Investments recorded as endowment and life income investments are those invested funds that cannot be used to fund current operations and thus are included in noncurrent assets. Investments held for future capital projects are included in noncurrent assets. Other long-term investments include amounts resulting from UAB's equity investment in other entities, as discussed in Note 4 and Note 8. All other investments are included as short-term investments.

Inventories: Inventories are carried at the lower of cost or market. Inventories consist primarily of medical supplies and pharmaceuticals.

Accounts Receivable: Accounts receivable consist primarily of patient receivables, tuition charged to students and amounts due from federal, state, and local governments, or private sources, in connection with reimbursement of allowable expenditures made pursuant to UAB's contracts and grants.

Capital Assets: All capital assets are carried at cost on date of acquisition (or in the case of gifts, at acquisition value on the date of donation), less accumulated depreciation (or in the case of assets leased under capital leases, net of accumulated amortization). UAB computes depreciation for buildings and building improvements (15-40 years) and for fixed equipment systems (3-20 years) using a component method. Depreciation of land improvements (40 years), library collection (10 years), and inventoried equipment (3-20 years) is computed on a straight-line basis. The University Hospital uses guidelines established by the American Hospital Association to assign useful lives to inventoried equipment.

Capital assets acquired under capital leases are amortized over the shorter of the lives of the respective leases or the estimated useful lives of the assets. Capital assets acquired through federal grants and contracts in which the Federal government retains a reversionary interest are capitalized and depreciated.

Computer software capitalization, which is included as inventoried equipment, includes the costs of software and implementation. Implementation costs include consulting expenses and allocation of internal salaries and fringes for the core implementation team.

Pledges: UAB receives gift pledges and bequests of financial support. Revenue is recognized when a pledge representing an unconditional promise to give is received and all eligibility requirements, including time requirements, have been met. In the absence of such a promise, revenue is recognized when the gift is received. Pledges are recorded at their gross, undiscounted amount. Endowment pledges do not meet eligibility requirements and are not recorded as assets until the related gift is received in accordance with the requirements of GASB Statement No. 33, *Accounting and Financial Reporting for Nonexchange Transactions*. Due to uncertainties with regard to their realization and valuation, bequest intentions and other conditional promises are not recognized as assets until the specified conditions are met.

Endowment Spending: The State Legislature adopted the Alabama Uniform Prudent Management of Institutional Funds Act ("UPMIFA"), effective January 1, 2009, which permits the Board of Trustees of the University of Alabama (the "Board") to appropriate an amount of realized and unrealized endowment appreciation as the Board determines to be prudent. UPMIFA prescribes guidelines for the expenditure of donor-restricted endowment funds in the absence of overriding, explicit donor stipulations. UPMIFA focuses on the entirety of a donor-restricted endowment fund, that is, both the original gift amount(s) and net appreciation. UPMIFA eliminates UMIFA's historic-dollar-value threshold, an amount below which an organization could not spend from the fund, in favor of a more robust set of guidelines about what constitutes prudent spending, explicitly requiring consideration of the duration and preservation of the fund.

UAB's policy is to retain the endowment realized and unrealized appreciation within an endowment after the spending rate distributions in a manner consistent with the standards of prudence prescribed by UPMIFA. The Board approved a spending rate for fiscal years September 30, 2021 and 2020 of 4.5%, based on a moving five-year average of the market (unit) value.

Prepaid Expenses and Unearned Scholarships: Prepaid expenses are composed of future expenses that have been paid in advance and include prepaid postage, travel, and other miscellaneous expenses. Unearned scholarship expense results from the Fall academic term spanning across the fiscal year-end. UAB prorates scholarship expense to recognize only the amounts incurred in each fiscal year.

Unearned Revenue: Unearned revenue consists primarily of student tuition and fees related predominantly to future fiscal years and amounts received from grant and contract sponsors that have not yet been earned under the terms of the agreements and, therefore, have not yet been included in the net position.

Federal Refundable Loans: Certain loans to students are administered by UAB with funding primarily supported by the federal government. UAB's statements of net position include both the notes receivable and the related federal refundable loan liability representing federal capital contributions and related activity owed upon termination of the program. The Federal Perkins Loan Program expired June 30, 2018. The University will continue operating the program and remit any excess cash annually for the pro rata federal and institutional capital contributions. As of September 30, 2021, \$1.3 million is payable to the Department of Education for its portion of the excess cash available at June 30, 2020.

Compensated Absences: UAB accrues annual leave for employees at rates based upon length of service and job classification. UAB accrues compensatory time based upon job classification and hours worked. These amounts are included in accounts payable and accrued liabilities.

Deferred Outflows of Resources: Deferred outflows of resources consist of bond deferred refunding amounts, pension obligations, and OPEB obligations (Trust and UAB Plan). Pension obligations include employer contributions to the Teachers' Retirement System subsequent to the Plan's measurement date, differences between expected and actual

experience, and changes in actuarial and other assumptions. The Trust's obligations include employer contributions to the Alabama Retired Education Employees' Health Care Trust subsequent to the Trust's measurement date, differences between expected and actual experience, and changes in proportion and differences between employer contributions and proportionate share of contributions. The UAB Plan's obligations include employer contributions to the UAB Health Care Plan subsequent to the Plan's measurement date for eligible disabled retirees.

Deferred Inflows of Resources: Deferred inflows of resources are composed of pension obligations and OPEB obligations (Trust and UAB Plan). Pension obligations include differences between expected and actual experience, changes in proportion and differences between employer contributions and proportionate share of contributions, and net difference between projected and actual earnings on pension plan investments. The Trust's obligations include changes in actuarial and other assumptions and net difference between projected and actual earnings on OPEB plan investments. The UAB Plan's obligations include differences between expected and actual experience and changes in actuarial and other assumptions.

Student Tuition and Fees and Scholarship Allowances and Student Aid: Student tuition and fees are presented net of scholarships and fellowships applied to student accounts, while stipends and other payments made directly to students are presented as scholarships and fellowships expense.

Grant and Contract Revenue: UAB receives grant and contract revenue from governmental and private sources. UAB recognizes revenue associated with the sponsored programs in accordance with GASB Statement No. 33, based on the terms of the individual grant or contract.

University Hospital Revenue: Net patient service revenue is reported at the University Hospital's estimated net realizable amounts from patients, third-party payors, and others for services rendered, including estimated retroactive revenue adjustments due to revenue audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered.

The University Hospital provides care to patients who meet certain criteria under its charity care policy without charge or at amounts less than its estimated rates. Because the University Hospital does not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue.

Auxiliary Enterprise Revenue: Auxiliary enterprise revenues primarily represent revenues generated by intercollegiate athletics and parking as well as subscriber premiums for Triton Health Systems, L.L.C.

Other Revenue: Other revenue represents primarily revenues generated by UAB for activities such as intellectual property income and the University of Alabama Health Services Foundation, P.C. ("HSF") transfers.

Equity Investments: Investments in affiliated companies where UAB can exercise significant influence and for which UAB's ownership interest is 50% or less are accounted for using the equity method. The investment in the Professional Liability Trust Fund ("PLTF") also is accounted for using the equity method. See Notes 4 and 8.

Nonoperating Revenues (Expenses): Nonoperating revenues and expenses include State educational appropriations, federal appropriations, Federal Pell grants, private gifts for other than capital purposes, investment income, net unrealized appreciation or depreciation in the fair value of investments, interest expense, loss on asset dispositions, and CARES Act funds for fiscal years 2021 and 2020.

COVID-19 Pandemic: In January 2020, the World Health Organization declared the novel Coronavirus ("COVID-19") a Public Health Emergency of International Concern. The outbreak of COVID-19 has caused domestic and global disruption in operations for institutions of higher education and healthcare organizations. The outbreak has also negatively impacted both the global financial markets and UAB's investments, including the investments held within the System Pools, and may continue to do so. Other adverse consequences of COVID-19 in the future may include, but are not limited to, decline in enrollment, decline in demand for University housing, decline in demand for University programs that involve travel, and additional volatility within UAB's investments. UAB believes it has sufficient liquidity to meet its operating and financing needs; however, given the difficulty in predicting the ultimate duration and severity of the impact of COVID-19 on UAB, the economy and the financial markets, the ultimate impact is unknown and cannot be reasonably quantified at this time.

Coronavirus (COVID-19) Emergency Grants for Higher Education: The Coronavirus Aid, Relief and Economic Security ("CARES") Act was signed into law in March 2020 to provide economic assistance for businesses and individuals that have been negatively impacted by the COVID-19 pandemic. The Higher Education Emergency Relief Fund ("HEERF I"), the Coronavirus Relief Fund ("CRF"), and Provider Relief Fund ("PRF") are authorized by the CARES Act.

The Higher Education Emergency Relief Fund II ("HEERF II") is authorized by the Coronavirus Response and Relief Supplemental Appropriations Act ("CRRSAA"), which was signed into law in December 2020. The CRRSAA funds support education in addition to the HEERF I CARES Act funding.

The Higher Education Emergency Relief Fund III ("HEERF III") is authorized by the American Rescue Plan ("ARP"), which was signed into law in March 2021 to provide support to institutions of higher education to serve students and ensure learning continues during the COVID-19 pandemic. ARP funds are in addition to funds authorized by the CRRSAA and CARES Act.

The HEERF funds are administered through the U.S. Department of Education and are designed to facilitate the distribution of emergency financial aid grants directly to students, as well as to provide funding for institutions negatively impacted by the COVID-19 pandemic. Under the terms of the student portion of this program, revenue is recognized once eligible expenditures associated with the distribution of aid to students have been incurred. For the institutional portions of this program, revenue is recognized as the University identifies eligible expenditures or lost revenues which qualify for reimbursement.

The Coronavirus Relief Fund is administered through the State of Alabama Department of Finance. The purpose of the Coronavirus Relief Fund appropriation is for the funds to be used to prevent, prepare for, and respond to coronavirus only. The CRF covers only those costs that are necessary expenditures incurred due to the public health emergency with respect to COVID-19. Eligibility to receive payment from the State's portion of funds from the CRF is contingent upon certifying that the University will: (1) use the funds in a lawful manner consistent with Section 601(d) of the Coronavirus Relief Fund and (2) will comply with any and all policies and directives issued by the Alabama Department of Finance related to the Coronavirus Relief Funds.

The Provider Relief Fund ("PRF") is administered through the U.S. Department of Health and Human Services ("HHS"). PRF payments may be used to cover lost revenue attributable to COVID-19 or health-related expenses purchased to prevent, prepare for, and respond to COVID-19. Providers are required to report the use of funds expended through June 30, 2021 by September 30, 2021 and funds expended through December 31, 2021 by March 31, 2022. Based on the most recent guidance, providers may be reimbursed for healthcare-related expenses attributable to coronavirus that another source has not reimbursed, as well as lost revenues as measured by one of three options, which include a) calculating based on the negative change in calendar year 2020 and 2021 patient care revenues compared to calendar year 2019 patient care revenues, b) calculating based on the negative change in calendar year 2020 and 2021 patient revenue compared to budgeted 2020 and 2021 patient care revenues, respectively, provided the budget had been established and approved prior to March 27, 2020, and c) calculating by another reasonable method of estimating revenues.

All COVID-19 emergency grants received during fiscal years 2021 and 2020 are included in nonoperating grants in the accompanying statements of revenues, expenses, and changes in net position.



Component Unit(s)

GASB Statement No. 14, The Financial Reporting Entity, as amended by GASB Statement No. 39, Determining Whether Certain Organizations are Component Units – an Amendment of GASB Statement No. 14, No. 61, The Financial Reporting Entity – an Amendment of GASB Statement No. 14 and 34 and No. 80, Blending Requirements for Certain Component Units – an amendment of GASB Statement No. 14, requires governmental entities to include in their financial statements as a component unit, organizations that are legally separate entities for which the governmental entity, as a primary organization, is financially accountable. The primary objective of these statements is to determine whether all entities associated with a primary government are potential component units and should be evaluated for inclusion in the financial reporting entity. The statements as amended provide additional guidance to determine whether certain organizations for which the primary government is not financially accountable should be reported as component units based on the nature and significance of their relationship with the primary government.

Southern Research Institute ("SRI") is a legally separate entity but its financial relationship with UAB is such that excluding SRI from the UAB financial report would be misleading. Management has therefore determined that SRI is a discretely presented component unit of UAB under GASB Statements No. 14 and No. 61. SRI reports financial results under principles prescribed under the GASB. SRI offers research and technology services to support industry and federal government agencies primarily in the areas of drug design and evaluation, environmental controls, materials engineering, and chemical and biological defense. The activities of SRI are maintained using a fiscal calendar year-end

that ends prior to UAB's fiscal year-end of September 30. The financial results of SRI are discretely presented in these financial statements.

UAB includes four blended component units, as follows: UAB Research Foundation ("UABRF"), UAB Athletics Foundation ("UABAF"), UAB Hospital Management, L.L.C. ("LLC") and Triton Health Systems, L.L.C. ("Triton"). The bylaws and corporate charters of UABRF allow UAB to appoint a majority of the board of directors and allow UAB to impose its will on the entity. UABRF operates for the exclusive benefit of UAB. UABAF was organized to support the UAB Athletics Department in its quest for excellence in all programs. UABAF operates as an extension of the UAB Athletics Department and it almost exclusively benefits the University. Additionally, LLC and Triton have governing bodies that are substantively the same as the governing body of UAB and there is a financial benefit or burden relationship between UAB and these entities. Therefore, management has determined that UABRF, UABAF, LLC and Triton (the Blended Component Units) constitute blended component units of UAB under GASB Statements No. 14 and No. 61. The Blended Component Units report financial results under principles prescribed under the GASB.

UABRF was organized exclusively for charitable, scientific, and educational purposes in order to benefit UAB. UABAF was formed in November 2015 as a nonprofit corporation organized to build loyalty and philanthropic support for the UAB athletic program and support the staff in coordinating, developing and improving a superior inter-collegiate athletics program. UABAF encourages alumni and friends to generously support the Athletics Department and contribute to scholarship funding for UAB's student athletes. The LLC was organized for the exclusive purpose of supporting UAB in connection with the management, administration, and operation of the University Hospital, including, without limitation, providing management, administrative, and staffing services to the University Hospital. Triton was formed to advance the educational and research mission of UAB and to educate and train physicians and other health care professionals. Triton is owned 99% by UAB and 1% by The UABEF.

UABRF and LLC maintain a September 30 year-end. UABAF maintains a June 30 year-end. The activities of Triton are maintained using a fiscal calendar year-end that ends prior to UAB's fiscal year-end of September 30. However, interfund cash transactions during the period from January 1 through September 30 have been eliminated. Since Triton qualifies as a major component unit under GASB Statement No. 61, financial information for the years ended December 31, 2020 and 2019 is presented below.

| CONDENSED STATEMENT OF NET POSITION Current assets Capital assets, net Other assets | \$ | 264,795,047 2,727,482 | \$ 261,535,804 |
|--|----------|--------------------------|-------------------|
| Capital assets, net | | | \$ 261 535 804 |
| | * | 2,727,482 | 201,000,001 |
| Other assets | * | | 3,946,551 |
| | * | 117,099,813 | 107,264,624 |
| TOTAL ASSETS | \$ | 384,622,342 | \$ 372,746,979 |
| Current liabilities | | 97,434,894 | 100,010,425 |
| Other noncurrent liabilities | | 633,846 | 899,448 |
| TOTAL LIABILITIES | | 98,068,740 | 100,909,873 |
| Net investment in capital assets | | 2,727,482 | 3,946,551 |
| Restricted nonexpendable net position | | 100,000 | 100,000 |
| Unrestricted net position | | 283,726,120 | 267,790,555 |
| TOTAL NET POSITION | | 286,553,602 | 271,837,106 |
| TOTAL LIABILITIES AND NET POSITION | \$ | 384,622,342 | \$ 372,746,979 |
| CONDENSED STATEMENT OF REVENUES, EXPENSES AND CHANGES IN NET POSITION | | | _ |
| Operating revenues | \$ | 845,745,980 | \$ 810,684,944 |
| Operating expenses | | (799,945,072) | (766,075,475) |
| Depreciation and amortization expense | | (1,282,472) | (1,286,839) |
| OPERATING INCOME | | 44,518,436 | 43,322,630 |
| Investment income | | 7,737,096 | 10,568,127 |
| Interest expense | | _ | (1,394) |
| Income tax expense | | (2,266,772) | (2,800,679) |
| INCOME BEFORE OTHER CHANGES IN NET POSITION | | 49,988,760 | 51,088,684 |
| Distributions to members | | (35,272,264) | (34,197,554) |
| INCREASE IN NET POSITION | | 14,716,496 | 16,891,130 |
| Net position, beginning of year | | 271,837,106 | 254,945,976 |
| NET POSITION, END OF YEAR | \$ | 286,553,602 | \$ 271,837,106 |
| CONDENSED STATEMENT OF CASH FLOWS | | | |
| Net cash provided by (used in): | | | |
| Operating activities | \$ | 37,114,595 | \$ 833,764 |
| Noncapital financing activities | | (35,272,264) | (34,197,554) |
| Capital and related financing activities | | (63,402) | (990,546) |
| Investing activities | | (1,540,132) | 7,670,724 |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | | 238,797 | (26,683,612) |
| Cash and cash equivalents, beginning of year | | 144,343,287 | 171,026,899 |
| CASH AND CASH EQUIVALENTS, END OF YEAR | \$ | 144,582,084 | \$ 144,343,287 |

(3)

Cash and Cash Equivalents

The Board approves, by resolution, all banks or other financial institutions utilized as depositories for UAB funds. Prior to approval, each proposed depository must provide evidence of its designation by the Alabama state treasurer as a qualified public depository under the Security for Alabama Funds Enhancement Act (SAFE). From time to time, the Board may request that the depository provide evidence of its continuing designation as a qualified public depository. In the past, the bank pledged collateral directly to each individual public entity. Under the mandatory SAFE program, each qualified public depository (QPD) is required to hold collateral for all its public deposits on a pooled basis in a custody account established for the State Treasurer as SAFE administrator. In the unlikely event a public entity should suffer a deposit loss due to QPD insolvency or default, a claim form would be filed with the state treasurer, who would use the SAFE pool collateral or other means to reimburse the loss. As of September 30, 2021 and 2020, respectively, UAB had cash and cash equivalents totaling \$520.6 million and \$705.3 million.

(4) Investments

The Board has the responsibility for the establishment of the investment policy and the oversight of the investments for the System and related entities. In order to facilitate System-wide investment objectives and achieve economies of scale, the Board previously established three distinct investment pools based primarily on the projected investment time-horizons for System funds: the Pooled Endowment Fund ("PEF"), Long Term Reserve Pool Fund ("LTRP") and the Short Term Liquidity Pool Fund ("STLP"); collectively, the "System Pools". In April 2020, the Board approved a merger of the STLP and the LTRP into one pool, the Liquidity and Capital Reserve Pool ("LCRP"). In July 2020, the Board closed the STLP and transferred the assets to the LTRP to create the new merged pool, with a new asset allocation. Pursuant to Board investment policies, each System or related entity may include all or a portion of their investments within the System sponsored investment pools. These investment funds are considered 'internal' investment pools under GASB Statement No. 31, Accounting and Financial Reporting for Certain Investments and for External Investment Pools with the assets pooled on a market value basis. Separately managed funds that reside with each entity are to be invested consistent with the asset mix of the corresponding System investment pool. UAB applies the same investment policies for separately held investments as those of the System Pools.

The following disclosures relate to both the System Pools, which include the investments of other System entities and other affiliated entities, and the UAB-specific investment portfolio.

Pooled Endowment Fund

The purpose of the PEF is to pool endowment and similar funds to support the System universities, University Hospital and related entities in carrying out their respective missions over a perpetual time frame. Accordingly, the primary investment objectives of the PEF are to preserve the purchasing power of the principal and provide a stable source of perpetual financial support to the endowment beneficiaries. To satisfy the long-term rate of return objective, the PEF relies on a total return strategy in which investment returns are achieved through both capital appreciation and natural income. Asset allocation targets are established to meet return objectives while providing adequate diversification in order to minimize investment volatility.

Long Term Reserve Pool Fund (effective July 1, 2020, merger with the STLP to form the LCRP)

The LTRP was a longer-term pool used as an investment vehicle to manage operating reserves with a time horizon of three to seven years. This fund had an investment objective of growth and income and was invested in a diversified asset mix of liquid, semi-liquid and illiquid securities. This fund can invest no more than 10% in illiquid assets.

Short Term Liquidity Pool Fund (effective July 1, 2020, merger with the LTRP to form the LCRP)

The STLP served as an investment vehicle to manage operating reserves with a time horizon of one to three years. This fund was also used to balance the other funds when looking at the System's entire asset allocation of operating reserves relative to its investment objectives. The STLP had an investment objective of income with preservation of capital and is invested in intermediate term fixed income securities. The fund held at least one large mutual fund to provide daily liquidity.

Liquidity and Capital Reserve Pool

The LCRP serves as an investment vehicle to manage operating reserves of the System universities, University Hospital, and related entities with an investment strategy that matches the duration of reserves to their projected needs. The goals of the pool are to preserve and grow capital, maximize returns without undue exposure to risk, and maintain sufficient liquidity for credit ratings. The pool is invested in a diversified asset mix of liquid, semi-liquid, and illiquid securities. The pool can invest no more than 15% in illiquid assets and must invest no less than 60% in liquid assets as defined by Board Rule 404.

Fair Value Measurements

GASB 72 sets forth the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under GASB 72 are described as follows:

- Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that UAB has the ability to access.
- Level 2 Inputs to the valuation methodology include:
- Quoted prices for similar assets or liabilities in active markets;
- Quoted prices for identical or similar assets or liabilities in inactive markets;
- Inputs other than quoted prices that are observable for the assets or liabilities;
- Inputs that are derived principally from or corroborated by observable market data by correlation or other means.
- Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement. Unobservable inputs reflect UAB's own assumptions about the inputs market participants would use in pricing the asset or liability (including assumptions about risk). Unobservable inputs are developed based on the best information available in the circumstances and may include UAB's own data.

GASB 72 allows for the use of net asset value ("NAV") as a practical expedient for valuation purposes for investment that do not have readily determinable fair value. Investments that use NAV in determining fair value are disclosed separately from the valuation hierarchy as presented herein.

The level within the hierarchy is based on the lowest level of input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The determination of what constitutes observable requires judgment by UAB's management. UAB management considers observable data to be that market data which is readily available, regularly distributed or updated, reliable, and verifiable, not proprietary, and provided by multiple independent sources that are actively involved in the relevant market.

The categorization of an investment within the hierarchy is based upon the relative observability of the inputs to its fair value measurement and does not necessarily correspond to UAB management's perceived risk of that investment.

The following is a description of the valuation methods and assumptions used by UAB to estimate the fair value of its investments. There have been no changes in the methods and assumptions used at September 30, 2021. The methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. UAB management believes its valuation methods are appropriate and consistent with other market participants. The use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

When available, quoted prices are used to determine fair value. When quoted prices in active markets are available, investments are classified within Level 1 of the fair value hierarchy. UAB's Level 1 investments primarily consist of investments in mutual funds, exchange traded funds, and both domestic and foreign equity funds.

UAB's Level 2 investments consist of mutual funds that are priced or traded at the end of the day.

UAB's Level 3 investments primarily consist of very illiquid securities. The inputs or methodologies used for valuing securities are not necessarily an indication of the risks associated with investing in those securities. Changes in valuation techniques may result in transfers into or out of an assigned level within the disclosure hierarchy. Valuation techniques utilized by UAB are appraisals, entry price at the date of donation, and other valuations typically based on management assumptions or expectations.

At September 30, 2021 and 2020, the fair value of UAB's investments based on the inputs used to value them is summarized as follows:

| | | | | 2021 | | | | | |
|--------------------------|---------|---|----------|-------------|----------|--------------------|------------------------|----------|-----------------------------------|
| | | Level 1 | | Level 2 | | Level 3 | NAV | | Total |
| Cash and equivalents: | | | | | | | | | |
| Commercial paper | \$ | 100,000 | \$ | _ | \$ | _ | \$ - | \$ | 100,000 |
| Equities: | | | | | | | | | |
| Common Stock | | 420,806 | | _ | | _ | _ | | 420,806 |
| Fixed Income Securities: | | | | | | | | | |
| Corporate bonds | | _ | | 148,895,846 | | _ | _ | | 148,895,846 |
| Commingled Funds: | | | | | | | | | |
| U.S. equity funds | | _ | | 1,057,467 | | _ | _ | | 1,057,467 |
| Non-U.S. equity funds | | _ | | 411,206 | | _ | _ | | 411,206 |
| Real Estate | | | | | | 159,600 | | | 159,600 |
| | \$ | 520,806 | \$ | 150,364,519 | \$ | 159,600 | <u>\$</u> | \$ | 151,044,925 |
| | | | | | | Equity inves | tments in partnerships | | 69,880,913 |
| | | | | | ι | JAB Portion of Sys | tem Pool Investments: | | |
| | | | | | | | oled Endowment Fund | | 712,833,170 |
| | | | | | | Liquidity and Capi | tal Reserve Pool Fund | | 2,670,715,589 |
| | | | | Total Net A | Asse | t Value with Syste | m Pooled Investments | \$ | 3,604,474,598 |
| | | | | | | | | | |
| | | LevelA | | 2020 | | 1 1 2 | NAV | | Takal |
| Cash and equivalents: | | Level 1 | | Level 2 | | Level 3 | NAV | _ | Total |
| Commercial paper | \$ | 100,000 | \$ | _ | \$ | _ | \$ - | \$ | 100,000 |
| Equities: | | | | | | | | | |
| Common Stock | | 422,310 | | _ | | _ | _ | | 422,310 |
| Fixed Income Securities: | | | | | | | | | |
| Corporate bonds | | _ | | 139,341,911 | | _ | _ | | 139,341,911 |
| Commingled Funds: | | | | ,, | | | | | , |
| U.S. equity funds | | _ | | 1,478,656 | | _ | _ | | 1,478,656 |
| Non-U.S. equity funds | | _ | | 15,625 | | _ | _ | | 15,625 |
| Real Estate | | _ | | _ | | 159,600 | _ | | 159,600 |
| Near Estate | \$ | 522,310.25 | \$ | 140,836,192 | \$ | 159,600 | \$ – | \$ | 141,518,102.25 |
| | <u></u> | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | <u> </u> | | <u> </u> | | tments in partnerships | · | 59,920,845 |
| | | | | | | | tem Pool Investments: | | 33,323,343 |
| | | | | | ر | • | oled Endowment Fund | | 541,012,824 |
| | | | | | | | tal Reserve Pool Fund | | 1,959,862,158 |
| | | | | Total Net A | | | m Pooled Investments | \$ | 2,702,313,929 |
| | | | | . 3 | | | | <u> </u> | ·, =, - · • ; • = - |

At September 30, 2021 and 2020, the fair value of investments for the System Pools based on the inputs used to value them is summarized as follows:

| POOL | ENID | OWME | NIT D | CI INID |
|------|------|------|-------|---------|
| | | | | |

| | | 2021 | | | |
|--------------------------------------|----------------|----------------|---------------|------------------|------------------|
| | Level 1 | Level 2 | Level 3 | NAV | Total |
| Receivables: | | | | | |
| Accrued Income Receivables | \$ | \$ | \$ | \$ | \$ 515,924 |
| Total Receivables | | | | | 515,924 |
| Cash Equivalents: | | | | | |
| Money Market Funds | 45,941,864 | | | | 45,941,864 |
| Total Cash Equivalents | 45,941,864 | _ | | | 45,941,864 |
| Equities: | | | | | |
| U.S. Common Stock | 175,095,293 | _ | _ | _ | 175,095,293 |
| Foreign Stock | 52,258,192 | | | | 52,258,192 |
| Total Equities | 227,353,485 | _ | | | 227,353,485 |
| Fixed Income Securities: | | | | | |
| U.S. Government Obligations | _ | 13,246,381 | _ | _ | 13,246,381 |
| Mortgage Backed Securities | _ | 14,281,482 | _ | _ | 14,281,482 |
| Corporate Bonds | _ | 33,019,460 | _ | _ | 33,019,460 |
| Non-U.S. Bonds | | 6,034,696 | | | 6,034,696 |
| Total Fixed Income Securities | _ | 66,582,019 | | | 66,582,019 |
| Commingled Funds: | | | | | |
| Non-U.S. Equity Funds | _ | 134,788,898 | _ | _ | 134,788,898 |
| Hedge Funds | _ | _ | _ | 785,762,770 | 785,762,770 |
| Private Equity Funds | _ | _ | 3,673,786 | 415,061,514 | 418,735,300 |
| Real Estate Funds | | | 7,610,408 | 314,943,245 | 322,553,653 |
| Total Commingled Funds | | 134,788,898 | 11,284,194 | 1,515,767,529 | 1,661,840,621 |
| Total Fund Investments | 273,295,349 | 201,370,917 | 11,284,194 | 1,515,767,529 | 2,001,717,989 |
| Total Fund Assets | \$ 273,295,349 | \$ 201,370,917 | \$ 11,284,194 | \$ 1,515,767,529 | \$ 2,002,233,913 |
| Total Fund Liabilities | | | | | (463,514) |
| Affiliated Entity Investments | | | | | (313,952,384) |
| Total Net Asset Value | | | | | \$ 1,687,818,015 |

POOLED ENDOWMENT FUND

| | | 2020 | | | |
|--------------------------------------|----------------|----------------|---------------|----------------|------------------|
| | Level 1 | Level 2 | Level 3 | NAV | Total |
| Receivables: | | | | | |
| Accrued Income Receivables | \$ | \$ | \$ | \$ | \$ 588,314 |
| Total Receivables | | | | | 588,314 |
| Cash Equivalents: | | | | | |
| Money Market Funds | 42,770,410 | | | | 42,770,410 |
| Total Cash Equivalents | 42,770,410 | | | | 42,770,410 |
| Equities: | | | | | |
| U.S. Common Stock | 114,821,118 | _ | _ | _ | 114,821,118 |
| U.S. Preferred Stock | _ | _ | _ | _ | _ |
| Foreign Stock | 38,691,556 | | | | 38,691,556 |
| Total Equities | 153,512,674 | | | _ | 153,512,674 |
| Fixed Income Securities: | | | | | |
| U.S. Government Obligations | _ | 6,061,927 | _ | _ | 6,061,927 |
| Mortgage Backed Securities | _ | 13,435,270 | _ | _ | 13,435,270 |
| Corporate Bonds | _ | 19,124,922 | _ | _ | 19,124,922 |
| Non-U.S. Bonds | | 3,975,272 | | | 3,975,272 |
| Total Fixed Income Securities | | 42,597,391 | | | 42,597,391 |
| Commingled Funds: | | | | | |
| U.S. Bond Funds | _ | 212,441,977 | _ | _ | 212,441,977 |
| Non-U.S. Bond Funds | _ | 38,073,557 | _ | _ | 38,073,557 |
| Hedge Funds | _ | _ | _ | 508,475,822 | 508,475,822 |
| Private Equity Funds | _ | _ | 2,297,985 | 256,095,913 | 258,393,898 |
| Real Estate Funds | | | 36,566,136 | 207,118,536 | 243,684,672 |
| Total Commingled Funds | | 250,515,534 | 38,864,121 | 971,690,271 | 1,261,069,926 |
| Total Fund Investments | 196,283,084 | 293,112,925 | 38,864,121 | 971,690,271 | 1,499,950,401 |
| Total Fund Assets | \$ 196,283,084 | \$ 293,112,925 | \$ 38,864,121 | \$ 971,690,271 | \$ 1,500,538,715 |
| Total Fund Liabilities | | | | | (337,805) |
| Affiliated Entity Investments | | | | | (237,483,192) |
| • | | | | | |

Total Net Asset Value

\$ 1,262,717,718

LIQUIDITY AND CAPITAL RESERVE POOL FUND

| | | 2021 | | | |
|--------------------------------------|----------------|------------------|----------|------------------|------------------|
| | Level 1 | Level 2 | Level 3 | NAV | Total |
| Receivables: | | | | | |
| Accrued Income Receivables | \$ | \$ | \$ | \$ | \$ 3,879,956 |
| LOC - Crimson Tide Foundation | | | | | 13,464,676 |
| Total Receivables | | | | | 17,344,632 |
| Cash Equivalents: | | | | | |
| Money Market Funds | 101,990,000 | | | | 101,990,000 |
| Total Cash Equivalents | 101,990,000 | | | | 101,990,000 |
| Equities: | | | | | |
| U.S. Common Stock | 470,698,065 | _ | _ | _ | 470,698,065 |
| Foreign Stock | 116,375,236 | | | | 116,375,236 |
| Total Equities | 587,073,301 | _ | | | 587,073,301 |
| Fixed Income Securities: | | | | | |
| U.S. Government Obligations | _ | 250,565,337 | _ | _ | 250,565,337 |
| Mortgage Backed Securities | _ | 239,316,613 | _ | _ | 239,316,613 |
| Collateralized Mortgage Obligations | _ | 21,324,002 | _ | _ | 21,324,002 |
| Corporate Bonds | _ | 204,635,474 | _ | _ | 204,635,474 |
| Non-U.S. Bonds | _ | 91,866,955 | _ | _ | 91,866,955 |
| Other Fixed Income Assets | | 10,780,861 | | | 10,780,861 |
| Total Fixed Income Securities | | 818,489,242 | | | 818,489,242 |
| Commingled Funds: | | | | | |
| U.S. Equity Funds | _ | 165,108,021 | _ | _ | 165,108,021 |
| Non-U.S. Equity Funds | _ | 334,327,898 | _ | _ | 334,327,898 |
| U.S. Bond Funds | _ | 495,084,539 | _ | _ | 495,084,539 |
| Hedge Funds | _ | _ | _ | 1,253,780,387 | 1,253,780,387 |
| Real Asset Funds | | | | 253,017,907 | 253,017,907 |
| Total Commingled Funds | | 994,520,458 | | 1,506,798,294 | 2,501,318,752 |
| Total Fund Investments | 689,063,301 | 1,813,009,700 | _ | 1,506,798,294 | 4,008,871,295 |
| Total Fund Assets | \$ 689,063,301 | \$ 1,813,009,700 | <u> </u> | \$ 1,506,798,294 | \$ 4,026,215,927 |
| Total Fund Liabilities | | | | | (3,334,581) |
| Affiliated Entity Investments | | | | | (259,048,937) |
| Total Net Asset Value | | | | | \$ 3,763,832,409 |

LIQUIDITY AND CAPITAL RESERVE POOL

| | | 2020 | | | |
|--------------------------------------|----------------|------------------|----------|------------------|------------------|
| | Level 1 | Level 2 | Level 3 | NAV | Total |
| Receivables: | | | | | |
| Accrued Income Receivables | \$ | \$ | \$ | \$ | \$ 3,681,520 |
| Total Receivables | | | | | 3,681,520 |
| Cash Equivalents: | | | | | |
| Money Market Funds | 122,282,756 | | | | 122,282,756 |
| Total Cash Equivalents | 122,282,756 | | | | 122,282,756 |
| Equities: | | | | | |
| U.S. Common Stock | 210,853,767 | _ | _ | _ | 210,853,767 |
| Foreign Stock | 76,692,824 | | | | 76,692,824 |
| Total Equities | 287,546,591 | _ | | _ | 287,546,591 |
| Fixed Income Securities: | | | | | |
| U.S. Government Obligations | _ | 74,438,886 | _ | _ | 74,438,886 |
| Mortgage Backed Securities | _ | 253,871,960 | _ | _ | 253,871,960 |
| Collateralized Mortgage Obligations | _ | 22,981,714 | _ | _ | 22,981,714 |
| Corporate Bonds | _ | 169,834,304 | _ | _ | 169,834,304 |
| Non-U.S. Bonds | | 85,166,218 | | | 85,166,218 |
| Total Fixed Income Securities | | 606,293,082 | | | 606,293,082 |
| Commingled Funds: | | | | | |
| U.S. Equity Funds | _ | 145,228,505 | _ | _ | 145,228,505 |
| Non-U.S. Equity Funds | _ | 356,462,581 | _ | _ | 356,462,581 |
| U.S. Bond Funds | _ | 306,086,677 | _ | _ | 306,086,677 |
| Hedge Funds | _ | _ | _ | 916,173,748 | 916,173,748 |
| Real Asset Funds | | | | 131,654,699 | 131,654,699 |
| Total Commingled Funds | | 807,777,763 | | 1,047,828,447 | 1,855,606,210 |
| Total Fund Investments | 409,829,347 | 1,414,070,845 | _ | 1,047,828,447 | 2,871,728,639 |
| Total Fund Assets | \$ 409,829,347 | \$ 1,414,070,845 | <u> </u> | \$ 1,047,828,447 | \$ 2,875,410,159 |
| Total Fund Liabilities | | | | | (791,152) |
| Affiliated Entity Investments | | | | | (214,311,956) |
| Total Net Asset Value | | | | | \$ 2,660,307,051 |

Additional information on fair values, unfunded commitments, remaining life, and redemption for investments measured at the NAV for the System Pools at September 30, 2021 and 2020 is as follows:

POOLED ENDOWMENT FUND

| | | 1, | JOL | ED ENDOWINEINT | 1 0110 | | |
|---|----|---------------|-----|-------------------------|----------------|--|---|
| 2021 | | | | | | | |
| | | Fair Value | | Unfunded Commitments | Remaining Life | Redemption Notice Period | Redemption Restrictions |
| Hedge funds - absolute return, credit, long/short equities | \$ | 785,762,770 | \$ | _ | No limit | Monthly,Quarterly, and Annually | Lock-up provisions ranging from none to 2 years |
| Private equity - private credit, buyouts, venture, secondary | | 415,061,514 | | 174,482,041 | 1-15 years | Partnerships ineligible for redemption | Not redeemable |
| Real assets - public real estate, natural resources, and infrastructure | | 86,098,351 | | _ | No limit | Monthly and Quarterly | None |
| Real assets - private real estate, natural resources, and infrastructure | | 228,844,894 | | 131,972,561 | 1-15 years | Partnerships ineligible for redemption | Not redeemable |
| | \$ | 1,515,767,529 | \$ | 306,454,602 | | | |

POOLED ENDOWMENT FUND

| | | 2020 | | | |
|--|-------------------|-----------------------------|----------------|--|---|
| | Fair Value | Unfunded commitments | Remaining Life | Redemption Notice Period | Redemption Restrictions |
| Hedge funds - absolute return, credit, long/short equities | \$ 508,475,822 | \$ _ | No limit | Monthly,Quarterly, and Annually | Lock-up provisions ranging from none to 2 years |
| Private equity - private credit, buyouts, venture, secondary | 256,095,913 | 185,895,557 | 1-10 years | Partnerships ineligible for redemption | Not redeemable |
| Real assets - public real estate, natural resources, and infrastructure | 44,328,885 | _ | No limit | Monthly and Quarterly | None |
| Real assets - private real estate, natural resources, and infrastructure | 162,789,651 | 92,293,798 | 1-15 years | Partnerships ineligible for redemption | Not redeemable |
| | \$ 971,690,271 | \$ 278,189,355 | | • | |

LIQUIDITY AND CAPITAL RESERVE FUND

| | | | 2021 | | | _ |
|---|---------------------|----|---------------------|----------------|------------------------------------|---|
| | Fair Value | C | Unfunded ommitments | Remaining Life | Redemption Notice Period | Redemption Restrictions |
| Hedge funds - absolute return, credit, long/short equities | \$ 1,253,780,387 | \$ | - | No limit | Monthly,Quarterly, and Annually | Lock-up provisions ranging from none to 2 years |
| Real assets - public real estate, natural resources, and infrastructure | 253,017,907 | | _ | No limit | Monthly and Quarterly | None |
| | \$ 1,506,798,294 | \$ | | | | |

LIQUIDITY AND CAPITAL RESERVE FUND

| | | | 2020 | | | |
|---|---------------------|----|-----------------------|----------------|------------------------------------|---|
| | Fair Value | _ | Infunded mmitments | Remaining Life | Redemption Notice Period | Redemption Restrictions |
| Hedge funds - absolute return, credit, long/short equities | \$ 916,173,748 | \$ | _ | No limit | Monthly,Quarterly, and Annually | Lock-up provisions ranging from none to 2 years |
| Real assets - public real estate, natural resources, and infrastructure | 131,654,699 | | _ | No limit | Monthly and Quarterly | None |
| | \$ 1,047,828,447 | \$ | | | | |

Investment Risk Factors

There are many factors that can affect the value of investments. Some, such as custodial credit risk, concentration of credit risk and foreign currency risk, may affect both equity and fixed income securities. Equity securities respond to such factors as economic conditions, individual company earnings performance and market liquidity, while fixed income securities are particularly sensitive to credit risks and changes in interest rates.

Credit Risk

Fixed income securities are subject to credit risk, which is the chance that a bond issuer will fail to pay interest or principal in a timely manner, or that negative perceptions of the issuer's ability to make these payments will cause security prices to decline. These circumstances may arise due to a variety of factors such as financial weakness, bankruptcy, litigation, and/or adverse political develop-ments. Certain fixed income securities, primarily obligations of the U.S. government or those explicitly guaranteed by the U.S. government, are not considered to have significant credit risk.

The investment policy recognizes that credit risk is appropriate in balanced investment pools such as the PEF and LCRP, and the credit quality of underlying fund investments is monitored on an ongoing basis. Fixed income investments within the PEF and LCRP include corporate, mortgage backed, asset backed, collateralized mortgage and U.S. treasury and/or agency bonds. In addition, approximately \$208.9 million and \$202.6 million in the PEF and LCRP, collectively, at September 30, 2021 and 2020, respectively, is invested in unrated fixed income securities, excluding fixed income commingled funds. Fixed income commingled funds and money market funds were approximately \$643.0 million and \$509.2 million in the PEF and LCRP, collectively, at September 30, 2021 and 2020, respectively.

The credit risk for fixed and variable income securities, for the System Pools, at September 30, 2021 and 2020 is as follows:

| | POOLED ENDO | OWME | NT FUND | LCRP FUND | | | |
|-------------------------------------|-------------------|------|-------------|-----------|---------------|----|---------------|
| | 2021 | | 2020 | | 2021 | | 2020 |
| Fixed or Variable Income Securities | | | | | | | |
| U.S. Government Obligations | \$ 13,246,381 | \$ | 6,061,927 | \$ | 250,565,337 | \$ | 74,438,886 |
| Other U.S. Denominated: | | | | | | | |
| AAA | 751,743 | | 1,759,641 | | 33,536,982 | | 68,457,473 |
| AA | 1,691,717 | | 2,522,307 | | 49,370,980 | | 36,093,014 |
| A | 12,042,928 | | 6,820,070 | | 135,358,729 | | 113,181,471 |
| BBB | 18,930,562 | | 9,988,712 | | 128,995,396 | | 110,647,518 |
| ВВ | 5,670,545 | | 4,393,666 | | 7,716,916 | | 11,683,200 |
| В | 242,759 | | _ | | 12,510,612 | | 150,423 |
| C and < C | _ | | _ | | 5,566,724 | | 46,695 |
| Unrated | 14,005,384 | | 11,051,069 | | 194,867,566 | | 191,594,402 |
| Commingled Funds: | | | | | | | |
| U.S. Bond Funds: Unrated | _ | | 38,073,557 | | 495,084,539 | | 306,086,677 |
| Non-U.S. Bond Funds: Unrated | _ | | _ | | _ | | _ |
| Money Market Funds: Unrated | 45,941,864 | | 42,770,410 | | 101,990,000 | | 122,282,756 |
| TOTAL | \$ 112,523,883 | \$ | 123,441,359 | \$ | 1,415,563,781 | \$ | 1,034,662,515 |

In accordance with the Board policy disclosed previously, credit risk for UAB's fixed and variable income securities held outside of the System Pools is managed by diversifying across issuers and limiting the amount of portfolio assets that are invested in non- investment grade securities.

The credit risk for fixed and variable income securities of UAB's separately held investments at September 30, 2021 and 2020 is as follows:

| | 2021 | 2020 |
|--------------------------------------|-------------------|-------------------|
| Fixed or Variable Income Securities | | |
| U.S. Government Guaranteed | \$ _ | \$ _ |
| Other U.S. and Non U.S. Denominated: | | |
| AAA | 148,895,846 | 139,341,911 |
| AA | _ | _ |
| A | _ | _ |
| BBB | _ | _ |
| BB | _ | _ |
| В | _ | _ |
| CCC | _ | _ |
| CC | _ | _ |
| Unrated | _ | _ |
| Commingled Funds: | | |
| U.S. Bond Funds: Unrated | _ | _ |
| Non-U.S. Bond Funds: Unrated | _ | _ |
| Money Market Funds: Unrated | _ | _ |
| Commercial Paper: Unrated | 100,000 | 100,000 |
| TOTAL | \$ 148,995,846 | \$ 139,441,911 |

Custodial Credit Risk

Custodial credit risk is the risk that in the event of the corporate failure of the custodian, the investment securities may not be returned.

Investment securities in the System Pools and UAB's separately held investments are registered in the Board's name by the custodial bank as an agent for the System. Other types of investments (e.g. open-ended mutual funds, money market funds) represent ownership interests that do not exist in physical or book-entry form. As a result, custodial credit risk is remote.

Concentration of Credit Risk

Concentration of credit risk is the risk associated with a lack of diversification, such as having substantial investments in a few individual issuers, thereby exposing the organization to greater risks resulting from adverse economic, political, regulatory, geographic, or credit developments.

As previously mentioned, credit risk in each investment pool and UAB's separately held portfolio is managed primarily by diversifying across issuers and limiting the amount of portfolio assets that can be invested in non-investment grade securities.

As of September 30, 2021 and 2020, there was no investment in a single issuer that represents 5% or more of total investments held by any single investment manager of the System Pools or UAB's separately held investment portfolio except for investments issued by the U.S. government and money market fund investments.

Interest Rate Risk

Interest rate risk is the risk that the value of fixed income securities will decline because of changing interest rates. The prices of fixed income securities with a longer time to maturity, measured by effective duration, tend to be more sensitive to changes in interest rates and, therefore, more volatile than those with shorter durations. Effective duration is the approximate change in price of a security resulting from a 100 basis point (1 percentage point) change in the level of interest rates. It is not a measure of time.

The Board does not have a specific policy relative to interest rate risk. As such, there are no restrictions on weighted average maturity for each investment pool as they are managed relative to the investment objectives and liquidity demands of the investors.

The effective durations in years for fixed or variable income securities, for the System Pools at September 30, 2021 and 2020 are as follows:

| | POOLED ENDO | OWMENT FUND | LCRP FUND | | |
|-----------------------------|-------------|-------------|-----------|------|--|
| | 2021 | 2020 | 2021 | 2020 | |
| U.S. Government Obligations | 9.8 | 11.9 | 3.2 | 3.4 | |
| Corporate Bonds | 6.1 | 7.3 | 2.5 | 3.0 | |
| Non-US Bonds | 6.1 | 7.3 | 2.5 | 3.0 | |
| Commingled Bond Funds | 0.0 | 3.3 | 2.5 | 2.9 | |
| Other Fixed Income | 0.0 | 0.0 | 1.9 | 0.0 | |

Investments may also include mortgage pass through securities and collateralized mortgage obligations that may be considered to be highly sensitive to changes in interest rates due to the existence of prepayment or conversion features.

The effective durations for fixed or variable income securities for UAB's separately held investments at September 30, 2021 and 2020 are as follows:

| | SEPARAT | ELY HELD |
|-----------------------|---------|----------|
| | 2021 | 2020 |
| Commingled Bond Funds | 3.4 | 2.7 |

At September 30, 2021 and 2020, the fair market values of these investments in the System Pools are as follows:

| | POOLED ENDO | WME | NT FUND | LCRP | FUNI | D |
|-------------------------------------|------------------|------------|------------|-------------------|------|-------------|
| | 2021 | | 2020 | 2021 | | 2020 |
| Mortgage Backed Securities | \$ 14,281,482 | \$ | 13,435,270 | \$ 239,316,613 | \$ | 253,871,960 |
| Collateralized Mortgage Obligations | | | | 21,324,002 | | 22,981,714 |
| TOTAL FIXED | \$ 14,281,482 | \$ | 13,435,270 | \$ 260,640,615 | \$ | 276,853,674 |

Mortgage Backed Securities. These securities are issued by the Federal National Mortgage Association ("Fannie Mae"), Government National Mortgage Association ("Ginnie Mae") and Federal Home Loan Mortgage Association ("Freddie Mac") and include short embedded prepayment options. Unanticipated prepayments by the obligees of the underlying asset reduce the total expected rate of return.

Collateralized Mortgage Obligations. Collateralized mortgage obligations ("CMOs") generate a return based upon either the payment of interest or principal on mortgages in an underlying pool. The relationship between interest rates and prepayments makes the fair value highly sensitive to changes in interest rates. In falling interest rate environments, the underlying mortgages are subject to a higher propensity of prepayments. In a rising interest rate environment, the opposite is true.

At September 30, 2021 and 2020, the effective durations for these securities held in the System Pools are as follows:

| | POOLED ENDO | WMENT FUND | LCRP | FUND | |
|-------------------------------------|-------------|------------|------|------|--|
| | 2021 | 2020 | 2021 | 2020 | |
| Mortgage Backed Securities | 3.6 | 2.9 | 2.6 | 2.0 | |
| Collateralized Mortgage Obligations | _ | _ | 6.6 | 2.6 | |

There are no mortgage backed securities or CMOs in UAB's separately held investments at September 30, 2021 and 2020.

Foreign Currency Risk

The strategic asset allocation policy for the PEF, the LCRP, and UAB's separately held investments includes an allocation to non-United States equity and fixed income securities. Currency hedging of foreign bonds and stocks is allowed under System policy. As of September 30, 2021 and 2020, all foreign investments in the System Pools and UAB's separately held investments are denominated in U.S. dollars and are in international commingled funds, which in turn invest in equity securities and bonds of foreign issuers except for foreign stock and non-U.S. bond funds denominated in U.S. dollars and held by each of the three pools as disclosed in previous tables.

Securities Lending

The System permits security lending as a mechanism to augment income. Loans of the securities are required to be collateralized by cash, letters of credit or securities issued or guaranteed by the U.S. Government or its agencies. The collateral must equal at least 102% of the current market value of the loaned securities. Securities lending contracts must state acceptable collateral for securities loaned, duties of the borrower, delivery of loaned securities and acceptable investment of the collateral. At September 30, 2021 and 2020, there were no securities on loan from the investment pools.

Joint Ventures

UAB accounts for its ownership of the PLTF as a joint venture, using the equity method in the amount of approximately \$69.9 million and \$59.9 million at September 30, 2021 and 2020, respectively. See Note 8 for further discussion of the PLTF.



Account receivable:

Accounts receivable consist of patient receivables, tuition charged to students and amounts due from federal, state and local governments, or private sources, in connection with reimbursement of allowable expenditures made pursuant to UAB's contracts and grants.

The composition of accounts receivable at September 30, 2021 and 2020 is summarized as follows:

| | 2021 | 2020 |
|--|-------------------|-------------------|
| Patient care | \$ 579,841,693 | \$ 473,302,106 |
| Receivables from sponsoring agencies | 93,499,257 | 89,713,630 |
| Student accounts | 47,080,570 | 56,979,455 |
| Other | 92,237,896 | 89,398,007 |
| Total accounts receivable | \$ 812,659,416 | \$ 709,393,198 |
| Less: Allowances for doubtful accounts from patient care | 199,997,424 | 172,792,838 |
| Less: Allowances for doubtful accounts from student accounts | 1,157,044 | 2,819,990 |
| Less: Allowances for doubtful accounts, other | 3,091,238 | 2,951,480 |
| ACCOUNTS RECEIVABLE, NET | \$ 608,413,710 | \$ 530,828,890 |

Loans receivable:

Loans receivable represent all amounts owed on promissory notes from debtors, including student loans made under the Federal Perkins Loan Program and other loan programs. The principal repayment and interest rate terms of federal and university loans vary considerably. The allowance for doubtful accounts only applies to University-funded notes and the University portion of federal student loans, since the University is not obligated to fund the federal portion of uncollected student loans. Federal loan programs are funded principally with federal advances to UAB under the Perkins and various health professions loan programs.

The composition of loans receivable at September 30, 2021 and 2020 is summarized in the table as follows:

| | 2021 | 2020 |
|--|------------------|------------------|
| Federal loan program | \$ 11,172,570 | \$ 12,307,521 |
| University loan funds | 2,338,606 | 2,306,822 |
| Other | 116,795 | 139,751 |
| Total loans receivable | \$ 13,627,971 | \$ 14,754,094 |
| Less allowance for doubtful accounts | 3,247,931 | 4,412,373 |
| Total loans receivable, net | \$ 10,380,040 | \$ 10,341,721 |
| Less: current portion | 1,824,938 | 1,994,471 |
| TOTAL LOANS RECEIVABLE OUTSTANDING, NONCURRENT | \$ 8,555,102 | \$ 8,347,250 |

Pledges receivable:

Pledges receivable represent unconditional promises to give from third party donors. Pledges for permanent endowments do not meet eligibility requirements, as defined by GASB Statement No. 33, until the related gift is received. Due to uncertainties with regard to their realization and valuation, bequest intentions and other conditional promises are not recognized as assets until the specified conditions are met.

The composition of pledges receivable at September 30, 2021 and 2020 is summarized in the following table.

| | 2021 | 2020 |
|--------------------------------|------------------|------------------|
| Operations | \$ 35,236,666 | \$ 29,874,012 |
| Capital | 7,478,690 | 10,266,972 |
| Total gift pledges | \$ 42,715,356 | \$ 40,140,984 |
| Less: current portion | 8,610,396 | 10,732,083 |
| TOTAL GIFT PLEDGES, NONCURRENT | \$ 34,104,960 | \$ 29,408,901 |

(6) Capital Assets

Capital assets as of September 30, 2021 and 2020 are summarized as follows:

| | | BEGINNING BALANCE | | ADDITIONS | | SALES/ ETIREMENTS/ TRANSFERS | ENDING BALANCE | | | | | |
|---|----|-------------------------------------|----|--------------------------------|----|------------------------------------|----------------|---|--|--|--|--|
| | o | ctober 1, 2020 | | | | | S | September 30, 2021 | | | | |
| UNIVERSITY AND BLENDED COMPONENT UNITS | | | | | | | | | | | | |
| Capital assets not being depreciated | | | | | | | | | | | | |
| Land | \$ | 87,075,170 | \$ | _ | \$ | (13,750) | \$ | 87,061,420 | | | | |
| Construction in progress | | 30,327,101 | | 21,054,256 | | (22,536,537) | | 28,844,820 | | | | |
| | | 117,402,271 | | 21,054,256 | | (22,550,287) | | 115,906,240 | | | | |
| Capital assets being depreciated | | | | | | | | | | | | |
| Land Improvements | | 61,582,591 | | 1,078,357 | | | | 62,660,948 | | | | |
| Buildings | | 1,802,926,979 | | 49,165,597 | | (10,342,532) | | 1,841,750,044 | | | | |
| Fixed Equipment Systems | | 89,398,977 | | 527,645 | | - (6.460.660) | | 89,926,622 | | | | |
| Equipment | | 393,974,359 | | 26,710,865 | | (6,469,668) | | 414,215,556 | | | | |
| Library Materials | | 133,503,852 2,481,386,758 | | 8,892,105 86,374,569 | | (16,812,200) | | 142,395,957 2,550,949,127 | | | | |
| Total Capital Assets | | 2,598,789,029 | | 107,428,825 | | (39,362,487) | | 2,666,855,367 | | | | |
| Less: Accumulated Depreciation | | 1,425,716,710 | | 81,504,308 | | (14,041,057) | | 1,493,179,961 | | | | |
| Total Net Capital Assets | \$ | 1,173,072,319 | \$ | | \$ | (25,321,430) | \$ | 1,173,675,406 | | | | |
| • | ÷ | , -,- , | ÷ | | | <u> </u> | ÷ | , ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | | | |
| UNIVERSITY HOSPITAL | | | | | | | | | | | | |
| Capital assets not being depreciated | \$ | 20,813,545 | \$ | | \$ | | \$ | 20,813,545 | | | | |
| Land Construction in progress | Ф | | Φ | 44 000 700 | Ф | (0.220.246) | Ф | | | | | |
| Construction in progress | | 14,170,963 | _ | 11,883,702 | | (8,220,316) | _ | 17,834,349 | | | | |
| | | 34,984,508 | | 11,883,702 | | (8,220,316) | | 38,647,894 | | | | |
| Capital assets being depreciated | | | | | | | | | | | | |
| Land Improvements | | 656,874 | | 48,565 | | _ | | 705,439 | | | | |
| Buildings | | 982,792,320 | | 14,314,104 | | (4,064,905) | | 993,041,519 | | | | |
| Fixed Equipment Systems | | 10,217,842 | | _ | | _ | | 10,217,842 | | | | |
| Equipment | | 576,012,153 | _ | 65,143,192 | | (12,118,538) | | 629,036,807 | | | | |
| | | 1,569,679,189 | | 79,505,861 | | (16,183,443) | | 1,633,001,607 | | | | |
| Total Capital Assets | | 1,604,663,697 | | 91,389,563 | | (24,403,759) | | 1,671,649,501 | | | | |
| Less: Accumulated Depreciation | | 993,505,603 | | 75,029,307 | | (11,371,521) | | 1,057,163,389 | | | | |
| Total Net Capital Assets | \$ | 611,158,094 | \$ | 16,360,256 | \$ | (13,032,238) | \$ | 614,486,112 | | | | |
| TOTAL UAB | | | | | | | | | | | | |
| Capital assets not being depreciated | | | | | | | | | | | | |
| Land | \$ | 107,888,715 | \$ | _ | \$ | (13,750) | \$ | 107,874,965 | | | | |
| Construction in progress | | 44,498,064 | | 32,937,958 | | (30,756,853) | | 46,679,169 | | | | |
| | | 152,386,779 | | 32,937,958 | | (30,770,603) | | 154,554,134 | | | | |
| Capital assets being depreciated | | | | | | | | | | | | |
| Land Improvements | | 62,239,465 | | 1,126,922 | | _ | | 63,366,387 | | | | |
| Buildings | | 2,785,719,299 | | 63,479,701 | | (14,407,437) | | 2,834,791,563 | | | | |
| Fixed Equipment Systems | | 99,616,819 | | 527,645 | | _ | | 100,144,464 | | | | |
| Equipment | | 969,986,512 | | 91,854,057 | | (18,588,206) | | 1,043,252,363 | | | | |
| Library Materials | | 133,503,852 | _ | 8,892,105 | | | | 142,395,957 | | | | |
| Total Capital Assets | | 4,051,065,947 | | 165,880,430 | | (32,995,643) | | 4,183,950,734 | | | | |
| Total Capital Assets Less: Accumulated Depreciation | | 4,203,452,726 2,419,222,315 | | 198,818,388 156,533,615 | | (63,766,246) | | 4,338,504,868 2,550,343,352 | | | | |
| TOTAL NET CAPITAL ASSETS | \$ | 1,784,230,411 | 4 | | \$ | (25,412,578) | <u>¢</u> | 1,788,161,516 | | | | |
| TO TAL NET CAPITAL ASSETS | ₽ | 1,704,230,411 | ₽ | 74,404,773 | Ψ | (30,353,008) | φ | 1,700,101,310 | | | | |

| | | BEGINNING BALANCE | | ADDITIONS | | SALES/ ETIREMENTS/ TRANSFERS | ENDING BALANC | | | | |
|---|-------------|-------------------------------------|----|---------------------------------|----------|------------------------------------|---------------|-------------------------------------|--|--|--|
| | c | October 1, 2019 | | | | | : | September 30, 2020 | | | |
| UNIVERSITY AND BLENDED COMPONENT UNITS | | | | | | | | | | | |
| Capital assets not being depreciated | | | | | | | | | | | |
| Land | \$ | 86,066,970 | \$ | 1,048,200 | \$ | (40,000) | \$ | 87,075,170 | | | |
| Construction in progress | | 52,312,275 | | 25,490,404 | | (47,475,578) | | 30,327,101 | | | |
| | | 138,379,245 | | 26,538,604 | | (47,515,578) | | 117,402,271 | | | |
| Capital assets being depreciated | | | | | | | | | | | |
| Land Improvements | | 52,732,629 | | 8,849,962 | | | | 61,582,591 | | | |
| Buildings | | 1,694,240,428 | | 111,536,098 | | (2,849,547) | | 1,802,926,979 | | | |
| Fixed Equipment Systems | | 88,599,723 | | 799,254 | | (7.577.405) | | 89,398,977 | | | |
| Equipment | | 384,302,938 | | 17,248,606 | | (7,577,185) | | 393,974,359 | | | |
| Library Materials | | 126,377,432 2,346,253,150 | _ | 7,126,420 145,560,340 | | (10,426,732) | _ | 133,503,852 2,481,386,758 | | | |
| Total Capital Assets | | 2,484,632,395 | | 172,098,944 | | (57,942,310) | | 2,598,789,029 | | | |
| Less: Accumulated Depreciation | | 1,356,183,436 | | 78,035,445 | | (8,502,169) | | 1,425,716,710 | | | |
| Total Net Capital Assets | \$ | 1,128,448,959 | \$ | 94,063,499 | \$ | (49,440,141) | \$ | 1,173,072,319 | | | |
| • | <u> </u> | .,, | Ť | 2 1,000,100 | <u> </u> | (12,112,114, | Ť | ,,,,,, | | | |
| UNIVERSITY HOSPITAL | | | | | | | | | | | |
| Capital assets not being depreciated | \$ | 20,813,545 | \$ | | \$ | | \$ | 20,813,545 | | | |
| Land Construction in progress | Ф | | Ф | 0.050.045 | Ф | (12.720.010) | Ф | | | | |
| Construction in progress | | 19,849,958 | | 8,050,915 | | (13,729,910) | _ | 14,170,963 | | | |
| | | 40,663,503 | | 8,050,915 | | (13,729,910) | | 34,984,508 | | | |
| Capital assets being depreciated | | | | | | | | | | | |
| Land Improvements | | 656,874 | | _ | | _ | | 656,874 | | | |
| Buildings | | 953,749,732 | | 29,042,588 | | _ | | 982,792,320 | | | |
| Fixed Equipment Systems | | 10,217,842 | | _ | | _ | | 10,217,842 | | | |
| Equipment | | 529,229,236 | | 66,364,704 | | (19,581,787) | | 576,012,153 | | | |
| | | 1,493,853,684 | | 95,407,292 | | (19,581,787) | | 1,569,679,189 | | | |
| Total Capital Assets | | 1,534,517,187 | | 103,458,207 | | (33,311,697) | | 1,604,663,697 | | | |
| Less: Accumulated Depreciation | | 939,938,988 | | 72,958,684 | | (19,392,069) | | 993,505,603 | | | |
| Total Net Capital Assets | \$ | 594,578,199 | \$ | 30,499,523 | \$ | (13,919,628) | \$ | 611,158,094 | | | |
| TOTAL UAB | | | | | | | | | | | |
| Capital assets not being depreciated | | | | | | | | | | | |
| Land | \$ | 106,880,515 | \$ | 1,048,200 | \$ | (40,000) | \$ | 107,888,715 | | | |
| Construction in progress | | 72,162,233 | | 33,541,319 | | (61,205,488) | | 44,498,064 | | | |
| | | 179,042,748 | | 34,589,519 | | (61,245,488) | | 152,386,779 | | | |
| Capital assets being depreciated | | | | | | | | | | | |
| Land Improvements | | 53,389,503 | | 8,849,962 | | _ | | 62,239,465 | | | |
| Buildings | | 2,647,990,160 | | 140,578,686 | | (2,849,547) | | 2,785,719,299 | | | |
| Fixed Equipment Systems | | 98,817,565 | | 799,254 | | _ | | 99,616,819 | | | |
| Equipment | | 913,532,174 | | 83,613,310 | | (27,158,972) | | 969,986,512 | | | |
| Library Materials | 126,377,432 | | | 7,126,420 | | | _ | 133,503,852 | | | |
| Total Capital Accets | | 3,840,106,834 | | 240,967,632 | | (30,008,519) | | 4,051,065,947 | | | |
| Total Capital Assets Less: Accumulated Depreciation | | 4,019,149,582 2,296,122,424 | | 275,557,151 150,994,129 | | (91,254,007) (27,894,238) | | 4,203,452,726 2,419,222,315 | | | |
| TOTAL NET CAPITAL ASSETS | \$ | 1,723,027,158 | \$ | 124,563,022 | • | (63,359,769) | <u>¢</u> | 1,784,230,411 | | | |
| IO INCIDEI ONI II NE AUGEIG | 4 | 1,723,027,130 | Ψ | 127,303,022 | Ψ | (00,009,709) | Ψ | 1,707,230,711 | | | |

(7) Long-Term Debt

Long-term debt activity for the years ended September 30, 2021 and 2020 is summarized as follows:

| | BEGINNING BALANCE | | ı | NEW DEBT | PRINCIPAL EPAYMENT | | ENDING BALANCE | | CURRENT PORTION |
|---|----------------------|--------------------|----|------------|-----------------------|----|----------------------|----|--------------------|
| | c | October 1, 2020 | | | | S | eptember 30, 2021 | | |
| UNIVERSITY | | | | | | | | _ | |
| Direct Borrowings and Direct Placement Other | | | | | | | | | |
| Leases Payable, 2.25% to 3.99% due annually through 2024 and 4.47% due monthly through 2022 | \$ | 294,333 | \$ | 100,257 | \$ 119,706 | \$ | 274,884 | \$ | 125,889 |
| General Receipts Bonds | | | | | | | | | |
| Birmingham General Revenue Bonds Series 2005A, 3.0% to 5.0% due annually through 2021 | | 3,390,000 | | _ | 3,390,000 | | _ | | _ |
| Birmingham General Revenue Bonds Series 2010A, 2.0% to 5.0% due annually through 2025 | | 10,080,000 | | _ | 1,895,000 | | 8,185,000 | | 1,950,000 |
| Birmingham General Revenue Bonds Series 2010C, 2.0% to 5.0% due annually through 2025 | | 7,150,000 | | _ | 1,645,000 | | 5,505,000 | | 1,700,000 |
| Birmingham General Revenue Bonds Series 2013A-1, 1.1.% due annually through 2021 | | 3,280,000 | | _ | 3,280,000 | | _ | | _ |
| Birmingham General Revenue Bonds Series 2013A-2, 2.25% to 5.0% due annually from 2022 through 2044 | | 72,595,000 | | _ | _ | | 72,595,000 | | 3,320,000 |
| Birmingham General Revenue Bonds Series 2013B, 1.99% due annually through 2030 | | 27,245,000 | | _ | 3,205,000 | | 24,040,000 | | 3,270,000 |
| Birmingham General Revenue Bonds Series 2013D-1, 1.97% due annually through 2024 | | 9,415,000 | | _ | 2,285,000 | | 7,130,000 | | 2,330,000 |
| Birmingham General Revenue Bonds Series 2013D-2, 4.0% to 5.0% due annually from 2025 through 2044 | | 78,325,000 | | _ | _ | | 78,325,000 | | _ |
| Birmingham General Revenue Bonds Series 2015A, 2.0% to 5.0% due annually through 2028 | | 21,755,000 | | _ | 2,865,000 | | 18,890,000 | | 3,005,000 |
| Birmingham General Revenue Bonds Series 2016A, 1.94% due annually from 2021 through 2027 | | 24,495,000 | | _ | 3,300,000 | | 21,195,000 | | 3,365,000 |
| Birmingham General Revenue Bonds Series 2016B, 4.0% to 5.0% due annually from 2028 through 2044 | | 95,585,000 | | _ | _ | | 95,585,000 | | _ |
| Birmingham General Revenue Bonds Series 2019A, 4.0% to 5.0% due annually from 2022 through 2030 | | 24,775,000 | | _ | _ | | 24,775,000 | | 1,135,000 |
| Birmingham General Revenue Bonds Series 2019B, 3.0% to 5.0% due annually from 2031 through 2049 | 1 | 45,940,000 | | _ | _ | | 145,940,000 | | _ |
| Birmingham General Revenue Bonds Series 2019C, 3.0% to 5.0% due annually from 2021 through 2041 | | 39,820,000 | | _ | 1,325,000 | | 38,495,000 | | 1,410,000 |
| Birmingham General Revenue Bonds Series 2019D, 2.15% to 4.0% due annually from 2021 through 2041 | | 35,725,000 | | _ | 195,000 | | 35,530,000 | | 205,000 |
| | \$ 59 | 99,869,333 | \$ | 100,257 | \$ 23,504,706 | \$ | 576,464,884 | \$ | 21,815,889 |
| Less (Plus): unamortized bond discount (premium) | | | | | | _ | (23,014,875) | | |
| TOTAL UNIVERSITY DEBT | | | | | | \$ | 599,479,759 | \$ | 21,815,889 |
| UNIVERSITY HOSPITAL | | | | | | | | | |
| Direct Borrowings and Direct Placement Other | | | | | | | | | |
| Lease Payable, 2.0% to 3.5% due monthly through 2023 | \$ | 2,973,634 | \$ | _ | \$ 1,512,694 | \$ | 1,460,940 | \$ | 1,386,568 |
| Note payable UAB Health System, 3.0% to 5.0% due annually through 2048 $$ | | 75,754,420 | | 17,654,000 | 1,413,277 | | 91,995,143 | | 1,464,525 |
| General Receipts Bonds | | | | | | | | | |
| Birmingham Hospital Revenue Bonds Series 2012A, 2.57% due annually through 2027 | | 10,626,000 | | _ | 1,400,000 | | 9,226,000 | | 1,437,000 |
| UAB Medicine Financing Authority Revenue Bonds Series 2016A, 1.2% due annually through 2022 | | 22,545,000 | | _ | 11,205,000 | | 11,340,000 | | 11,340,000 |
| UAB Medicine Financing Authority Revenue Bonds Series 2016B, 3.125% to 5.0% due annually from 2023 through 2041 | 3 | 02,530,000 | | _ | _ | | 302,530,000 | | _ |
| UAB Medicine Financing Authority Revenue Bonds Series 2017A, 2.13% due annually from 2025 through 2027 | | 18,385,000 | | _ | _ | | 18,385,000 | | _ |
| UAB Medicine Financing Authority Revenue Bonds Series 2017B, 3.0% to 5.0% due annually from 2028 through 2042 | | 44,810,000 | | _ | _ | | 44,810,000 | | _ |
| | \$ 4 | 77,624,054 | \$ | 17,654,000 | \$ 15,530,971 | \$ | 479,747,083 | \$ | 15,628,093 |
| Less (Plus): unamortized bond discount (premium) | | | | | | | (21,861,997) | _ | |
| TOTAL UNIVERSITY HOSPITAL DEBT | | | | | | \$ | 501,609,080 | \$ | 15,628,093 |
| TOTAL UAB | \$1,0 | 77,493,387 | \$ | 17,754,257 | \$ 39,035,677 | \$ | 1,056,211,967 | \$ | 37,443,982 |
| Less (Plus): unamortized bond discount (premium) | | | | · · | <u> </u> | _ | (44,876,872) | _ | |
| TOTAL UAB DEBT | | | | | | \$ | 1,101,088,839 | \$ | 37,443,982 |
| | | | | | | | | | |

| | BEGINNING BALANCE October 1, 2019 | NEW DEBT | PRINCIPAL REPAYMENT | ENDING BALANCE September 30, 2020 | CURRENT PORTION |
|---|--|---------------|------------------------|--|--------------------|
| UNIVERSITY | | | | | |
| Direct Borrowings and Direct Placement Other Leases Payable, 3.19% due annually through 2019 and 4.47% due monthly through 2021 | \$ 345,339 | \$ 109,947 | \$ 160,953 | \$ 294,333 | \$ 97,295 |
| General Receipts Bonds | | | | | |
| Birmingham General Revenue Bonds Series 2005A, 3.0% to 5.0% due annually through 2021 $$ | 6,620,000 | _ | 3,230,000 | 3,390,000 | 3,390,000 |
| Birmingham General Revenue Bonds Series 2010A, 2.0% to 5.0% due annually through 2025 | 44,715,000 | _ | 34,635,000 | 10,080,000 | 1,895,000 |
| Birmingham General Revenue Bonds Series 2010B, 1.0% to 5.8% due annually through 2020 | 45,040,000 | _ | 45,040,000 | _ | _ |
| Birmingham General Revenue Bonds Series 2010C, 2.0% to 5.0% due annually through 2025 | 10,645,000 | _ | 3,495,000 | 7,150,000 | 1,645,000 |
| Birmingham General Revenue Bonds Series 2013A-1, 1.1.% due annually through 2021 | 6,525,000 | _ | 3,245,000 | 3,280,000 | 3,280,000 |
| Birmingham General Revenue Bonds Series 2013A-2, 2.25% to 5.0% due annually from 2022 through 2044 | 72,595,000 | _ | _ | 72,595,000 | _ |
| Birmingham General Revenue Bonds Series 2013B, 1.99% due annually through 2030 | 30,380,000 | _ | 3,135,000 | 27,245,000 | 3,205,000 |
| Birmingham General Revenue Bonds Series 2013C, 1.0% to 1.45% due annually through 2020 | 525,000 | _ | 525,000 | _ | _ |
| Birmingham General Revenue Bonds Series 2013D-1, 1.97% due annually through 2024 | 11,655,000 | _ | 2,240,000 | 9,415,000 | 2,285,000 |
| Birmingham General Revenue Bonds Series 2013D-2, 4.0% to 5.0% due annually from 2025 through 2044 | 78,325,000 | _ | _ | 78,325,000 | _ |
| Birmingham General Revenue Bonds Series 2015A, 2.0% to 5.0% due annually through 2028 | 24,485,000 | _ | 2,730,000 | 21,755,000 | 2,865,000 |
| Birmingham General Revenue Bonds Series 2016A, 1.94% due annually from 2021 through 2027 | 24,495,000 | _ | _ | 24,495,000 | 3,300,000 |
| Birmingham General Revenue Bonds Series 2016B, 4.0% to 5.0% due annually from 2028 through 2044 | 95,585,000 | _ | _ | 95,585,000 | _ |
| Birmingham General Revenue Bonds Series 2019A, 4.0% to 5.0% due annually from 2022 through 2030 | 24,775,000 | _ | _ | 24,775,000 | _ |
| Birmingham General Revenue Bonds Series 2019B, 3.0% to 5.0% due annually from 2031 through 2049 | 145,940,000 | _ | _ | 145,940,000 | _ |
| Birmingham General Revenue Bonds Series 2019C, 3.0% to 5.0% due annually from 2021 through 2041 | _ | 39,820,000 | _ | 39,820,000 | 1,325,000 |
| Birmingham General Revenue Bonds Series 2019D, 2.15% to 4.0% due annually from 2021 through 2041 | \$ – | 35,725,000 | _ | 35,725,000 | 195,000 |
| | \$622,650,339 | \$ 75,654,947 | \$ 98,435,953 | \$ 599,869,333 | \$ 23,482,295 |
| Less (Plus): unamortized bond discount (premium) | | | | (25,215,240) | |
| TOTAL UNIVERSITY DEBT | | | | \$ 625,084,573 | \$ 23,482,295 |
| UNIVERSITY HOSPITAL | | | | | |
| Direct Borrowings and Direct Placement Other | | | | | |
| Lease Payable, 2.0% to 3.75% due monthly through 2020 | \$ 4,564,178 | \$ - | \$ 1,590,544 | \$ 2,973,634 | \$ 1,512,694 |
| Note payable UAB Health System, 3.0% to 5.0% due annually through 2048 $$ | 76,861,182 | _ | 1,106,762 | 75,754,420 | 1,149,682 |
| General Receipts Bonds | | | | | |
| Birmingham Hospital Revenue Bonds Series 2012A, 2.57% due annually through 2027 | 11,989,000 | _ | 1,363,000 | 10,626,000 | 1,400,000 |
| UAB Medicine Financing Authority Revenue Bonds Series 2016A, 1.2% due annually through 2022 | 33,620,000 | _ | 11,075,000 | 22,545,000 | 11,205,000 |
| UAB Medicine Financing Authority Revenue Bonds Series 2016B, 3.125% to 5.0% due annually from 2023 through 2041 | 302,530,000 | _ | _ | 302,530,000 | _ |
| UAB Medicine Financing Authority Revenue Bonds Series 2017A, 2.13% due annually from 2025 through 2027 | 18,385,000 | _ | _ | 18,385,000 | _ |
| UAB Medicine Financing Authority Revenue Bonds Series 2017B, 3.0% to 5.0% due annually from 2028 through 2042 | 44,810,000 | _ | _ | 44,810,000 | _ |
| | \$ 492,759,360 | \$ - | \$ 15,135,306 | \$ 477,624,054 | \$ 15,267,376 |
| Less (Plus): unamortized bond discount (premium) | | | | (23,227,743) | |
| TOTAL UNIVERSITY HOSPITAL DEBT | | | | \$ 500,851,797 | \$ 15,267,376 |
| TOTAL UAB | \$1,115,409,699 | \$ 75,654,947 | \$ 113,571,259 | \$1,077,493,387 | \$ 38,749,671 |
| Less (Plus): unamortized bond discount (premium) | | | | (48,442,983) | |
| TOTAL UAB DEBT | | | | \$1,125,936,370 | \$ 38,749,671 |

Maturities and interest on Direct Borrowings and Direct Placement Other and General Receipts Bonds for the next five years and in subsequent five-year incremental periods are presented in the table below:

Direct Borrowings and Direct Placement Other

| | | | UN | VERSITY | | | _ | UNI | VEF | RSITY HOSPI | TAL | | _ | | | | | |
|-----------|----|--------------------|----|---------|----|-----------|----|------------|-----|-------------|-----|-------------|-----------|------------|----------|------------|-------|-------------|
| Year | Р | Principal Interest | | Total | | Principal | | Interest | | Total | | | Principal | | Interest | | Total | |
| 2022 | \$ | 125,889 | \$ | 16,492 | \$ | 142,381 | \$ | 2,851,093 | \$ | 2,875,003 | \$ | 5,726,096 | \$ | 2,976,982 | \$ | 2,891,495 | \$ | 5,868,477 |
| 2023 | | 97,879 | | 8,858 | | 106,737 | | 1,535,936 | | 2,824,803 | | 4,360,739 | | 1,633,815 | | 2,833,661 | | 4,467,476 |
| 2024 | | 51,116 | | 4,051 | | 55,167 | | 1,530,199 | | 2,793,471 | | 4,323,670 | | 1,581,315 | | 2,797,522 | | 4,378,837 |
| 2025 | | _ | | _ | | _ | | 1,641,755 | | 2,760,647 | | 4,402,402 | | 1,641,755 | | 2,760,647 | | 4,402,402 |
| 2026 | | _ | | _ | | _ | | 2,185,733 | | 2,724,767 | | 4,910,500 | | 2,185,733 | | 2,724,767 | | 4,910,500 |
| 2027-2031 | | _ | | _ | | _ | | 14,437,126 | | 12,777,166 | | 27,214,292 | | 14,437,126 | | 12,777,166 | | 27,214,292 |
| 2032-2036 | | _ | | _ | | _ | | 16,455,435 | | 10,744,160 | | 27,199,595 | | 16,455,435 | | 10,744,160 | | 27,199,595 |
| 2037-2041 | | _ | | _ | | _ | | 19,293,977 | | 7,891,969 | | 27,185,946 | | 19,293,977 | | 7,891,969 | | 27,185,946 |
| 2042-2046 | | _ | | _ | | _ | | 22,899,729 | | 4,279,747 | | 27,179,476 | | 22,899,729 | | 4,279,747 | | 27,179,476 |
| 2047-2048 | | | | | | | | 10,625,100 | _ | 527,363 | | 11,152,463 | _ | 10,625,100 | | 527,363 | _ | 11,152,463 |
| TOTAL | \$ | 274.884 | \$ | 29.401 | \$ | 304.285 | \$ | 93.456.083 | \$ | 50.199.096 | \$ | 143.655.179 | \$ | 93.730.967 | \$ | 50.228.497 | \$ | 143.959.464 |

General Receipts Bonds

| | _ | | U | NIVERSITY | | | _ | UNI | UNIVERSITY HOSPITAL TOTAL | | | | | | | | | | | |
|-----------|----|-------------|----|--------------|----|-------------|----|-------------|---------------------------|-------------|-------|-------------|----|-------------|----|-------------|----|--------------|--|--|
| Year | | Principal | | Interest | | Total Princ | | Principal | Interest | | Total | | | Principal | | Interest | | Total | | |
| 2022 | \$ | 21,690,000 | \$ | 21,259,481 | \$ | 42,949,481 | \$ | 12,777,000 | \$ | 15,796,814 | \$ | 28,573,814 | \$ | 34,467,000 | \$ | 37,056,295 | \$ | 71,523,295 | | |
| 2023 | | 22,575,000 | | 20,504,443 | | 43,079,443 | | 10,276,000 | | 15,623,289 | | 25,899,289 | | 32,851,000 | | 36,127,732 | | 68,978,732 | | |
| 2024 | | 22,460,000 | | 19,750,277 | | 42,210,277 | | 10,711,000 | | 15,145,280 | | 25,856,280 | | 33,171,000 | | 34,895,557 | | 68,066,557 | | |
| 2025 | | 23,565,000 | | 19,013,850 | | 42,578,850 | | 11,347,000 | | 14,636,516 | | 25,983,516 | | 34,912,000 | | 33,650,366 | | 68,562,366 | | |
| 2026 | | 23,200,000 | | 18,235,862 | | 41,435,862 | | 13,739,000 | | 14,250,402 | | 27,989,402 | | 36,939,000 | | 32,486,264 | | 69,425,264 | | |
| 2027-2031 | | 112,655,000 | | 78,790,988 | | 191,445,988 | | 79,661,000 | | 62,553,309 | | 142,214,309 | | 192,316,000 | | 141,344,297 | | 333,660,297 | | |
| 2032-2036 | | 110,040,000 | | 56,533,757 | | 166,573,757 | | 103,135,000 | | 43,844,525 | | 146,979,525 | | 213,175,000 | | 100,378,282 | | 313,553,282 | | |
| 2037-2041 | | 116,740,000 | | 34,032,264 | | 150,772,264 | | 130,505,000 | | 19,645,025 | | 150,150,025 | | 247,245,000 | | 53,677,289 | | 300,922,289 | | |
| 2042-2046 | | 87,975,000 | | 12,952,775 | | 100,927,775 | | 14,140,000 | | 486,063 | | 14,626,063 | | 102,115,000 | | 13,438,838 | | 115,553,838 | | |
| 2047-2049 | _ | 35,290,000 | | 1,671,406 | | 36,961,406 | | _ | | | _ | | | 35,290,000 | | 1,671,406 | _ | 36,961,406 | | |
| TOTAL | 4 | 576 190 000 | 4 | 282 7/15 103 | ¢ | 252 935 103 | 4 | 386 391 000 | 4 | 201 921 223 | ¢ | 588 272 223 | ¢ | 962 481 000 | ¢ | 484 726 326 | | 1447 207 326 | | |

Pledged revenues for 2021 and 2020, as defined by the Series 2012A Hospital Revenue Trust Indenture, are as follows:

| UNIVERSITY HOSPITAL BONDS | 2021 | 2020 |
|---------------------------|---------------------|------------------|
| Total pledged revenues | \$ 2,490,817,657 | \$ 2,147,652,347 |

Pledged revenues for 2021 and 2020, as defined by the Series 2005A, 2010A, 2010B, 2010C, 2013A, 2013B, 2013C, 2013D, 2015A, 2016A, 2016B, 2019A and 2019B General Revenue Trust Indentures, are as follows:

| UNIVERSITY BONDS | 2021 | 2020 |
|---|-------------------|-------------------|
| Tuition fees | \$ 336,412,781 | \$ 330,385,766 |
| Indirect cost recovery | 112,448,434 | 100,590,292 |
| Sales and service of educational activities | 67,666,602 | 59,351,275 |
| Auxiliary sales and service | 36,611,584 | 40,269,522 |
| Endowment and investment income | 33,944,327 | 36,426,430 |
| Other sources | 35,235,066 | 46,928,047 |
| TOTAL PLEDGED REVENUES | \$ 622,318,794 | \$ 613,951,332 |

The University defeased certain indebtedness during fiscal year 2020 with the 2019 Series C and D bond issuance. For this defeasance, funds were deposited in escrow trust accounts sufficient to provide for the subsequent payment of principal and interest on the defeased indebtedness. Under the trust agreements, funds deposited in the trust accounts were invested in obligations of the U.S. Government. The University estimates that the amounts on deposit will be sufficient to satisfy the debt service requirements on the defeased indebtedness and that the defeasance will result in lower overall debt service payments to the University. Should the amounts on deposit not be sufficient to retire the defeased indebtedness upon maturity, the University would be responsible to satisfy the shortfall. The University

remains legally obligated for the repayment of the defeased indebtedness. Neither the assets of the trust accounts nor the defeased indebtedness are included in the accompanying statements of net position. There was no principal outstanding on the 2019 defeased indebtedness at September 30, 2021. The principal outstanding on the 2019 defeased indebtedness at September 30, 2020 was approximately \$75.5 million.

The undiscounted cash flows required to service principal and interest under the old bonds as of September 30, 2020, would have been \$115.7 million compared to undiscounted cash flow requirements of \$105.1 million under the new bonds. The economic gain to the University of the bond refinancing in fiscal year 2020 was calculated to be approximately \$8.3 million using an effective interest rate of approximately 2.4% applied to the old and new bond cash flow requirements.

In November 2019, the University issued \$39.8 million and \$35.7 million in Series 2019C and Series 2019D General Revenue Bonds, respectively. The bonds pay interest at varying rates of 3.0% to 5.0% and 2.15% to 4.0%, respectively, with principal due annually through October 1, 2041. The proceeds of these offering are being used for the purposes of advance refunding Series 2010A, 2010B, and 2010C General Revenue Bonds; and paying costs and expenses associated with this issue. These bonds were issued at a premium of \$5.8 million resulting in total proceeds of \$81.4 million.

In June 2019, the University issued \$24.8 million in Series 2019A General Revenue Bonds. The bonds pay interest at a rate of 4.00% with principal due annually through October 1, 2029. In June 2019, the University issued \$145.9 million in Series 2019B General Revenue Bonds, \$75.1 million of which was in the form of Serial Bonds and \$71.9 million of which was in the form of Term Bonds. The bonds pay interest at varying rates of 3.0% to 5.0% with principal due annually through October 1, 2041 and October 1, 2048, respectively. The proceeds of both the Series 2019A and 2019B bonds will be used for the purposes of financing a portion of the cost of certain capital improvements to the UAB campus, as well as paying costs and expenses associated with this issue. These bonds were issued at a premium of \$16.4 million resulting in total cash received of \$187.1 million.

In June 2019, the UAB Medicine Finance Authority issued \$8.1 million in Series 2019A Revenue Bonds and \$103.3 million in Series 2019B Revenue Bonds, the proceeds of which were loaned to UAB Health System pursuant to Series 2019A and Series 2019B loan agreements. Concurrently, University Hospital entered into a loan agreement with UAB Health System for \$77 million of the 2019A and 2019B bond proceeds for the purpose of financing capital improvement projects. In January 2021, University Hospital borrowed an additional \$17.7 million of the 2019A and 2019B bond proceeds from UAB Health System. Of the total amount borrowed, \$42.5 million was distributed to University Hospital as of September 30, 2020 and September 30,2021. As University Hospital is legally obligated to repay \$94.7 million and is currently paying principal and interest on this full amount, University Hospital has reflected the full \$94.7 million on its statement of net position as long-term debt and \$52.2 million as Due from affiliate on the statement of net position. University Hospital pays interest to UAB Health System on the entire amount, regardless of the amount outstanding. There are no financial covenants related to the loan between University Hospital and UAB Health System.

The UAB general revenue bonds and the Hospital Revenue Trust Indentures are subject to certain covenants with the most restrictive being those on the Hospital's 2012A series issuance. These covenants, among other things, require the University Hospital to ensure pledged revenues are sufficient for debt service coverage by a ratio of 1.1 times. UAB and the University Hospital are in compliance with all financial covenants as of September 30, 2021.

The UAB Medicine Financing Authority's Revenue Trust Indentures are also subject to certain covenants. These covenants require the obligated group to ensure pledged revenues are sufficient for debt service coverage by a ratio of 1.1 times. The obligated group is in compliance with all financial covenants as of September 30, 2021



UAB manages risks related to medical malpractice, general liability, and employee health care through a combination of self-insurance, risk pooling arrangements, and commercial insurance coverage.

UAB's medical malpractice liability is managed by PLTF, a professional liability trust fund. PLTF functions as a risk-sharing vehicle for UAB and more than ten nongovernmental organizations. PLTF covers liabilities of the covered parties, including UAB, arising from reported claims, claims that are incurred but not reported, and future costs of handling these claims. The liabilities are generally based on present value actuarial valuations discounted at a rate of 4% in 2021 and 2020. The associated risks of claims are subject to aggregate limits, with excess liability coverage provided by independent insurers to protect participants against losses should a claim arise that exceeds PLTF coverage limits. Although UAB is the sponsor of PLTF, it is not the predominant participant in the fund.

The PLTF's policy committee establishes the premium rate of participants based on recommendations from consulting actuaries and considering the assumption of risk from the PLTF's date of inception. Premiums paid to the PLTF are provided by UAB, HSF, and other participants. In addition, certain legal and administrative services are provided to the PLTF by the University of Alabama System.

The PLTF agreement requires a flat \$15 million of all PLTF assets to be held in liquid assets. At September 30, 2021 and 2020, the liquid assets of the PLTF, as defined by the agreement, were in compliance with the agreement.

As discussed in Note 4, UAB accounts for its ownership of the PLTF under the equity method of accounting and it is not included in the table below.

General liability is subject to various claims and aggregate limits, with excess liability coverage provided by an independent insurer. General liability and employee health care claims and expenses are reported when it is probable that a loss has occurred and the amount of the loss can be reasonably estimated. Those losses include an estimate of claims that have been incurred but not reported and the future costs of handling claims. The liabilities are based on actuarial valuations and are reported at present value. The discount rate used for the general liability was 2% in both 2021 and 2020. Changes in the total self-insured liabilities for the years ended September 30, 2021 and 2020 are presented as follows for UAB:

| SELF INSURED LIABILITIES | | 2020 | | |
|--|----|--------------|----|--------------|
| Balance, beginning of year | \$ | 7,765,761 | \$ | 7,669,735 |
| Claims incurred and changes in estimates | \$ | 78,523,589 | \$ | 62,939,205 |
| Claim payments | \$ | (82,741,166) | \$ | (62,843,179) |
| BALANCE, END OF YEAR | \$ | 3,548,184 | \$ | 7,765,761 |



Eligible employees of the University and University Hospital participate in the mandatory Teachers' Retirement System of Alabama ("TRS"), a cost sharing, multiple-employer public retirement system designated as a defined benefit plan. In addition, eligible employees may elect to participate in a voluntary 403(b) defined contribution retirement plan. Prior to fiscal year 2020, the plan offered to eligible employees a choice between two recordkeepers, Teachers Insurance and Annuity Association ("TIAA") and the Variable Annuity Life Insurance Company ("VALIC"). Effective in fiscal year 2020, the System, in conjunction with its participating universities and with the Board's approval, transitioned to a single recordkeeper with TIAA serving as sole-vendor for the plan.

Defined Benefit Plan - TRS

Plan Description. The TRS, a cost-sharing multiple-employer public employee retirement plan, was established as of September 15, 1939, pursuant to the Code of Alabama 1975, Title 16, Chapter 25 (Act 419 of the Legislature of 1939) for the purpose of providing retirement allowances and other specified benefits for qualified persons employed by State-supported educational institutions. The responsibility for the general administration and operation of the TRS is vested in its Board of Control which consists of 15 trustees. The plan is administered by the Retirement Systems of Alabama ("RSA"). The Code of Alabama 1975, Title 16, Chapter 25 grants the authority to establish and amend the benefit terms to the TRS Board of Control. The Plan issues a publicly available financial report that can be obtained at www.rsa-al.gov.

Benefits provided. State law establishes retirement benefits as well as death and disability benefits and any ad hoc increase in postretirement benefits for the TRS. Benefits for TRS members vest after 10 years of creditable service. TRS members who retire after age 60 with 10 years or more of creditable service or with 25 years of service (regardless of age) are entitled to an annual retirement benefit, payable monthly for life. Service and disability retirement benefits are based on a guaranteed minimum or a formula method, with the member receiving payment under the method that yields the highest monthly benefit. Under the formula method, members of the TRS are allowed 2.0125% of their average final compensation (highest 3 of the last 10 years) for each year of service.

Act 377 of the Legislature of 2012 established a new tier of benefits (Tier 2) for members hired on or after January 1, 2013. Tier 2 TRS members are eligible for retirement after age 62 with 10 years or more of creditable service and are entitled to an annual retirement benefit, payable monthly for life. Service and disability retirement benefits are based on

a guaranteed minimum or a formula method, with the member receiving payment under the method that yields the highest monthly benefit. Under the formula method, Tier 2 members of the TRS are allowed 1.65% of their average final compensation (highest 5 of the last 10 years) for each year of service. Members are eligible for disability retirement if they have 10 years of credible service, are currently in-service, and determined by the RSA Medical Board to be permanently incapacitated from further performance of duty. Preretirement death benefits equal to the annual earnable compensation of the member as reported to the Plan for the preceding year ending June 30 are paid to a qualified beneficiary.

Contributions. Covered members of the TRS contributed 5% of earnable compensation to the TRS as required by statute until September 30, 2011. From October 1, 2011, to September 30, 2012, covered members of the TRS were required by statute to contribute 7.25% of earnable compensation. Effective October 1, 2012, covered members of the TRS are required by statute to contribute 7.50% of earnable compensation. Certified law enforcement, correctional officers, and firefighters of the TRS contributed 6% of earnable compensation as required by statute until September 30, 2011. From October 1, 2011, to September 30, 2012, certified law enforcement, correctional officers, and firefighters of the TRS were required by statute to contribute 8.25% of earnable compensation. Effective October 1, 2012, certified law enforcement, correctional officers, and firefighters of the TRS are required by statute to contribute 8.50% of earnable compensation.

Tier 2 covered members of the TRS contribute 6% of earnable compensation to the TRS as required by statute. Tier 2 certified law enforcement, correctional officers, and firefighters of the TRS are required by statute to contribute 7% of earnable compensation.

UAB's contractually required contribution rate for the year ended September 30, 2021 was 12.36% of annual pay for Tier 1 members and 11.22% of annual pay for Tier 2 members. UAB's contribution rate for the year ended September 30, 2020 was 12.43% of annual pay for Tier 1 members and 11.34% of annual pay for Tier 2 members.

These required contribution rates are a percent of annual payroll, actuarially determined as an amount that, when combined with member contributions, is expected to finance the costs of benefits earned by members during the year, with an additional amount to finance any unfunded accrued liability. The total contribution requirement for fiscal years 2021, 2020 and 2019 is as follows:

| | 2021 | 2020 | 2019 |
|------------------------|-------------------|-------------------|-------------------|
| Employer Contributions | \$ 96,839,000 | \$ 98,485,000 | \$ 97,824,000 |
| Employee Contributions | 57,052,000 | 57,688,000 | 57,345,000 |
| TOTAL CONTRIBUTIONS | \$ 153,891,000 | \$ 156,173,000 | \$ 155,169,000 |

Pensionable salaries and wages for covered employees participating in TRS were approximately \$947.5 million during fiscal year 2021 and \$946.1 million during fiscal year 2020.

Pension Liabilities, Pension Expense, and Deferred Outflows of Resources and Deferred Inflows of Resources Related to Pensions. At September 30, 2021 and September 30, 2020, the financial statements of UAB reflected a liability of \$1.41 billion and \$1.25 billion, respectively, for its proportionate share of the collective net pension liability, as prescribed by GASB 68. At September 30, 2021, the collective net pension liability was measured as of September 30, 2020 and the total pension liability used to calculate the net pension liability was determined by an actuarial valuation as of September 30, 2019. UAB's proportion of the collective net pension liability was based on the employers' shares of contributions to the pension plan relative to the total employer contributions of all participating TRS employers. At September 30, 2020, UAB's proportion was 11.43%, which was a increase of 0.16% from its proportion measured as of September 30, 2019. At September 30, 2019, UAB's proportion was 11.26%, which was a decrease of 0.49% from its proportion measured as of September 30, 2018.

For the years ended September 30, 2021 and September 30, 2020, UAB recognized pension expense of \$132.5 million and \$112.2 million, respectively. At September 30, 2021 and 2020, UAB reported deferred outflows of resources and deferred inflows of resources related to pensions from the following sources:

| 2021 | Outfle | Deferred ows of Resources | Inflo | Deferred vs of Resources |
|---|--------|---------------------------|-------|-----------------------------|
| Differences between expected and actual experience | \$ | 69,947,000 | \$ | 24,511,000 |
| Changes of assumptions | | 14,700,000 | | _ |
| Net difference between projected and actual earnings on pension plan investments | | 104,961,000 | | _ |
| Changes in proportion and differences between Employer contributions and proportionate share of contributions | | 13,898,000 | | 34,807,000 |
| Employer contributions subsequent to the measurement date | | 96,839,000 | | |
| TOTAL | \$ | 300,345,000 | \$ | 59,318,000 |

| 2020 | Outflo | Deferred ows of Resources | Inflo | Deferred ws of Resources |
|---|--------|------------------------------|-------|-----------------------------|
| Differences between expected and actual experience | \$ | 18,408,000 | \$ | 41,292,000 |
| Changes of assumptions | | 38,360,000 | | _ |
| Net difference between projected and actual earnings on pension plan investments | | 43,354,000 | | _ |
| Changes in proportion and differences between Employer contributions and proportionate share of contributions | | _ | | 48,878,000 |
| Employer contributions subsequent to the measurement date | | 98,485,000 | | |
| TOTAL | \$ | 198,607,000 | \$ | 90,170,000 |

\$96.8 million reported as deferred outflows of resources related to pensions resulting from UAB contributions subsequent to the measurement date will be recognized as a reduction of the net pension liability in the year ending September 30, 2022. Other amounts reported as deferred outflows of resources and deferred inflows of resources related to pensions will be recognized in pension expense (income) as follows:

| rears | ending | September | 30: |
|-------|--------|-----------|-----|
| | 2022 | | |

| 2022 | \$ 22,649,000 |
|------------|------------------|
| 2023 | 44,522,000 |
| 2024 | 48,038,000 |
| 2025 | 28,979,000 |
| 2026 | _ |
| Thereafter | _ |

Actuarial assumptions. The total pension liability as of September 30, 2020 was determined by an actuarial valuation as of September 30, 2019 using the following actuarial assumptions, applied to all periods included in the measurement:

| Inflation | 2.75% |
|----------------------------|--------------|
| Investment rate of return* | 7.70% |
| Projected salary increases | 3.25 - 5.00% |

^{*}Net of pension plan investment expense

The actuarial assumptions used in the actuarial valuation as of September 30, 2019, were based on the results of an investigation of the economic and demographic experience for the TRS based upon participant data as of September 30, 2015. The Board of Control accepted and approved these changes in September 2016 which became effective the beginning of fiscal year 2016.

Mortality rates for TRS were based on the RP-2000 White Collar Mortality Table projected to 2020 using scale BB and adjusted 115% for males and 112% for females age 78 and older.

The long-term expected rate of return on pension plan investments was determined using a log-normal distribution analysis in which best-estimate ranges of expected future real rates of return (expected returns, net of pension plan investment expense and inflation) are developed for each major asset class. These ranges are combined to produce

the long-term expected rate of return by weighting the expected future real rates of return by the target asset allocation percentage and by adding expected inflation. The target asset allocation and best estimates of geometric real rates of return for each major asset class are as follows:

| | Target Allocation | Long-Term Expected Rate of Return* |
|---------------------------------------|----------------------|--|
| Fixed Income | 17.00 % | 4.40 % |
| U.S. Large Stocks | 32.00 % | 8.00 % |
| U.S. Mid Stocks | 9.00 % | 10.00 % |
| U.S. Small Stocks | 4.00 % | 11.00 % |
| International Developed Market Stocks | 12.00 % | 9.50 % |
| International Emerging Market Stocks | 3.00 % | 11.00 % |
| Alternatives | 10.00 % | 10.10 % |
| Real Estate | 10.00 % | 7.50 % |
| Cash | 3.00 % | 1.50 % |
| TOTAL | 100.00 % | |

^{*}Includes assumed rate of inflation of 2.50%

Discount rate. The discount rate used to measure the total pension liability was 7.70%. The projection of cash flows used to determine the discount rate assumed that plan member contributions will be made at the current contribution rate and that the employer contributions will be made at rates equal to the difference between actuarially determined contribution rates and the member rate. Based on those assumptions, components of the pension plan's fiduciary net position were projected to be available to make all projected future benefit payments of current plan members. Therefore, the long-term expected rate of return on pension plan investments was applied to all periods of projected benefit payments to determine the total pension liability.

Sensitivity of UAB's proportionate share of the net pension liability to changes in the discount rate. The following table reflects UAB's proportionate share of the net pension liability, as prescribed by GASB 68, calculated using the discount rate of 7.70%, as well as what UAB's proportionate share of the net pension liability would be if it were calculated using a discount rate that is 1-percentage-point lower (6.70%) or 1-percentage-point higher (8.70%) than the current rate:

| | 1 | l% Decrease | Current Rate | 1% Increase |
|---|----|---------------|---------------------|---------------------|
| UAB's proportionate share of collective net pension liability | \$ | 1,885,647,000 | \$ 1,413,306,000 | \$ 1,013,651,000 |

Pension plan fiduciary net position. Detailed information about the pension plan's fiduciary net position is available in the separately issued RSA Comprehensive Annual Report for the fiscal year ended September 30, 2020. The supporting actuarial information is included in the GASB Statement No. 67 Report for the TRS prepared as of September 30, 2020. The auditor's report on the Schedule of Employer Allocation and Pension Amounts by Employer and accompanying note detail by employer and in aggregate information needed to comply with GASB 68. The additional financial and actuarial information is available at is available at http://www.rsa-al.gov/index.php/employers/financial-reports/gasb-68-reports/

Other Retirement Plans

As previously noted, certain employees also participate in a voluntary 403(b) plan, which is a defined contribution plan. In defined contribution plans, benefits depend solely on amounts contributed plus investment earnings. All full-time regular monthly employees are eligible to participate from the date of employment. UAB contributes a matching amount of up to 5% of total salaries for participating employees. UAB's contribution is funded as it accrues and, along with that of the employee, is immediately and fully vested. The contributions for fiscal years 2021 and 2020, excluding employee amounts not eligible for matching, were approximately \$68.9 million and \$64.1 million, which included approximately \$34.5 million and \$32.0 million each from UAB and its employees, respectively.

The LLC sponsors a voluntary 403(b) retirement plan for eligible employees. The 403(b) plan is a voluntary, defined-contribution, tax-deferred as well as Roth after tax plan governed by Internal Revenue Code 403(b). TIAA is the administrator for the voluntary retirement program. Employees are vested after 3 years of employment. Eligibility for matching is for all full-time and part-time regular, twelve-hour shift, and weekend staff employees.

In fiscal year 2020, employer matching contributions in the voluntary 403(b) Plan (inclusive of The University of Alabama, The University of Alabama at Birmingham, The University of Alabama in Huntsville, and the UA System

Office), and the UAB Hospital Management, LLC 403(b) Plan were temporarily suspended for the period of May 2020 through September 2020. The suspension was due to uncertainty concerning the potential financial impacts of the COVID-19 Pandemic and was a joint management decision by Senior Administration of the UA System and each University

The University, the University Hospital, LLC and UABRF total salaries and wages for fiscal years 2021 and 2020 were approximately \$1.40 billion and \$1.33 billion, respectively. Total salaries and wages during fiscal years 2021 and 2020 for covered employees participating in TRS were approximately \$815.5 million and \$816.8 million, respectively. Total salaries and wages during fiscal years 2021 and 2020 for covered employees participating in the 403(b) Plan were approximately \$760.7 million and \$710.1 million, respectively.

Triton sponsors a 401(k) plan covering substantially all employees who have completed at least six months of service. Information regarding this benefit is presented in Triton's annual report.

Compensated Absences

Certain UAB employees accumulate vacation and sick leave at varying rates depending upon their years of continuous service and their payroll classification, subject to maximum limitations. Upon termination of employment, employees are paid unused accrued vacation at their regular rate of pay up to a designated maximum number of days.

In accordance with GASB Statement No. 16, *Accounting for Compensated Absences*, the financial statements include accruals of approximately \$84 million and \$78 million as of September 30, 2021 and 2020, respectively, for accrued vacation pay and salary-related payments associated with vacation pay. There is no such accrual recognized for sick leave benefits because there is no terminal cash benefit available to employees for accumulated sick leave.

(10)

Post-Employment Benefits

UAB offers other postemployment health care benefits ("OPEB") to all employees who officially retire from UAB. Health care benefits are offered through the Alabama Retired Education Employees Health Care Trust Plan with TRS or certain retired employees may elect to continue to participate in UAB's group health plan until they are eligible for Medicare by paying the full cost of the plan premium. TRS offers health care benefits through a cost-sharing multiple-employer defined benefit health care plan administered by the Public Education Employee Health Insurance Plan ("PEEHIP"). Retired employees age sixty-five or older who are eligible for Medicare must enroll in the Medicare Coordinated Plan under which Medicare is the primary insurer and UAB's health care plan becomes the secondary insurer. Despite the availability of the UAB plan, most retirees elect to participate in the PEEHIP with TRS, in which case the retirees pay a portion of the PEEHIP premium, with UAB paying an allocation towards the cost of retiree coverage.

Certain retirees may also elect to continue their basic term life insurance coverage and accidental death and dismemberment insurance up to certain maximum amounts. The retirees pay the full amount of the premiums in such cases. Retirees are not eligible for tuition assistance benefits themselves. However, their unmarried dependent children may qualify in some cases.

PEEHIP

Plan description. The Alabama Retired Education Employees' Health Care Trust (the "Trust") is a cost-sharing multiple-employer defined benefit postemployment healthcare plan that administers healthcare benefits to the retirees of participating state and local educational institutions. The Trust was established under the Alabama Retiree Health Care Funding Act of 2007 which authorized and directed the Public Education Employees' Health Insurance Board ("PEEHI Board") to create an irrevocable trust to fund postemployment healthcare benefits to retirees participating in PEEHIP. Active and retiree health insurance benefits are paid through the PEEHIP. In accordance with GASB, the Trust is considered a component unit of the State of Alabama (the "State") and is included in the State's Annual Financial Report.

The PEEHIP was established in 1983 pursuant to the provisions of the *Code of Alabama 1975, Title 16, Chapter 25A (Act 83-455)* to provide a uniform plan of health insurance for active and retired employees of state and local educational institutions which provide instruction at any combination of grades K-14 (collectively, eligible employees), and to provide a method for funding the benefits related to the plan. The four-year universities participate in the plan with respect to their retired employees, and are eligible and may elect to participate in the plan with respect to their active employees. Responsibility for the establishment of the health insurance plan and its general administration and operations is vested in the PEEHI Board. The PEEHI Board is a corporate body for purposes of management of the health insurance plan. The *Code of Alabama 1975, Section 16-25A-4* provides the PEEHI Board with the authority to amend the benefit

provisions in order to provide reasonable assurance of stability in future years for the plan. All assets of the PEEHIP are held in trust for the payment of health insurance benefits. The Teachers' Retirement System of Alabama ("TRS") has been appointed as the administrator of the PEEHIP and, consequently, serves as the administrator of the Trust.

Benefits provided. PEEHIP offers a basic hospital medical plan to active members and non-Medicare eligible retirees. Benefits include inpatient hospitalization for a maximum of 365 days without a dollar limit, inpatient rehabilitation, outpatient care, physician services, and prescription drugs.

Active employees and non-Medicare eligible retirees who do not have Medicare eligible dependents can enroll in a health maintenance organization (HMO) in lieu of the basic hospital medical plan. The HMO includes hospital medical benefits, dental benefits, vision benefits, and an extensive formulary. However, participants in the HMO are required to receive care from a participating physician in the HMO plan.

The PEEHIP offers four optional plans (Hospital Indemnity, Cancer, Dental, and Vision) that may be selected in addition to or in lieu of the basic hospital medical plan or HMO. The Hospital Indemnity Plan provides a per-day benefit for hospital confinement, maternity, intensive care, cancer, and convalescent care. The Cancer Plan covers cancer disease only and benefits are provided regardless of other insurance. Coverage includes a per-day benefit for each hospital confinement related to cancer. The Dental Plan covers diagnostic and preventative services, as well as basic and major dental services. Diagnostic and preventative services include oral examinations, teeth cleaning, x-rays, and emergency office visits. Basic and major services include fillings, general aesthetics, oral surgery not covered under a Group Medical Program, periodontics, endodontics, dentures, bridgework, and crowns. Dental services are subject to a maximum of \$1,250 per year for individual coverage and \$1,000 per person per year for family coverage. The Vision Plan covers annual eye examinations, eye glasses, and contact lens prescriptions.

PEEHIP members may opt to elect the PEEHIP Supplemental Plan as their hospital medical coverage in lieu of the PEEHIP Hospital Medical Plan. The PEEHIP Supplemental Plan provides secondary benefits to the member's primary plan provided by another employer. Only active and non-Medicare retiree members and dependents are eligible for the PEEHIP Supplemental Plan. There is no premium required for this plan, and the plan covers most out-of-pocket expenses not covered by the primary plan. The plan cannot be used as a supplement to Medicare, the PEEHIP Hospital Medical Plan, or the State or Local Governmental Plans administered by the State Employees' Insurance Board (the "SEIB").

Effective January 1, 2020, Medicare eligible members and Medicare eligible dependents who are covered on a retiree contract were enrolled in the Humana Group Medicare Advantage plan for PEEHIP. The plan is fully insured, and members are able to have all of their Medicare Part A (hospital insurance), Part B (medical insurance), and Part D (prescription drug coverage) in one convenient plan. Retirees can continue to see their same providers with no interruption and see any doctor who accepts Medicare on a national basis. Members have the same benefits in and out-of-network and there is no additional retiree cost share if a retiree uses an out-of-network provider and no balance billing from the provider.

Contributions. The Code of Alabama 1975, Section 16-25A-8 and the Code of Alabama 1975, Section, 16-25A-8.1 provide the Board with the authority to set the contribution requirements for plan members and the authority to set the employer contribution requirements for each required class, respectively. Additionally, the Board is required to certify to the Governor and the Legislature, the amount, as a monthly premium per active employee, necessary to fund the coverage of active and retired member benefits for the following fiscal year. The Legislature then sets the premium rate in the annual appropriation bill.

For employees who retired after September 30, 2005, but before January 1, 2012, the employer contribution of the health insurance premium set forth by the Board for each retiree class is reduced by 2% for each year of service less than 25 and increased by 2% percent for each year of service over 25 subject to adjustment by the Board for changes in Medicare premium costs required to be paid by a retiree. In no case does the employer contribution of the health insurance premium exceed 100% of the total health insurance premium cost for the retiree.

For employees who retired after December 31, 2011, the employer contribution to the health insurance premium set forth by the Board for each retiree class is reduced by 4% for each year of service less than 25 and increased by 2% for each year over 25, subject to adjustment by the Board for changes in Medicare premium costs required to be paid by a retiree. In no case does the employer contribution of the health insurance premium exceed 100% of the total health insurance premium cost for the retiree. For employees who retired after December 31, 2011, who are not covered by Medicare, regardless of years of service, the employer contribution to the health insurance premium set forth by the Board for each retiree class is reduced by a percentage equal to 1% multiplied by the difference between the Medicare entitlement age and the age of the employee at the time of retirement as determined by the Board. This reduction in the employer contribution ceases upon notification to the Board of the attainment of Medicare coverage.

OPEB Liabilities, OPEB Expense, and Deferred Outflows of Resources and Deferred Inflows of Resources Related to OPEB. At September 30, 2021 and 2020, the financial statements of UAB reflected a liability of \$680.4 million and \$265.2 million, respectively for its proportionate share of the net OPEB liability, as prescribed by GASB 75. The net OPEB liability was measured as of September 30, 2020 and the total OPEB liability used to calculate the net OPEB liability was determined by an actuarial valuation as of September 30, 2019. UAB's proportion of the net OPEB liability was based on a projection of UAB's share of contributions to the OPEB plan relative to the projected contributions of all participating PEEHIP employers, actuarially determined. At September 30, 2020, UAB's proportion was 10.48%, which was an increase of 3.46% from its proportion measured as of September 30, 2019.

For the years ended September 30, 2021 and 2020, UAB recognized an OPEB expense of \$26.2 million and an OPEB benefit of \$24.5 million, respectively with no special funding situations. At September 30, 2021 and 2020, UAB reported deferred outflows of resources and deferred inflows of resources related to the PEEHIP plan from the following sources:

| 2021 | Deferred Outflows of Resources | | De | Deferred Inflows of Resources | |
|---|-----------------------------------|-------------|----|----------------------------------|--|
| Differences between expected and actual experience | \$ 17,255,266 | | | 244,631,528 | |
| Changes of assumptions | | 237,669,500 | | 126,349,962 | |
| Net difference between projected and actual earnings on OPEB plan investments | | _ | | 28,691 | |
| Changes in proportion and differences between Employer contributions and proportionate share of contributions | | 275,052,969 | | 84,816,231 | |
| Employer contributions subsequent to the measurement date | | 18,240,187 | | | |
| TOTAL | \$ | 548,217,922 | \$ | 455,826,412 | |

| 2020 | | rred Outflows of Resources | Deferred Inflows of Resources | | |
|---|--------------|-------------------------------|----------------------------------|-------------|--|
| Differences between expected and actual experience | \$ 8,780,366 | | | 203,329,026 | |
| Changes of assumptions | | 12,677,222 | | 109,839,367 | |
| Net difference between projected and actual earnings on OPEB plan investments | | 547,032 | | _ | |
| Changes in proportion and differences between Employer contributions and proportionate share of contributions | | 62,695,436 | | 107,161,311 | |
| Employer contributions subsequent to the measurement date | | 20,775,402 | | | |
| TOTAL | \$ | 105,475,458 | \$ | 420,329,704 | |

\$18.2 million reported as deferred outflows of resources related to OPEB resulting from UAB's contributions subsequent to the measurement date will be recognized as a reduction of the net OPEB liability in the year ending September 30, 2022. Other amounts reported as deferred outflows of resources and deferred inflows of resources related to OPEB will be recognized in OPEB expense as follows:

Years ending September 30:

| 2022 | \$ (8,872,627) |
|------|-------------------|
| 2023 | (7,836,120) |
| 2024 | (10,500,464) |
| 2025 | (11,690,510) |

2026 67,235,113 Thereafter 45,815,931

Actuarial assumptions. The total OPEB liability for the PEEHIP was determined by an actuarial valuation as of September 30, 2019, using the following actuarial assumptions, applied to all periods included in the measurement:

| Inflation | 2.75% |
|---|---------------|
| Projected Salary Increase ¹ | 3.25% - 5.00% |
| Long-Term Investment Rate of Return ² | 7.25% |
| Municipal Bond Index Rate at the Measurement | 2.25% |
| Municipal Bond Index Rate at the Prior | 3.00% |
| Projected Year for Fiduciary Net Position (FNP) to be | 2040 |
| Single Equivalent Interest Rate the Measurement | 3.05% |
| Single Equivalent Interest Rate the Prior | 5.50% |
| Healthcare Cost Trend Rate | |
| Pre-Medicare Eligible | 6.75% |
| Medicare Eligible | ** |
| Ultimate Trend Rate | |
| Pre-Medicare Eligible | 4.75% in 2027 |
| Medicare Eligible | 4.75% in 2024 |

¹Includes 3.00% wage inflation.

Mortality rates for the period after service retirement to the RP-2000 White Collar Mortality Table projected to 2020 using scale BB and adjusted 115% for all ages for males and 112% for ages 78 and over for females. The rates of disabled mortality were based on the RP-2000 Disabled Mortality Table projected to 2020 using scale BB and adjusted 105% for males and 120% for females.

The decremental assumptions used in the valuation were selected based on the actuarial experience study prepared as of September 30, 2015, submitted to and adopted by the Teachers' Retirement System of Alabama Board on September 13, 2016.

The remaining actuarial assumptions (e.g., initial per capita costs, health care cost trends, rate of plan participation, rates of plan election, etc.) were based on the September 30, 2019 valuation.

The long-term expected return on plan assets is to be reviewed as part of regular experience studies prepared every five years, in conjunction with similar analysis for the Teachers' Retirement System of Alabama. Several factors should be considered in evaluating the long-term rate of return assumption, including long-term historical data, estimates inherent in current market data, and a log-normal distribution analysis in which best-estimate ranges of expected future real rates of return (expected return, net of investment expense and inflation), as developed for each major asset class. These ranges should be combined to produce the long-term expected rate of return by weighting the expected future real rates of return by the target asset allocation percentage and then adding expected inflation. The assumption is intended to be a long-term assumption and is not expected to change absent a significant change in the asset allocation, a change in the inflation assumption, or a fundamental change in the market that alters expected returns in future years.

The long-term expected rate of return on the OPEB plan investments is determined based on the allocation of assets by asset class and by the mean and variance of real returns. The target asset allocation and best estimates of expected geometric real rates of return for each major asset class is summarized below:

| | Target Allocation | Long-Term Expected Real Rate of Return* |
|---------------------------------------|----------------------|---|
| Fixed Income | 30.00 % | 4.40 % |
| U.S. Large Stocks | 38.00 % | 8.00 % |
| U.S. Mid Stocks | 8.00 % | 10.00 % |
| U.S. Small Stocks | 4.00 % | 11.00 % |
| International Developed Market Stocks | 15.00 % | 9.50 % |
| Cash | 5.00 % | 1.50 % |
| TOTAL | 100.00 % | |

^{*} Geometric mean, includes 2.5% inflation

²Compounded annually, net of investment expense, and includes inflation.

^{**}Initial Medicare claims are set based on scheduled increases through plan year 2022.

Discount Rate. The discount rate (also known as the Single Equivalent Interest Rate (SEIR), as described by GASB 74) used to measure the PEEHIP total OPEB liability at September 30, 2020 was 3.05%. The discount rate used to measure the total OPEB liability at the prior measurement date was 5.50%. Premiums paid to the Public Education Employees' Health Insurance Board for active employees shall include an amount to partially fund the cost of coverage for retired employees. The projection of cash flows used to determine the discount rate assumed that plan contributions will be made at the current contribution rates. Each year, the State specifies the monthly employer rate that participating school systems must contribute for each active employee. Approximately, 14.802% of the employer contributions were used to assist in funding retiree benefit payments in 2020. It is assumed that the 14.802% will increase at the same rate as expected benefit payments for the closed group until reaching an employer rate of 20.000%, at which point this amount will increase by 1.00% in subsequent years. The discount rate determination will use a municipal bond rate to the extent the trust is projected to run out of money before all benefits are paid. Therefore, the projected future benefit payments for all current plan members were projected through 2118. The long-term rate of return is used until the assets are expected to be depleted in 2040, after which the municipal bond rate is used.

Sensitivity of the UAB's proportionate share of the net OPEB liability to changes in the healthcare cost trend rates. The following table reflects UAB's proportionate share of the net OPEB liability of the Trust, as prescribed by GASB 75, calculated using the current healthcare trend rate, as well as what the net OPEB liability would be if calculated using 1-percentage-point lower or 1-percentage-point higher than the current rate. A 1-percent-point decrease would change the current healthcare trend rate from 6.75% to 5.75%, the pre-Medicare from 4.75% to 3.75%, the Medicare eligible from 4.75% to 5.75% to 5.75%, the Medicare eligible from 4.75% to 5.75%.

| | Healthcare 1% Decrease Trend Rate 19 | | | | | 1% Increase |
|--|--------------------------------------|-------------|----|-------------|----|-------------|
| UAB's proportionate share of the collective net OPEB liability | \$ | 537,883,539 | \$ | 680,431,790 | \$ | 865,981,167 |

The following table reflects UAB's proportionate share of the net OPEB liability of the Trust, as prescribed by GASB 75, calculated using the discount rate of 3.05%, as well as what the net OPEB liability would be if calculated using 1-percentage-point lower or 1-percentage-point higher than the current rate:

| | 2.05% | 3.05% | 4.05% | | |
|--|-------------------|-------------------|-------|-------------|--|
| UAB's proportionate share of the collective net OPEB liability | \$ 834,584,896 | \$ 680,431,790 | \$ | 558,000,835 | |

OPEB plan fiduciary net position. Detailed information about the OPEB plan's fiduciary net position is located in the Trust's financial statements for the fiscal year ended September 30, 2020. The supporting actuarial information is included in the GASB Statement No. 74 Report for PEEHIP prepared as of September 30, 2020. Additional financial and actuarial information is available at www.rsa-al.gov.

UAB Plan

Plan description. The UAB plan is considered a single-employer plan which is administered by University of Alabama at Birmingham ("UAB"). The UAB Plan offers its members hospital benefits, major medical benefits, a prescription drug program and a basic term life insurance up to an established maximum policy limit. The health care benefits cover medical and hospitalization costs for retirees and their dependents. The portion of the UAB plan related to health care may be amended by the approval of the President of UAB upon recommendation from the Benefits Committee. The portion of the UAB plan related to the life insurance may be amended by the System.

Benefits provided. UAB employees can participate in the UAB plan as a retiree if the following condition are met; retiree has 25 years of creditable service, regardless of age (Tier I only), or retiree has 10 years of service and is 60 years old (62 years old for Tier II), or retiree has 10 years of service and is determined disabled by the Social Security Administration or the Teachers' Retirement System of Alabama's Medical Board. These retired UAB employees may elect to continue to participate in UAB Plan until they are eligible for Medicare by paying the full cost of the plan premium. Retired employees age 65 or older who are eligible for Medicare must enroll in the Medicare Coordinated Plan under which Medicare is the primary insurer and UAB Plan becomes the secondary insurer. Despite the availability of the UAB Plan, most retirees elect to participate in the PEEHIP with TRS. The UAB Plan consists of hospital benefits, major medical benefits, a prescription drug program and a basic term life insurance up to an established maximum policy limit.

Employees included in the actuarial valuation include active employees, retirees and disabled employees enrolled in the medical plan and retirees not enrolled in the medical plan with retiree life insurance. The following table summarizes the membership of the UAB Plan as of September 30, 2020, the Valuation Date.

| Membership: | 2021 |
|--|--------|
| Inactive Employees or Beneficiaries Currently Receiving Benefits | 238 |
| Inactive Members Entitled To But Not Yet Receiving Benefits | _ |
| Active Employees | 10,824 |
| TOTAL MEMBERSHIP | 11 062 |

Contributions. UAB retired employees make contributions to the plan by making premium payments associated with their selected health plan option. Eligible disabled retirees are responsible for only the employee portion of those premiums and UAB is responsible for the employer portion. All other UAB retirees are responsible for the full premium cost of the plan and in no case does the employer contribute to the plan.

OPEB Liabilities, OPEB Expense, and Deferred Outflows of Resources and Deferred Inflows of Resources Related to OPEB. At September 30, 2021 and 2020, UAB reported a total OPEB liability ("TOL") of \$5.3 million and \$6.3 million, respectively. The TOL is based upon an Entry Age Normal ("EAN") actuarial funding method as of the valuation date, September 30, 2019. Since the valuation date at which the TOL is determined is before the measurement date, the TOL must be rolled forward to the measurement date.

For the years ended September 30, 2021 and 2020, UAB recognized an OPEB benefit of \$1,240,589 and \$644,580, respectively with no special funding situations. At September 30, 2021 and 2020, UAB reported deferred outflows of resources and deferred inflows of resources related to the UAB plan from the following sources:

| 2021 | Deferro R | Deferred Inflows of Resources | | | |
|---|--------------|----------------------------------|----|------------------------------|--|
| Differences between expected and actual experience | \$ | _ | \$ | 5,668,729 | |
| Changes of assumptions | | 75,946 | | 4,632,413 | |
| Employer contributions subsequent to the measurement period | | 1,895,059 | | _ | |
| TOTAL | \$ | 1,971,005 | \$ | 10,301,142 | |
| 2020 | | ed Outflows of esources | | rred Inflows of Resources | |
| Differences between expected and actual experience | \$ | _ | \$ | 6,076,784 | |
| Changes of assumptions | | _ | | 5,360,627 | |
| Employer contributions subsequent to the measurement period | | 1,411,559 | | _ | |
| TOTAL | \$ | 1,411,559 | \$ | 11,437,411 | |

Other amounts reported as deferred outflows of resources and deferred inflows of resources related to OPEB will be recognized in OPEB expense as follows:

| Year ended Septe | mber 30: | |
|------------------|----------|-------------|
| 2021 | \$ | (1,563,353) |
| 2022 | | (1,563,353) |
| 2023 | | (1,563,353) |
| 2024 | | (1,563,353) |
| 2025 | | (1,550,356) |
| Thereafter | | (2,421,428) |

Actuarial assumptions. The total OPEB liability for the UAB Plan was determined by an actuarial valuation as of September 30, 2019, using the following actuarial assumptions, applied to all periods included in the measurement:

| Inflation | 2.75 % |
|--|---------------|
| Real Wage Growth | 0.25 % |
| Projected Salary Increases ¹ | 3.25% - 5.00% |
| Wage inflation. | 3.00 % |
| Municipal Bond Index Rate at the Measurement Date | 2.25 % |
| Municipal Bond Index Rate at the Prior Measurement Date | 2.66 % |
| Healthcare Cost Trend Rate | |
| Pre-Medicare Medical and Prescription Drug (decreasing to an ultimate rate of 4.75% by 2027) | 6.75 % |

¹Includes 3.00% wage inflation.

Mortality rates for the period after service retirement for the UAB plan are according to the RP-2000 White Collar Mortality Table projected to 2020 using scale BB and adjusted 115% for all ages for males and 112% for ages 78 and over for females. The rates of disabled mortality were based on the RP-2000 Disabled Mortality Table projected to 2020 using scale BB and adjusted 105% for males and 120% for females.

The demographic actuarial assumptions for retirement, disability incidence, withdrawal, and salary increases used in the September 30, 2019 valuation were based on the actuarial experience study prepared as of September 30, 2015, submitted to and adopted by the Teachers' Retirement System of Alabama Board on September 13, 2016.

The remaining actuarial assumptions (e.g., initial per capita costs, health care cost trends, rate of plan participation, rates of plan election, etc.) used in the September 30, 2019 valuation were based on a review of recent plan experience performed concurrently with the September 30, 2019 valuation.

The UAB Plan does not hold any plan assets, as such, there are no long-term expected rate of return or target allocation presented.

Discount Rate. The discount rate, as defined by Paragraph 155 of GASB 75 is to be a 20-year tax-exempt municipal bond (rating AA/Aa or higher) rate (Municipal Bond Index Rate) The Municipal Bond Index Rate used for this purpose is the average of the Bond Buyer General Obligation 20-year Municipal Bond Index, the Fidelity General Obligation AA 20-year Municipal Bond Index, and the S&P High Grade 20-year Municipal Bond Index. The rates as of September 30, 2020 were 2.21%, 2.41%, and 2.14% for the Bond Buyer, Fidelity, and S&P Municipal Bond Indices respectively. These three rates resulted in an averaged Municipal Bond Index Rate of 2.25%. This is a change from the Municipal Bond Index Rate of 2.66% as of the Prior Measurement Date, which used a single source from the Bond Buyer (www.bondbuyer.com).

Sensitivity of the UAB Plan's net OPEB liability to changes in the healthcare cost trend rates. The following table presents the total OPEB Liability of the UAB Plan, calculated using the current healthcare trend rate, as well as what the total OPEB Liability would be if calculated using 1-percentage-point lower or 1-percentage-point higher than the current rate. A 1-percent-point decrease would change the current healthcare trend rate from 6.75% to 5.75% and pre-Medicare from 4.75% to 3.75%. A 1-percent-point increase would change the current healthcare trend rate from 6.75% to 7.75% and the pre-Medicare from 4.75% to 5.75%.

| | | Cı | ırrent Healthcare | |
|----------------------------|-----------------|----|-------------------|-----------------|
| | 1% Decrease | | Trend Rate | 1% Increase |
| UAB's total OPEB liability | \$ 5,132,275 | \$ | 5,280,513 | \$ 5,437,514 |

The following table presents the total OPEB Liability of the UAB Plan, calculated using the discount rate of 2.25%, as well as what the total OPEB liability would be if calculated using 1-percentage-point lower or 1-percentage-point higher than the current rate:

| | 1.25% | | | 2.25% | 3.25% | |
|----------------------------|-------|-----------|----|-----------|-----------------|--|
| UAB's total OPEB liability | \$ | 5,499,885 | \$ | 5,280,513 | \$ 5,075,331 | |

Changes in the Total OPEB Liability. Since the UAB Plan does not meet the definition within paragraph 4 of GASB Statement No 75, UAB is disclosing a schedule of changes in the total OPEB liability below:

| | | 2021 |
|---|----|-----------|
| Total OPEB Liability as of September 30, 2020 | \$ | 6,251,332 |
| Changes for the year: | | |
| Service cost | | 168,931 |
| Interest on TOL and cash flows | | 153,833 |
| Changes in benefit terms | | _ |
| Difference between expected and actual experience | | (436,896) |
| Changes of assumptions or other inputs | | 85,758 |
| Benefit payments | | (942,445) |
| Net changes | \$ | (970,819) |
| Total OPEB Liability as of September 30, 2021 | \$ | 5,280,513 |
| | | |

^{*}The service cost include interest for the year.

(11)

Federal Direct Student Loan Program

The Federal Direct Student Loan Program ("FDSLP") was established under the Higher Education Act of 1965, as amended in the Student Loan Reform Act of 1993. The FDSLP enables an eligible student or parent to obtain a loan to pay for the student's cost of attendance directly through the university rather than through private lenders. UAB began participation in the FDSLP on July 1, 1994. As a university qualified to originate loans, UAB is responsible for handling the complete loan process, including funds management, as well as promissory note functions. UAB is not responsible for collection of these loans. During the years ended September 30, 2021 and 2020, UAB disbursed approximately \$163.2 million and \$166.6 million, respectively, under the FDSLP.

(12) Grants and Contracts

At September 30, 2021 and 2020, UAB had been awarded approximately \$907.5 million and \$703.1 million, respectively, in grants and contracts which have not been expended. These awards, which represent commitments of sponsors to provide funds for specific research, training, and service projects, have not been reflected in the financial statements.

(13) Operating Expenses by Function

Total operating expenses by functional classification for the years ended September 30, 2021 and 2020 are as follows for UAB:

2021 Operating Expenses

(by functional classification)

| | Salaries, Wages, and Benefits | | Supplies and Services | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | preciation and Amortization | So | cholarships and Fellowships | Total |
|-------------------------------------|----------------------------------|----|--------------------------|----|-------------|----|------------|---------------------|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--------------------------------|----|--------------------------------|-------|
| Instruction | \$ 259,960,374 | \$ | 33,060,944 | \$ | | \$ | _ | \$ 293,021,318 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Research | 206,051,685 | | 132,301,420 | | _ | | _ | 338,353,105 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Public service | 113,748,440 | | 68,723,953 | | _ | | _ | 182,472,393 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Academic support | 161,076,915 | | 8,826,999 | | _ | | _ | 169,903,914 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Student services | 29,096,394 | | 10,491,179 | | _ | | _ | 39,587,573 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Institutional support | 129,108,352 | | 111,476,998 | | _ | | _ | 240,585,350 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Operations and maintenance of plant | 41,346,247 | | 31,906,518 | | _ | | _ | 73,252,765 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Scholarships and fellowships | _ | | _ | | _ | | 55,053,095 | 55,053,095 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| University Hospital | 951,567,782 | | 1,109,083,108 | | _ | | _ | 2,060,650,890 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Auxiliary | 71,672,708 | | 668,172,085 | | _ | | _ | 739,844,793 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Depreciation | _ | | _ | | 156,533,614 | | _ | 156,533,614 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| TOTAL OPERATING EXPENSES | \$ 1,963,628,897 | \$ | 2,174,043,204 | \$ | 156,533,614 | \$ | 55,053,095 | \$ 4,349,258,810 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

2020 Operating Expenses

(by functional classification)

| | S | alaries, Wages, and Benefits | Supplies and Services | Depreciation and Amortization | | Scholarships and Fellowships | | | Total |
|-------------------------------------|----|---------------------------------|--------------------------|----------------------------------|-------------|---------------------------------|------------|----|---------------|
| Instruction | \$ | 248,045,998 | \$ 35,951,295 | \$ | _ | \$ | _ | \$ | 283,997,293 |
| Research | | 181,566,808 | 112,611,840 | | _ | | _ | | 294,178,648 |
| Public service | | 109,176,136 | 58,006,813 | | _ | | _ | | 167,182,949 |
| Academic support | | 158,931,068 | 13,366,872 | | _ | | _ | | 172,297,940 |
| Student services | | 27,963,265 | 10,844,232 | | _ | | _ | | 38,807,497 |
| Institutional support | | 95,295,882 | 122,914,000 | | _ | | _ | | 218,209,882 |
| Operations and maintenance of plant | | 36,974,761 | 31,733,410 | | _ | | _ | | 68,708,171 |
| Scholarships and fellowships | | _ | _ | | _ | | 35,285,313 | | 35,285,313 |
| University Hospital | | 836,833,734 | 963,286,381 | | _ | | _ | | 1,800,120,115 |
| Auxiliary | | 71,257,173 | 652,837,364 | | _ | | _ | | 724,094,537 |
| Depreciation | | _ | _ | | 150,994,130 | | _ | | 150,994,130 |
| TOTAL OPERATING EXPENSES | \$ | 1,766,044,825 | \$ 2,001,552,207 | \$ | 150,994,130 | \$ | 35,285,313 | \$ | 3,953,876,475 |

(14) Contingencies and Commitments

UAB has sovereign immunity and is, therefore, in the opinion of UAB counsel, immune to ordinary tort actions including those based on medical malpractice or general injury to patients. Consequently, while UAB is sometimes named as defendant in malpractice actions and other actions for injuries arising in the University Hospital, it has consistently been dismissed from those lawsuits on the basis of the sovereign immunity doctrine. That doctrine also protects UAB from vicarious liability arising from the negligence of its employees. To the extent that UAB employees are sued in their individual capacity for actions related to their official duties within the line and scope of their employment, UAB has defended those actions and paid for any resulting costs through its self-insured trust fund. While UAB is not aware of any impending threat to this doctrine, UAB is a named insured under the terms of the PLTF and excess insurance purchased from commercial companies (Note 8). There are some exceptions to the sovereign immunity doctrine, most notably federal court cases arising under the federal constitution or federal statutes.

UAB is engaged in various legal actions in the ordinary course of business. Management does not believe the ultimate outcome of these actions will have a material adverse effect on the financial statements. However, the settlement of legal actions is subject to inherent uncertainties and it is possible that such outcomes could differ materially from management's current expectations.

Amounts received or receivable from grantor agencies are subject to audit and adjustments by such agencies, principally the United States Government. Any disallowed claims, including amounts already collected, may constitute a liability of UAB. The amount, if any, of expenditures that may be disallowed by the grantor cannot be determined at this time, although UAB expects any such amounts to be immaterial.

UAB has contracted for the construction and renovation of several facilities. At September 30, 2021 and 2020, the estimated remaining cost to complete the construction and renovation of these facilities was approximately \$293 million and \$165 million, respectively, which is expected to be financed from private gifts, grants, bond proceeds, and UAB reserves.

(15) Segment Reporting

As discussed in Note 1, UAB's two significant identifiable activities that have bonds outstanding where revenue is pledged in support of the bonds are the University and the University Hospital. Condensed financial statement information related to the University and University Hospital as of and for the years ended September 30, 2021 and 2020 is as follows:

| UNIVERSITY | 2021 | 2020 | | |
|--|---------------------|------|---------------|--|
| CONDENSED STATEMENTS OF NET POSITION | | | | |
| Current assets | \$ 987,138,944 | \$ | 836,713,735 | |
| Capital assets, net | 1,170,350,281 | | 1,168,528,126 | |
| Other assets | 1,139,082,387 | | 874,816,846 | |
| TOTAL ASSETS | \$ 3,296,571,612 | \$ | 2,880,058,707 | |
| DEFERRED OUTFLOW OF RESOURCES | \$ 562,409,447 | \$ | 211,159,055 | |
| TOTAL ASSETS AND DEFERRED OUTFLOWS OF RESOURCES | \$ 3,858,981,059 | \$ | 3,091,217,762 | |
| Current liabilities | 325,135,087 | | 349,237,084 | |
| Long-term debt | 577,663,870 | | 601,602,280 | |
| Other noncurrent liabilities | 1,373,463,571 | | 991,756,471 | |
| TOTAL LIABILITIES | \$ 2,276,262,528 | \$ | 1,942,595,835 | |
| DEFERRED INFLOW OF RESOURCES | \$ 318,523,939 | \$ | 319,605,203 | |
| Net investment in capital assets | 608,224,952 | | 609,155,955 | |
| Restricted nonexpendable | 390,565,083 | | 405,387,849 | |
| Restricted expendable | 548,697,797 | | 305,788,404 | |
| Unrestricted | (283,293,240) | | (491,315,484) | |
| TOTAL NET POSITION | \$ 1,264,194,592 | \$ | 829,016,724 | |
| TOTAL LIABILITIES, DEFERRED INFLOWS AND NET POSITION | \$ 3,858,981,059 | \$ | 3,091,217,762 | |

| UNIVERSITY | | 2021 | 2020 | |
|--|----|---------------|---------------------|--|
| CONDENSED STATEMENTS OF REVENUES, EXPENSES AND CHANGES IN NET POSITION | | | | |
| Tuition and fees, net | \$ | 243,476,387 | \$ 244,929,737 | |
| Grant and contract revenue | | 526,727,010 | 483,921,581 | |
| Sales and services, educational | | 67,666,602 | 59,351,275 | |
| Other operating revenues | | 71,846,650 | 87,197,569 | |
| Salaries, wages, and benefits | | (955,714,291) | (877,227,836) | |
| Supplies and services | | (417,106,329) | (408,331,442) | |
| Depreciation | | (80,221,836) | (76,748,607) | |
| Scholarships and fellowships | | (55,047,847) | (35,276,313) | |
| OPERATING LOSS | | (598,373,653) | (522,184,036) | |
| State appropriations | | 276,997,252 | 270,077,351 | |
| Investment income | | 307,137,486 | 2,940,208 | |
| Interest expense | | (17,114,882) | (22,083,632) | |
| Gifts | | 57,336,704 | 15,640,326 | |
| Other nonoperating revenues | | 115,065,144 | 61,156,771 | |
| INCOME (LOSS) BEFORE OTHER CHANGES IN NET POSITION | | 141,048,051 | (194,453,012) | |
| Capital gifts and grants | | 1,645,260 | 1,854,223 | |
| State capital funds | | 3,610,767 | _ | |
| Endowment gifts | | 33,163,130 | 17,755,898 | |
| Intergovernmental transfers | | 255,710,660 | 194,127,825 | |
| INCREASE IN NET POSITION | | 435,177,868 | 19,284,934 | |
| Net position, beginning of year | | 829,016,724 | 809,731,790 | |
| NET POSITION, END OF YEAR | \$ | 1,264,194,592 | \$ 829,016,724 | |
| UNIVERSITY | | 2021 | 2020 | |
| CONDENSED STATEMENTS OF CASH FLOWS | | | | |
| Net cash provided by (used in): | | | | |
| Operating activities | \$ | (508,645,596) | \$ (428,799,771) | |
| Noncapital financing activities | | 737,375,180 | 570,845,198 | |
| Investing activities | | (55,038,798) | (28,338,182) | |
| Capital and related financing activities | | (123,157,539) | (167,695,054) | |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | - | 50,533,247 | (53,987,809) | |
| Cash and cash equivalents, beginning of year | | 164,957,059 | 218,944,868 | |
| CASH AND CASH EQUIVALENTS, END OF YEAR | \$ | 215,490,306 | \$ 164,957,059 | |

| UNIVERSITY HOSPITAL | | 2021 | 2020 | | |
|--|----|-----------------|------|-----------------|--|
| CONDENSED STATEMENTS OF NET POSITION | | | | | |
| Current assets | \$ | 1,520,821,759 | \$ | 1,374,342,040 | |
| Capital assets, net | | 614,486,113 | | 611,158,094 | |
| Other assets | _ | 858,068,604 | | 621,138,676 | |
| TOTAL ASSETS | \$ | 2,993,376,476 | \$ | 2,606,638,810 | |
| DEFERRED OUTFLOW OF RESOURCES | \$ | 300,205,570 | \$ | 107,671,675 | |
| TOTAL ASSETS AND DEFERRED OUTFLOWS OF RESOURCES | \$ | 3,293,582,046 | \$ | 2,714,310,485 | |
| Current liabilities | | 392,305,418 | | 381,660,778 | |
| Long-term debt | | 485,980,987 | | 485,584,419 | |
| Other noncurrent liabilities | | 754,073,771 | | 555,745,556 | |
| TOTAL LIABILITIES | \$ | 1,632,360,176 | \$ | 1,422,990,753 | |
| DEFERRED INFLOW OF RESOURCES | \$ | 206,921,616 | \$ | 202,331,913 | |
| Net investment in capital assets | | 175,035,236 | | 155,581,621 | |
| Restricted nonexpendable | | 128,099 | | 128,099 | |
| Restricted expendable | | 40,600,146 | | 35,958,408 | |
| Unrestricted | | 1,238,536,773 | | 897,319,691 | |
| TOTAL NET POSITION | \$ | 1,454,300,254 | \$ | 1,088,987,819 | |
| TOTAL LIABILITIES, DEFERRED INFLOWS AND NET POSITION | \$ | 3,293,582,046 | \$ | 2,714,310,485 | |
| | | | | | |
| UNIVERSITY HOSPITAL | | 2021 | | 2020 | |
| CONDENSED STATEMENTS OF REVENUES, EXPENSES AND CHANGES IN NET POSITION | | | | | |
| Operating revenues | \$ | 2,472,630,202 | \$ | 2,109,843,405 | |
| Operating expenses | | (2,060,744,108) | | (1,800,229,075) | |
| Depreciation expense | | (75,029,306) | | (72,958,684) | |
| OPERATING INCOME | | 336,856,788 | | 236,655,646 | |
| Economic relief funds | | 412,719 | | 71,281,071 | |
| State appropriations | | 37,955,804 | | 36,887,361 | |
| Investment income | | 241,041,041 | | 2,225,634 | |
| Interest expense | | (18,165,739) | | (18,042,761) | |
| Gifts | | 104,779 | | 495,224 | |
| Other nonoperating expenses | | (327,872) | | (176,882) | |
| INCOME BEFORE OTHER CHANGES IN NET POSITION | | 597,877,520 | | 92,669,647 | |
| Intergovernmental transfers | | (232,565,085) | | (191,732,311) | |
| INCREASE IN NET POSITION | | 365,312,435 | | 137,592,982 | |
| Net position, beginning of year | | 1,088,987,819 | | 951,394,837 | |
| NET POSITION, END OF YEAR | \$ | 1,454,300,254 | \$ | 1,088,987,819 | |
| | | | | | |
| UNIVERSITY HOSPITAL | | 2021 | | 2020 | |
| CONDENSED STATEMENTS OF CASH FLOWS | | | | | |
| Net cash provided by (used in): | | | | | |
| Operating activities | | 343,851,057 | | 482,366,417 | |
| Noncapital financing activities | | (190,862,468) | | (87,024,110) | |
| Investing activities | | (289,430,880) | | (41,132,386) | |
| Capital and related financing activities | | (116,498,135) | | (108,557,784) | |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | | (252,940,426) | | 245,652,137 | |
| Cash and cash equivalents, beginning of year | | 334,173,935 | | 88,521,798 | |
| CASH AND CASH EQUIVALENTS, END OF YEAR | \$ | 81,233,509 | \$ | 334,173,935 | |

(16) Health Care Services

Net Patient Service Revenue

The University Hospital has agreements with governmental and other third-party payors that provide for reimbursement to the University Hospital at amounts different from its established rates. Contractual adjustments under third-party reimbursement programs represent the difference between the University Hospital's billings at established rates for services and amounts reimbursed by third-party payors. A summary of the basis of reimbursement with major third-party payors follows:

Medicare. Substantially all acute-care services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to the patient classification systems that are based on clinical, diagnostic, and other factors. Additionally, the University Hospital is reimbursed for both its direct and indirect medical education costs (as defined), principally based on per-resident prospective payment amounts and certain adjustments to prospective rate-per-discharge operating reimbursement payments. The University Hospital generally is reimbursed for certain retroactively settled items at tentative rates, with final settlement determined after submission of annual cost reports by the University Hospital and audits by the Medicare fiscal intermediary, the University Hospital's cost reports have been audited and settled for all fiscal years through 2012. Revenue from the Medicare program accounted for approximately 18% and 20% of the University Hospital's net patient service revenue for the years ended September 30, 2021 and 2020, respectively.

Section 302 of the Tax Relief and Health Care Act of 2006 authorized a permanent program involving the use of third-party recovery audit contractors (RACs) to identify Medicare overpayments and underpayments made to providers. As of September 30, 2021, the University Hospital reported claims in various stages of review based on the requests received by the RACs during the fiscal year. Payment recoveries resulting from RAC reviews are appealable through administrative and judicial processes, and the University Hospital intends to pursue the reversal of adverse determinations, where appropriate. The University Hospital cannot predict with certainty the impact of the Medicare RAC program on our future results of operations or cash flows.

Blue Cross. Inpatient services rendered to Blue Cross subscribers are paid at a prospectively determined per diem rate. Outpatient services are reimbursed at a prospectively determined rate or under a cost reimbursement methodology. The method of reimbursement is determined by the procedures that are performed. For outpatient services reimbursed under the cost reimbursement methodology, a final settlement is determined after submission of annual cost reports by the University Hospital and audits thereof by Blue Cross. The University Hospital's Blue Cross cost reports have been audited and settled for all fiscal years through 2016. Effective December 1, 2016 Blue Cross outpatient services began being reimbursed under the Enhanced Ambulatory Payment Group (EAPG) methodology. This is a prospective payment methodology with no retroactive settlement. Revenue from the Blue Cross program accounted for approximately 35% and 33% of the University Hospital's net patient service revenue for the years ended September 30, 2021 and 2020, respectively.

Medicaid. Inpatient services rendered to Medicaid program beneficiaries are reimbursed at all-inclusive prospectively determined per diem rates. Outpatient services are reimbursed based on an established fee schedule. The University Hospital is designated as a Disproportionate Share Hospital (DSH) and receives payments under the Medicaid DSH program. In addition, as a participant in the Alabama Medicaid Plan, the University Hospital also receives supplemental payments based on formulas established by the Alabama Medicaid Agency. The net benefit associated with the University Hospital's participation in these programs, totaling approximately \$168.2 million and \$103.1 million in 2021 and 2020, respectively, is included in net patient service revenue in the accompanying statement of revenues, expenses and changes in net position. There can be no assurance that the University Hospital will continue to qualify for future participation in these programs or that the programs will not ultimately be discontinued or materially modified. Revenue from the Medicaid program accounted for approximately 16% and 15% of the University Hospital's net patient service revenue for the years ended September 30, 2021 and 2020, respectively.

Other. The University Hospital has also entered into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. The basis for payments to the University Hospital under these agreements includes discounts from established charges and prospectively determined daily and case rates. The composition of University Hospital operating revenue follows:

| | | 2020 | |
|--|----|-----------------|---------------------|
| Gross Patient Service Revenue | \$ | 9,562,939,692 | \$ 8,092,812,292 |
| Less Provision for Contractual and Other Adjustments | | (7,196,037,301) | (6,120,310,515) |
| Less Provision for Bad Debts | | (248,640,077) | (187,887,453) |
| Net Patient Service Revenue | \$ | 2,118,262,314 | \$ 1,784,614,324 |
| Capitation Revenue | | 79,939,250 | 82,320,021 |
| Other Operating Revenue | | 274,428,638 | 242,909,060 |
| TOTAL UNIVERSITY HOSPITAL SALES REVENUE | \$ | 2,472,630,202 | \$ 2,109,843,405 |

Charity Care

The University Hospital maintains records to identify and monitor the level of charity care it provides. These records include the amount of charges foregone for services and supplies furnished under its charity care policy, the estimated costs of those services, and supplies and equivalent service statistics.

The estimated cost of charity care provided during the years ended September 30, 2021 and 2020 was approximately \$36.6 million and \$35.2 million, respectively, calculated based on the ratio of total direct and indirect costs to establish charges applied to the charges foregone under the charity care policy.

| | | 2020 | |
|--|----|-------------|-------------------|
| Approximate charges foregone, based on established rates | \$ | 137,442,012 | \$ 128,828,588 |
| Percentage of charity charges to total charges | | 1.4% | 1.6% |

Credit Risk

The University Hospital grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The mix of receivables from patients and third-party payors at September 30, 2021 and 2020 follows:

| | 2021 | 2020 |
|------------|------|------|
| Other | 43% | 43% |
| Blue Cross | 40% | 35% |
| Medicare | 11% | 15% |
| Medicaid | 6% | 7% |
| | 100% | 100% |

Related Parties

The University Hospital and the other divisions of UAB provide a variety of support services to each other. The cost of these services is allocated to the end user on bases which vary according to the service being furnished. These services are paid for by transfers of funds which reduce operating expenses of the unit providing the service and are included in the operating costs of the unit receiving the service. Administrative and purchased services provided by UAB and allocated to and reimbursed by the University Hospital during the years ended September 30, 2021 and 2020 were approximately \$36.1 million and \$37.3 million, respectively. In addition, during the years ended September 30, 2021 and 2020, the University Hospital transferred approximately \$232.6 million and \$191.7 million, respectively, to UAB to support UAB's academic and medical programs.

As noted in footnote 7, In June 2019, the UAB Medicine Finance Authority issued \$8.1 million in Series 2019A Revenue Bonds and \$103.4 million in Series 2019B Revenue Bonds, the proceeds of which were loaned to UAB Health System pursuant to Series 2019A and Series 2019B loan agreements. Concurrently, University Hospital entered into a loan agreement with UAB Health System for \$77.0 million of the 2019A and 2019B bond proceeds for the purpose of financing capital improvement projects. In January 2021, University Hospital borrowed an additional \$17.7 million of the 2019A and 2019B bond proceeds from UAB Health System. Of the total amount borrowed, \$42.5 million was distributed to University Hospital as of September 30, 2020 and September 30, 2021. As University Hospital is legally obligated to repay \$94.7 million and is currently paying principal and interest on this full amount, University Hospital has reflected the full \$94.7 million on its statement of net position as long-term debt and \$52.2 million as Due from affiliate on the statement of net position. University Hospital pays interest to UAB Health System on the entire amount, regardless of the amount outstanding. There are no financial covenants related to the loan between University Hospital and UAB Health System.

During 2008, the University Hospital entered into an operating agreement with HSF whereby HSF would lease two floors of the Women and Infants Center ("WIC"). HSF reimbursed the University Hospital for construction costs of this space as they were incurred on a square-footage basis. Total reimbursements are being amortized as rent revenue on a straight-line basis over a period equal to the 90 year total lease term, commencing on February 22, 2010, the date the building was placed into service. The University Hospital had received reimbursements from HSF totaling approximately \$14.7 million in 2021 and 2020, of which approximately \$12.6 million and \$12.8 million respectively, is included in the accompanying statement of net position as unearned revenue-other for the years ended September 30, 2021 and 2020, respectively.

The Board and the HSF's board have entered into an agreement under which UAB and HSF have established a common management group, the UAB Health System (Health System), to provide management for their existing and future health care delivery operations.

In connection with its agreement with the Health System, the University Hospital partially funded the operations of the Health System and its corporate office, charging approximately \$17.4 million and \$14.8 million to other operating expense in fiscal year 2021 and 2020, respectively. In addition, the Health System periodically makes payments on behalf of the University Hospital for which it is reimbursed. The University Hospital had a net payable to the Health System of approximately \$6.9 million and \$9.8 million at September 30, 2021 and 2020, respectively. University Hospital also made equity transfers of approximately \$86.9 million and \$86.8 million to the Health System during fiscal year 2021 and 2020, respectively.

In March 2014, the University Hospital assumed operations of the outpatient clinics in The Kirklin Clinic and entered into an agreement with HSF to lease the land and the building known as The Kirklin Clinic. The initial term of the lease, which is cancellable by either party upon proper written notice and without penalty, is five years, with automatic one-year renewals thereafter.

VF's primary purpose is to provide a group medical practice for physicians who are faculty members in the UAB School of Medicine Huntsville program. It is governed by a 17-member board of directors, consisting of three nonvoting members and 14 voting members, of whom seven are affiliated with UAB.

The University Hospital received premium revenue (capitation fees) of approximately \$80 million and \$82 million from Triton during the years ended September 30, 2021 and 2020, respectively.

The University Hospital purchased \$550 million and \$458 million in management, administrative, and staffing services from the LLC during the years ended September 30, 2021 and 2020, respectively. Payment for contract labor as reported on the Statements of Cash Flows includes amounts paid to employees of the LLC and HSF.



Recently Issued Pronouncements

The GASB issued Statement No. 87, *Leases*, in June 2017. The objective of this Statement is to better meet the information needs of financial statement users by improving accounting and financial reporting for leases by governments. This statement is effective for reporting periods beginning after June 15, 2021. UAB anticipates that the adoption of GASB 87 will have a material impact on the financial statements.

The GASB issued Statement No. 90, *Majority Equity Interest - An Amendment of GASB Statements No. 14 and No. 61*, in August 2018. The primary objectives of this Statement are to improve the consistency and comparability of reporting a government's majority equity interest in a legally separate organization and to improve the relevance of financial statement information for certain component units. This statement is effective for reporting periods beginning after December 15, 2019. UAB has determined there was no material impact from its adoption of GASB 90.

The GASB issued Statement No. 91, Conduit Debt Obligations, in May 2019. The objectives of this Statement are to provide a single method of reporting conduit debt obligations by issuers and eliminate diversity in practice associated with (1) commitments extended by issuers, (2) arrangements associated with conduit debt obligations, and (3) related note disclosures. This statement is effective for reporting periods beginning after December 15, 2021. UAB has determined there will be no material impact from its adoption of GASB 91.

The GASB issued Statement No. 92, *Omnibus 2020, in January 2020.* The objectives of this Statement are to enhance comparability in accounting and financial reporting and to improve the consistency of authoritative literature by addressing practice issues that have been identified during implementation and application of certain GASB

Statements. The statement is effective for reporting periods beginning after June 15, 2021. UAB has determined there will be no material impact from its adoption of GASB 92.

The GASB issued Statement No. 93, *Replacement of Interbank Offered Rates*, in March 2020. The objective of this Statement is to address those and other accounting and financial reporting implications that result from the replacement of the IBOR. The requirements of this Statement, except for paragraphs 11b, 13, and 14 are effective for reporting periods beginning after June 15, 2020. The requirement in paragraph 11b is effective for reporting periods ending after December 31, 2021. The requirements in paragraphs 13 and 14 are effective for fiscal years periods beginning after June 15, 2021, and all reporting periods thereafter. UAB has determined there was no material impact from its adoption of the portions of GASB 93 which were effective for reporting periods beginning after June 15, 2020, and there will be no material impact from its adoption of the portions of the Statement effective for reporting periods beginning after June 15, 2021 and December 31, 2021.

The GASB issued Statement No. 94, *Public-Private and Public-Public Partnerships and Availability Payment Arrangements*, in March 2020. The objective of this Statement is to improve financial reporting by addressing issues related to public-private partnership arrangements. This Statement also provides guidance for accounting and financial reporting for availability payment arrangements. The statement is effective for reporting periods beginning after June 15, 2022. UAB has determined there will be no material impact from its adoption of GASB 94.

The GASB issued Statement No. 95, Postponement of the Effective Dates of Certain Authoritative Guidance, in May 2020. The objective of this Statement is to provide temporary relief to governments and other stakeholders in light of the COVID-19 pandemic. That objective is accomplished by postponing the effective dates of certain provisions in Statements 83 - 93. The effective dates disclosed above have been adjusted to reflect this deferral. UAB will apply the GASB 95 postponement of effective dates.

The GASB issued Statement No. 96, Subscription-Based Information Technology Arrangements, in May 2020. The objective of this Statement is to provide guidance on the accounting and financial reporting for subscription-based information technology arrangements for government end users. The statement is effective for reporting periods beginning after June 15, 2022. UAB is evaluating whether there will be any material impact from its adoption of GASB 96.

The GASB issued Statement No. 97, Certain Component Unit Criteria, and Accounting and Financial Reporting for Internal Revenue Code Section 457 Deferred Compensation Plans - an amendment of GASB Statements No. 14 and No. 84, and a supersession of GASB Statement No. 32, in June 2020. The primary objectives of this Statement are to (1) increase consistency and comparability related to the reporting of fiduciary component units in circumstances in which a potential component unit does not have a governing board and the primary government performs the duties that a governing board typically would perform; (2) mitigate costs associated with the reporting of certain defined contribution pension plans, defined contribution other postemployment benefit (OPEB) plans, and employee benefit plans other than pension plans or OPEB plans (other employee benefit plans) as fiduciary component units in fiduciary fund financial statements; and (3) enhance the relevance, consistency, and comparability of the accounting and financial reporting for Internal Revenue Code (IRC) Section 457 deferred compensation plans (Section 457 plans) that meet the definition of a pension plan and for benefits provided through those plans. The requirements in (1) paragraph 4 of this Statement as it applies to defined contribution pension plans, defined contribution OPEB plans, and other employee benefit plans and (2) paragraph 5 of this Statement are effective immediately. All other requirements of this Statement are effective for reporting periods beginning after June 15, 2021. UAB has determined there was no material impact from its adoption of the portions of GASB 97 which were effective immediately, and there will be no material impact from its adoption of the portions of this Statement effective for reporting periods beginning after June 15, 2021.

The GASB issued Statement No. 98, The Annual Comprehensive Financial Report, in October 2021. This Statement establishes the term annual comprehensive financial report and its acronym ACFR. That new term and acronym replace instances of comprehensive annual financial report and its acronym in generally accepted accounting principles for state and local governments. The requirements of this Statement are effective for fiscal years ending after December 15, 2021. UAB's early adoption of GASB 98 during fiscal year 2021 had no material impact on its financial statements.

The University of Alabama at Birmingham Required Supplementary Information (Unaudited)

The following required supplementary information relates to UAB's participation in the Teachers' Retirement System of Alabama. (Dollars in thousands)

Schedule of UAB's Proportionate Share of the Net Pension Liability Teachers' Retirement Plan of Alabama

| | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|--|--------------|-------------|--------------|--------------|-------------|--------------|--------------|
| Employer's proportion of the net pension liability | 11.425593 % | 11.260686 % | 11.750518 % | 11.814264 % | 11.863961 % | 11.916376 % | 12.188512 % |
| Employer's proportionate share of the collective net pension liability | \$ 1,413,306 | \$1,245,083 | \$ 1,168,305 | \$ 1,161,162 | \$1,284,396 | \$ 1,247,128 | \$ 1,107,275 |
| Employer's covered payroll during the measurement period | \$ 946,085 | \$ 940,203 | \$ 916,059 | \$ 901,338 | \$ 876,899 | \$ 864,300 | \$ 880,666 |
| Employer's proportionate share of the collective net pension liability as a percentage of its covered payroll | 149.38 % | 132.43 % | 127.54 % | 128.83 % | 146.47 % | 144.29 % | 125.73 % |
| Plan fiduciary net position as a percentage of the total collective pension liability | 67.72 % | 69.85 % | 72.29 % | 71.50 % | 67.93 % | 67.51 % | 71.01 % |

Schedule of UAB's Contributions Teachers' Retirement Plan of Alabama

| | 2021 | 2020 | _ | 2019 | 2018 | 2017 | | 2016 | 2015 | |
|--|---------------|---------------|----|---------|---------------|---------------|----|---------|------|---------|
| Contractually required contribution | \$ 96,839 | \$ 98,485 | \$ | 94,900 | \$ 91,228 | \$ 88,660 | \$ | 86,334 | \$ | 84,999 |
| Contributions in relation to the contractually required contribution required contribution | \$ 96,839 | \$ 98,485 | \$ | 94,900 | \$ 91,228 | \$ 88,660 | \$ | 86,334 | \$ | 84,999 |
| Contribution deficiency (excess) | _ | _ | | _ | _ | _ | | _ | | _ |
| Employer's covered payroll | \$ 947,482 | \$ 946,085 | \$ | 940,203 | \$ 916,059 | \$ 901,338 | \$ | 876,899 | \$ | 864,300 |
| Contributions as a percentage of covered payroll covered payroll | 10.22% | 10.41% | | 10.09% | 9.96% | 9.84% | | 9.85% | | 9.83% |

Notes to Schedules

Employer's covered payroll: The payroll on which contributions to a pension plan are based.

Measurement period:

For fiscal year 2021, the measurement period is October 1, 2019 – September 30, 2020 For fiscal year 2020, the measurement period is October 1, 2018 – September 30, 2019 For fiscal year 2019, the measurement period is October 1, 2017 – September 30, 2018 For fiscal year 2018, the measurement period is October 1, 2016 – September 30, 2017 For fiscal year 2017, the measurement period is October 1, 2015 – September 30, 2016 For fiscal year 2016, the measurement period is October 1, 2014 – September 30, 2015 For fiscal year 2015, the measurement period is October 1, 2013 – September 30, 2014

The University of Alabama at Birmingham Required Supplementary Information (Unaudited)

The following required supplementary information related to UAB's participation in the Alabama Retired Education Employees' Health Care Trust (PEEHIP).

Schedule of UAB's Proportionate Share of the Net OPEB Liability Alabama Retired Education Employees' Health Care Trust (PEEHIP)

| | 2021 | _ | 2020 | 2019 | 2018 |
|--|-------------------|----|-------------|-------------------|-------------------|
| Employers' proportion of the net OPEB liability | 10.484536 % | | 7.028808 % | 8.029386 % | 8.670675 % |
| Employer's proportionate share of the net OPEB liability | \$ 680,431,790 | \$ | 265,180,609 | \$ 659,913,266 | \$ 644,008,211 |
| Employer's covered payroll during the measurement period | \$ 951,987,983 | \$ | 911,573,992 | \$ 922,919,000 | \$ 908,353,000 |
| Employer's covered payroll OPEB liability (asset) as a percentage of its covered payroll | 71.47 % | | 29.09 % | 71.50 % | 70.90 % |
| Plan fiduciary net position as a percentage of the total OPEB liability | 19.80 % | | 28.14 % | 14.81 % | 15.37 % |

Schedule of UAB's Contributions to the Alabama Retired Education Employees' Health Care Trust (PEEHIP)

| | 2021 | | | 2020 | | 2019 | | 2018 | | |
|--|------|-------------|----|-------------|----|-------------|----|-------------|--|--|
| Contractually required contribution | \$ | 18,240,187 | \$ | 20,775,402 | \$ | 19,976,210 | \$ | 19,713,541 | | |
| Contributions in relation to the contractually required contribution | \$ | 18,240,187 | \$ | 20,775,402 | \$ | 19,976,210 | \$ | 19,713,541 | | |
| Contribution deficiency (excess) | | _ | | _ | | _ | | _ | | |
| Employer's covered payroll | \$ | 955,043,349 | \$ | 951,987,983 | \$ | 911,573,992 | \$ | 922,919,000 | | |
| Contributions as a percentage of covered payroll | | 1.91 % | | 2.18 % | , | 2.19 % | , | 2.14 % | | |

Notes to Schedules

Employer's covered payroll: The payroll on which contributions to an OPEB plan are based.

Measurement period:

For fiscal year 2021, the measurement period is October 1, 2019 – September 30, 2020 For fiscal year 2020, the measurement period is October 1, 2018 – September 30, 2019 For fiscal year 2019, the measurement period is October 1, 2017 – September 30, 2018 For fiscal year 2018, the measurement period is October 1, 2016 – September 30, 2017

The University of Alabama at Birmingham Required Supplementary Information (Unaudited)

The following required supplementary information is related to the UAB Health Care Plan.

Schedule of Change in UAB Health Care Plan's Total OPEB Liability

| | | 2021 | | 2020 | 2019 | _ | 2018 |
|--|----|-------------|----|--------------|-------------------|----|-------------|
| Total OPEB Liability | \$ | 6,251,332 | \$ | 17,698,575 | \$ 20,320,823 | \$ | 26,032,496 |
| Service cost* | | 168,931 | | 169,614 | 168,312 | | 6,230,996 |
| Interest on TOL and cash flows | | 153,833 | | 708,983 | 691,351 | | 690,596 |
| Changes in benefit terms | | _ | | _ | _ | | (6,710,449) |
| Difference between expected and actual experience | | (436,896) | | (6,173,296) | (787,087) | | _ |
| Changes of assumptions or other inputs | | 85,758 | | (4,662,781) | (767,436) | | (961,631) |
| Benefit payments | _ | (942,445) | _ | (1,489,763) | (1,927,388) | _ | (4,961,185) |
| Net changes in Total OPEB Liability | | (970,819) | | (11,447,243) | \$ (2,622,248) | \$ | (5,711,673) |
| Total OPEB Liability - Beginning | \$ | 6,251,332 | \$ | 17,698,575 | \$ 20,320,823 | \$ | 26,032,496 |
| Total OPEB Liability - Ending | \$ | 5,280,513 | \$ | 6,251,332 | \$ 17,698,575 | \$ | 20,320,823 |
| Covered payroll | \$ | 951,987,983 | \$ | 911,573,992 | \$ 922,919,000 | \$ | 908,353,000 |
| Total OPEB Liability as a percentage of covered-employee payroll | | 0.55 % | | 0.69 % | 1.92 % | | 2.24 % |

^{*}The service cost include interest for the year.

Notes to Schedules

Employer's covered payroll: The payroll on which contributions to an OPEB plan are based.

Measurement period:

For fiscal year 2021, the measurement period is October 1, 2019 – September 30, 2020 For fiscal year 2020, the measurement period is October 1, 2018 – September 30, 2019 For fiscal year 2019, the measurement period is October 1, 2017 – September 30, 2018 For fiscal year 2018, the measurement period is October 1, 2016 – September 30, 2017

The University of Alabama at Birmingham Administration

As of September 30, 2021

Ray L. Watts, M.D. President



Pamela Benoit, Ph.D. Senior Vice President for Academic Affairs and Provost

Brian D. Burnett, Ph.D. Senior Vice President for Finance and Administration

Thomas I. Brannan Vice President for Advancement

Christopher S. Brown, Ph.D. Vice President for Research

Curtis A. Carver, Jr., Ph.D. Vice President for Information Technology and Chief Information Officer

Paulette Patterson Dilworth, Ph.D. Vice President for Diversity, Equity and Inclusion

William Ferniany, Ph.D. CEO, UAB Health System

John R. Jones, III, Ph.D. Vice President for Student Affairs

Selwyn M. Vickers, M.D. Senior Vice President for Medicine and Dean, UAB Marnix E. Heersink School of Medicine Shannon Blanton, Ph.D. Dean, UAB Honors College

Andrew J. Butler, MPT, MBA, Ph.D. Dean, School of Health Professions

Michelle Robinson, D.M.D. Interim Dean, School of Education

Paul C. Erwin, M.D., DrPH Dean, School of Public Health

Doreen C. Harper, Ph.D., R.N., FAAN Dean, School of Nursing

Jeffery W. Holmes, M.D. Dean, School of Engineering

Eric P. Jack, Ph.D. Dean, Collat School of Business

Lori L. McMahon, Ph.D. Dean, Graduate School

Kasia Gonnerman, MA Dean, UAB Libraries

Kelly K. Nichols, O.D., MPH, Ph.D., FAAO Dean, School of Optometry

Russell Taichman, D.M.D., DMSc. Dean, School of Dentistry

Kecia M. Thomas, Ph.D. Dean, College of Arts and Sciences

The Board of Trustees of The University of Alabama

As of September 30, 2021

| The Honorable Kay Ivey Governor of Alabama President ex officio | |
|---|-----------------------|
| W. Stancil Stranes, President pro tempore Sixth Congressional District | Trustees Emeriti |
| | Paul W. Bryant, Jr. |
| Mike Brock Second Congressional District | Angus R. Cooper II |
| Karen P. Brooks Seventh Congressional District | John H. England, Jr. |
| Ronald W. Gray Fifth Congressional District | Joseph C. Espy III |
| Barbara Humphrey Seventh Congressional District | Joseph L. Fine |
| Vanessa Leonard Sixth Congressional District | Sandral Hullett, M.D. |
| W. Davis Malone III Second Congressional District | Andria Scott Hurst |
| Evelyn VanSant Mauldin Fourth Congressional District | John D. Johns |
| Harris V. Morrissette First Congressional District | Peter L. Lowe |
| Scott M. Phelps Fourth Congressional District | John J. McMahon, Jr. |
| William Britt Sexton Fifth Congressional District | John T. Oliver, Jr. |
| Kenneth O'Neal Simon Seventh Congressional District | Joe H. Ritch |
| Marietta M. Urquhart First Congressional District | Finis E. St. John IV |
| Kenneth L. Vandervoort, M.D. Third Congressional District | Cleophus Thomas, Jr. |
| James W. Wilson III Third Congressional District | John Russell Thomas |